(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 August 2008 (21.08.2008)

PCT

(10) International Publication Number
WO 2008/100618 A2

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01) *A61P 37/00* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:
PCT/US2008/002108

(22) International Filing Date:
15 February 2008 (15.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/889,977 15 February 2007 (15.02.2007) US
12/031,010 14 February 2008 (14.02.2008) US

(71) Applicant *(for all designated States except US)*: **SUNESIS PHARMACEUTICALS, INC.** [US/US]; 341 Oyster Point Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **AMERIKS, Michael, K.** [US/US]; 3211 Galloway Drive, San Diego, CA 92122 (US). **AXE, Frank, U.** [US/US]; 14595 Surrey Junction Lane, Sutter Creek, CA 95685 (US). **CAI, Hui** [US/US]; 11213 Corte Belleza, San Diego, CA 92130 (US). **EDWARDS, James, P.** [US/US]; 8723 Hesby Court, San Diego, CA 92129-3367 (US). **GLEASON, Elizabeth, Ann** [US/US]; 2426 Wightman Street, San Diego, CA 92104 (US). **GRICE, Cheryl, A.** [US/US]; 3449 Camino Corte, Carlsbad, CA 92009 (US). **MEDUNA, Steven, P.** [US/US]; 9975 Paseo Montril, San Diego, CA 92129 (US). **TAYS, Kevin, L.** [US/US]; 1435 Big Canyon Terrace, Cardiff by the Sea, CA 92007 (US). **WICKBOLDT, Alvah, T.** [US/US]; 235 Market Street 101, San Diego, CA 92101 (US). **WIENER, John, J.M.** [US/US]; 357 Playa del Sur #2, La Jolla, CA 92037 (US).

(74) Agents: **FARSIOU, David, N.** et al.; Woodcock Washburn LLP, Cira Centre, 12th Floor, 2929 Arch Street, Philadelphia, PA 19104 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

WO 2008/100618 A2

(54) Title: CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

(57) Abstract: Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

[0000] This application claims the benefit of US provisional patent application serial number 60/889,977, filed February 15, 2007 and US patent application serial number 12/031,010, filed February 14, 2008, both of which are incorporated herein by reference.

Field

[0001] The present invention relates to certain carbon-linked tetrahydro-pyrazolo-pyridine compounds, pharmaceutical compositions containing them, and methods of using them for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity.


Background

[0002] Cathepsin S is one of the major cysteine proteases expressed in the lysosome of antigen presenting cells, mainly dendritic cells, B cells and macrophages. Cathepsin S is best known for its critical function in the proteolytic digestion of the invariant chain chaperone molecules, thus controlling antigen presentation to $CD4^+$ T cells by major histocompatibility complex class II molecules or to $NK1.1^+$ T cells via CD1 molecules. Cathepsin S also appears to participate in direct processing of exogenous antigens for presentation by MHC class II to $CD4^+$ T cells or crosspresentation by MHC class I molecules to $CD8^+$ T cells. In addition, cathepsin S in secreted form is implicated in degradation of extracellular matrix, which may contribute to the pathology of a number of diseases, including arthritis, atherosclerosis, and chronic obstructive pulmonary disease. Therefore, inhibition of cathepsin S is a promising target for the development of novel therapeutics for a variety of indications. For a review, see: Thurmond, R.L. et al. *Curr. Opin. Invest. Drugs* 2005, 6(5), 473-482.

[0003] Pyrazole inhibitors of cathepsin S were disclosed in a series of applications from Ortho-McNeil, and additional publications on this work have also appeared (See: U.S. Pat. Appl. Publ. Nos. 2002/0040020, 2003/0078419, and 2002/0040019; Wei, J. et al. *Bioorg. Med. Chem. Lett.* 2007, 17, 5525-5528; Grice, C.A. et al. *Bioorg. Med. Chem. Lett.* 2006, 16, 2209-2212; and Gustin, D.J. et al. *Bioorg. Med. Chem. Lett.* 2005, 15, 1678-1691). See also: Thurmond, R.L. et al. *J. Pharm. Exp. Ther.* 2004, 308, 268-276; and Thurmond, R.L. et al. *J. Med. Chem.* 2004, 47, 4799-4801). However, there remains a need for potent cathepsin S modulators with desirable pharmaceutical properties.

Summary

[0004] In one aspect the invention relates to compounds of the following Formula (I):



(I)

wherein:

R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated monocyclic heterocycloalkyl group, each group optionally containing one additional heteroatom ring member that is O, S, or NR^a, and each group unsubstituted or substituted with one, two, or three R^b substituents;

where R^a is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -CO(phenyl), or -CO_2C_{1-4}alkyl, or a monocyclic cycloalkyl ring, phenyl ring, or monocyclic heteroaryl ring, each ring unsubstituted or substituted with OH, C_{1-4}alkyl, CF_3, halo, -OC_{1-4}alkyl, cyano, or -COC_{1-4}alkyl; and

each R^b substituent is independently:

i) OH, C_{1-4}alkyl, -C_{1-4}alkyl-OH, CF_3, -NR^cR^d, halo, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, -CO_2H, or -$CONR^eR^f$;

ii) a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

iii) a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

iv) a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

v) two R^b substituents on the same carbon taken together with the carbon to which they are attached form a saturated monocyclic heterocycloalkyl group, unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

vi) two R^b substituents form a methylene or ethylene bridge; or

vii) two R^b substituents on adjacent carbons taken together with the carbons to which they are attached form a saturated monocyclic cycloalkyl group or saturated monocyclic heterocycloalkyl group, each group unsubstituted or

substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

where R^c is H or C_{1-4}alkyl;

R^d is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COC_{1-4}alkyl-OH, -CO_2C_{1-4}alkyl,–$CONR^xR^y$, or –SO_2C_{1-4}alkyl;

where R^x and R^y are each independently H or C_{1-4}alkyl; and

R^e and R^f are each independently H or C_{1-4}alkyl;

R^3 is H, OH, C_{1-4}alkyl, or -OC_{1-4}alkyl;

R^4 is H; C_{1-4}alkyl; -COC_{1-4}alkyl unsubstituted or substituted with OH, F, -$OCOC_{1-4}$alkyl, or -NR^tR^u; -$COCF_3$; -CO-(monocyclic heteroaryl); -CO-(C-linked monocyclic heterocycloalkyl); -CO-(phenyl); -SO_2C_{1-4}alkyl; -SO_2CF_3; -$SO_2NR^tR^u$; -$CONR^tR^u$; -$COCO_2C_{1-4}$alkyl; or –$COCONR^tR^u$;

where R^t and R^u are each independently H, C_{1-4}alkyl, or –COC_{1-4}alkyl; or R^t and R^u taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring;

R^5 is halo or CF_3;

each R^6 is independently H or F;

D is –C≡C–R^7, –CH=CH–R^8, –$(CH_2)_{2-3}$–R^8, or –$(CH_2)_{3-5}$–R^9;

where R^7 is:

I) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -NR^gR^h, phenyl, or phenoxy, each phenyl or phenoxy being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^g and R^h are each independently H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, or -SO_2-phenyl; or R^g and R^h taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl group; or

II) a monocyclic cycloalkyl group, phenyl group, or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^8 is a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^9 is OH or -NR^nR^o;

where R^n is H or C_{1-4}alkyl; and


R^o is H, C_{1-4}alkyl, monocyclic cycloalkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, -SO_2-phenyl, -SO_2-benzyl, or -$SO_2NR^pR^q$, each phenyl or benzyl group being unsubstituted or substituted with one or two R^k substituents;

where R^p and R^q are each independently H or C_{1-4}alkyl;

or R^n and R^o taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl ring unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where each R^k substituent in D is independently:

a) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -OC_{1-4}alkyl-OH, halo, -CO_2C_{1-4}alkyl, CO_2H, CN, -NR^rR^s, -N(R^r)CO-phenyl, -N(R^r)SO_2C_{1-4}alkyl, -N(R^r)SO_2-phenyl, -SO_2C_{1-4}alkyl, phenyl, or phenoxy;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, -CH_2OH, or -CO_2C_{1-4}alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or –CH_2-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, -OC_{1-4}alkyl, -OCF_3, -$OCHF_2$, -$NR^{dd}R^{ee}$, -CO_2C_{1-4}alkyl, -SC_{1-4}alkyl, and -SO_2C_{1-4}alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl;

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-OH, -C_{1-4}alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, -$CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH; or

d) OH; -OC_{1-4}alkyl; halo; CF_3; -CHO; -CO_2C_{1-4}alkyl; CO_2H; CN; -NO_2; -$CONR^rR^s$, -NR^rR^s; -N(R^r)-phenyl; -N(R^r)-benzyl; -N(R^r)-phenethyl; -N(R^r)COC_{1-4}alkyl; -N(R^r)CO-phenyl; -N(R^r)SO_2C_{1-4}alkyl; -N(R^r)SO_2-phenyl; -SO_2C_{1-4}alkyl; phenoxy;

or a heteroaryl group; where each phenyl, benzyl, phenethyl, phenoxy, or heteroaryl group is unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and

R^s is H, C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-CN, -C_{2-4}alkyl-OH, -C_{2-4}alkyl-$NR^{bb}R^{cc}$, -C_{1-4}alkylCO_2C_{1-4}alkyl, -C_{1-4}alkylCO_2H, C_{3-4}alkenyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

and pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

[0005] In certain embodiments, the compound of Formula (I) is a compound selected from those species described or exemplified in the detailed description below.

[0006] In a further aspect, the invention relates to pharmaceutical compositions each comprising: (a) an effective amount of at least one chemical entity selected from compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, and metabolites thereof; and (b) a pharmaceutically acceptable excipient.

[0007] In another aspect, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by cathepsin S activity, comprising administering to the subject in need of such treatment an effective amount of at least one chemical entity selected from compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, and metabolites thereof. Diseases, disorders and medical conditions that are mediated by cathepsin S activity include those referred to herein.

[0008] In another aspect, the chemical entities of the present invention are useful as cathepsin S modulators. Thus, the invention is directed to a method for modulating cathepsin S activity, including when such receptor is in a subject, comprising exposing cathepsin S to an effective amount of at least one chemical entity selected from compounds of Formula (I), pharmaceutically acceptable salts of

compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I).

[0009] Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

Detailed Description


[0010] For the sake of brevity, the disclosures of the publications, including patents, cited in this specification are herein incorporated by reference.

[0011] As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non-limiting sense.

[0012] The term "alkyl" refers to a saturated, straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which also may be structurally depicted by a bond, "/"), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.


[0013] The term "alkenyl" refers to a straight- or branched-chain alkenyl group having 2 to 12 carbons in the chain. Examples of alkenyl groups include vinyl, propenyl, 2-methyl-propenyl, butenyl, butadienyl, 2-methyl-butenyl, pentenyl, 2-methyl-pentenyl, 2-ethyl-pentenyl, 3-methyl-pentenyl, hexenyl, and groups that in light of the ordinary skill in the art and the teachings hereing would be considered equivalent to any one of the foregoing examples.

[0014] The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:




[0015] A "heterocycloalkyl" refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated or partially saturated and has from 3 to 12 ring

atoms per ring structure selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur. In preferred embodiments, heterocycloalkyl rings have one or two heteroatoms. The ring structure may optionally contain up to two oxo groups on carbon or sulfur ring members. Illustrative entities, in the form of properly bonded moieties, include:



[0016] The term "heteroaryl" refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle. Illustrative examples of heteroaryl groups include the following entities, in the form of properly bonded moieties:



[0017] Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.

[0018] The term "halogen" represents chlorine, fluorine, bromine, or iodine. The term "halo" represents chloro, fluoro, bromo, or iodo.

[0019] The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. Where the term "substituted" is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system that yields a stable chemical structure.

[0020] Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., *cis* and *trans* isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to represent hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.

[0021] To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term "about". It is understood that, whether the term "about" is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.

[0022] Reference to a chemical entity herein stands for a reference to any one of: (a) the actually recited form of such chemical entity, and (b) any of the forms of such chemical entity in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R-COOH, encompasses reference to any one of, for example, R-$COOH_{(s)}$, R-$COOH_{(sol)}$, and R-

$COO^-_{(sol)}$. In this example, $R\text{-}COOH_{(s)}$ refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; $R\text{-}COOH_{(sol)}$ refers to the undissociated form of the compound in a solvent; and $R\text{-}COO^-_{(sol)}$ refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields $R\text{-}COO^-$ upon dissociation in the medium being considered. In another example, an expression such as "exposing an entity to compound of formula R-COOH" refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as $R\text{-}COOH_{(aq)}$ and/or $R\text{-}COO^-_{(aq)}$, where the subscript "(aq)" stands for "aqueous" according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.

[0023] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^2H, ^3H, ^{11}C, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{32}P, ^{33}P, ^{35}S, ^{18}F, ^{36}Cl, and ^{125}I, respectively. Such isotopically labelled compounds are useful in metabolic studies (preferably with ^{14}C), reaction kinetic studies (with, for example ^2H or ^3H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays,

or in radioactive treatment of patients. In particular, an ^{18}F or ^{11}C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., ^{2}H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0024] When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.

[0025] By way of a first example on substituent terminology, if substituent $S^1_{example}$ is one of S_1 and S_2, and substituent $S^2_{example}$ is one of S_3 and S_4, then these assignments refer to embodiments of this invention given according to the choices $S^1_{example}$ is S_1 and $S^2_{example}$ is S_3; $S^1_{example}$ is S_1 and $S^2_{example}$ is S_4; $S^1_{example}$ is S_2 and $S^2_{example}$ is S_3; $S^1_{example}$ is S_2 and $S^2_{example}$ is S_4; and equivalents of each one of such choices. The shorter terminology "$S^1_{example}$ is one of S_1 and S_2, and $S^2_{example}$ is one of S_3 and S_4" is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to any generic substituent symbol used herein.

[0026] Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent $S_{example}$ is one of S_1, S_2, and S_3, this listing refers to embodiments of this invention for which $S_{example}$ is S_1; $S_{example}$ is S_2; $S_{example}$ is S_3; $S_{example}$ is one of S_1 and S_2; $S_{example}$ is one of S_1 and S_3; $S_{example}$ is one of S_2 and S_3; $S_{example}$ is one of S_1, S_2 and S_3; and $S_{example}$ is any equivalent of each one of these choices. The shorter terminology "$S_{example}$ is one of S_1, S_2, and S_3" is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology,

which is stated in generic terms, is meant to illustrate the various substituent assignments described herein. The foregoing convention given herein for substituents extends, when applicable, to any generic substituent symbol used herein.


[0027] The nomenclature "C_{i-j}" with j > i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized. By way of example, the term C_{1-3} refers independently to embodiments that have one carbon member (C_1), embodiments that have two carbon members (C_2), and embodiments that have three carbon members (C_3).

[0028] The term C_{n-m}alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies $n \leq N \leq m$, with $m > n$.

[0029] Any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed. For example, reference to disubstituent –A-B-, where $A \neq B$, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.

[0030] According to the foregoing interpretive considerations on assignments and nomenclature, it is understood that explicit reference herein to a set implies, where chemically meaningful and unless indicated otherwise, independent reference to embodiments of such set, and reference to each and every one of the possible embodiments of subsets of the set referred to explicitly.

[0031] In some embodiments of Formula (I), $-NR^1R^2$ is a structure of Formula (II):



(II)

wherein:

W is NR^a, O, S, or $C(R^{b1})(R^{b2})$;

where R^a is H or C_{1-4}alkyl;

R^{b1} is H, OH, or C_{1-4}alkyl; and

R^{b2} is H; C_{1-4}alkyl; a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, $-OC_{1-4}$alkyl, NR^cR^d, or halo; or a monocyclic heterocycloalkyl

group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, NR^cR^d, or halo;


one of R^{b3} and R^{b4} is H and the other is H or C_{1-4}alkyl;

p is 0, 1, or 2; and

q is 0, 1, 2, or 3;

with the proviso that when W is NR^a, O, or S, then p and q are each greater than or equal to 1.

[0032] In other embodiments, $-NR^1R^2$ is a structure of Formula (III):



(III)

wherein W is O or S; and R^{b5} and R^{b6} are each independently H or C_{1-4}alkyl.

[0033] In other embodiments of Formula (I), R^1 and R^2 taken together with the nitrogen to which they are attached form azetidine, pyrrolidine, piperidine, piperazine substituted with R^a, morpholine, or thiomorpholine, each unsubstituted or substituted with one, two, or three R^b substituents as described for Formula (I). In other embodiments, R^1 and R^2 taken together with the nitrogen to which they are attached form piperidine, piperazine substituted with R^a, or morpholine, each unsubstituted or substituted with one, two, or three R^b substituents as described for Formula (I). In other embodiments, R^1 and R^2 taken together with the nitrogen to which they are attached form 1,1-dioxo-1λ^6-thiomorpholine, thiomorpholine 1-oxide, piperazinone substituted with R^a, [1,4]oxazepane, each unsubstituted or substituted with one, two, or three R^b substituents; or 2,5-diaza-bicyclo[2.2.1]heptane substituted with R^a, 2-oxa-5-aza-bicyclo[2.2.1]heptane, 2-oxa-6-aza-spiro[3.3]heptane, or hexahydro-furo[3,4-c]pyrrole, each of the latter four groups unsubstituted or substituted with one R^b substituent.

[0034] In some embodiments, R^a is H, methyl, isopropyl, acetyl, or tert-butoxycarbonyl. In other embodiments, R^a is phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, benzoyl, pyridyl, 1-hydroxy-pyridyl, or cyclobutyl.

[0035] In some embodiments, each R^b substituent is independently OH, methyl, CF_3, methoxycarbonyl, dimethylamino, acetamido, tert-butoxycarbamoyl, fluoro, or methoxy. In other embodiments, each R^b substituent is independently carbamoyl, amino, ethoxycarbonyl, carboxy, hydroxymethyl, 2-hydroxyacetylamino, methanesulfonylamino, or tert-butyl; or two R^b substituents on the same carbon taken together with the carbon to which they are attached form a dioxolane ring. In other embodiments, R^b is pyrrolidinyl, 2-oxo-pyrrolidinyl, or piperidinyl, each optionally

substituted. In other embodiments, R^b is 2-oxo-piperidinyl, morpholinyl, 1-tert-butoxycarbonyl-piperidin-4-yl, 1-methyl-piperidin-4-yl, or 1-acetyl-piperidin-4-yl. In still other embodiments, R^b is pyrrolidin-1-yl, 2-oxo-pyrrolidin-1-yl, or 5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-onyl, or two R^b substituents on the same carbon taken together with the carbon to which they are attached form 2-oxo-pyrrolidin-3-yl. In still other embodiments, R^b is phenyl or pyridyl, each optionally substituted.

[0036] In some embodiments, R^3 is H or OH.

[0037] In some embodiments, R^4 is $-SO_2CH_3$, $-CONH_2$, or $-COCONH_2$. In other embodiments, R^4 is dimethylaminooxalyl, acetyl, dimethylsulfamoyl, methylcarbamoyl, dimethylcarbamoyl, 2-aminoacetyl, 2-acetoxyacetyl, 2-acetylamino-acetyl, tetrahydrofuran-2-carbonyl, or morpholine-4-carbonyl. In other embodiments, R^4 is $-SO_2CH_3$.

[0038] In some embodiments, R^5 is chloro or CF_3. In other embodiments, R^5 is chloro.

[0039] In some embodiments, each R^6 is H.


[0040] In some embodiments, D is $-C\equiv C-R^7$, and R^7 is benzyl, phenethyl, phenpropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, butyl, phenoxymethyl, 2-methylpropyl, diethylaminomethyl, (1,1-dioxo-1λ^6-thiomorpholin-4-yl)-methyl, benzamidomethyl, or (benzenesulfonamido)methyl. In other embodiments, R^7 is cyclopentyl, cyclohexyl, phenyl, thiophenyl, or pyridyl, each unsubstituted or substituted with one or two R^k substituents. In other embodiments, R^7 is phenyl, unsubstituted or substituted with two R^k substituents. In still other embodiments, R^7 is 1H-indol-5-yl, 4-cyanomethyl-phenyl, 3-cyanomethyl-phenyl, 4-hydroxymethyl-phenyl, 3-hydroxymethyl-phenyl, 4-hydroxy-phenyl, 4-(3-carboxy-propyl)-phenyl, 4-(2-carboxy-ethyl)-phenyl, 4-(methoxycarbonyl)methyl-phenyl, 3-(methoxycarbonyl)methyl-phenyl, thiophen-2-yl, 3,4-dichloro-phenyl, 4-(4-iodo-phenoxy)-phenyl, 4-carboxymethyl-phenyl, 3-carboxymethyl-phenyl, 4-phenoxy-phenyl, 4-bromo-phenyl, 4-carboxy-phenyl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, thiophen-3-yl, 2-methoxy-phenyl, 3-chlorophenyl, 2-chlorophenyl, 3-hydroxyphenyl, 4-chlorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-fluorophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2-trifluoromethylphenyl, 2-methylphenyl, 3-trifluoromethylphenyl, 4-amino-phenyl, phenyl, 4-(tert-butoxcarbamoyl)methyl-phenyl, benzyl, phenethyl, phenpropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, butyl, cyclohexyl, (diethylamino)methyl, (1,1-dioxo-1λ^6-thiomorpholin-4-yl)methyl, 2-methylpropyl, phenoxymethyl, (benzamido)methyl, (benzenesulfonamido)methyl, 4-acetamido-phenyl, 4-aminomethyl-phenyl, 4-(methanesulfonamido)methyl-phenyl, 4-

(benzenesulfonamido)methyl-phenyl, 4-(acetamido)methyl-phenyl, 4-(benzamido)methyl-phenyl, 4-(benzylamino)methyl-phenyl, 4-(4-methyl-benzylamino)methyl-phenyl, 4-(4-chloro-benzylamino)methyl-phenyl, 4-[benzyl(methyl)amino]methyl-phenyl, 4-pyrrolidin-1-ylmethyl-phenyl, 4-piperidin-1-ylmethyl-phenyl, or 1,2,3,4-tetrahydro-isoquinolin-1-yl.

[0041] In some embodiments, each R^k substituent in D is independently a methyl or ethyl group unsubstituted or substituted with OH, methoxy, fluoro, $-CO_2CH_3$, CO_2H, CN, amino, tert-butoxycarbamoyl, methylsulfonamido, acetamido, pyrrolidinyl, or piperidinyl.

[0042] In still other embodiments, each R^k substituent in D is a methyl group substituted with NR^rR^s. In other embodiments, each R^k substituent in D is methylaminomethyl, dimethylaminomethyl, diethylaminomethyl, isobutylaminomethyl, tert-butoxycarbonylamino-methyl, (2-hydroxyethyl)aminomethyl, (3-hydroxypropyl)aminomethyl, (methoxycarbonylmethyl-amino)-methyl, (carboxymethyl-amino)-methyl, (2,2,2-trifluoroethyl-amino)-methyl, allylamino-methyl, (2-hydroxy-2-methyl-propylamino)-methyl, ethylaminomethyl, propylaminomethyl, [bis-(2-hydroxy-ethyl)-amino]-methyl, 3-hydroxy-propoxymethyl, phenylsulfonylamino-methyl, or benzoylamino-methyl. In other embodiments, each R^k substituent in D is 3,4-dihydro-1H-isoquinolin-2-ylmethyl, 1,3-dihydro-isoindol-2-ylmethyl, 4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-ylmethyl, or 4-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-piperidin-1-ylmethyl, morpholin-4-ylmethyl.

[0043] In still other embodiments, each R^k substituent in D is independently OH, methoxy, chloro, bromo, fluoro, CF_3, CO_2H, CN, amino, dimethylamino, acetylamino, methylsulfonamido, or methylsulfonyl. In other embodiments, each R^k substituent in D is phenoxy, 4-iodo-phenoxy, benzylamino, cyanomethyl-amino, benzimidazol-2-yl, phenethyl-amino, 3-(tert-butoxycarbonyl-methyl-amino)-propylcarbamoyl, 3-methylamino-propylcarbamoyl, pyrrolidine-1-carbonyl, 3-hydroxy-pyrrolidine-1-carbonyl, piperazine-1-carbonyl, [1,4]diazepane-1-carbonyl, 3-hydroxy-propylcarbamoyl, or 2-morpholin-4-yl-ethylcarbamoyl.

[0044] In further embodiments, R^k is a substituent of formula  . In other embodiments, R^k is phenethylamino-methyl, cyclopropylamino-methyl, cyclobutylamino-methyl, cyclopentylamino-methyl, cyclohexylamino-methyl, cyclopropylmethylamino-methyl, benzylamino-methyl, (4-chloro-benzylamino)-methyl, (4-methanesulfonyl-benzylamino)-methyl, (2-chloro-benzylamino)-methyl, (3-chloro-

benzylamino)-methyl, (2-fluoro-benzylamino)-methyl, (3-fluoro-benzylamino)-methyl, (4-fluoro-benzylamino)-methyl, (3,4-dichloro-benzylamino)-methyl, (2-methoxy-benzylamino)-methyl, (3-methoxy-benzylamino)-methyl, (4-methoxy-benzylamino)-methyl, (2-methyl-benzylamino)-methyl, (3-methyl-benzylamino)-methyl, (4-methyl-benzylamino)-methyl, (4-dimethylamino-benzylamino)-methyl, (4-isopropoxy-benzylamino)-methyl, (4-difluoromethoxy-benzylamino)-methyl, (4-amino-benzylamino)-methyl, (benzyl)-methyl-amino)-methyl, [(4-chloro-benzyl)-methyl-amino]-methyl, (1-phenyl-ethylamino)-methyl, phenylaminomethyl, [(pyridin-2-ylmethyl)-amino]-methyl, [(pyridin-3-ylmethyl)-amino]-methyl, [(pyridin-4-ylmethyl)-amino]-methyl, (2-hydroxy-1-phenyl-ethylamino)-methyl, [(methoxycarbonyl-phenyl-methyl)-amino]-methyl, [(thiophen-2-ylmethyl)-amino]-methyl, [(thiophen-3-ylmethyl)-amino]-methyl, (2-thiophen-2-yl-ethylamino)-methyl, [(3-methyl-thiophen-2-ylmethyl)-amino]-methyl, [(furan-2-ylmethyl)-amino]-methyl, [(2-trifluoromethyl-furan-3-ylmethyl)-amino]-methyl, (1,2,3,4-tetrahydro-naphthalen-1-ylamino)-methyl, indan-1-ylaminomethyl, (2-hydroxy-indan-1-ylamino)-methyl, [(thiazol-2-ylmethyl)-amino]-methyl, [(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl, [(tetrahydro-furan-2-ylmethyl)-amino]-methyl, or [(tetrahydro-pyran-4-ylmethyl)-amino]-methyl. In still other embodiments, R^k is (pyridin-2-ylmethyl)-carbamoyl, (pyridin-3-ylmethyl)-carbamoyl, (pyridin-4-ylmethyl)-carbamoyl, benzyl-carbamoyl, (4-chlorobenzyl)-carbamoyl, (pyrrolidin-2-ylmethyl)-carbamoyl, (pyrrolidin-3-ylmethyl)-carbamoyl, 2-hydroxy-1-phenyl-ethylcarbamoyl, (morpholin-2-ylmethyl)-carbamoyl, (piperidin-3-ylmethyl)-carbamoyl, or (azetidin-3-ylmethyl)-carbamoyl. In still other embodiments, R^k is pyridin-2-ylmethoxymethyl, pyridin-3-ylmethoxymethyl, pyridin-4-ylmethoxymethyl, piperidin-4-ylmethoxymethyl, morpholin-2-ylmethoxymethyl, pyrrolidin-3-yloxymethyl, or 1-tert-butoxycarbonyl-pyrrolidin-3-yloxymethyl.

[0045] In still further embodiments, two adjacent R^k substituents taken together with the ring to which they are attached form a bicyclic fused ring system selected from the group consisting of indole, tetrahydroisoquinoline, 3,4-dihydro-2H-isoquinolin-1-one, 2,3,4,5-tetrahydro-1H-benzo[d]azepine, 2,3,4,5-tetrahydro-1H-benzo[c]azepine, 2,3-dihydro-1H-isoindole, benzimidazole, imidazole, 1H-pyrrolo[2,3-b]pyridine, and 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, each fused ring system optionally substituted. In other embodiments, the fused ring system is substituted with methyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, hydroxymethyl, ethoxycarbonylmethyl, allyl, acetyl, $-COCF_3$, tert-butoxycarbonyl, methoxycarbonyl, carboxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, pyrrolidine-1-carbonyl, piperidine-1-carbonyl, 4-methyl-piperazine-1-carbonyl, or morpholine-4-carbonyl.


[0046] In some embodiments, R^r is H or methyl.

[0047] In some embodiments, R^s is H, methyl, acetyl, or tert-butoxycarbonyl. In still other embodiments, R^r and R^s taken together with the nitrogen to which they are attached form azetidinyl, pyrrolidinyl, or piperidinyl, each unsubstituted or substituted with methyl, OH, methoxy, fluoro, or CF_3.

[0048] In some embodiments, D is $-CH=CH-R^8$ or $-(CH_2)_{2-3}-R^8$, and R^8 is phenyl, unsubstituted or substituted with one or two R^k substituents. In other embodiments, R^8 is 1H-indol-5-yl, phenyl, 4-phenoxyphenyl, 3-hydroxyphenyl, 4-chlorophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2-methylphenyl, or 4-hydroxymethyl-phenyl.

[0049] In some embodiments, D is $-(CH_2)_{3-5}-R^9$, and R^9 is OH. In other embodiments, R^9 is NR^nR^o. In other embodiments, R^9 is dimethylamino, cyclopentylamino, acetamido, or methanesulfonamido. In other embodiments, R^9 is benzamido, benzenesulfonamido, or benzylsulfonamido, each unsubstituted or substituted with one or two R^k substituents. In other embodiments, R^9 is pyrrolidine, piperidine, morpholine, piperazine, or azepine, each unsubstituted or substituted with methyl, OH, fluoro, or CF_3. In other embodiments, R^9 is OH, benzamido, methanesulfonamido, benzene-sulfonamido, benzylsulfonamido, 3,4-dichlorobenzenesulfonamido, 4-chlorobenzene-sulfonamido, 4-methylbenzenesulfonamido, 4-methoxybenzene-sulfonamido, N,N-dimethyl-sulfamoylurea, acetamido, 2-carboxybenzenesulfonamido, 2-nitrobenzene-sulfonamido, 3-chlorobenzenesulfonamido, 3-methoxybenzene-sulfonamido, 2-methylbenzene-sulfonamido, 2-chlorobenzenesulfonamido, 3-nitrobenzenesulfonamido, 3-methylbenzenesulfonamido, 3-cyanobenzenesulfonamido, 3-methanesulfonyl-benzenesulfonamido, 2-methanesulfonyl-benzenesulfonamido, pyrrolidin-1-yl, piperidin-1-yl, 3-methyl-pipieridin-1-yl, 4,4-difluoro-piperidin-1-yl, morpholin-4-yl, 4-methyl-piperazin-1-yl, azepan-1-yl, or cyclopentylamino.

[0050] In some embodiments, compounds of Formula (I) are selected from compounds of the following Formula (IV):



(IV)

wherein:

W is O or S;

R^{b5} and R^{b6} are each independently H or C_{1-4}alkyl;

R^3 is H or OH;

R^4 is $-SO_2CH_3$, $-CONH_2$, or $-COCONH_2$;

R^5 is chloro; and

each R^k substituent is independently:

a) a methyl group or ethyl group, each group unsubstituted or substituted with OH, $-OC_{1-4}$alkyl, halo, $-CO_2C_{1-4}$alkyl, CO_2H, CN, $-NR^rR^s$, $-N(R^r)CO$-phenyl, $-N(R^r)SO_2C_{1-4}$alkyl, $-N(R^r)SO_2$-phenyl, or $-SO_2C_{1-4}$alkyl;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and


R^s is H, C_{1-4}alkyl, C_{1-4}alkyl-CF_3, C_{1-4}alkyl-CN, C_{2-4}alkyl-OH, C_{2-4}alkyl-$NR^{bb}R^{cc}$, $-C_{1-4}$alkylCO_2C_{1-4}alkyl, $-C_{1-4}$alkylCO_2H, C_{3-4}alkenyl, $-COC_{1-4}$alkyl, or $-CO_2C_{1-4}$alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, $-COC_{1-4}$alkyl, or $-CO_2C_{1-4}$alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, $-OC_{1-4}$alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, $-CH_2OH$, or $-CO_2C_{1-4}$alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or $-CH_2$-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, $-OC_{1-4}$alkyl, $-OCF_3$, $-OCHF_2$, $NR^{dd}R^{ee}$, $-CO_2C_{1-4}$alkyl, $-SC_{1-4}$alkyl, and $-SO_2C_{1-4}$alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl; or

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-OH, -C_{1-4}alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, $CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH;

and pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

Other embodiments include combinations of the above variable definitions for Formula (I) and Formula (IV).

[0051] The invention includes also pharmaceutically acceptable salts of the compounds represented by Formula (I), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.

[0052] A "pharmaceutically acceptable salt" is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S.M. Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and *Handbook of Pharmaceutical Salts, Properties, Selection, and Use,* Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. A compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates,

benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

[0053] If the compound of Formula (I) contains a basic nitrogen, the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.

[0054] If the compound of Formula (I) is an acid, such as a carboxylic acid or sulfonic acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

[0055] The invention also relates to pharmaceutically acceptable prodrugs of the compounds of Formula (I), pharmaceutical compositions containing such pharmaceutically acceptable prodrugs, and treatment methods employing such pharmaceutically acceptable prodrugs. The term "prodrug" means a precursor of a designated compound that, following administration to a subject, yields the compound *in vivo* via a chemical or physiological process such as solvolysis or enzymatic cleavage, or under physiological conditions (e.g., a prodrug on being brought to physiological pH is converted to the compound of Formula (I)). A "pharmaceutically acceptable prodrug" is a prodrug that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to the subject. Illustrative procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

[0056] Examples of prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I). Examples of amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.

[0057] Additional types of prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters. Examples of amides include those derived from ammonia, primary C_{1-6}alkyl amines and secondary di(C_{1-6}alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyl or heteroaryl ring moieties. Examples of amides include those that are derived from ammonia, C_{1-3}alkyl primary amines, and di(C_{1-2}alkyl)amines. Examples of esters of the invention include C_{1-7}alkyl, C_{5-7}cycloalkyl, phenyl, and phenyl(C_{1-6}alkyl) esters. Preferred esters include methyl esters. Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, following procedures such as those outlined in *Adv. Drug Delivery Rev.* 1996, *19*, 115. Carbamate derivatives of hydroxy and amino groups may also yield prodrugs. Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally

substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs. Prodrugs of this type may be prepared as described in *J. Med. Chem.* 1996, *39*, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.

[0058] The present invention also relates to pharmaceutically active metabolites of compounds of Formula (I), and uses of such metabolites in the methods of the invention. A "pharmaceutically active metabolite" means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof. Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., *J. Med. Chem.* 1997, *40*, 2011-2016; Shan, et al., *J. Pharm. Sci.* 1997, *86 (7)*, 765-767; Bagshawe, *Drug Dev. Res.* 1995, *34*, 220-230; Bodor, *Adv. Drug Res.* 1984, *13*, 224-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen, et al., eds., Harwood Academic Publishers, 1991).

[0059] The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites (collectively, "active agents") of the present invention are useful in the methods of the invention.

[0060] The compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites, whether alone or in combination, (collectively, "active agents") of the present invention are useful as cathepsin S modulators in the methods of the invention. Such methods for modulating cathepsin S activity comprise exposing cathepsin S to an effective amount of at least one chemical entity selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I). Embodiments of this invention inhibit cathepsin S activity.

[0061] In some embodiments, the cathepsin S is in a subject with a disease, disorder, or medical condition mediated through modulation of the cathepsin S, such as those described herein. Symptoms or disease states are intended to be included within the scope of "medical conditions, disorders, or diseases."

[0062] Accordingly, the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through cathepsin S activity, such as an autoimmune disease, an allergic condition, inflammation, a bowel disorder, tissue transplant rejection, pain, or cancer. Active agents according to the invention may therefore be used as immunomodulating agents, immunosuppressants, anti-allergy agents, anti-inflammatory agents, analgesics, or anti-cancer agents.

[0063] In some embodiments, an active agent of the present invention is administered to treat lupus, asthma, allergic reaction, atopic allergy, hay fever, atopic dermatitis, food allergy, rhinitis (such as allergic rhinitis and the inflammation caused by non-allergic rhinitis), skin immune system disorders (such as psoriasis), uveitis, inflammation, upper airway inflammation, Sjögren's syndrome, arthritis, rheumatoid arthritis, osteoarthritis, type I diabetes, atherosclerosis, multiple sclerosis, coeliac disease, inflammatory bowel disease (IBD), chronic obstructive pulmonary disorder (COPD), tissue transplant rejection, pain, neuropathic pain, chronic pain (such as pain due to conditions such as cancer, neuropathic pain, rheumatoid arthritis, osteoarthritis and inflammatory conditions), or cancer (and cancer-related processes such as angiogenesis, tumor growth, cell proliferation, and metastasis). In certain embodiments, an active agent of the present invention is administered to treat psoriasis, pain, multiple sclerosis, atherosclerosis, or rheumatoid arthritis.

[0064] Thus, the active agents may be used to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated through cathepsin S activity. The term "treat" or "treating" as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of cathepsin S activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of cathepsin S activity. The term "subject" refers to a mammalian patient in need of such treatment, such as a human. "Modulators" include both inhibitors and activators, where "inhibitors" refer to compounds that decrease, prevent, inactivate, desensitize or down-regulate cathepsin S expression or activity, and "activators" are compounds that increase, activate, facilitate, sensitize, or up-regulate cathepsin S expression or activity.

[0065] In treatment methods according to the invention, an effective amount of at least one active agent according to the invention is administered to a subject

suffering from or diagnosed as having such a disease, disorder, or condition. An "effective amount" means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. An exemplary dose is in the range of from about 0.001 to about 200 mg of active agent per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, or about 0.1 to 10 mg/kg daily in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, an illustrative range for a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

[0066] Once improvement of the patient's disease, disorder, or condition has occurred, the dose may be adjusted for preventative or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.

[0067] In addition, the active agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions. The additional active ingredients may be coadministered separately with an active agent of Formula (I) or included with such an agent in a pharmaceutical composition according to the invention. In an exemplary embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by cathepsin S activity, such as another cathepsin S modulator or a compound active against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.

[0068] The active agents of the invention are used, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises: (a) an effective amount of at least one active agent in accordance with the invention; and (b) a pharmaceutically acceptable excipient.

[0069] A "pharmaceutically acceptable excipient" refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[0070] Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using suitable pharmaceutical excipients and compounding techniques known or that become available to those skilled in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.

[0071] The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. Preferably, the compositions are formulated for intravenous infusion, topical administration, or oral administration.

[0072] For oral administration, the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the active agents may be formulated to yield a dosage of, e.g., from about 0.05 to about 50 mg/kg daily, or from about 0.05 to about 20 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.

[0073] Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary

disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.

[0074] Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.

[0075] Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.

[0076] The active agents of this invention may also be administered by non-oral routes. For example, compositions may be formulated for rectal administration as a suppository. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 µg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.

[0077] For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to

vehicle. Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.

[0078] Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.


[0079] Exemplary chemical entities useful in methods of the invention will now be described by reference to illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and replaced as appropriate with the desired substituent. In addition, artisans will note that the various transformations described in the following Schemes may be performed in a different order than that depicted. Unless otherwise specified, the variables are as defined above in reference to Formula (I).

[0080] Abbreviations and acronyms used herein include the following:

Term	Acronym
Tetrahydrofuran	THF
N,N-Dimethylformamide	DMF
N,N-Dimethylacetamide	DMA
Dimethyl sulfoxide	DMSO
Ethyl acetate	EtOAc
tert-Butylcarbamoyl	Boc
Bovine serum albumin	BSA
High-pressure liquid chromatography	HPLC
Thin layer chromatography	TLC
Diisobutylaluminum hydride	DIBAL-H
Acetate	OAc
Acetic acid	AcOH
O-(7-Azabenzotriazol-1-yl)-N,N.N',N'-tetramethyluronium hexafluorophosphate	HATU
1-Hydroxy-7-azabenzotriazole	HOAt

Diisopropylethylamine	DIPEA
4-(Dimethylamino)pyridine	DMAP
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride	EDC
1-Hydroxybenzotriazole	HOBt
Methanesulfonyl chloride	MsCl
Tetrabutylammonium fluoride	TBAF
(Trimethylsilyl)acetylene	TMSA
Triethylamine	TEA
Trifluoroacetic acid	TFA
Phenyl	Ph
Dichloroethane	DCE
1,8-Diazabicyclic[5.4.0]undec-7-ene	DBU
Methanol	MeOH
Ethanol	EtOH
Dibenzylideneacetone	dba
Diethyl ether	Et_2O
Isopropanol	IPA


SCHEME A



[0081] Referring to Scheme A, the tetrahydro-pyrazolo-pyridine core structure of Formula (I) may be prepared from commercially available piperidones (X). Installation of the R^4 substituent is accomplished through, for example, alkylation, acylation, sulfonylation, amide formation, or other suitable methods known in the art to provide ketones (XI). Alternatively, an amine protecting group, such as a Boc group, may be installed, and, at a later point in the synthesis, be removed (for example, by treatment with an acid such as HCl or TFA) and replaced with R^4 (See Scheme F). Enamine formation according to general methods gives enamines (XII), which are then reacted with acyl chlorides, ArC(O)Cl, where Ar is a suitable substituted phenyl group, in the presence of a suitable tertiary amine base, to form enamines (XIII) or the

corresponding beta-diketones, or a mixture thereof (not isolated). *In situ* reaction of the enamines with hydrazine generates pyrazoles (XIV).

SCHEME B




[0082] Where Ar is a suitably substituted group as in Formula (XV), where substituent X is iodide, bromide, or trifluoromethanesulfonate (triflate), formation of alkynes (XVI) may be accomplished by any one of several methods, as depicted in Scheme B. In some embodiments, a three-step process is employed, including: 1) palladium-catalyzed coupling with a suitably protected alkyne ≡-PG, where PG is, for example, a trialkylsilyl group such as trimethylsilyl; 2) deprotection of the alkyne with, for example, a fluoride source such as TBAF; and 3) coupling with a suitable reagent R^7X, where R^7 is as defined for Formula (I) and substituent X is as defined above, to give alkynes (XVI). Alternatively, palladium-mediated coupling of compounds (XV) with alkynes ≡-R^7 yields alkynes (XVI) in one step. In preferred embodiments, palladium-catalyzed couplings are performed in the presence of a palladium(0) catalyst such as $PdCl_2(PPh_3)_2$, $Pd(PPh_3)_4$, or $Pd_2(dba)_3$, or a mixture thereof, a copper(I) salt such as copper(I) iodide, a tertiary amine base such as Et_3N or DBU, in a polar aprotic solvent such as THF or DMF or a mixture thereof, at a temperature from about room temperature to the reflux temperature of the solvent. Alkynes (XVI) may then be hydrogenated or otherwise reduced using methods known in the art to provide alkanes and alkenes (XVII), where ALK is C_{2-5}alkyl or C_2-alkenyl. In another embodiment, phenyl groups (XV) where substituent X is iodide may be coupled with suitably substitued Reformatsky reagents (where substituent X is preferably Cl) in the presence of a palladium catalyst to form alkanes (XVIIa) in one step.

[0083] One skilled in the art will recognize that the chemistry described in Scheme B may be used with alkynes other than ≡-R^7 or ≡-PG or reagents other than $XZn(C_{2-5}alkyl)R^8/R^9$ to generate other embodiments of Formula (I) or intermediates that

are amenable to subsequent conversion into other embodiments of Formula (I). Examples of such conversions are shown in Scheme C. For example, where R^7 is substituted with one or two R^k substituents, such substituents may be present for the couplings shown in Scheme B, or such substituents may be installed in subsequent reaction step(s).

SCHEME C




(XVIII) (XIX)

(XX) (XVII)

[0084] As shown in Scheme C, protected amines (XVIII), where Y is ethynyl, ethynyl-(C_{1-4}alkyl), or C_{3-5}alkyl, and PG is a suitable nitrogen protecting group, such as a Boc or phthalimide group, may be protected and converted into substituted amines (XIX). Exemplary transformations include reactions with suitably substituted alkyl halides, sulfonyl chlorides, acyl chlorides, or carboxylic acids. Alternatively, ethers (XX), where PG is H or a suitable hydroxyl protecting group, may be optionally deprotected and subsequently acylated, alkylated, or activated by conversion to the corresponding iodide, bromide, chloride, tosylate, or mesylate, and then displaced with suitable nucleophiles. The intermediate alcohols may also be oxidized to the corresponding aldehydes and reacted with amines using reductive amination methods known in the art.


SCHEME D



[0085] Two variations for the installation of the propyl amino chain are shown in Scheme D. One skilled in the art will recognize an amine protecting group, such as a Boc group, may be installed in place of the R^4 shown, and, at a later point in the synthesis, be removed (for example, by treatment with an acid such as HCl or TFA) and replaced with R^4. Pyrazoles (XXI) are alkylated with optionally protected reagents (XXII), where R^3 is H, C_{1-4}alkyl, -OC_{1-4}alkyl, or a protected hydroxyl group, T is an aldehyde, a protected aldehyde, -CH_2-OH, a -CH_2-(protected hydroxyl) group, -CH_2-Cl, or –$CH_2NR^1R^2$, and LG is a suitable leaving group, such as a chloride, bromide, iodide, mesylate or tosylate, to give compounds (XXIII). Where T is a protected aldehyde (such as an acetal) or protected hydroxyl group, deprotection of (XXIII) is accomplished under general conditions. Resulting aldehydes are reacted with amines (XXIV) under reductive amination conditions, to provide propyl amines (XXV) where R^3 is H, C_{1-4}alkyl, or -OC_{1-4}alkyl. Alcohols are converted to suitable leaving groups (LG), and displaced with amines HNR^1R^2, or are oxidized to the corresponding aldehydes for coupling with amines HNR^1R^2 by reductive amination. One skilled in the art will recognize that transformations from T to –$CH_2NR^1R^2$ may be performed at any one of several later points in the synthesis. Where T is –$CH_2NR^1R^2$, the alkylation step leads to compounds (XXV) directly.


[0086] Alternatively, pyrazoles (XXI) are reacted with epichlorohydrin or glycidylnosylate (each optionally as racemic mixtures or single enantiomers), in the presence of a suitable base, to give epoxides (XXVI). Epoxide opening with amines (XXIV), preferably at elevated temperatures, yields propyl amines (XXV) where R^3 is OH.

SCHEME E



[0087] In another embodiment, shown in Sheme E, addition of pyrazoles (XXI) to α,β-unsaturated nitriles (XXVI), in the presence of a suitable base, such as aq. NaOH, generates nitriles (XXVII). Reduction of the nitriles to the corresponding aldehydes (XXIII, not shown) is accomplished with a reducing agent such as DIBAL-H. Reductive amination of aldehydes (XXIII) with amines (XXIV) gives amines (XXV) as described in Scheme D.

SCHEME F



[0088] In preferred embodiments, compounds of Formula (IV) are prepared as shown in Scheme F. N-Boc-Piperidone (XXX) is reacted with cyclic secondary amines HNR_2, such as pyrrolidine, morpholine, or piperidine, in the presence of a catalytic amount of an acid catalyst such as p-toluenesulfonic acid or citric acid, in a solvent such as benzene or toluene, under dehydrating conditions (involving, for example, addition of molecular sieves or reaction at reflux temperature with a Dean-Stark trap), to form enamines (XXXI). Enamines (XXXI) are reacted with acid chlorides (XXXII, where

substituent X is as defined above), prepared using methods known in the art, in the presence of a tertiary amine base such as TEA, DIPEA, or DBU, in a solvent such as CH_2Cl_2, DCE, or toluene, to provide enamines (XXXIII) or their corresponding beta-diketones (not shown), or a mixture thereof. Such compounds are not isolated, but are reacted directly with hydrazine, in a solvent such as MeOH or EtOH, to form pyrazoles (XXXIV).

[0089] The Boc protecting group of compounds (XXXIV) is removed using methods known in the art. In preferred embodiments, compounds (XXXIV) are treated with HCl or TFA in a solvent such as CH_2Cl_2 or 1,4-dioxane, to give the corresponding secondary amines (not shown, R^4 = H). Installation of R^4 substituents other than H is accomplished using standard methods, including alkylation, acylation, amide coupling, sulfonylation, and other suitable transformations. In preferred embodiments, reaction with methanesulfonyl chloride in presence of a suitable tertiary amine base, or with oxamic acid in the presence of a coupling agent such as 1,1'-carbonyldiimidazole, provides pyrazoles (XXXV).

[0090] Alkylation of pyrazoles (XXXV) with reagents (XXXVI, where substituent X is iodo, bromo, chloro, mesylate or trifluoromethanesulfonate (triflate)), in the presence of a suitable base, gives compounds (XXXVII). Alkylations may also be performed as shown in Schemes D and E. In preferred embodiments, X in formula (XXXVI) is chloro, and reactions are performed using in DMF using Cs_2CO_3 as the base.

[0091] Compounds of Formula (IV) are prepared by reaction of compounds (XXXVII) under palladium-catalyzed conditions with alkynes (XXXVIII). In preferred embodiments, palladium-catalyzed couplings are performed in the presence of a palladium(0) catalyst such as $PdCl_2(PPh_3)_2$, $Pd(PPh_3)_4$, or $Pd_2(dba)_3$, or a mixture thereof, a copper(I) salt such as copper(I) iodide, a tertiary amine base such as TEA, DIPEA, or DBU, in a polar aprotic solvent such as THF or DMF or a mixture thereof, at a temperature from about room temperature to the reflux temperature of the solvent. In further preferred embodiments, substituents R^k are present in reagents (XXXVIII). In alternative embodiments, suitable surrogate substituents are present, and the R^k substituents are formed in subsequent reaction steps using standard chemical transformations.

[0092] Additional preferred embodiments, including preferred solvents, temperatures, reagents, and other conditions, are provided in the Examples below.

[0093] Compounds of Formula (I) may be converted to their corresponding

salts using methods described in the art. For example, an amine of Formula (I) may be treated with trifluoroacetic acid, HCl, citric acid, oxalic acid, tartaric acid, 2-oxo-butanoic acid, 2-oxo-hexanoic acid, 2-keto-glutaric acid, 2-pyrrolidone-5-carboxylic acid, or phosphoric acid in a solvent such as CH_3CN, Et_2O, CH_2Cl_2, THF, or MeOH to provide the corresponding salt form. Alternatively, compounds of Formula (I) may be converted to their corresponding tartrate salts by reaction with tartaric acid in Et_2O, CH_2Cl_2, THF, or MeOH; to their corresponding monoethyl oxalate salts by reaction with mono- or diethyl oxalate in CH_3CN; or to their corresponding 2-oxo-pentanoate salts by reaction with 2-oxo-pentanoic acid in CH_3CN.

[0094] Those skilled in the art will recognize that the chemical transformations described above may be performed in a different order than that depicted in the above Schemes. Compounds prepared according to the schemes described above may be obtained as single enantiomers, diastereomers, or regioisomers, by enantio-, diastero-, or regiospecific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as racemic (1:1) or non-racemic (not 1:1) mixtures or as mixtures of diastereomers or regioisomers. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one skilled in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, single isomers may be separated using conventional methods such as chromatography or crystallization.

[0095] The following specific examples are provided to further illustrate the invention and various preferred embodiments.

EXAMPLES

Chemistry:

[0096] In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.

[0097] Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt). Where solutions are "dried," they are generally dried over a drying agent such as Na_2SO_4 or $MgSO_4$. Where mixtures, solutions, and extracts were "concentrated", they were typically concentrated on a rotary evaporator under reduced pressure.

[0098] Microwave reactions were performed on a Personal Chemistry Emrys Optimizer. Individual reactions were heated to the desired temperature and held at that temperature for the allotted time.

[0099] Analytical HPLC retention times are reported in minutes, and were obtained on an Agilent HP-1100 instrument with a Phenomenex Luna C-18 (5 uM, 4.6 x 150 mm) column, with a flow rate of 1 mL/min, detection at 230, 254, and 280 nM, and a gradient of 10 to 100% CH_3CN (0.05% TFA)/H_2O (0.05% TFA).

[0100] Preparatory HPLC purifications were typically performed under one of the following sets of conditions:

Method A: Compounds were purified on a Phenomenex Synergi column (4 μm, 21x150 mm), with a flow rate of 25 mL/min, and solvent conditions as described for Analytical HPLC.

Method B: Compounds were injected onto a YMC column (C-18, 5 μM, 30 x 75 mm); with a flow rate of 30 mL/min; UV detection at 254 and 280 nM; and a gradient of 0 to 100% CH_3CN (0.05% TFA)/H_2O (0.05% TFA) over 21 min. The purified compounds were analyzed and tested as TFA salts following lyophilization, or as HCl salts following basic aqueous work up and treatment with dry HCl in 1,4-dioxane, Et_2O, or MeOH.

Method C: Compounds were injected onto an Intersil ODS-3 column (C-18, 3 μM, 30 x 100 mm); with a flow rate of 90 mL/min; UV detection at 254 and 280 nM; and a gradient of 0 to 60% CH_3CN/H_2O (0.05% TFA) over 2 min. The purified compounds were analyzed and tested as TFA salts following lyophilization, or as HCl salts following basic aqueous work up and treatment with dry HCl in 1,4-dioxane, Et_2O, or MeOH.

Method D: Compounds were injected onto an Intersil ODS-3 column (C-18, 3 μM, 30 x 100 mm); a flow rate of 90 mL/min; UV detection at 254 and 280 nM, and a gradient of 0 to 60% CH_3CN/H_2O (0.1% formic acid) over 2 min. The purified compounds were analyzed and tested as formic acid salts unless noted otherwise.

Method E: Compounds were injected onto a Phenomenex Luna column (C-18, 10 μM, 50 x 250 mm); with a flow rate of 100 mL/min; UV detection at 254 and 280 nM; and a gradient of 0 to 100% CH_3CN (0.05% TFA)/H_2O (0.05% TFA) over 35 min. The purified compounds were analyzed and tested as TFA salts following lyophilization, or as HCl salts following basic aqueous work up and treatment with dry HCl in 1,4-dioxane, Et_2O, or MeOH.


Method F: Compounds were injected onto a Xbridge Prep column (C-18, 5 μM, 30 x 100 mm); with a flow rate of 30 mL/min; UV detection at 254 and 280 nM; and a gradient of 5 to 99% CH_3CN /H_2O (20 mM NH_4OH) over 18 min. The purified

compounds were analyzed and tested as HCl salts following lyophilization and treatment with dry HCl in 1,4-dioxane, Et_2O, or MeOH.

[0101] Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. The MS data presented is the m/z found (typically $[M+H]^+$) for the molecular ion.

[0102] Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers (400, 500, or 600 MHz). The format of the ^1H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (multiplicity, coupling constant *J* in Hz, integration). All ^1H NMR data was acquired in CD_3OD solvent unless otherwise indicated.

[0103] Chemical names were generated using ChemDraw Version 6.0.2 (CambridgeSoft, Cambridge, MA) or ACD/Name Version 9 (Advanced Chemistry Development, Toronto, Ontario, Canada).



Intermediate 1; 3-(4-Chloro-3-trimethylsilanylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0104] A. 1-Methanesulfonyl-piperidin-4-one. To a solution of 4-piperidone monohydrate hydrochloride (90 g, 586 mmol) in $CHCl_3$ (300 mL) and H_2O (300 mL) was added K_2CO_3 (324 g, 2340 mmol). The slurry was cooled to 0 ºC and treated with methanesulfonyl chloride (MsCl; 136 mL, 1.76 mol) by dropwise addition over a 1 h period (gas evolution was observed). The reaction mixture was allowed to stir for 72 h and was partitioned between CH_2Cl_2 (500 mL) and aq. $NaHCO_3$ (500 mL). The aqueous layer was extracted with CH_2Cl_2 (3 x 200 mL). The organic layer was washed with 1% $KHSO_4$ (250 mL), dried (Na_2SO_4), and concentrated to give the desired product (90.5 g, 87%) as a white solid. HPLC: R_t = 2.2. MS (ESI): mass calcd. for $C_6H_{11}NO_3S$, 178.1; m/z found, 178.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 3.60 (t, *J* = 6.5, 4H), 2.89 (s, 3H), 2.59 (t, *J* = 6.3, 4H).

[0105] B. 3-(4-Chloro-3-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a solution of the above piperidone (10 g, 56 mmol) and *p*-toluenesulfonic acid (40 mg) in benzene (60 mL) was added morpholine (4.9 mL, 56

mmol). The reaction mixture was heated in a flask equipped with a condenser and a Dean-Stark trap at 90 ºC for 16 h. The reaction mixture was cooled and concentrated to give the desired enamine as a beige solid, which was used without further purification. The enamine was dissolved in CH_2Cl_2 (40 mL), treated with TEA (9.4 mL, 67.2 mmol), and cooled to 0 ºC. To this solution was added 4-chloro-3-iodobenzoyl chloride* (16.9 g, 56 mmol). The reaction mixture was allowed to warm to rt, stirred for 14 h, and then concentrated. The resulting red oil was diluted with EtOH (56 mL) and treated with hydrazine (5.34 mL, 170 mmol) at 0 ºC. The resulting slurry was allowed to warm to rt and stirred for 16 h. EtOAc (120 mL) was added, and after 2 h the resulting precipitate was filtered and washed with additional EtOAc to afford the desired product as a white solid (8.80 g, 36%). HPLC: R_t = 6.08. MS (ESI): mass calcd. for $C_{13}H_{13}ClIN_3O_2S$, 437.7; m/z found, 438.1 $[M+H]^+$. ^1H NMR (DMSO-d_6): 8.05 (d, J = 1.9, 1H), 7.51 (d, J = 8.3, 1H), 7.43 (dd, J = 8.4, 1.9, 2H), 4.30 (s, 2H), 3.36 (t, J = 5.8, 2H), 3.30 (br s, 1H), 2.86 (s, 3H), 2.69 (t, J = 5.6, 2H).


[0106] *4-Chloro-3-iodobenzoyl chloride was prepared by dissolving 4-chloro-3-iodobenzoic acid (15.8 g, 56 mmol) in CH_2Cl_2 (40 mL) and treating with oxalyl chloride (4.1 mL, 46.7 mmol) and a catalytic amount of DMF (400 µL; vigorous gas evolution). The mixture was stirred at rt for 3 h. The reaction mixture was concentrated to afford a white solid, which was used without further purification.

[0107] C. 3-(4-Chloro-3-iodo-phenyl)-1-(2-[1,3]dioxolan-2-yl-ethyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. A slurry of the above pyrazole (10 g, 22.8 mmol) and Cs_2CO_3 (11.9 g, 45.6 mmol) in DMF (75 mL) was stirred at rt for 2 h. 2-(2-Bromoethyl)1,3-dioxolane (3.5 mL, 34.2 mmol) was added dropwise and stirring maintained for 2 days. Ice water was added slowly to form a precipitate. The white solid was collected by suction filtration and washed with H_2O and Et_2O to afford the desired product (10.4 g, 85%). HPLC: R_t = 6.98. MS (ESI): mass calcd. for $C_{18}H_{21}ClIN_3O_4S$, 537.8; m/z found, 538.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.15 (s, 1H), 7.46-7.45 (m, 2H), 4.83 (t, J = 4.6, 1H), 4.49 (s, 2H), 4.17 (t, J = 7.1, 2H), 4.01-3.97 (m, 2H), 3.89-3.86 (m, 2H), 3.65 (t, J = 5.8, 2H), 2.89 (s, 3H), 2.87 (t, J = 5.8, 2H), 2.28-2.26 (m, 2H).

[0108] D. 3-(4-Chloro-3-iodo-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. A mixture of the above acetal (4.65 g, 8.64 mmol) and 1 N HCl (19 mL) in acetone (75 mL) was heated at 55 ºC for 5 h. The clear solution was concentrated to remove acetone, and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4),

filtered, and concentrated to give a white solid, which was used directly in the next reaction. The crude aldehyde was dissolved in CH_2Cl_2 (80 mL) and morpholine (2.5 mL, 28.6 mmol) and acetic acid (1.0 mL) were added sequentially. After 10 min, $NaB(OAc)_3H$ (3.48 g, 13 mmol) was added and stirring was continued for 2.5 days. After the addition of 1 N NaOH, the layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered, and concentrated to give an orange oil. Purification (SiO_2; 0-3% 2 M NH_3 in $MeOH/CH_2Cl_2$) afforded the title compound as a white solid (2.9 g, 60%). HPLC: R_t = 4.78. MS (ESI): mass calcd. for $C_{20}H_{26}ClIN_4O_3S$, 564.9; m/z found, 566.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.15 (s, 1H), 7.46-7.45 (m, 2H), 4.49 (s, 2H), 4.09 (t, *J* = 6.8, 2H), 3.70 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.8, 2H), 2.90 (s, 3H), 2.89 (t, *J* = 5.8, 2H), 2.44-2.39 (br m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.11-2.03 (m, 2H).


[0109] E. 3-(4-Chloro-3-trimethylsilanylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a solution of the above iodoarene (1.0 g, 1.8 mmol), $PdCl_2(PPh)_3$ (124 mg, 0.177 mmol), and CuI (34 mg, 0.177 mmol) in degassed THF (10 mL) was added TEA (1.2 mL, 8.85 mmol), followed by (trimethylsilyl)acetylene (TMSA; 276 μL). The reaction mixture was stirred under N_2 at rt for 17 h. Satd. aq. $NaHCO_3$ was added, and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered, and concentrated to give a brown oil. Purification (SiO_2; 0-3% 2 M NH_3 in $MeOH/CH_2Cl_2$) afforded the desired product as a beige solid (860 mg, 91%). HPLC: R_t = 5.45. MS (ESI): mass calcd. for $C_{25}H_{35}ClN_4O_3SSi$, 535.2; m/z found, 536.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.73 (d, *J* = 2.0, 1H), 7.46 (dd, *J* = 8.4, 2.1, 1H), 7.40 (d, *J* = 8.2, 1H), 4.51 (s, 2H), 4.09 (t, *J* = 6.8, 2H), 3.70 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 2.90 (s, 3H), 2.89 (t, *J* = 5.7, 2H), 2.43-2.38 (br m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.10-2.03 (m, 2H), 0.29 (s, 9H).



Example 1; 3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0110] A. 3-(4-Chloro-3-ethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a solution of 3-(4-chloro-3-trimethylsilanylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (947 mg, 1.77 mmol) in THF (7 mL) was added tetrabutylammonium fluoride (1.0 M in THF; 2.0 mL, 1.95 mmol) dropwise. The resulting solution was stirred at rt for 30 min, then diluted with H_2O. The aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered, and concentrated to give a black oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a yellow oil (550 mg, 67%). HPLC: R_t = 4.62. MS (ESI): mass calcd. for $C_{22}H_{27}ClN_4O_3S$, 463.0; m/z found, 464.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.75 (d, J = 2.1, 1H), 7.52 (dd, J = 8.4, 2.2, 1H), 7.43 (d, J = 8.4, 1H), 4.49 (s, 2H), 4.09 (t, J = 6.9, 2H), 3.71 (t, J = 4.6, 4H), 3.64 (t, J = 5.7, 2H), 2.91 (s, 3H), 2.88 (t, J = 5.7, 2H), 2.47-2.42 (br m, 4H), 2.36 (t, J = 7.1, 2H), 2.11-2.00 (m, 3H).


[0111] B. 3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a solution of the above alkyne (120 mg, 0.259 mmol), 5-iodoindole (82 mg, 0.337 mmol), $PdCl_2(PPh_3)_2$ (18 mg, 0.026 mmol), and CuI (4.9 mg, 0.026 mmol) in degassed THF (2.4 mL) was added TEA (108 μL, 0.777 mmol). The reaction mixture was stirred at rt under N_2 for 16 h. The mixture was concentrated and the resulting black oil was purified (SiO_2; 0-5% 2 M NH_3 in MeOH/CH_2Cl_2) to provide the title compound as a white solid (132 mg, 88%). HPLC: R_t = 4.73. MS (ESI): mass calcd. for $C_{30}H_{32}ClN_5O_3S$, 578.1; m/z found, 579.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.60 (s, 1H), 7.92-7.90 (m, 1H), 7.80 (t, J = 1.2, 1H), 7.44 (d, J = 1.2, 2H), 7.40 (dd, J = 8.4, 1.5, 1H), 7.35 (d, J = 8.4, 1H), 7.23-7.20 (m, 1H), 6.56-6.54 (m, 1H), 4.50 (s, 2H), 4.07 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.60 (t, J = 5.7, 2H), 2.88 (s, 3H), 2.83 (t, J = 5.7, 2H), 2.41-2.37 (br m, 4H), 2.31 (t, J = 6.8, 2H), 2.08-2.01 (m, 2H).



Example 2; 3-{4-Chloro-3-[2-(1H-indol-5-yl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0112] A pressure tube containing a suspension of 3-[4-chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (45 mg, 0.079 mmol) and PtO_2 (8.5 mg) in 1:1 EtOH/EtOAc (4 mL) was placed in a shaker under H_2 (20 psi). After 17 h, the reaction mixture was filtered through diatomaceous earth and concentrated to give a brown oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a white powder (39 mg, 85%). HPLC: R_t = 5.10. MS (ESI): mass calcd. for $C_{30}H_{36}ClN_5O_3S$, 582.2; m/z found, 583.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.25 (br s, 1H), 7.52-7.45 (m, 2H), 7.40 (d, J = 8.2, 1H), 7.35-7.31 (m, 2H), 7.19-7.16 (m, 1H), 7.07 (dd, J = 8.3, 1.5, 1H), 6.51-6.48 (m, 1H), 4.39 (s, 2H), 4.08 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.62 (t, J = 5.8, 2H), 3.13-3.08 (m, 2H), 3.06-3.00 (m, 2H), 2.91-2.84 (m, 2H), 2.84 (s, 3H), 2.44-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.02 (m, 2H).

[0113] The compounds in Examples 3-14 were prepared according to the methods described for Intermediate 1 and Example 1, substituting the appropriate iodide for 5-iodoindole in Example 1, Step B.




Example 3; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile.

[0114] HPLC: R_t = 4.81. MS (ESI): mass calcd. for $C_{30}H_{32}ClN_5O_3S$, 578.1; m/z found, 579.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.81 (d, J = 1.9, 1H), 7.62-7.59 (m, 2H), 7.50 (dd, J = 8.4, 2.1, 2H), 7.34 (d, J = 8.4, 2H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.79 (s, 2H), 3.70 (t, J= 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H).




Example 4; (3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile.

[0115] HPLC: R_t = 5.43. MS (ESI): mass calcd. for $C_{30}H_{32}ClN_5O_3S$, 578.1; m/z found, 579.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 2.0, 1H), 7.59-7.55 (m, 2H), 7.53-7.33 (m, 4H), 4.55 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.78 (s, 2H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.90 (t, J = 5.6, 2H), 2.43-2.39 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.12-2.04 (m, 2H).




Example 5; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol.

[0116] HPLC: R_t = 4.82. MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_4S$, 569.1; m/z found, 570.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.8, 1H), 7.61-7.57 (m, 2H), 7.51-7.44 (m, 2H), 7.37 (d, J = 8.3, 2H), 4.73 (s, 2H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.87 (br s, 1H).




Example 6; (3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol.

[0117] MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_4S$, 569.1; m/z found, 570.3 $[M+H]^+$.




Example 7; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol.

[0118] HPLC: R_t = 4.61. MS (ESI): mass calcd. for $C_{28}H_{31}ClN_4O_4S$, 555.1; m/z found, 556.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77-7.75 (m, 1H), 7.42-7.37 (m, 4H), 6.81-6.77 (m, 2H), 4.50 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.70 (t, J = 4.5, 4H), 3.61 (t, J = 5.3, 2H), 2.91 (s, 3H), 2.86 (t, J = 5.6, 2H), 2.46-2.41 (m, 4H), 2.37 (t, J = 6.9, 2H), 2.12-2.04 (m, 2H).




Example 8; 4-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-butyric acid.

[0119] HPLC: R_t = 4.89. MS (ESI): mass calcd. for $C_{32}H_{37}ClN_4O_5S$, 625.2; m/z found, 626.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (s, 1H), 7.52 (d, J = 8.0, 2H), 7.47 (s, 2H), 7.21 (d, J = 8.0, 2H), 4.52 (s, 2H), 4.11 (t, J = 6.7, 2H), 3.74 (t, J = 4.2, 4H), 3.68-3.63 (m, 4H), 3.10 (dd, J = 14.6, 7.3, 1H), 2.93 (s, 3H), 2.92-2.88 (m, 2H), 2.69 (t, J = 7.6, 2H), 2.53-2.47 (br m, 3H), 2.41 (t, J = 7.0, 2H), 2.33 (t, J = 7.4, 2H), 2.14-2.06 (m, 2H), 2.00-1.91 (m, 2H).




Example 9; 3-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-propionic acid.

[0120] HPLC: R_t = 4.64. MS (ESI): mass calcd. for $C_{31}H_{35}ClN_4O_5S$, 611.2; m/z found, 612.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.70 (s, 1H), 7.45 (d, *J* = 7.5, 2H), 7.38 (d, *J* = 8.4, 2H), 7.22 (d, *J* = 7.8, 2H), 6.68 (br s, 1H), 4.50 (s, 2H), 4.01 (t, *J* = 6.5, 2H), 3.77-3.71 (m, 4H), 3.61-3.56 (m, 2H), 2.97 (t, *J* = 7.1, 2H), 2.88 (s, 3H), 2.78-2.73 (m, 2H), 2.65 (t, *J* = 7.1, 2H), 2.61-2.54 (m, 4H), 2.49 (t, *J* = 6.7, 2H), 2.07 (t, *J* = 6.6, 2H).




Example 10; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester.

[0121] MS (ESI): mass calcd. for $C_{31}H_{35}ClN_4O_5S$, 611.2; m/z found, 612.3 $[M+H]^+$.




Example 11; (3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester.

[0122] MS (ESI): mass calcd. for $C_{31}H_{35}ClN_4O_5S$, 611.2; m/z found, 612.3 $[M+H]^+$.




Example 12; 3-(4-Chloro-3-thiophen-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0123] HPLC: R_t = 4.91. MS (ESI): mass calcd. for $C_{26}H_{29}ClN_4O_3S_2$, 545.1; m/z found, 546.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 2.0, 1H), 7.49 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.37-7.33 (m, 2H), 7.04 (dd, *J* = 5.2, 3.7, 1H), 4.53 (s, 2H), 4.13-4.08 (m, 2H), 3.70 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 2.91 (s, 3H), 2.88 (t, *J* = 5.8, 2H), 2.44-2.38 (br m, 4H), 2.33 (t, *J* = 6.8, 2H), 2.11-2.03 (m, 2H).




Example 13; 3-[4-Chloro-3-(3,4-dichloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0124] MS (ESI): mass calcd. for $C_{28}H_{29}Cl_3N_4O_3S$, 608.0; m/z found, 609.2 $[M+H]^+$.




Example 14; 3-{4-Chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0125] MS (ESI): mass calcd. for $C_{34}H_{34}ClIN_4O_4S$, 757.1; m/z found, 758.2 $[M+H]^+$.




Example 15; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid, trifluoroacetic acid salt.

[0126] To a solution of (4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester (19 mg, 0.031 mmol) in 2:1 EtOH/H_2O (0.9 mL) was added NaOH (3.7 mg, 0.093 mmol). The reaction mixture was stirred at rt for 30 min and then purified directly by reverse-phase HPLC (0.05% TFA/10-98% MeCN/H_2O) to afford the title compound as an off-white solid (11.7 mg, 53%). HPLC: R_t = 4.75. MS (ESI): mass calcd. for $C_{30}H_{33}ClN_4O_5S$, 597.1; m/z found, 598.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.74 (d, J = 1.6, 1H), 7.56-7.53 (m, 2H), 7.46-7.43 (m, 2H), 7.32-7.29 (m, 2H), 4.50 (s, 2H), 4.12 (t, J = 6.5, 2H), 3.95 (br m, 4H), 3.65-3.63 (m, 4H), 3.62 (br s, 1H), 3.15-3.09 (m, 2H), 2.92 (s, 3H), 2.82 (t, J = 5.6, 4H), 2.39-2.31 (br m, 4H).



Example 16; (3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid.


[0127] The title compound was prepared from (3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester according to the method described in Example 15. MS (ESI): mass calcd. for $C_{30}H_{33}ClN_4O_5S$, 597.1; m/z found, 598.3 $[M+H]^+$.



Example 17; 3-[4-Chloro-3-(4-phenoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0128] Formic acid (12 μL) was added to a degassed solution of 3-{4-chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (119 mg, 0.157 mmol), $Pd(OAc)_2$ (3.6 mg, 0.016 mmol), PPh_3 (8.2 mg, 0.032 mmol), and TEA (66 μL, 0.473 mmol) in DMF (1.5 mL). The reaction mixture was heated at 60 ºC under N_2 for 1.5 h. After cooling to rt, saturated (satd.) aq. $NaHCO_3$ was added, and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a brown oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a white solid (51 mg, 52%). MS (ESI): mass calcd. for $C_{34}H_{35}ClN_4O_4S$, 631.2; m/z found, 632.3 $[M+H]^+$.

[0129] The compounds in Example 18-54 were prepared using methods analogous to those described for Intermediate 1, substituting the appropriate alkyne for TMSA in Step E.




Example 18; 3-[3-(4-Bromo-phenylethynyl)-4-chloro-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0130] HPLC: R_t = 5.61. MS (ESI): mass calcd. for $C_{28}H_{30}BrClN_4O_3S$, 618.0; m/z found, 619.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.9, 1H), 7.53-7.44 (m, 6H), 4.54 (s, 2H), 4.10 (t, J = 6.7, 2H), 3.70 (t, J = 4.4, 4H), 3.66 (t, J = 5.7, 2H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.32 (t, J = 6.6, 2H).




Example 19; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzoic acid.

[0131] HPLC: R_t = 4.66. MS (ESI): mass calcd. for $C_{29}H_{31}ClN_4O_5S$, 583.1; m/z found, 584.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.06 (d, J = 8.2, 2H), 7.80 (s, 1H), 7.67 (d, J = 8.2, 2H), 7.54-7.50 (m, 2H), 4.54 (s, 2H), 4.28-4.18 (m, 2H), 4.06-4.00 (br m, 4H), 3.60 (t, J = 5.7, 2H), 3.24-3.13 (m, 4H), 3.08-3.01 (m, 2H), 2.98 (s, 3H), 2.82-2.77 (m, 2H).



Example 20; 3-(4-Chloro-3-pyridin-4-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0132] HPLC: R_t = 4.02. MS (ESI): mass calcd. for $C_{27}H_{30}ClN_5O_3S$, 540.1; m/z found, 541.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.65-8.62 (m, 2H), 7.83 (d, J = 2.0, 1H), 7.54 (dd, J = 8.4, 2.1, 1H), 7.50-7.44 (m, 3H), 4.54 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.70 (t, J = 4.5, 4H), 3.66 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.92-2.88 (m, 2H), 2.44-2.39 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.12-2.04 (m, 2H).



Example 21; 3-(4-Chloro-3-pyridin-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0133] HPLC: R_t = 4.34. MS (ESI): mass calcd. for $C_{27}H_{30}ClN_5O_3S$, 540.1; m/z found, 541.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.83 (s, 1H), 8.58 (d, J = 3.9, 1H), 7.88 (dt, J =

1.9, 7.9, 1H), 7.83 (d, J = 2.0, 1H), 7.52 (dd, J = 8.4, 2.1, 1H), 7.47 (d, J = 8.4, 1H), 7.34-7.29 (m, 1H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.90 (t, J = 5.8, 2H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H).




Example 22; 3-(4-Chloro-3-pyridin-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0134] HPLC: R_t = 4.50. MS (ESI): mass calcd. for $C_{27}H_{30}ClN_5O_3S$, 540.1; m/z found, 541.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.65 (d, J = 4.5, 1H), 7.86 (d, J = 2.1, 1H), 7.72 (dt, J = 1.7, 7.7, 1H), 7.63-7.60 (m, 1H), 7.56 (dd, J = 8.4, 2.1, 1H), 7.47 (d, J = 8.4, 1H), 7.30-7.26 (m, 1H), 4.52 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.92 (s, 3H), 2.89 (t, J = 5.7, 2H), 2.43-2.39 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.03 (m, 2H).




Example 23; 3-(4-Chloro-3-thiophen-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0135] HPLC: R_t = 5.15. MS (ESI): mass calcd. for $C_{26}H_{29}ClN_4O_3S_2$, 545.1; m/z found, 546.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.61 (dd, J = 3.0, 1.1, 1H), 7.49 (dd, J = 8.4, 2.1, 1H), 7.44 (d, J = 8.4, 1H), 7.33 (dd, J = 5.0, 3.0, 1H), 7.25 (dd, J = 5.0, 1.1, 1H), 4.53 (s, 2H), 4.09 (t, J = 6.8, 1H), 3.69 (t, J = 4.5, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.89 (t, J = 5.7, 2H), 2.42-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 24; 3-[4-Chloro-3-(2-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0136] HPLC: R_t = 5.18. MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_4S$, 569.1; m/z found, 570.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.83 (d, J = 1.5, 1H), 7.56 (dd, J = 7.6, 1.7, 1H), 7.47-7.44 (m, 2H), 7.36-7.31 (m, 1H), 6.98-6.91 (m, 2H), 4.52 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.93 (s, 3H), 3.70 (t, J = 4.6, 4H), 3.64 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.88 (t, J = 5.7, 2H), 2.44-2.38 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.03 (m, 2H).




Example 25; 3-[4-Chloro-3-(3-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0137] HPLC: R_t = 5.60. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_3S$, 573.6; m/z found, 574.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 2.0, 1H), 7.60-7.57 (m, 1H), 7.53-7.45 (m, 3H), 7.36-7.28 (m, 2H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.90 (t, J = 5.7, 2H), 2.43-2.39 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.12-2.05 (m, 2H).




Example 26; 3-[4-Chloro-3-(2-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0138] HPLC: R_t = 5.48. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_3S$, 573.6; m/z found, 574.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.85 (d, J = 1.8, 1H), 7.65-7.62 (m, 1H), 7.50-7.43 (m, 3H), 7.32-7.27 (m, 2H), 4.53 (s, 2H), 4.15-4.08 (m, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.91-2.87 (m, 2H), 2.90 (s, 3H), 2.43-2.39 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H).




Example 27; 3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol.

[0139] HPLC: R_t = 4.80. MS (ESI): mass calcd. for $C_{28}H_{31}ClN_4O_4S$, 555.1; m/z found, 556.6 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.69 (d, J = 2.1, 1H), 7.45 (dd, J = 8.5, 2.1, 1H), 7.36 (d, J = 8.4, 1H), 7.18 (t, J = 7.9, 1H), 7.10-7.06 (m, 1H), 6.88-6.87 (m, 1H), 6.81-6.78 (m, 1H), 4.47 (s, 2H), 4.07 (t, J = 6.7, 2H), 3.71 (t, J = 4.5, 4H), 3.54 (t, J = 5.7, 2H), 2.88 (s, 3H), 2.77 (t, J = 5.5, 2H), 2.48-2.43 (br m, 4H), 2.38 (t, J = 7.1, 2H), 2.09-2.01 (m, 2H).




Example 28; 3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0140] HPLC: R_t = 5.56. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_3S$, 573.6; m/z found, 574.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 2.0, 1H), 7.54-7.48 (m, 2H), 7.46 (d, J = 8.4, 2H), 7.37-7.33 (m, 2H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.89 (t, J = 5.9, 2H), 2.42-2.38 (br m, 4H), 2.32 (t, J = 6.9, 2H), 2.11-2.04 (m, 2H).




Example 29; 3-(4-Chloro-3-p-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0141] MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_3S$, 553.1; m/z found, 554.6 $[M+H]^+$.




Example 30; 3-[4-Chloro-3-(4-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0142] MS (ESI): mass calcd. for $C_{29}H_{30}ClF_3N_4O_3S$, 607.1; m/z found, 608.3 $[M+H]^+$.




Example 31; 3-[4-Chloro-3-(4-fluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0143] MS (ESI): mass calcd. for $C_{28}H_{30}ClFN_4O_3S$, 557.1; m/z found, 558.3 $[M+H]^+$.




Example 32; 3-[4-Chloro-3-(4-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0144] MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_4S$, 569.1; m/z found, 570.3 $[M+H]^+$.




Example 33; 3-[4-Chloro-3-(2,4-difluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0145] MS (ESI): mass calcd. for $C_{28}H_{29}ClF_2N_4O_3S$, 575.1; m/z found, 576.3 $[M+H]^+$.




Example 34; 3-[4-Chloro-3-(2-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0146] MS (ESI): mass calcd. for $C_{29}H_{30}ClF_3N_4O_3S$, 607.1; m/z found, 608.3 $[M+H]^+$.




Example 35; 3-(4-Chloro-3-o-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0147] MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_3S$, 553.1; m/z found, 554.6 $[M+H]^+$.




Example 36; 3-[4-Chloro-3-(3-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0148] MS (ESI): mass calcd. for $C_{29}H_{30}ClF_3N_4O_3S$, 607.1; m/z found, 608.3 $[M+H]^+$.




Example 37; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde.

[0149] MS (ESI): mass calcd. for $C_{29}H_{31}ClN_4O_4S$, 567.1; m/z found, 568.3 $[M+H]^+$.




Example 38; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine.

[0150] HPLC: R_t = 4.47. MS (ESI): mass calcd. for $C_{28}H_{32}ClN_5O_3S$, 554.1; m/z found, 555.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.74 (s, 1H), 7.43-7.36 (m, 4H), 6.64 (d, J = 8.5, 2H), 4.50 (s, 2H), 4.09 (t, J = 6.9, 2H), 3.93 (br s, 2H), 3.72 (t, J = 4.3, 4H), 3.62 (t, J = 5.6, 2H), 2.89 (s, 3H), 2.88-2.84 (m, 2H), 2.50-2.45 (br m, 4H), 2.39 (t, J = 6.8, 2H), 2.14-2.06 (m, 2H).




Example 39; 3-(4-Chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0151] HPLC: R_t = 5.19. MS (ESI): mass calcd. for $C_{28}H_{31}ClN_3O_3S$, 539.1; m/z found, 540.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.7, 1H), 7.61-7.59 (m, 2H), 7.47-7.44 (m, 2H), 7.38-7.36 (m, 3H), 4.52 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.69 (t, J = 4.4, 4H), 3.64 (t, J = 5.7, 2H), 2.89-2.87 (m, 5H), 2.40-2.39 (m, 4H), 2.32 (t, J = 1.7, 2H), 2.08-2.05 (m, 2H).




Example 40; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester.

[0152] MS (ESI): mass calcd. for $C_{34}H_{42}ClN_5O_5S$, 668.3; m/z found, 669.6 $[M+H]^+$.




Example 41; 3-[4-Chloro-3-(3-phenyl-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0153] HPLC: R_t = 5.20. MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_3S$, 553.1; m/z found, 554.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.71 (d, J = 1.9, 1H), 7.49-7.40 (m, 4H), 7.38-7.33 (m, 2H), 7.28-7.23 (m, 1H), 4.49 (s, 2H), 4.07 (t, J = 6.8, 2H), 3.92 (s, 2H), 3.69 (t, J = 4.4, 4H), 3.62 (t, J = 5.7, 2H), 2.87 (s, 3H), 2.86 (t, J = 5.4, 2H), 2.44-2.39 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 42; 3-[4-Chloro-3-(4-phenyl-but-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0154] HPLC: R_t = 5.35. MS (ESI): mass calcd. for $C_{30}H_{35}ClN_4O_3S$, 567.2; m/z found, 568.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.63 (d, J = 2.1, 1H), 7.47-7.44 (m, 2H), 7.39 (d, J = 8.4, 1H), 7.33-7.30 (m, 3H), 7.25-7.20 (m, 1H), 4.50 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.69 (t, J = 4.5, 4H), 3.64 (t, J = 5.8, 2H), 2.98 (t, J = 7.5, 2H), 2.89 (s, 3H), 2.88 (t, J = 5.7, 2H), 2.78 (t, J = 7.5, 2H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 43; 3-[4-Chloro-3-(5-phenyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0155] HPLC: R_t = 5.58. MS (ESI): mass calcd. for $C_{31}H_{37}ClN_4O_3S$, 581.2; m/z found, 582.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.67 (d, J = 2.0, 1H), 7.45 (dd, J = 8.4, 2.1, 1H), 7.40 (d, J = 8.4, 1H), 7.22-7.17 (m, 1H), 4.49 (s, 2H), 4.08 (t, J = 6.8, 2H), 3.68 (t, J = 4.6, 4H), 3.62 (t, J = 5.8, 2H), 2.88-2.82 (m, 4H), 2.87 (s, 3H), 2.49 (t, J = 6.9, 2H), 2.41-2.37 (br m, 4H), 2.31 (t, J = 6.8, 2H), 2.09-2.01 (m, 2H), 2.01-1.92 (m, 2H).




Example 44; 3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-yn-1-ol.

[0156] MS (ESI): mass calcd. for $C_{23}H_{29}ClN_4O_4S$, 493.0; m/z found, 494.4 $[M+H]^+$.




Example 45; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-but-3-yn-1-ol.

[0157] MS (ESI): mass calcd. for $C_{24}H_{31}ClN_4O_4S$, 507.1; m/z found, 508.4 $[M+H]^+$.




Example 46; 5-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-pent-4-yn-1-ol.

[0158] MS (ESI): mass calcd. for $C_{25}H_{33}ClN_4O_4S$, 521.1; m/z found, 522.4 $[M+H]^+$.



Example 47; 3-(4-Chloro-3-hex-1-ynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0159] HPLC: R_t = 5.33. MS (ESI): mass calcd. for $C_{26}H_{35}ClN_4O_3S$, 519.1; m/z found, 520.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.65 (d, J = 2.0, 1H), 7.43 (dd, J = 8.4, 2.1, 1H), 7.39 (d, J = 8.4, 1H), 4.50 (s, 2H), 4.08 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.64 (t, J = 5.8, 2H), 2.89 (s, 3H), 2.88 (t, J = 5.8, 2H), 2.49 (t, J = 7.0, 2H), 2.42-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.09-2.02 (m, 2H), 1.68-1.60 (m, 2H), 1.58-1.48 (m, 2H), 0.96 (t, J = 7.3, 3H).



Example 48; 3-(4-Chloro-3-cyclohexylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0160] HPLC: R_t = 5.61. MS (ESI): mass calcd. for $C_{28}H_{37}ClN_4O_3S$, 545.2; m/z found, 546.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.67-7.65 (m, 1H), 7.41-7.40 (m, 2H), 4.51 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.89 (s, 3H), 2.88 (t,

J = 5.8, 2H), 2.73-2.66 (m, 1H), 2.44-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H), 1.94-1.86 (m, 2H), 1.84-1.75 (m; 2H), 1.66-1.52 (m, 3H), 1.44-1.35 (m, 3H).




Example 49; (3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-diethyl-amine.

[0161] HPLC: R_t = 3.98. MS (ESI): mass calcd. for $C_{27}H_{38}ClN_5O_3S$, 548.2; m/z found, 549.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.61 (d, J = 2.0, 1H), 7.39 (dd, J = 8.4, 2.1, 1H), 7.34 (d, J = 8.4, 1H), 4.43 (s, 2H), 4.02 (t, J = 6.8, 2H), 3.66 (s, 2H), 3.62 (t, J = 4.6, 4H), 3.57 (t, J = 5.8, 2H), 2.82 (s, 3H), 2.81 (t, J = 5.9, 2H), 2.61 (q, J = 7.2, 4H), 2.35-2.31 (br m, 4H), 2.25 (t, J = 6.8, 2H), 2.03-1.96 (m, 2H), 1.07 (t, J = 7.2, 6H).




Example 50; 3-{4-Chloro-3-[3-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0162] MS (ESI): mass calcd. for $C_{27}H_{36}ClN_5O_5S_2$, 610.2; m/z found, 611.3 $[M+H]^+$.




Example 51; 3-[4-Chloro-3-(4-methyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0163] MS (ESI): mass calcd. for $C_{26}H_{35}ClN_4O_3S$, 519.1; m/z found, 520.4 $[M+H]^+$.




Example 52; 3-[4-Chloro-3-(3-phenoxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0164] MS (ESI): mass calcd. for $C_{29}H_{33}ClN_4O_4S$, 569.1; m/z found, 570.3 $[M+H]^+$.



Example 53; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzamide.


[0165] MS (ESI): mass calcd. for $C_{30}H_{34}ClN_5O_4S$, 596.2; m/z found, 597.4 $[M+H]^+$.



Example 54; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzenesulfonamide.


[0166] MS (ESI): mass calcd. for $C_{29}H_{34}ClN_5O_5S_2$, 632.2; m/z found, 633.4 $[M+H]^+$.

[0167] The compounds in Examples 55-65 were prepared using methods analogous to those described in Example 2. The alkynes used as starting materials for Examples 55-65 are described in the preceding examples.




Example 55; 3-{4-Chloro-3-[2-(4-phenoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0168] MS (ESI): mass calcd. for $C_{34}H_{39}ClN_4O_4S$, 635.2; m/z found, 636.4 $[M+H]^+$.



Example 56; 3-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenol.


[0169] MS (ESI): mass calcd. for $C_{28}H_{35}ClN_4O_4S$, 559.1; m/z found, 560.4 $[M+H]^+$.



Example 57; 3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0170] HPLC: R_t = 5.89. MS (ESI): mass calcd. for $C_{28}H_{34}Cl_2N_4O_3S$, 577.6; m/z found, 578.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.42-7.38 (m, 2H), 7.33 (dd, J = 8.3, 2.1, 1H), 7.27-7.23 (m, 2H), 7.17-7.13 (m, 2H), 4.44 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.70 (t, J =

4.6, 2H), 3.65 (t, J = 5.8, 2H), 3.06-3.01 (m, 2H), 2.94-2.87 (m, 4H), 2.89 (s, 3H), 2.43-2.37 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 58; 3-{4-Chloro-3-[2-(4-methoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0171] HPLC: R_t = 5.22. MS (ESI): mass calcd. for $C_{29}H_{37}ClN_4O_4S$, 573.2; m/z found, 574.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.46 (d, J = 2.0, 1H), 7.39 (d, J = 8.3, 1H), 7.33 (dd, J = 8.3, 2.1, 1H), 7.18-7.14 (m, 2H), 6.87-6.83 (m, 2H), 4.45 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.79 (s, 3H), 3.70 (t, J = 4.6, 4H), 3.64 (t, J = 5.8, 2H), 3.06-3.01 (m, 2H), 2.91-2.87 (m, 4H), 2.88 (s, 3H), 2.44-2.40 (br m, 4H), 2.34 (t, J = 6.9, 2H), 2.11-2.03 (m, 2H).




Example 59; 3-{4-Chloro-3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0172] HPLC: R_t = 5.80. MS (ESI): mass calcd. for $C_{28}H_{33}ClF_2N_4O_3S$, 579.1; m/z found, 580.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.43 (d, J = 2.0, 1H), 7.39 (d, J = 8.3, 1H), 7.33 (dd, J = 8.3, 2.1, 1H), 7.15-7.08 (m, 1H), 6.82-6.76 (m, 2H), 4.45 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.71 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 3.06-3.01 (m, 2H), 2.97-2.91 (m, 2H), 2.90-2.86 (m, 2H), 2.89 (s, 3H), 2.45-2.41 (br m, 4H), 2.35 (t, J = 6.9, 2H), 2.11-2.05 (m, 2H).




Example 60; 3-[4-Chloro-3-(2-o-tolyl-ethyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0173] HPLC: R_t = 5.40. MS (ESI): mass calcd. for $C_{29}H_{37}ClN_4O_3S$, 557.2; m/z found, 558.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.49 (d, J = 2.0, 1H), 7.40 (d, J = 8.3, 1H), 7.33 (dd, J = 8.3, 2.1, 1H), 7.22-7.11 (m, 3H), 4.44 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.63 (t, J = 5.8, 2H), 3.04-2.99 (m, 2H), 2.96-2.86 (m, 4H), 2.87 (s, 3H), 2.43-2.38 (br m, 4H), 2.36 (s, 3H), 2.32 (t, J = 6.6, 2H), 2.10-2.03 (m, 2H).




Example 61; [4-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenyl]-methanol.

[0174] HPLC: R_t = 4.70. MS (ESI): mass calcd. for $C_{29}H_{37}ClN_4O_4S$, 573.2; m/z found, 574.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.39 (d, J = 8.2, 1H), 7.37-7.32 (m, 2H), 7.27 (d, J = 8.1, 2H), 7.19 (d, J = 8.0, 2H), 4.63 (s, 2H), 4.39 (s, 2H), 4.07 (t, J = 6.8, 2H), 3.67 (t, J = 4.6, 4H), 3.63 (t, J = 5.8, 2H), 3.10-3.02 (m, 2H), 2.98-2.92 (m, 2H), 2.89-2.83 (m, 2H), 2.86 (s, 3H), 2.45 (br s, 1H), 2.42-2.36 (br m, 4H), 2.31 (t, J = 6.9, 2H), 2.10-2.01 (m, 2H).




Example 62; 3-(4-Chloro-3-phenethyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0175] HPLC: R_t = 5.24. MS (ESI): mass calcd. for $C_{28}H_{35}ClN_4O_3S$, 543.1; m/z found, 544.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.48 (d, *J* = 2.0, 1H), 7.39 (d, *J* = 8.3, 1H), 7.32 (dd, *J* = 8.1, 2.2, 2H), 7.31-7.18 (m, 5H), 4.44 (s, 2H), 4.09 (t, *J* = 6.7, 2H), 3.69 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.7, 2H), 3.09-3.04 (m, 2H), 2.97-2.92 (m, 2H), 2.89-2.86 (m, 2H), 2.87 (s, 3H), 2.43-2.38 (br m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 63; 3-[4-Chloro-3-(3-phenyl-propyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0176] HPLC: R_t = 5.42. MS (ESI): mass calcd. for $C_{29}H_{37}ClN_4O_3S$, 557.2; m/z found, 558.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.51 (d, *J* = 2.0, 1H), 7.36 (d, *J* = 8.3, 1H), 7.31-7.26 (m, 4H), 7.23-7.17 (m, 2H), 4.49 (s, 2H), 4.09 (t, *J* = 6.8, 2H), 3.69 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.8, 2H), 2.90-2.85 (m, 2H), 2.86 (s, 3H), 2.84-2.78 (m, 2H), 2.72 (t, *J* = 7.8, 2H), 2.42-2.38 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.09-1.95 (m, 4H).




Example 64; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzamide.

[0177] MS (ESI): mass calcd. for $C_{30}H_{38}ClN_5O_4S$, 600.2; m/z found, 601.5 $[M+H]^+$.




Example 65; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide.

[0178] HPLC: R_t = 4.82. MS (ESI): mass calcd. for $C_{29}H_{38}ClN_5O_5S_2$, 636.2; m/z found, 637.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.87-7.84 (m, 2H), 7.59-7.54 (m, 1H), 7.52-7.47 (m, 2H), 7.44 (d, *J* = 1.7, 1H), 7.37-7.31 (m, 2H), 4.87 (t, *J* = 6.1, 1H), 4.51 (s, 2H), 4.09 (t, *J* = 6.8, 2H), 3.69 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.8, 2H), 2.99 (q, *J* = 6.5, 2H), 2.91 (s, 3H), 2.89 (t, *J* = 5.8, 2H), 2.79-2.74 (m, 2H), 2.43-2.38 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.10-2.03 (m, 2H), 1.86-1.78 (m, 2H).




Example 66; N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetamide.

[0179] To a solution of 4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine (80 mg, 0.144 mmol) and pyridine (28 μL, 0.347 mmol) in CH_2Cl_2 (1.4 mL) was added Ac_2O (17 μL, 0.173 mmol) dropwise. The reaction mixture was stirred at rt for 14 h and transferred directly to a silica gel column. Purification (SiO_2; 0-10% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a clear oil (65 mg, 76%). HPLC: R_t = 5.90. MS (ESI): mass calcd. for $C_{30}H_{34}ClN_5O_4S$, 596.2; m/z found, 597.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.8, 1H), 7.72 (s, 1H), 7.57-7.51 (m, 4H), 7.48-7.42 (m, 2H), 4.52 (s, 2H), 4.09 (t, *J* = 6.8, 2H), 3.69 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.8, 2H), 2.90 (s, 3H), 2.90-2.86 (m, 2H), 2.42-2.38 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.18 (s, 3H), 2.10-2.04 (m, 2H).



Example 67; 3-(4-Chloro-3-*Z*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0180] To a pressure tube containing a mixture of 3-(4-chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (100 mg, 0.185 mmol), and Lindlar's catalyst (100 mg) in EtOAc (6 mL) was added quinoline (75 mg). The tube was placed in a shaker under 15 psi of H_2 for 5 h. The reaction mixture was filtered through diatomaceous earth and concentrated to give a yellow oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a clear oil. The compound was obtained and analyzed as a 1.5:1 mixture of atropisomers at rt. HPLC: R_t = 5.11 (major), 5.24 (minor). MS (ESI): mass calcd. for $C_{28}H_{33}ClN_4O_3S$, 541.1; m/z found, 542.3 $[M+H]^+$. Major atropisomer: ^1H NMR ($CDCl_3$): 7.81-7.15 (m, 4.8H), 6.73 (d, *J* = 12.2, 0.6H), 6.68 (d, *J* = 12.2, 0.6H), 4.04 (s, 1.2H), 4.02 (t, *J* = 6.8, 1.2H), 3.67 (t, *J* = 4.7, 2.4H), 3.53 (t, *J* = 5.8, 1.2H), 2.79 (t, *J* = 5.7, 1.2H), 2.77 (s, 1.8H), 2.39-2.34 (br m, 2.4H), 2.28 (t, *J* = 6.9, 1.2H), 2.04-1.96 (m, 1.2H). Minor atropisomer: ^1H NMR ($CDCl_3$): 7.81-7.15 (m, 4H), 4.53 (s, 0.8H), 4.10 (t, *J* = 6.8, 0.8H), 3.70 (t, *J* = 4.5, 1.6H), 3.64 (t, *J* = 5.7, 0.8H), 2.90 (s, 1.2H), 2.88 (t, *J* = 4.4, 0.8H), 2.43-2.39 (br m, 1.6H), 2.33 (t, *J* = 6.7, 0.8H), 2.11-2.04 (m, 0.8H).



Example 68; 3-(4-Chloro-3-*E*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.


[0181] A solution of 3-(4-chloro-3-iodo-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (100 mg, 0.177 mmol), *trans*-cinnamylboronic acid (29 mg, 0.195 mmol), $PdCl_2$(dppf)-CH_2Cl_2 (14.5 mg, 0.018 mmol), and K_3PO_4 (45 mg, 0.212 mmol) in degassed DMF (1.0 mL) was heated at 50 ºC under N_2 for 16 h. After cooling to rt, the reaction mixture was diluted with H_2O and extracted with CH_2Cl_2 (2x). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered, and concentrated to give a brown oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a clear oil (57 mg, 60%). HPLC: R_t = 5.29. MS (ESI): mass calcd. for $C_{28}H_{33}ClN_4O_3S$, 541.1; m/z found, 542.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.97 (d, *J* = 2.0, 1H), 7.59-7.56 (m, 2H), 7.52 (d, *J* = 16.3, 1H), 7.46-7.28 (m, 5H), 7.16 (d, *J* = 16.3, 1H), 4.55 (s, 2H), 4.13 (t, *J* = 6.9, 2H),

3.71 (t, J = 4.6, 4H), 3.67 (t, J = 5.8, 2H), 2.91 (t, J = 5.8, 2H), 2.89 (s, 3H), 2.45-2.40 (br m, 4H), 2.35 (t, J = 6.8, 2H), 2.13-2.05 (m, 2H).



Example 69; 4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine.

[0182] To a solution of (4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester (622 mg, 0.931 mmol) in CH_2Cl_2 (4.7 mL) was added TFA (1.2 mL). The reaction mixture was stirred at rt for 1 h and then concentrated. Purification (SiO_2; 0-5% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a white foam (400 mg, 76%). MS (ESI): mass calcd. for $C_{29}H_{34}ClN_5O_3S$, 568.1; m/z found, 569.5 $[M+H]^+$.




Example 70; N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methanesulfonamide.

[0183] To a solution of 4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine (70 mg, 0.123 mmol) and pyridine (22 μL, 0.272 mmol) in CH_2Cl_2 (1.2 mL) was added MsCl (11 μL, 0.136 mmol). The reaction mixture was stirred at rt for 16 h and transferred directly to a silica gel column. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a clear oil (65 mg, 82%). HPLC: R_t = 4.73. MS (ESI): mass calcd. for $C_{30}H_{36}ClN_5O_5S_2$, 646.2; m/z found, 647.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.8, 1H), 7.61-7.57 (m, 2H), 7.51-7.44 (m, 2H), 7.38-7.34 (m,


2H), 4.98 (br t, J = 6.0, 1H), 4.53 (s, 2H), 4.34 (d, J = 6.1, 2H), 4.10 (t, J = 6.8, 2H), 3.69 (t, J = 4.5, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.89 (s, 3H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.03 (m, 2H).

[0184] The compounds in Examples 71-72 were prepared using methods analogous to those described in Example 70, substituting the appropriate sulfonyl chloride or acid chloride for MsCl.




Example 71; N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzenesulfonamide.

[0185] HPLC: R_t = 5.19. MS (ESI): mass calcd. for $C_{35}H_{38}ClN_5O_5S_2$, 708.3; m/z found, 709.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.88-7.84 (m, 1H), 7.78 (d, J = 1.9, 1H), 7.62-7.57 (m, 1H), 7.54-7.45 (m, 6H), 7.19 (d, J = 8.2, 2H), 5.10 (t, J = 6.1, 1H), 4.52 (s, 2H), 4.16 (d, J = 6.2, 2H), 4.10 (t, J = 6.8, 2H), 3.68 (t, J = 4.5, 4H), 3.64 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.42-2.37 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H).




Example 72; N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-acetamide.

[0186] MS (ESI): mass calcd. for $C_{31}H_{36}ClN_5O_4S$, 610.2; m/z found, 611.5 $[M+H]^+$.




Example 73; N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzamide.

[0187] HPLC: R_t = 5.05. MS (ESI): mass calcd. for $C_{36}H_{38}ClN_5O_4S$, 672.3; m/z found, 673.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.83-7.79 (m, 3H), 7.58-7.54 (m, 2H), 7.53-7.41 (m, 5H), 7.35 (d, *J* = 8.2, 2H), 6.65 (br t, *J* = 5.6, 1H), 4.66 (d, *J* = 5.8, 2H), 4.52 (s, 2H), 4.09 (t, *J* = 6.7, 2H), 3.68 (t, *J* = 4.6, 4H), 3.64 (t, *J* = 5.8, 2H), 2.89 (s, 3H), 2.89-2.86 (m, 2H), 2.42-2.37 (br m, 4H), 2.31 (t, *J* = 6.8, 2H), 2.10-2.02 (m, 2H).



Example 74; Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine.


[0188] A solution of 4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine (87 mg, 0.153 mmol), benzaldehyde (17.2 μL, 0.17 mmol), and AcOH (9 μL, 0.153 mmol) in CH_2Cl_2 (1.5 mL) was stirred at rt for 30 min. The mixture was treated with $NaB(OAc)_3H$ (42 mg, 0.20 mmol) and was stirred for 16 h. The reaction mixture was transferred directly to a silica gel column and purified (SiO_2; 0-5% 2 M NH_3 in $MeOH/CH_2Cl_2$) to afford the title compound as a clear oil (25 mg, 25%). HPLC: R_t = 4.37. MS (ESI): mass calcd. for $C_{36}H_{40}ClN_5O_3S$, 658.3; m/z found, 659.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, *J* = 1.8, 1H), 7.58-7.55 (m, 2H), 7.50-7.45 (m, 2H), 7.37-7.33 (m, 6H), 7.29-7.25 (m, 1H), 4.53 (s, 2H), 4.10 (t, *J* = 6.8, 2H), 3.83 (s, 2H), 3.81 (s, 2H), 3.69 (t, *J* = 4.5, 4H), 3.65 (t, *J* = 5.7, 2H), 2.90 (s, 3H), 2.89 (t, *J* = 5.7, 2H), 2.42-2.38 (br m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.11-2.03 (m, 2H), 1.73 (br s, 1H).



Example 75; (4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-(4-methyl-benzyl)-amine.


[0189] A solution of 4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde (50 mg, 0.088 mmol), 4-methylbenzylamine (13.4 μL, 0.106 mmol), and AcOH (6 μL, 0.106 mmol) in CH_2Cl_2 (1.0 mL) were stirred at rt for 30 min. The mixture was treated with $NaB(OAc)_3H$ (24 mg, 0.106 mmol) and was stirred for 14 h. The reaction mixture was transferred directly to a silica gel column and purified (SiO_2; 0-5% 2 M NH_3 in MeOH/CH_2Cl_2) to afford the title compound as a clear oil (30 mg, 50%). MS (ESI): mass calcd. for $C_{37}H_{42}ClN_5O_3S$, 672.3; m/z found, 673.2 $[M+H]^+$.

[0190] The compounds in Examples 76-79 were prepared using methods analogous to those described in Example 75, substituting the appropriate amine for 4-methylbenzylamine.




Example 76; (4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine.

[0191] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_3S$, 692.7; m/z found, 693.2 $[M+H]^+$.




Example 77; Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methyl-amine.

[0192] MS (ESI): mass calcd. for $C_{37}H_{42}ClN_5O_3S$, 672.3; m/z found, 673.2 $[M+H]^+$.




Example 78; 3-[4-Chloro-3-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0193] MS (ESI): mass calcd. for $C_{33}H_{40}ClN_5O_3S$, 622.2; m/z found, 623.2 $[M+H]^+$.



Example 79; 3-[4-Chloro-3-(4-piperidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine.

[0194] MS (ESI): mass calcd. for $C_{34}H_{42}ClN_5O_3S$, 636.3; m/z found, 637.3 $[M+H]^+$.



Example 80; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide.

[0195] A. 2-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-isoindole-1,3-dione. This compound was prepared according to the methods described for Intermediate 1, substituting N-propargylphthalimide for TMSA in Step E. HPLC: R_t = 4.48. MS (ESI): mass calcd. for $C_{31}H_{32}ClN_5O_5S$, 622.2; m/z found, 623.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.90 (dd, J = 5.4, 3.0, 2H), 7.75 (dd, J = 5.5, 3.1, 2H), 7.68 (d, J = 2.1, 1H), 7.45 (dd, J = 8.5, 2.1, 1H), 7.37 (d, J = 8.4, 1H), 4.75 (s, 2H), 4.48 (s, 2H), 4.07 (t, J = 6.8, 2H), 3.68 (t, J = 4.5, 4H), 3.63 (t, J = 5.7, 2H), 2.90 (s, 3H), 2.87 (t, J = 5.7, 2H), 2.42-2.37 (m, 4H), 2.30 (t, J = 6.8, 2H), 2.08-2.01 (m, 2H).


[0196] B. 3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynylamine. To a solution of the above phthalimide (172 mg, 0.276 mmol) in 1:1 EtOH/DMF (2 mL) was added hydrazine monohydrate (134 μL). The reaction mixture was stirred at rt for 16 h, diluted with satd. aq. $NaHCO_3$, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a yellow oil. Purification (SiO_2; 0-10% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a white solid (86 mg, 63%). HPLC: R_t = 3.84. MS (ESI): mass calcd. for $C_{23}H_{30}ClN_5O_3S$, 492.0; m/z found, 493.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.67 (d, J = 2.1, 1H), 7.49 (dd, J = 8.4, 2.1, 1H), 7.41 (d, J = 8.4, 1H), 4.52 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.73 (s, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.89 (t, J = 5.7, 2H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.58 (br s, 2H).

[0197] C. 3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propylamine. This compound was prepared from the above propynyl amine according to the methods described in Example 2. HPLC: R_t = 3.97. MS (ESI): mass calcd. for $C_{23}H_{34}ClN_5O_3S$, 496.1; m/z found, 497.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.54 (d, J = 2.0, 1H), 7.36 (d, J = 8.3, 1H), 7.30 (dd, J = 8.3, 2.2, 1H), 4.50 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.70 (t, J = 4.5, 4H), 3.65 (t, J =

5.8, 2H), 3.28 (t, J = 7.1, 2H), 2.90-2.80 (m, 4H), 2.88 (s, 3H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-1.99 (m, 6H).


[0198] D. N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide. To a solution of the above amine (50 mg, 0.101 mmol) and pyridine (20 μL) in CH_2Cl_2 (1.0 mL) was added MsCl (10 μL, 0.121 mmol). The reaction mixture was stirred at rt for 16 h. The mixture was concentrated and the crude residue transferred directly to a silica gel column. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a white foam (49 mg, 84%). HPLC: R_t = 4.42. MS (ESI): mass calcd. for $C_{24}H_{36}ClN_5O_5S_2$, 574.2; m/z found, 575.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.49 (s, 1H), 7.37 (d, J = 8.3, 1H), 7.38-7.36 (m, 2H), 4.69 (t, J = 6.1, 1H), 4.51 (s, 2H), 4.09 (t, J = 6.9, 2H), 3.70 (t, J = 4.6, 4H), 3.64 (t, J = 5.8, 2H), 3.19 (q, J = 6.7, 2H), 2.96 (s, 3H), 2.91 (s, 3H), 2.90-2.83 (m, 4H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.03 (m, 2H), 1.98-1.91 (m, 2H).

[0199] The compounds in Examples 81-87 were prepared using methods analogous to those described in Example 80, Step D, substituting the appropriate sulfonyl chloride, acid chloride, or sulfamoyl chloride for MsCl.




Example 81; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-C-phenyl-methanesulfonamide.

[0200] MS (ESI): mass calcd. for $C_{30}H_{40}ClN_5O_5S_2$, 650.3; m/z found, 651.5 $[M+H]^+$.




Example 82; 3,4-Dichloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide.

[0201] MS (ESI): mass calcd. for $C_{29}H_{36}Cl_3N_5O_5S_2$, 705.1; m/z found, 706.4 $[M+H]^+$.




Example 83; 4-Chloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide.

[0202] MS (ESI): mass calcd. for $C_{29}H_{36}Cl_3N_5O_5S_2$, 705.1; m/z found, 706.4 $[M+H]^+$.




Example 84; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methyl-benzenesulfonamide.

[0203] MS (ESI): mass calcd. for $C_{30}H_{40}ClN_5O_5S_2$, 650.3; m/z found, 651.5 $[M+H]^+$.




Example 85; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methoxy-benzenesulfonamide.

[0204] MS (ESI): mass calcd. for $C_{30}H_{40}ClN_5O_6S_2$, 666.3; m/z found, 667.5 $[M+H]^+$.




Example 86; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-N,N-dimethyl-sulfamoylurea.

[0205] MS (ESI): mass calcd. for $C_{25}H_{39}ClN_6O_5S_2$, 603.2; m/z found, 604.4 $[M+H]^+$.



Example 87; N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-acetamide.

[0206] MS (ESI): mass calcd. for $C_{25}H_{36}ClN_5O_4S$, 538.1; m/z found, 539.5 $[M+H]^+$.



Example 88; 2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid, trifluoroacetic acid salt.

[0207] A. 1-(1-{3-[3-(4-Chloro-3-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperidin-4-yl)-pyrrolidin-2-one. This compound was prepared according to the method described in Intermediate 1, Step D, substituting 1-piperidin-4-yl-pyrrolidin-2-one for morpholine. HPLC: R_t = 4.65. MS (ESI): mass calcd. for $C_{25}H_{33}ClIN_5O_3S$, 646.0; m/z found, 647.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.15 (s, 1H), 7.45 (m, 2H), 4.48 (s, 2H), 4.07 (t, *J* = 6.8, 2H), 4.00-3.91 (m, 1H), 3.64 (t, *J* = 5.7, 2H), 3.35 (t, *J* = 7.0, 2H), 2.93-2.86 (m, 4H), 2.90 (s, 3H), 2.39 (t, *J* = 8.1, 2H), 2.32 (t, *J* = 6.9, 2H), 2.08-1.97 (m, 6H), 1.70-1.63 (m, 4H).

[0208] B. 2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-prop-2-ynyl}-isoindole-1,3-dione. This compound was prepared from the above iodide according to the method described in Example 80, Step A. HPLC: R_t = 4.79. MS (ESI): mass calcd. for $C_{36}H_{39}ClN_6O_5S$, 703.3; m/z found, 704.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.90 (dd, *J* = 5.4, 3.1, 2H), 7.75 (dd, *J* = 5.4, 3.1, 2H), 7.68 (d, *J* = 2.0, 1H), 7.45 (dd, *J* = 8.4, 2.1, 1H), 7.37 (d, *J* = 8.4), 4.75 (s, 2H), 4.48 (s, 2H), 4.06 (t, *J* = 6.7, 2H), 4.00-3.91 (m, 1H), 3.64 (t, *J* = 5.7, 2H), 3.35 (t, *J* = 7.0, 2H), 2.93-2.85 (m, 4H), 2.91 (s, 3H), 2.38 (t, *J* = 8.1, 2H), 2.32 (t, *J* = 6.9, 2H), 2.08-1.96 (m, 6H), 1.70-1.62 (m, 4H).


[0209] C. 2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-isoindole-1,3-dione. This compound was prepared from the above alkyne according to the method described in Example 2. HPLC: R_t = 4.82. MS (ESI): mass calcd. for $C_{36}H_{43}ClN_6O_5S$, 707.3; m/z found, 708.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.84 (dd, *J* = 5.4, 3.0, 2H), 7.72 (dd, *J* = 5.4, 3.1, 2H), 7.57 (d, *J* = 2.0, 1H), 7.35-7.33 (m, 2H), 4.54 (s, 2H), 4.08 (t, *J* = 6.8, 2H), 4.00-3.91 (m, 1H), 3.79 (t, *J* = 7.0, 2H), 3.65 (t, *J* = 5.6, 2H), 3.35 (t, *J* = 7.0, 2H), 2.93-2.86 (m, 4H), 2.92 (s, 3H), 2.83 (t, *J* = 7.5, 2H), 2.38 (t, *J* = 8.1, 2H), 2.33 (t, *J* = 6.9, 2H), 2.10-1.97 (m, 8H), 1.70-1.62 (m, 4H).

[0210] D. 2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid methyl ester. To a solution of the above phthalimide (461 mg, 0.656 mmol) in EtOH (3.3 mL) was added hydrazine monohydrate (319 μL, 6.56 mmol). The reaction mixture was stirred at rt for 18 h. The resulting precipitate was filtered, and the filter cake washed with CH_2Cl_2. The filtrate was concentrated to provide a white solid, which was used directly in the next reaction without further purification.

[0211] To a solution of the crude amine (74 mg, 0.128 mmol) and pyridine (46 μL, 0.563 mmol) in CH_2Cl_2 (1.3 mL) was added 2-chlorosulfonyl-benzoic acid methyl ester (66 mg, 0.282 mmol). The reaction mixture was stirred at rt for 26 h and then transferred directly to a silica gel column. Purification (SiO_2; 0-5% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a clear oil (88 mg, 89%). HPLC: R_t = 4.85. MS (ESI): mass calcd. for $C_{36}H_{47}ClN_6O_7S_2$, 775.4; m/z found, 776.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.09-8.06 (m, 1H), 7.84-7.81 (m, 1H), 7.64-7.61 (m, 2H), 7.45 (s, 1H), 7.35-7.33 (m, 2H), 6.04 (t, J = 6.1, 1H), 4.52 (s, 2H), 4.08 (t, J = 6.7, 2H), 4.00-3.92 (m, 1H), 3.99 (s, 3H), 3.65 (t, J = 5.6, 2H), 3.35 (t, J = 7.0, 2H), 3.06 (q, J = 6.5, 2H), 2.93-2.86 (m, 4H), 2.91 (s, 3H), 2.79 (t, J = 7.5, 2H), 2.38 (t, J = 8.1, 2H), 2.33 (t, J = 6.9, 2H), 2.09-1.96 (m, 6H), 1.88-1.80 (m, 2H), 1.70-1.62 (m, 4H).


[0212] E. 2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid, trifluoroacetic acid salt. To a solution of the above ester (63 mg, 0.078 mmol) in THF (0.8 mL) was added LiOH (2 M in H_2O; 0.2 mL). The reaction mixture was stirred at rt for 12 h, and then purified directly by reverse-phase HPLC (0.05% TFA/10-98% MeCN/H_2O) to provide the TFA salt of the title compound as a white solid (63 mg, 91%). HPLC: R_t = 4.68. MS (ESI): mass calcd. for $C_{35}H_{45}ClN_6O_7S_2$, 761.4; m/z found, 762.2 $[M+H]^+$. ^1H NMR (CD_3OD): 7.98-7.94 (m, 1H), 7.83-7.78 (m, 1H), 7.70-7.61 (m, 2H), 7.58 (s, 1H), 7.43-7.39 (m, 2H), 4.46 (s, 2H), 4.26 (t, J = 6.0, 2H), 4.10-4.02 (m, 1H), 3.67-3.58 (br m, 2H), 3.35-3.24 (m, 4H), 3.17-2.95 (m, 4H), 2.97 (s, 3H), 2.92 (t, J = 5.6, 2H), 2.81 (t, J = 7.3, 2H), 2.34 (t, J = 8.0, 2H), 2.33-2.29 (m, 2H), 2.01-1.94 (m, 4H), 1.90-1.78 (m, 6H).

[0213] The compounds in Examples 89-100 were prepared using methods analogous to those described in Example 88, Steps A-D, with the appropriate substituent changes.




Example 89; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-nitro-benzenesulfonamide.

[0214] HPLC: R_t = 4.82. MS (ESI): mass calcd. for $C_{34}H_{44}ClN_7O_7S_2$, 762.4; m/z found, 763.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.13-8.10 (m, 1H), 7.85-7.82 (m, 1H), 7.74-7.71 (m, 2H), 7.45 (d, *J* = 1.5, 1H), 7.35-7.33 (m, 2H), 5.54 (br s, 1H), 4.50 (s, 2H), 4.08 (t, *J* = 6.8, 2H), 4.00-3.91 (m, 1H), 3.65 (t, *J* = 5.7, 2H), 3.35 (t, *J* = 7.0, 2H), 3.17 (t, *J* = 6.4, 2H), 2.93-2.86 (m, 4H), 2.91 (s, 3H), 2.80 (t, *J* = 7.5, 2H), 2.38 (t, *J* = 8.1, 2H), 2.33 (t, *J* = 6.9, 2H), 2.10-1.96 (m, 6H), 1.93-1.85 (m, 2H), 1.70-1.62 (m, 4H).




Example 90; 3-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide.

[0215] HPLC: R_t = 4.95. MS (ESI): mass calcd. for $C_{34}H_{44}ClN_6O_5S_2$, 751.8; m/z found, 753.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.85 (t, *J* = 1.8, 1H), 7.76-7.73 (m, 1H), 7.55-7.52 (m, 1H), 7.47-7.42 (m, 2H), 7.35-7.33 (m, 2H), 5.19 (br t, *J* = 5.7, 1H), 4.51 (s, 2H), 4.07 (t, *J* = 6.8, 2H), 4.00-3.91 (m, 1H), 3.65 (t, *J* = 5.7, 2H), 3.35 (t, *J* = 7.0, 2H), 3.17 (t, *J* = 6.4, 2H), 3.00 (dd, *J* = 12.8, 6.6, 4H), 2.94-2.86 (m, 4H), 2.91 (s, 3H), 2.79 (t, *J* = 7.5, 2H), 2.39 (t, *J* = 8.1, 2H), 2.34 (t, *J* = 6.9, 2H), 2.10-1.96 (m, 6H), 1.89-1.85 (m, 2H), 1.70-1.62 (m, 4H).




Example 91; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide.

[0216] MS (ESI): mass calcd. for $C_{34}H_{45}ClN_6O_5S_2$, 717.4; m/z found, 718.5 $[M+H]^+$.




Example 92; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-4-methyl-benzenesulfonamide.

[0217] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_5S_2$, 731.4; m/z found, 732.5 $[M+H]^+$.




Example 93; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methoxy-benzenesulfonamide.

[0218] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_6S_2$, 747.4; m/z found, 748.3 $[M+H]^+$.




Example 94; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methyl-benzenesulfonamide.

[0219] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_5S_2$, 731.4; m/z found, 732.3 $[M+H]^+$.




Example 95; 2-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide.

[0220] MS (ESI): mass calcd. for $C_{34}H_{44}Cl_2N_6O_5S_2$, 751.8; m/z found, 753.2 $[M+H]^+$.




Example 96; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-nitro-benzenesulfonamide.

[0221] MS (ESI): mass calcd. for $C_{34}H_{44}ClN_7O_7S_2$, 762.4; m/z found, 763.2 $[M+H]^+$.




Example 97; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methyl-benzenesulfonamide.

[0222] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_5S_2$, 731.4; m/z found, 732.3 $[M+H]^+$.




Example 98; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-cyano-benzenesulfonamide.

[0223] MS (ESI): mass calcd. for $C_{35}H_{44}ClN_7O_5S_2$, 742.4; m/z found, 743.3 $[M+H]^+$.




Example 99; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methanesulfonyl-benzenesulfonamide.

[0224] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_7S_3$, 795.5; m/z found, 796.2 $[M+H]^+$.



Example 100; N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methanesulfonyl-benzenesulfonamide.

[0225] MS (ESI): mass calcd. for $C_{35}H_{47}ClN_6O_7S_3$, 795.5; m/z found, 796.3 $[M+H]^+$.



Example 101; 1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.


[0226] A. 1-[1-(3-{3-[4-Chloro-3-(3-hydroxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. This compound was prepared following the methods described in Example 80, Step A, substituting propargyl alcohol for N-propargylphthalimide. HPLC: R_t = 4.30. MS (ESI): mass calcd. for $C_{28}H_{36}ClN_5O_4S$, 574.2; m/z found, 575.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.64 (d, J = 2.1, 1H), 7.48 (dd, J = 8.4, 2.1, 1H), 7.39 (d, J = 8.4, 1H), 4.54 (s, 2H), 4.46 (s, 2H), 4.05 (t, J = 6.8, 2H), 3.99-3.91 (m, 1H), 3.61 (t, J = 5.7, 2H), 3.35 (t, J = 7.0, 2H), 2.94 (br s, 1H), 2.91 (s, 3H), 2.89-2.83 (m, 4H), 2.39 (t, J = 7.9, 2H), 2.34 (t, J = 7.2, 2H), 2.10-1.97 (m, 6H), 1.71-1.64 (m, 4H).

[0227] B. 1-[1-(3-{3-[4-Chloro-3-(3-hydroxy-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. This compound was prepared from the above alkyne following the methods described in Example 2. MS (ESI): mass calcd. for $C_{28}H_{40}ClN_5O_4S$, 578.2; m/z found, 579.3.

[0228] C. 1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. To a solution of the above alcohol (584 mg, 1.01 mmol) and pyridine (250 μL, 3.03 mmol) in CH_2Cl_2 (8 mL) was added MsCl (120 μL, 1.52 mmol). The reaction mixture was stirred at rt for 4 h, diluted with H_2O, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a tan solid, which was used directly without further purification. To a solution of the crude mesylate (100 mg, 0.152 mmol) in EtOH (1.0 mL) was added pyrrolidine (3.04 mmol). The reaction mixture was heated to 60 ºC and stirred for 16 h. The solvent was removed and the crude residue was purified (SiO_2; 2 M NH_3 in MeOH/CH_2Cl_2) to provide the title compound as a white solid (54 mg, 71%). HPLC: R_t = 4.01. MS (ESI): mass calcd. for $C_{32}H_{47}ClN_6O_3S$, 631.3; m/z found, 632.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.52 (d, J = 2.0, 1H), 7.36 (d, J = 8.2, 1H), 7.29 (dd, J = 8.3, 2.1, 1H), 4.50 (s, 2H), 4.08 (t, J = 6.8, 2H), 4.01-3.93 (m, 1H), 3.65 (t, J = 5.7, 2H), 3.35 (t, J = 7.0, 2H), 2.93-2.86 (m,


4H), 2.89 (s, 3H), 2.83-2.78 (m, 2H), 2.55-2.49 (m, 6H), 2.39 (t, J = 7.9, 2H), 2.33 (t, J = 7.0, 2H), 2.09-2.03 (m, 8H), 2.09-1.97 (m, 6H), 1.92-1.85 (m, 2H), 1.80-1.76 (m, 4H), 1.70-1.63 (m, 4H).

[0229] The compounds in Examples 102-108 were prepared using methods analogous to those described in Example 101 with the appropriate substituent changes.




Example 102; 1-[1-(3-{3-[4-Chloro-3-(3-piperidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0230] MS (ESI): mass calcd. for $C_{33}H_{49}ClN_6O_3S$, 645.3; m/z found, 646.3 $[M+H]^+$.




Example 103; 1-{1-[3-(3-{4-Chloro-3-[3-(3-methyl-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one.

[0231] MS (ESI): mass calcd. for $C_{34}H_{51}ClN_6O_3S$, 659.3; m/z found, 660.4 $[M+H]^+$.




Example 104; 1-{1-[3-(3-{4-Chloro-3-[3-(4,4-difluoro-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one.

[0232] MS (ESI): mass calcd. for $C_{33}H_{47}ClF_2N_6O_3S$, 681.3; m/z found, 682.4 $[M+H]^+$.




Example 105; 1-[1-(3-{3-[4-Chloro-3-(3-morpholin-4-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0233] MS (ESI): mass calcd. for $C_{32}H_{47}ClN_6O_4S$, 647.3; m/z found, 648.3 $[M+H]^+$.




Example 106; 1-{1-[3-(3-{4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one.

[0234] MS (ESI): mass calcd. for $C_{33}H_{50}ClN_7O_3S$, 660.3; m/z found, 661.4 $[M+H]^+$.




Example 107; 1-[1-(3-{3-[3-(3-Azepan-1-yl-propyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0235] MS (ESI): mass calcd. for $C_{34}H_{51}ClN_6O_3S$, 659.3; m/z found, 660.3 $[M+H]^+$.



Example 108; 1-[1-(3-{3-[4-Chloro-3-(3-cyclopentylamino-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0236] MS (ESI): mass calcd. for $C_{33}H_{49}ClN_6O_3S$, 645.3; m/z found, 646.3 $[M+H]^+$.



Example 109; 1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.


[0237] A. 1-[1-(3-{3-[4-Chloro-3-(4-hydroxy-but-1-ynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. This compound was prepared following the methods described in Example 101, Step A, substituting for 3-butyn-1-ol for propargyl alcohol. HPLC: R_t = 4.33. MS (ESI): mass calcd. for $C_{29}H_{38}ClN_5O_4S$, 588.2; m/z found, 589.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.68 (d, J = 1.3, 1H), 7.45 (dd, J = 8.4, 1.6, 1H), 7.40 (d, J = 8.4, 1H),

4.49 (s, 2H), 4.06 (t, J = 6.6, 2H), 3.99-3.91 (m, 1H), 3.85 (t, J = 6.2, 1H), 3.63 (t, J = 5.7, 2H), 3.35 (t, J = 7.0, 2H), 2.93-2.84 (m, 4H), 2.90 (s, 3H), 2.76 (t, J = 6.3, 2H), 2.39 (t, J = 7.9, 2H), 2.33 (t, J = 7.2, 2H), 2.09-1.97 (m, 6H), 1.70-1.62 (m, 4H).

[0238] B. 1-[1-(3-{3-[4-Chloro-3-(4-hydroxy-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. This compound was prepared from the above alkyne following the methods described in Example 101, Step B. MS (ESI): mass calcd. for $C_{29}H_{42}ClN_5O_4S$, 592.2; m/z found, 593.4 $[M+H]^+$.


[0239] C. 1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one. The title compound was prepared from the above alcohol following the methods described in Example 101, Step C. HPLC: R_t = 4.07. MS (ESI): mass calcd. for $C_{33}H_{49}ClN_6O_3S$, 645.3; m/z found, 646.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.50 (d, J = 2.0, 1H), 7.35 (d, J = 8.2, 1H), 7.28 (dd, J = 8.3, 2.1, 1H), 4.50 (s, 2H), 4.08 (t, J = 6.8, 2H), 4.01-3.92 (m, 1H), 3.65 (t, J = 5.7, 2H), 3.35 (t, J = 7.0, 2H), 2.92-2.87 (m, 4H), 2.89 (s, 3H), 2.78 (t, J = 7.3, 2H), 2.54-2.47 (m, 6H), 2.39 (t, J = 7.9, 2H), 2.33 (t, J = 7.0, 2H), 2.09-1.98 (m, 6H), 1.80-1.75 (m, 4H), 1.71-1.60 (m, 8H).

[0240] The compounds in Examples 110-115 were prepared using methods analogous to those described in Example 109 with the appropriate substituent changes.




Example 110; 1-[1-(3-{3-[4-Chloro-3-(4-piperidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0241] MS (ESI): mass calcd. for $C_{34}H_{51}ClN_6O_3S$, 659.3; m/z found, 660.4 $[M+H]^+$.




Example 111; 1-{1-[3-(3-{4-Chloro-3-[4-(3-methyl-piperidin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one.

[0242] MS (ESI): mass calcd. for $C_{35}H_{53}ClN_6O_3S$, 673.4; m/z found, 674.4 $[M+H]^+$.




Example 112; 1-{1-[3-(3-{4-Chloro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one.

[0243] MS (ESI): mass calcd. for $C_{34}H_{52}ClN_7O_3S$, 674.4; m/z found, 675.4 $[M+H]^+$.




Example 113; 1-[1-(3-{3-[4-Chloro-3-(4-morpholin-4-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0244] MS (ESI): mass calcd. for $C_{33}H_{49}ClN_6O_4S$, 661.3; m/z found, 662.4 $[M+H]^+$.




Example 114; 1-[1-(3-{3-[3-(4-Azepan-1-yl-butyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0245] MS (ESI): mass calcd. for $C_{35}H_{53}ClN_6O_3S$, 673.4; m/z found, 674.5 $[M+H]^+$.



Example 115; 1-[1-(3-{3-[4-Chloro-3-(4-cyclopentylamino-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0246] MS (ESI): mass calcd. for $C_{34}H_{51}ClN_6O_3S$, 659.3; m/z found, 660.4 $[M+H]^+$.



Example 116; 1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one.

[0247] A. 3-Amino-4-trifluoromethyl-benzoic acid. A mixture of 3-nitro-4-trifluoromethylbenzoic acid (19.5g, 83 mmol) and 10% Pd/C (4 g) in EtOAc (300 mL) was shaken under 40 psi of H_2 in a pressure vessel. The vessel was repeatedly refilled until the pressure stabilized at 40 psi. Shaking was continued for 10 min, and then N_2 was bubbled through the mixture for 30 min. The resulting black mixture was filtered

through diatomaceous earth and washed with MeOH. The filtrate was concentrated to afford the desired product as a white solid (19.5 g, 98%), which needed no further purification. HPLC: R_t = 5.46. MS (ESI): mass calcd. for $C_8H_6F_3NO_2$, 205.1; m/z found, 204.3 $[M-H]^-$. ^1H NMR (CD_3OD): 7.51 (s, 1H), 7.45 (d, J = 8.2, 1H), 7.30 (d, J = 8.0, 1H), 5.02 (br s, 3H).


[0248] B. 3-Iodo-4-trifluoromethyl-benzoic acid. To a –5 ºC slurry of the above aniline (16.6 g, 80.9 mmol) and conc. H_2SO_4 (33 mL) in H_2O (17 mL) was added a solution of $NaNO_2$ (6.7 g, 97.1 mmol) in H_2O (25 mL). The mixture was stirred at 0 ºC for 1 h, then treated with a solution of KI (26.9 g, 161.8 mmol) and I_2 (1 crystal) in H_2O (30 mL). The reaction mixture was stirred for 1 h at rt and then heated at reflux for 4 h, during which time significant foaming and frothing was observed. The thick brown mixture was cooled to 0 ºC, diluted with satd. aq. $Na_2S_2O_3$ (100 mL), and filtered to provide a beige solid. The solid was washed with H_2O and recrystallized from CH_3CN to afford the desired product as a white solid (18.3 g, 72%). HPLC: R_t = 6.33. MS (ESI): mass calcd. for $C_8H_4F_3IO_2$, 316.0; m/z found, 315.2 $[M-H]^-$. ^1H NMR (CD_3OD): 8.68 (s, 1H), 8.11 (d, J = 7.9, 1H), 7.73 (d, J = 8.2, 1H), 4.44 (br s, 1H).

[0249] C. 3-(3-Iodo-4-trifluoromethyl-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a 0 ºC solution of the above acid (6.3 g, 20 mmol) and oxalyl chloride (1.9 mL, 22 mmol) in benzene (20 mL) was added DMF (0.15 mL). The reaction mixture was warmed to rt and stirred for 5 h. The mixture was concentrated to afford a white solid, which was used directly in the next reaction following the procedure outlined in Intermediate 1, Step B. HPLC: R_t = 6.25. MS (ESI): mass calcd. for $C_{14}H_{13}F_3IN_3O_2S$, 471.2; m/z found, 472.3 $[M+H]^+$. ^1H NMR (DMSO-d_6): 8.39 (s, 1H), 7.82 (d, J = 8.3, 1H), 7.72 (d, J = 8.3, 1H), 4.49 (s, 2H), 3.52 (t, J = 5.7, 2H), 3.00 (s, 3H), 2.85 (t, J = 5.6, 2H).

[0250] D. 1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one. To a slurry of the above pyrazole (1.28 g, 2.72 mmol) and Cs_2CO_3 (1.33 g, 4.08 mmol) in DMF (9 mL) was added epichlorohydrin (1.26 g, 13.6 mmol). The reaction mixture was stirred at rt for 17 h, then cooled to 0 ºC, and treated slowly with ice water. The resulting precipitate was filtered to provide the desired epoxide as a white solid, which was used directly in the next reaction. The crude epoxide (105 mg, 0.199 mmol) suspended in EtOH (1.0 mL) and treated with 1-piperidin-4-yl-pyrrolidin-2-one (37 mg, 0.219 mmol). The reaction mixture was heated at reflux for 16 h and then concentrated. Purification (SiO_2; 0-3% 2 M NH_3 in


MeOH/CH_2Cl_2) provided a white solid, which was converted to the title compound following the procedure described in Intermediate 1, Step E, substituting 4-chloro-ethynylbenzene for TMSA. HPLC: R_t = 5.45. MS (ESI): mass calcd. for $C_{34}H_{37}ClF_3N_5O_4S$, 704.2; m/z found, 705.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.91 (s, 1H), 7.72 (d, 8.3, 1H), 7.61 (d, *J* = 8.3, 1H), 7.50 (d, *J* = 8.5, 2H), 7.35 (d, *J* = 8.6, 2H), 4.58 (dd, *J* = 18.4, 14.6, 2H), 4.19 (dd, *J* = 13.8, 2.8, 1H), 4.15-4.09 (br m, 1H), 4.02-3.94 (br m, 2H), 3.73-3.62 (m, 2H), 3.34 (t, *J* = 7.0, 2H), 3.09-2.99 (m, 2H), 2.95-2.92 (m, 2H), 2.89 (s, 3H), 2.49-2.34 (m, 5H), 2.16-2.09 (m, 1H), 2.04-1.96 (m, 2H), 1.78-1.61 (m, 4H).

[0251] The compounds in Examples 117-122 were prepared using methods analogous to those described in Example 116, with the appropriate substituent changes.




Example 117; 1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester.

[0252] HPLC: R_t = 5.73. MS (ESI): mass calcd. for $C_{32}H_{34}ClF_3N_4O_5S$, 679.2; m/z found, 680.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.91 (s, 1H), 7.71 (d, *J* = 8.3, 1H), 7.61 (d, *J* = 8.2, 1H), 7.50 (d, *J* = 8.6, 2H), 7.35 (d, *J* = 8.6, 2H), 4.58 (dd, *J* = 22.5, 14.4, 2H), 4.20 (dd, *J* = 13.7, 2.9, 1H), 4.17-4.14 (m, 1H), 4.01 (dd, *J* = 13.6, 6.5, 1H), 3.75-3.61 (m, 2H), 3.68 (s, 3H), 3.11-3.04 (m, 1H), 2.96-2.93 (m, 2H), 2.89 (s, 3H), 2.49-2.31 (m, 4H), 2.15-2.10 (m, 1H), 1.94-1.90 (m, 2H), 1.83-1.66 (m, 4H).




Example 118; 8-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-2,8-diaza-spiro[4.5]decan-1-one.

[0253] HPLC: R_t = 5.43. MS (ESI): mass calcd. for $C_{33}H_{35}ClF_3N_5O_4S$, 690.2; m/z found, 691.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.91 (s, 1H), 7.71 (d, J = 8.3, 1H), 7.60 (d, J = 8.3, 1H), 7.50 (d, J = 8.6, 2H), 7.35 (d, J = 8.6, 2H), 6.37 (s, 1H), 4.58 (dd, J = 21.4, 14.5, 2H), 4.20 (dd, J = 13.7, 2.8, 1H), 4.16-4.12 (br m, 1H), 4.02 (dd, J = 13.6, 6.6, 1H), 3.75-3.61 (m, 2H), 3.32 (t, J = 6.9, 2H), 3.11-3.04 (m, 1H), 2.96-2.93 (m, 2H), 2.89 (s, 3H), 2.83-2.80 (br m, 1H), 2.50-2.37 (m, 3H), 2.18-2.12 (m, 1H), 2.02 (t, J = 6.9, 2H), 2.01-1.85 (m, 3H), 1.46 (br m, 2H).




Example 119; 1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide.

[0254] HPLC: R_t = 5.31. MS (ESI): mass calcd. for $C_{31}H_{33}ClF_3N_5O_4S$, 664.2; m/z found, 665.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.91 (s, 1H), 7.71 (d, J = 8.3, 1H), 7.60 (d, J = 8.3, 1H), 7.50 (d, J = 8.5, 2H), 7.35 (d, J = 8.6, 2H), 6.58 (br s, 1H), 6.49 (br s, 1H), 4.57 (dd, J = 19.1, 14.5, 2H), 4.19 (dd, J = 13.8, 2.8, 1H), 4.16-4.09 (br m, 1H), 4.00 (dd, J = 13.8, 6.7, 1H), 3.73-3.61 (m, 2H), 3.14-3.03 (m, 1H), 2.99-2.84 (m, 2H), 2.89 (s, 3H), 2.45-2.35 (m, 2H), 2.32-2.24 (m, 1H), 2.20-2.12 (m, 1H), 2.06-1.98 (m, 1H), 1.86-1.63 (m, 4H).




Example 120; 3-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one.

[0255] HPLC: R_t = 5.69. MS (ESI): mass calcd. for $C_{39}H_{42}ClF_3N_8O_4S$, 811.3; m/z found, 812.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.92 (s, 1H), 7.71 (d, *J* = 8.3, 1H), 7.62 (d, *J* = 7.7, 1H), 7.50 (dt, *J* = 2.1, 8.6, 2H), 7.35 (dt, *J* = 2.1, 8.6, 2H), 7.03 (d, *J* = 8.5, 1H), 6.16 (d, *J* = 8.5, 1H), 4.59 (dd, *J* = 23.5, 15.0, 2H), 4.41-4.33 (m, 1H), 4.23 (dd, *J* = 13.8, 2.7, 1H), 4.19-4.13 (br m, 1H), 4.05 (dd, *J* = 13.8, 6.8, 1H), 3.77-3.63 (m, 2H), 3.34 (s, 3H), 3.16-3.05 (m, 1H), 3.03 (s, 6H), 2.98-2.93 (m, 2H), 2.90 (s, 3H), 2.86-2.70 (m, 2H), 2.57-2.44 (m, 3H), 2.26-2.20 (m, 1H), 1.77-1.74 (br m, 2H).



Example 121; [1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.


[0256] HPLC: R_t = 5.96. MS (ESI): mass calcd. for $C_{35}H_{41}ClF_3N_5O_5S$, 736.3; m/z found, 737.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.91 (s, 1H), 7.71 (d, *J* = 8.3, 1H), 7.60 (d, *J* = 8.8, 1H), 7.52-7.48 (m, 2H), 7.38-7.33 (m, 2H), 4.57 (dd, *J* = 20.5, 14.5, 2H), 4.47 (br s, 1H), 4.18 (dd, *J* = 13.8, 2.8, 1H), 4.15-4.07 (br m, 1H), 3.99 (dd, *J* = 13.8, 6.8, 1H), 3.73-3.60 (m, 2H), 3.47 (br s, 1H), 3.09-3.02 (m, 1H), 2.96-2.86 (m, 3H), 2.88 (s, 3H), 2.77-2.70 (br m, 1H), 2.47-2.34 (m, 3H), 2.12 (t, *J* = 11.1, 1H), 1.93 (br d, *J* = 11.1, 2H), 1.49-1.36 (m, 2H), 1.44 (s, 9H).



Example 122; 1-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol.


[0257] MS (ESI): mass calcd. for $C_{29}H_{30}ClF_3N_4O_4S$, 623.1; m/z found, 624.4 $[M+H]^+$.

[0258] The compounds in Examples 123-131 were prepared from 3-(4-chloro-3-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (Intermediate 1, Step B) according to the methods described in Example 116, Step D, substituting the appropriate amine for 1-piperidin-4-yl-pyrrolidin-2-one.



Example 123; 2-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-cyclopentanone.


[0259] HPLC: R_t = 5.29. MS (ESI): mass calcd. for $C_{33}H_{37}Cl_2N_5O_4S$, 670.7; m/z found, 671.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.7, 1H), 7.54-7.47 (m, 4H), 7.35 (dd, J = 6.6, 1.9, 2H), 4.55 (d, J = 4.3, 2H), 4.17 (dd, J = 13.8, 2.8, 1H), 4.13-4.07 (m, 1H), 4.02-3.96 (m, 2H), 3.73-3.62 (m, 3H), 3.34 (t, J = 7.0, 2H), 3.08-2.99 (m, 2H), 2.94-2.91 (m, 3H), 2.85 (s, 3H), 2.45-2.37 (m, 5H), 2.00 (t, J = 7.6, 2H), 1.75-1.61 (m, 4H).



Example 124; 1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol.


[0260] HPLC: R_t = 5.47. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_4S$, 589.6; m/z found, 590.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.5, 1H), 7.54-7.50 (m, 2H),

7.48-7.45 (m, 2H), 7.37-7.32 (m, 2H), 4.53 (dd, *J* = 18.3, 14.5, 2H), 4.18 (dd, *J* = 13.3, 2.9, 1H), 4.17-4.10 (m, 1H), 4.02-3.96 (m, 1H), 3.74-3.59 (m, 7H), 3.07-2.99 (m, 1H), 2.94-2.88 (m, 1H), 2.87 (s, 3H), 2.65-2.58 (m, 2H), 2.48-2.38 (m, 4H).




Example 125; 1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol.

[0261] HPLC: R_t = 5.64. MS (ESI): mass calcd. for $C_{29}H_{32}Cl_2N_4O_3S$, 587.6; m/z found, 588.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, *J* = 1.9, 1H), 7.53 (d, *J* = 8.5, 2H), 7.49-7.47 (m, 2H), 7.35 (d, *J* = 8.5, 2H), 4.55 (dd, *J* = 24.4, 14.5, 2H), 4.16 (dd, *J* = 13.7, 2.8, 1H), 4.13-4.08 (m, 1H), 3.98 (dd, *J* = 13.7, 6.8, 1H), 3.73-3.60 (m, 2H), 3.12-3.05 (m, 1H), 2.96-2.90 (m, 1H), 2.88 (s, 3H), 2.56 (br m, 2H), 2.42-2.27 (m, 4H), 1.59-1.52 (m, 4H), 1.47-1.42 (m, 3H).




Example 126; 3-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one.

[0262] HPLC: R_t = 5.60. MS (ESI): mass calcd. for $C_{38}H_{42}Cl_2N_8O_4S$, 777.8; m/z found, 778.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, *J* = 1.9, 1H), 7.53-7.45 (m, 4H), 7.34 (dd, *J* = 6.6, 2.0, 2H), 7.03 (d, *J* = 8.5, 1H), 6.16 (d, *J* = 8.5, 1H), 4.56 (dd, *J* = 23.7, 14.5, 2H), 4.40-4.32 (m, 1H), 4.21 (dd, *J* = 13.8, 2.7, 1H), 4.17-4.11 (m, 1H), 4.02 (dd, *J* = 13.8, 6.8, 1H), 3.76-3.61 (m, 2H), 3.33 (s, 3H), 3.16-3.07 (m, 2H), 3.03 (s, 6H), 2.96-2.90 (m, 2H), 2.89 (s, 3H), 2.86-2.69 (m, 2H), 2.53-2.42 (m, 3H), 2.23-2.18 (m, 1H), 1.78-1.71 (m, 2H).




Example 127; 1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester.

[0263] HPLC: R_t = 5.36. MS (ESI): mass calcd. for $C_{31}H_{34}Cl_2N_4O_5S$, 645.6; m/z found, 646.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, *J* = 1.8, 1H), 7.54-7.45 (m, 4H), 7.35 (dt, *J* = 2.1, 8.6, 2H), 4.55 (dd, *J* = 22.8, 14.5, 2H), 4.17 (dd, *J* = 13.8, 2.8, 1H), 4.14-4.08 (m, 1H), 3.98 (dd, *J* = 13.8, 6.8, 1H), 3.74-3.60 (m, 2H), 3.68 (s, 3H), 3.06 (dt, *J* = 5.5, 16.1, 1H), 2.94-2.87 (m, 2H), 2.88 (s, 3H), 2.79-2.76 (br m, 1H), 2.44-2.29 (m, 4H), 2.08-2.03 (br m, 1H), 1.92-1.88 (br m, 3H), 1.80-1.63 (m, 2H).




Example 128; 1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide.

[0264] HPLC: R_t = 4.97. MS (ESI): mass calcd. for $C_{30}H_{33}Cl_2N_5O_4S$, 630.6; m/z found, 631.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.6, 1H), 7.54-7.51 (m, 2H), 7.48-7.47 (m, 2H), 7.37-7.33 (m, 2H), 5.63 (br s, 1H), 5.53 (br s, 1H), 4.54 (dd, *J* = 20.0, 14.5, 2H), 4.17 (dd, *J* = 13.7, 2.8, 1H), 4.14-4.08 (m, 1H), 3.98 (dd, *J* = 13.7, 6.6, 1H), 3.73-3.59 (m, 2H), 3.09-2.84 (m, 4H), 2.88 (s, 3H), 2.44-2.26 (m, 4H), 2.20-2.11 (m, 1H), 2.06-1.99 (m, 1H), 1.89-1.63 (m, 4H).




Example 129; 1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-pyrrolidin-1-yl-propan-2-ol.

[0265] HPLC: R_t = 5.53. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_3S$, 573.6; m/z found, 574.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, *J* = 1.9, 1H), 7.54-7.51 (m, 2H), 7.50-7.46 (m, 2H), 7.36-7.33 (m, 2H), 4.54 (dd, *J* = 20.2, 14.5, 2H), 4.18 (dd, *J* = 13.8, 2.8, 1H), 4.13-4.07 (br m, 2H), 3.99 (dd, *J* = 13.8, 7.0, 1H), 3.72-3.58 (m, 2H), 3.08-3.01 (m, 1H), 2.94-2.85 (m, 1H), 2.87 (s, 3H), 2.66-2.61 (m, 3H), 2.53-2.47 (m, 2H), 2.43 (dd, *J* = 12.0, 4.4, 1H), 1.80-1.73 (m, 6H).




Example 130; [1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.

[0266] HPLC: R_t = 5.51. MS (ESI): mass calcd. for $C_{34}H_{41}Cl_2N_5O_5S$, 702.7; m/z found, 703.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.6, 1H), 7.52 (d, *J* = 8.6, 2H), 7.48-7.46 (m, 2H), 7.35 (d, *J* = 8.6, 2H), 4.54 (dd, *J* = 20.6, 14.5, 2H), 4.48-4.45 (br s, 1H), 4.16 (dd, *J* = 13.8, 2.7, 1H), 4.12-4.07 (br m, 1H), 3.97 (dd, *J* = 13.8, 6.8, 1H), 3.72-3.59 (m, 2H), 3.46 (br s, 1H), 3.07-3.01 (m, 1H), 2.92-2.84 (m, 2H), 2.87 (s, 3H), 2.76-2.70 (br m, 1H), 2.44-2.34 (m, 3H), 2.11 (t, *J* = 11.1, 1H), 1.96-1.88 (br m, 2H), 1.44 (s, 9H), 1.41-1.31 (m, 3H).




Example 131; 4-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester.

[0267] HPLC: R_t = 5.57. MS (ESI): mass calcd. for $C_{33}H_{39}Cl_2N_5O_5S$, 688.7; m/z found, 689.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.5, 1H), 7.55-7.51 (m, 2H), 7.49-7.47 (m, 2H), 7.37-7.34 (m, 2H), 4.55 (dd, J = 19.9, 14.5, 2H), 4.22-4.09 (m, 3H), 4.00 (dd, J = 13.6, 6.5, 1H), 3.74-3.61 (m, 2H), 3.47-3.38 (br m, 4H), 3.08-3.01 (m, 1H), 2.95-2.87 (m, 1H), 2.89 (s, 3H), 2.61-2.54 (m, 2H), 2.49-2.35 (m, 4H), 1.45 (s, 9H).




Example 132; 1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperazin-1-yl-propan-2-ol.

[0268] To a solution of 4-(3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester (117 mg, 0.161 mmol) in CH_2Cl_2 (1.1 mL) was added TFA (0.5 mL). The reaction mixture was stirred at rt for 1 h and then concentrated to give a brown oil. Purification (SiO_2; 0-10% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a clear oil (80 mg, 84%). MS (ESI): mass calcd. for $C_{28}H_{31}Cl_2N_5O_3S$, 588.6; m/z found, 589.3 $[M+H]^+$.



Example 133; 1-(4-Amino-piperidin-1-yl)-3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propan-2-ol.

[0269] This compound was prepared from [1-(3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester according to the method described in Example 132. MS (ESI): mass calcd. for $C_{29}H_{33}Cl_2N_5O_3S$, 602.6; m/z found, 603.4 $[M+H]^+$.



Example 134; 1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol.

[0270] A. 7-Bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester. To a solution of 7-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride (4.0 g, 16.1 mmol) and Et_3N (6.7 mL, 48.3 mmol) in CH_2Cl_2 (500 mL) was added di-*tert*-butyl-dicarbonate (4.2 g, 19.2 mmol). After 18 h at rt, the mixture was concentrated and the product was purified on SiO_2 (EtOAc/hexanes) to afford a clear oil (5.00 g, 99%).


[0271] B. 7-Trimethylsilanylethynyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester. To a solution of the above bromide (3.0 g, 9.6 mmol), $PdCl_2(PPh)_3$ (675 mg, 0.96 mmol), and CuI (183 mg, 0.96 mmol) in degassed DMF (50 mL) was added ethynyltrimethylsilane (2.7 mL, 19.2 mmol), followed by Et_3N (4.0 mL, 28.9 mmol). The reaction mixture was stirred under N_2 at 60 °C for 1 h. The mixture was diluted with satd. aq. $NaHCO_3$ and extracted with EtOAc (x2). The combined organic extracts were washed with water (x3), dried (Na_2SO_4), filtered, and concentrated to give a brown oil. Purification on SiO_2 (EtOAc/hexanes) afforded the desired product (2.78 g, 88%).

[0272] C. 7-Ethynyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester. To a solution of the above alkyne (2.7 g, 8.45 mmol) in THF (150 mL) was added tetrabutylammonium fluoride (1.0 M in THF; 16.9 mL, 16.9 mmol). After 1 h at rt, the mixture was diluted with water and extracted with EtOAc (x3). The combined organic extracts were washed with water (x3), dried (Na_2SO_4), filtered, and concentrated to give

a brown oil. Purification on SiO_2 (EtOAc/hexanes) provided the title compound as a yellow solid (1.82 g, 84%).

[0273] D. 7-{2-Chloro-5-[1-(2-hydroxy-3-piperidin-1-yl-propyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester. To a solution of 1-[7-(4-chloro-3-iodo-phenyl)-2-methanesulfonyl-2,3,4,5-tetrahydro-1H-[2]pyridin-5-yl]-3-piperidin-1-yl-propan-2-ol (25 mg, 0.04 mmol), $PdCl_2(PPh)_3$ (3 mg, 0.004 mmol), and CuI (1 mg, 0.004 mmol) in degassed THF (1 mL) was added the above alkyne (17 mg, 0.065 mmol) in degassed THF (200 μL), followed by Et_3N (200 μL, 0.129 mmol). The reaction mixture was stirred under N_2 at 50 °C for 18 h. Additional alkyne (17 mg, 0.065 mmol) in degassed THF (200 μL) was added and the mixture was heated at 50 °C for an additional 1 h. The mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (x3). The combined organic extracts were dried (Na_2SO_4) and concentrated to give a brown oil. Purification by preparative thin layer chromatography (SiO_2, 3% MeOH/NH_3/CH_2Cl_2) afforded the desired product as a yellow oil (26 mg, 87%).

[0274] E. 1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol. To a solution of 7-{2-chloro-5-[1-(2-hydroxy-3-piperidin-1-yl-propyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (23 mg, 0.033 mmol) in CH_2Cl_2 (1 mL), was added HCl (1.0 M in Et_2O; 100 μL, 0.100 mmol). After 1 h at rt, additional CH_2Cl_2 (1 mL) and HCl (1.0 M in Et_2O; 1 mL, 1.00 mmol) were added and the mixture was stirred for an additional 1 h. HCl (4.0 M in dioxane; 400 μL, 1.6 mmol) was added and the mixture was stirred for an additional 1 h, then was concentrated to afford the desired product. HPLC: R_t= 4.31. MS (ESI): mass calculated for $C_{32}H_{38}ClN_5O_3S$, 607.2; m/z found, 608.3 $[M+H]^+$. ^1H NMR (CD_3OD): 7.87 (s, 1H), 7.60 (dd, J = 17.9, 8.4, 2H), 7.52-7.46 (m, 2H), 7.32 (d, J = 7.9, 1H), 4.53 (s, 2H), 4.50 (br s, 1H), 4.40 (s, 2H), 4.21 (dd, J = 12.6, 4.8, 2H), 3.68-3.64 (m, 4H), 3.66 (s, 3H), 3.62-3.50 (m, 4H), 3.18 (dd, J = 14.1, 8.2, 3H), 3.11-2.97 (m, 6H), 1.98-1.71 (m, 4H).




Example 135; 1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide.

[0275] A. 1-{3-[3-(4-Chloro-3-iodo-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperidine-4-carboxylic acid amide. The title compound was prepared using methods analogous to those described in Example 1, Steps A-D, substituting isonipecotamide for morpholine in Step D.

[0276] B. 7-(5-{1-[3-(4-Carbamoyl-piperidin-1-yl)-propyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester. The title compound was prepared using methods analogous to those described in Example 134, Steps A-D.

[0277] C. 1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide. To a 0 °C solution of 7-(5-{1-[3-(4-carbamoyl-piperidin-1-yl)-propyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester (80 mg, 0.109 mmol) in CH_2Cl_2 (3 mL) was added TFA (100 μL, 1.32 mmol). After 30 min at 0 °C, additional TFA (1 mL, 13.2 mmol) was added. After 30 min, the mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2. The organic layer was removed and aqueous layer was decanted to leave an oil which was combined with the organic layer and concentrated. The residue was dissolved in MeOH, sonicated, and decanted from precipitates. The MeOH solution was concentrated to afford the desired product (10 mg, 14%). HPLC: R_t= 4.14. MS (ESI): mass calcd. for $C_{33}H_{39}ClN_6O_3S$, 634.3; m/z found, 635.3 $[M+H]^+$. ^1H NMR (CD_3OD): 7.86 (d, J = 1.8, 1H), 7.59 (dt, J = 14.2, 5.2, 2H), 7.53-7.48 (m, 1H), 7.46 (s, 1H), 7.32 (d, J = 8.0, 1H), 4.51 (s, 2H), 4.40 (s, 2H), 4.23 (t, J = 6.4, 2H), 3.69-3.60 (m, 4H), 3.53 (t, J = 6.4, 2H), 3.24-3.13 (m, 4H), 3.04-2.90 (m, 4H), 2.98 (s, 3H), 2.59-2.47 (m, 1H), 2.39-2.28 (m, 2H), 2.07 (d, J = 13.9, 2H), 1.96-1.82 (m, 2H).



Example 136; [3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester.

[0278] A. 3-(4-Chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. This compound was prepared according to the method described in Intermediate 1, Step B, substituting 4-oxo-piperidine-1-carboxylic acid tert-butyl ester for 1-methanesulfonyl-piperidin-4-one. HPLC: R_t = 7.69. MS (ESI): mass calcd. for $C_{17}H_{19}ClIN_3O_2$, 459.7; m/z found, 460.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.08 (br s, 1H), 7.45 (br m, 2H), 4.63 (br s, 2H), 3.73 (br m, 2H), 2.75 (br m, 2H), 1.49 (s, 9H).

[0279] B. 3-(4-Chloro-3-iodo-phenyl)-1-(2-cyano-ethyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. To a solution of the above pyrazole (2.8 g, 6.09 mmol) and acrylonitrile (14 mL) in THF (14 mL) was added 1% aq. NaOH (5.6 mL) dropwise. The reaction mixture was stirred at rt for 8 h, diluted with satd. aq. NH_4Cl, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a brown paste. Recrystallization from EtOH afforded the title compound as a white solid (2.24g, 72%). HPLC: R_t = 7.91. MS (ESI): mass calcd. for $C_{20}H_{22}ClIN_4O_2$, 512.8; m/z found, 514.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.18 (s, 1H), 7.51-7.46 (br m, 2H), 4.60 (br s, 2H), 4.30 (t, J = 6.5, 2H), 3.76-3.72 (br m, 2H), 2.98 (t, J = 6.5, 2H), 2.80-2.78 (br m, 2H), 1.49 (s, 9H).

[0280] C. 3-(4-Chloro-3-iodo-phenyl)-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. To a –78 ºC solution of the above nitrile (2.39 g, 4.66 mmol) in CH_2Cl_2 (23 mL) was added DIBAL-H (1.5 M in toluene; 7.75 mL, 5.17 mmol) dropwise. The mixture was stirred at –78 ºC for 30 min and then warmed to rt for 30 min. The reaction mixture was cooled to –78 ºC and MeOH (15 mL) was added dropwise. The mixture was warmed to rt over 1 h and 1 N H_2SO_4 (10 mL) was added. After 1 h, the cloudy mixture was diluted with satd. aq. potassium sodium tartrate and extracted with CH_2Cl_2 (3x). The combined organic extracts were washed with brine, dried (Na_2SO_4), filtered and concentrated to give a white foam, which was used directly in the next reaction. The reductive amination was

conducted in a similar manner to that reported in Intermediate 1, Step D, to provide the title compound as a white solid (1.43 g, 52%). HPLC: R_t = 5.42. MS (ESI): mass calcd. for $C_{24}H_{32}ClIN_4O_3$, 586.9; m/z found, 588.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.18 (d, J = 2.1, 1H), 7.54-7.49 (m, 2H), 4.60 (br s, 2H), 4.08 (t, J = 6.8, 2H), 3.76-3.71 (br m, 2H), 3.70 (br t, J = 4.5, 4H), 2.74 (br t, J = 5.4, 2H), 2.43-2.38 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.09-2.01 (m, 2H), 1.49 (s, 9H).

[0281] D. 3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. This compound was prepared from the above iodide according to the method described in Intermediate 1, Step E, substituting 4-chloro-ethynylbenzene for TMSA. HPLC: R_t = 6.43. MS (ESI): mass calcd. for $C_{32}H_{36}Cl_2N_4O_3$, 595.6; m/z found, 596.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.85 (s, 1H), 7.65-7.42 (m, 2H), 7.51 (d, J = 8.3, 2H), 7.37-7.32 (m, 2H), 4.65 (br s, 2H), 4.09 (t, J = 6.8, 2H), 3.78-3.71 (br m, 2H), 3.69 (br t, J = 4.5, 4H), 2.75 (br t, J = 5.2, 2H), 2.43-2.37 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.10-2.02 (m, 2H), 1.49 (s, 9H).

[0282] E. 3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. To a solution of the above carbamate (1.45 g, 2.43 mmol) in CH_2Cl_2 (20 mL) was added TFA (5 mL) dropwise. The reaction mixture was stirred at rt for 3 h and then concentrated to give an orange oil. Purification (SiO_2; 0-10% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a clear oil (1.11 g, 92%). HPLC: R_t = 4.53. MS (ESI): mass calcd. for $C_{27}H_{28}Cl_2N_4O$, 495.5; m/z found, 496.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.82 (d, J = 2.1, 1H), 7.52-7.49 (m, 3H), 7.43 (d, J = 8.4, 1H), 7.34 (dd, J = 6.6, 2.0, 2H), 4.10-4.06 (m, 4H), 3.70 (t, J = 4.6, 4H), 3.18 (t, J = 5.4, 2H), 2.92 (br s, 1H), 2.72 (t, J = 5.7, 2H), 2.42 (br m, 4H), 2.34 (t, J = 6.9, 2H), 2.09-2.03 (m, 2H).

[0283] F. [3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester. To a solution of the above amine (100 mg, 0.202 mmol) and pyridine (36 μL, 0.444 mmol) in CH_2Cl_2 (2.0 mL) was added methyl chlorooxoacetate (20 μL, 0.222 mmol) dropwise. The reaction mixture was stirred at rt for 1.5 h, diluted with satd. aq. $NaHCO_3$, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a yellow oil. Purification (SiO_2; 0-3% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a clear oil (104 mg, 89%). HPLC: R_t = 5.36. MS (ESI): mass calcd. for $C_{30}H_{30}Cl_2N_4O_4$, 581.5; m/z found, 582.4 $[M+H]^+$. ^1H NMR ($CDCl_3$, 2:1 mixture of rotamers): 7.83 (d, J = 2.1, 0.7H), 7.78 (d, J = 2.0, 0.3H),

7.57-7.40 (m, 4H), 7.35 (dd, J = 8.6, 2.0, 2H), 4.83 (s, 1.3H), 4.66 (s, 0.7H), 4.15-4.08 (m, 2H), 3.98 (t, J = 5.9, 1H), 3.93 (s, 2H), 3.87 (s, 1H), 3.75-3.69 (m, 5H), 2.91 (t, J = 5.6, 1H), 2.86 (t, J = 5.8, 1H), 2.40 (br m, 4H), 2.35-2.29 (m, 2H), 2.11-2.06 (m, 2H).

Alternative Synthesis of 3-(4-Chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester.


[0284] A. 4-Morpholin-4-yl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester. In a 3-L round-bottom flask equipped with a Dean-Stark trap, a reflux condenser and an internal thermocouple, *N*-Boc-piperidone (200 g, 1.0 mol, 1.0 equiv), toluene (2 L), morpholine (92 mL, 1.05 mol, 1.05 equiv), and *p*-toluenesulfonic acid (1.0 g, 0.005 mmol, 0.5% equiv) were added sequentially. The reaction solution was refluxed under N_2 for 16 h (about 18 mL water was collected). The solvent was evaporated and the residue was used directly in the next reaction (colorless oil, ~270 g, 100%).

[0285] B. 4-Chloro-3-iodo-benzoyl chloride. In a 5-L round-bottom flask equipped with a magnetic stirring bar and a gas scrubber, 4-chloro-3-iodobenzoic acid (275 g, 0.975 mol, 1.0 equiv) was suspended in CH_2Cl_2 (3 L) and DMF (2 mL, 0.026 mol, 2.5% equiv) was added. Under N_2 at 0 °C, oxalyl chloride (93.5 mL, 1.1 mol, 1.1 equiv) was added dropwise over 1 h. The ice bath was removed and the reaction solution was stirred at rt for 16 h. The solvent was evaporated and the residue was used directly in the next reaction (~290 g, 100%).

[0286] C. 3-(4-Chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. 4-Morpholin-4-yl-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (270 g, 1.0 mol, 1.0 equiv) was dissolved in CH_2Cl_2 (1.6 L) and then Et_3N (209 mL, 1.5 mol, 1.5 equiv) was added. At 0 °C under N_2, a solution of 4-chloro-3-iodo-benzoyl chloride (290 g, 1.0 mol, 1.0 equiv) in CH_2Cl_2 (400 mL) was added over 30 min. The ice bath was then removed and the reaction solution was stirred at rt for 3 h. All the volatile solvents were removed in vacuo and the residue was re-dissolved in EtOH (1.5 L). At 0 °C, anhydrous NH_2NH_2 (47 mL, 1.5 mol, 1.5 equiv) was added over 30 min (exothermic reaction). The reaction solution was stirred at rt for 16 h. The precipitated white solid was collected by filtration and washed with cold EtOH to afford the desired pyrazole product (white solid, ~ 333 g, 0.73 mol, >95% purity, 73%). The mother liquor was concentrated and was partitioned between CH_2Cl_2 and H_2O. Emulsion was observed due to the low solubility of the desired product in CH_2Cl_2. The insoluable solid was collected by filtration to provide an additional portion of the desired product. The organic layer was warmed slightly to assist phase separation. The organic layer was washed with water (3x), dried, and concentrated. The crude


product (filtered material plus residue) was recrystallized from hot CH_3CN to give the title compound (74 g, 0.16 mmol, 16%). The total yield was 89% for the three steps.

[0287] The compounds in Examples 137-142 were prepared using methods analogous to those described in Example 136, substituting the appropriate acid chloride for methyl chlorooxoacetate in Step F.




Example 137; [3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyridin-2-yl-methanone.

[0288] HPLC: R_t = 5.48. MS (ESI): mass calcd. for $C_{33}H_{31}Cl_2N_5O_2$, 600.6; m/z found, 601.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.60 (t, J = 4.8, 1H), 7.90 (d, J = 2.0, 1H), 7.87-7.77 (m, 1H), 7.76-7.70 (m, 1H), 7.63 (dd, J = 8.4, 2.1, 1H), 7.56-7.46 (m, 3H), 7.42-7.33 (m, 4H), 4.99 (s, 1H), 4.14-4.08 (m, 3H), 3.86 (t, J = 5.6, 1H), 3.72-3.68 (m, 4H), 2.98-2.90 (m, 2H), 2.44-2.38 (br m, 4H), 2.37-2.31 (m, 2H), 2.13-2.05 (m, 2H).




Example 138; [3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-furan-2-yl-methanone.

[0289] HPLC: R_t = 5.27. MS (ESI): mass calcd. for $C_{32}H_{30}Cl_2N_4O_3$, 589.5; m/z found, 590.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.86 (s, 1H), 7.54-7.50 (m, 3H), 7.46 (d, J = 8.4, 2H), 7.37-7.33 (m, 2H), 7.08 (d, J = 3.2, 1H), 6.52-6.50 (m, 1H), 4.95 (br s, 2H), 4.11 (t, J = 6.9, 2H), 4.05 (t, J = 5.6, 2H), 3.70 (t, J = 4.6, 4H), 2.96-2.90 (br m, 2H), 2.45-2.39 (br m, 4H), 2.34 (t, J = 6.8, 2H), 2.12-2.06 (m, 2H).




Example 139; 1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2,2-trifluoro-ethanone.

[0290] MS (ESI): mass calcd. for $C_{29}H_{27}Cl_2F_3N_4O_2$, 591.5; m/z found, 592.4 $[M+H]^+$.




Example 140; 1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-fluoro-ethanone.

[0291] MS (ESI): mass calcd. for $C_{29}H_{29}Cl_2FN_4O_2$, 555.5; m/z found, 556.4 $[M+H]^+$.




Example 141; [3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(tetrahydro-furan-2-yl)-methanone.

[0292] MS (ESI): mass calcd. for $C_{32}H_{34}Cl_2N_4O_3$, 593.6; m/z found, 594.4 $[M+H]^+$.




Example 142; Acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester.

[0293] MS (ESI): mass calcd. for $C_{31}H_{32}Cl_2N_4O_4$, 595.5; m/z found, 596.4 $[M+H]^+$.



Example 143; 1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-hydroxy-ethanone.


[0294] To a slurry of acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester (105 mg, 0.176 mmol) in 2:1 MeOH/H_2O (1.5 mL) was added NaOH (14 mg, 0.352 mmol). The reaction mixture was stirred at rt for 2 h, diluted with satd. aq. $NaHCO_3$, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated to give a yellow oil. Purification (SiO_2; 0-5% 2 M NH_3 in MeOH/CH_2Cl_2) provided the title compound as a white solid (62 mg, 64%). MS (ESI): mass calcd. for $C_{29}H_{30}Cl_2N_4O_3$, 553.5; m/z found, 554.4 $[M+H]^+$.



Example 144; 3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.


[0295] This compound was prepared according to the methods described in Example 136, substituting trimethylsilyl isocyanate for methyl chlorooxoacetate in Step F. HPLC: R_t = 4.81. MS (ESI): mass calcd. for $C_{28}H_{29}Cl_2N_5O_2$, 538.5; m/z found, 539.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 2.0, 1H), 7.52-7.50 (m, 2H), 7.43 (d, J = 8.4, 2H), 7.34 (d, J = 8.5, 2H), 4.90 (s, 2H), 4.58 (s, 2H), 4.12-4.06 (m, 2H), 3.74 (t, J = 5.6, 2H), 3.68 (t, J = 4.5, 4H), 2.77 (t, J = 5.4, 2H), 2.39 (br m, 4H), 2.32 (t, J = 6.8, 2H), 2.08-1.99 (m, 2H).

[0296] The compounds in Examples 145-149 were prepared using methods analogous to those described in Example 2. The alkynes used as starting materials for Examples 145-149 are described in the preceding examples.



Example 145; 3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.


[0297] HPLC: R_t = 5.04. MS (ESI): mass calcd. for $C_{28}H_{33}Cl_2N_5O_2$, 542.5; m/z found, 543.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.43 (d, J = 1.8, 1H), 7.36 (dd, J = 8.3, 2.0, 2H), 7.26-7.23 (m, 2H), 7.16-7.13 (m, 2H), 4.61 (br s, 2H), 4.47 (s, 2H), 4.09 (t, J = 6.9, 2H), 3.76 (t, J = 5.7, 2H), 3.69 (t, J = 4.6, 4H), 3.06-3.01 (m, 2H), 2.95-2.90 (m, 2H), 2.78 (t, J = 5.7, 2H), 2.42-2.38 (br m, 4H), 2.33 (t, J = 6.8, 2H), 2.13-2.05 (m, 2H).



Example 146; 1-{1-[3-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-piperidin-4-yl}-pyrrolidin-2-one.


[0298] HPLC: R_t = 5.33. MS (ESI): mass calcd. for $C_{34}H_{41}ClF_3N_5O_4S$, 708.3; m/z found, 709.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.68 (d, J = 8.2, 1H), 7.54 (s, 1H), 7.46 (d,

J = 8.2, 1H), 7.28-7.25 (m, 2H), 7.17-7.13 (m, 2H), 4.49 (dd, J = 18.5, 14.6, 2H), 4.19 (dd, J = 13.8, 2.8, 1H), 4.16-4.09 (m, 1H), 4.04-3.96 (m, 2H), 3.73-3.62 (m, 2H), 3.34 (t, J = 7.0, 2H), 3.13-2.99 (m, 4H), 2.95-2.86 (m, 5H), 2.88 (s, 3H), 2.50-2.42 (m, 3H), 2.39 (t, J = 8.2, 2H), 2.05-1.97 (m, 3H), 1.76-1.62 (m, 4H).




Example 147; 1-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol.

[0299] HPLC: R_t = 5.56. MS (ESI): mass calcd. for $C_{29}H_{34}ClF_3N_4O_4S$, 627.1; m/z found, 628.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.68 (d, J = 8.2, 1H), 7.53 (s, 1H), 7.46 (d, J = 8.2, 1H), 7.28-7.25 (m, 2H), 7.17-7.14 (m, 2H), 4.49 (dd, J = 19.4, 14.5, 2H), 4.21 (dd, J = 13.7, 2.8, 1H), 4.18-4.13 (m, 1H), 4.02 (dd, J = 13.6, 6.7, 1H), 3.75-3.62 (m, 6H), 3.12-3.02 (m, 3H), 2.96-2.87 (m, 4H), 2.88 (s, 3H), 2.66-2.60 (m, 2H), 2.50-2.40 (m, 4H).



Example 148; 8-[3-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-2,8-diaza-spiro[4.5]decan-1-one.


[0300] HPLC: R_t = 5.21. MS (ESI): mass calcd. for $C_{32}H_{39}Cl_2N_5O_4S$, 660.7; m/z found, 661.5 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.40-7.30 (m, 4H), 7.23 (d, J = 7.5, 2H), 7.13 (d, J = 7.9, 2H), 4.43 (dd, J = 17.8, 15.0, 2H), 4.17-4.10 (m, 2H), 4.01-3.94 (m, 1H), 3.70-3.60 (m, 2H), 3.35-3.33 (m, 1H), 3.30 (t, J = 6.8, 2H), 3.07-2.99 (m, 3H), 2.93-2.78 (m, 5H), 2.87 (s, 3H), 2.45-2.38 (m, 2H), 2.30 (br t, J = 10.8, 2H), 2.10 (br t, J = 11.7, 2H), 2.02 (t, J = 6.9, 2H), 1.95-1.82 (m, 2H).



Example 149; 1-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol.

[0301] HPLC: R_t = 5.47. MS (ESI): mass calcd. for $C_{28}H_{30}Cl_2N_4O_4S$, 589.6; m/z found, 590.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.5, 1H), 7.54-7.50 (m, 2H), 7.48-7.46 (m, 2H), 7.36-7.33 (m, 2H), 4.53 (dd, J = 18.3, 14.5, 2H), 4.18 (dd, J = 13.3, 2.9, 1H), 4.17-4.10 (m, 1H), 3.99 (dd, J = 13.7, 6.6, 1H), 3.71-3.60 (m, 6H), 3.07-2.99 (m, 1H), 2.93-2.85 (m, 2H), 2.87 (s, 3H), 2.65-2.58 (m, 2H), 2.48-2.38 (m, 4H).

[0302] Unless otherwise specified, the compounds in Examples 150-621 were prepared as free base, hydrochloride salt, trifluoroacetic acid salt, citric acid, or formic acid salt forms.



Example 150; 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide.

[0303] A. 3-(4-Chloro-3-iodo-phenyl)-1-(3-hydroxy-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. A mixture of 3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (21.0 mmol) and Cs_2CO_3 (43.8 mmol) in DMF (73 mL) at 0 °C, was treated with 3-bromo-propan-1-ol (32.9 mmol). The mixture was stirred at rt for 15 h. The mixture was poured into water and extracted with EtOAc (3x). The combined organic layers were washed satd. aq. NaCl (4x). The organic phase was dried and concentrated, and the resulting oil was purified (SiO_2; 10-50% EtOAc/hexanes) to afford the title

compound (74%). MS (ESI): mass calcd. for $C_{20}H_{25}ClIN_3O_3$, 517.06; m/z found, 518.1 $[M+H]^+$.

[0304] B. 3-(4-Chloro-3-iodo-phenyl)-1-(3-oxo-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. A solution of the alcohol above (9.8 mmol) and Dess-Martin periodinane (14.7 mmol) in CH_2Cl_2 (43.4 mL) was stirred for 2 h at rt. The mixture was poured into satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (3x). The combined organic layers were dried and concentrated. The resulting oil was passed through a plug of SiO_2 eluting with CH_2Cl_2 and EtOAc. The filtrate was concentrated and used immediately. MS (ESI): mass calcd. for $C_{20}H_{23}ClIN_3O_3$, 515.05; m/z found, 516.1 $[M+H]^+$.

[0305] C. 3-(4-Chloro-3-iodo-phenyl)-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. This compound was prepared from the aldehyde above according to the method described for Intermediate 1, Part D. MS (ESI): mass calcd. for $C_{24}H_{32}ClIN_4O_3$, 586.12; m/z found, 587.2 $[M+H]^+$.

[0306] D. 3-[4-Chloro-3-(4-{[(4-chloro-benzyl)-(2,2,2-trifluoro-acetyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. This compound was prepared according to the method described for Intermediate 1, Part E, substituting N-(4-chloro-benzyl)-N-(4-ethynyl-benzyl)-2,2,2-trifluoro-acetamide for (trimethylsilyl)acetylene. MS (ESI): mass calcd. for $C_{42}H_{44}Cl_2F_3N_5O_4$, 809.27; m/z found, 810.2 $[M+H]^+$.


[0307] E. N-(4-Chloro-benzyl)-N-(4-{2-chloro-5-[1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl] phenylethynyl}-benzyl)-2,2,2-trifluoro-acetamide. This compound was prepared according to the method described in Example 136, Part E. MS (ESI): mass calcd. for $C_{37}H_{36}Cl_2F_3N_5O_2$, 709.22; m/z found, 710.2 $[M+H]^+$.

[0308] F. N-(4-{5-[5-Aminooxalyl-1-(3-morpholin-4-yl-propyl)-3a,4,5,6,7,7a-hexahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chloro-phenylethynyl}-benzyl)-N-(4-chloro-benzyl)-2,2,2-trifluoro-acetamide. To N-(4-chloro-benzyl)-N-(4-{2-chloro-5-[1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl] phenylethynyl}-benzyl)-2,2,2-trifluoro-acetamide (0.132 mmol) was added oxalamic acid (0.527 mmol), HATU (0.264 mmol), HOAT (0.5 M in DMF; 530 µL), DMF (0.66 mL), and iPr_2NEt (0.396 mmol). The mixture was stirred at 80 °C for 26.5 h. The mixture was poured into satd. aq. $NaHCO_3$ (10 mL). The aqueous phase was extracted CH_2Cl_2 (3 x 10 mL) and EtOAc (2 x 10 mL). The combined organic layers were dried and concentrated.

The resulting oil was purified (SiO_2; 0-5% 0.2 M NH_3 in MeOH/CH_2Cl_2) to afford the title compound as an oil (60%, 0.080 mmol). MS (ESI): mass calcd. for $C_{39}H_{39}Cl_2F_3N_6O_4$, 782.24; m/z found, 783.2 $[M+H]^+$.

[0309] G. 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide. A mixture of N-(4-{5-[5-aminooxalyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chloro-phenylethynyl}-benzyl)-N-(4-chloro-benzyl)-2,2,2-trifluoro-acetamide (0.026 mmol) and K_2CO_3 (0.153 mmol) in MeOH/H_2O (2:1, 1.5 mL) was stirred for 30 min. The mixture was poured into H_2O, extracted with CH_2Cl_2 (2x) and EtOAc (2x). The combined organic layers were dried and concentrated. The resulting oil was purified using preparatory HPLC (Method E). MS (ESI): mass calcd. for $C_{37}H_{38}Cl_2N_6O_3$, 684.24; m/z found, 685.2 $[M+H]^+$. ^1H NMR: 7.92-7.81 (m, 1H), 7.68-7.63 (m, 3H), 7.60-7.56 (m, 3H), 7.55-7.52 (m, 2H), 7.50-7.44 (m, 2H), 4.80 (s, 1H), 4.32-4.23 (m, 6H), 4.05-3.91 (m, 4H), 3.78 (t, J = 12, 2H), 3.51 (d, J = 12, 2H), 3.31-3.23 (m, 6H), 3.15 (dt, J = 12, 3, 2H), 3.00-2.87 (m, 2H), 2.42-2.33 (m, 2H).


[0310] The compounds in Examples 151-155 were prepared using methods analogous to those described in Example 150, substituting oxalamic acid with the appropriate carboxylic acids (Step F), or substituting oxalamic acid, HATU, HOAt, iPr_2NEt, and DMF with the appropriate sulfonyl chlorides, acid chlorides, or isocyanates in CH_2Cl_2, with exceptions or alterations where noted.



Example 151; 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.


[0311] The compound was purified using preparatory HPLC (Method E; HCl salt). MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6O_2$, 656.24; m/z found, 657.2 $[M+H]^+$. ^1H NMR: 7.93 (d, J = 1.9, 1H), 7.68-7.64 (m, 3H), 7.63-7.59 (m, 3H), 7.59-7.54 (m, 3H), 7.49-7.45 (m, 2H), 4.76 (s, 1H), 4.35-4.25 (m, 7H), 4.02 (dd, J = 13, 2.9, 2H), 3.90 (t, J

= 5.5, 2H), 3.84 (dd, *J* = 25, 13, 2H), 3.52 (d, *J* = 12, 2H), 3.30-3.25 (m, 4H), 3.17 (dt, *J* = 12, 3.4, 2H), 2.96 (t, *J* = 5.2, 2H), 2.46-2.36 (m, 2H).




Example 152; 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N,N-dimethyl-2-oxoacetamide.

[0312] The compound was purified using preparatory HPLC (Method F; HCl salt). MS (ESI): mass calcd. for $C_{39}H_{42}Cl_2N_6O_3$, 712.27; m/z found, 713.3 $[M+H]^+$. ^1H NMR: 7.89 (m, 1H), 7.70-7.65 (m, 3H), 7.63-7.58 (m, 3H), 7.57-7.54 (m, 2H), 7.52-7.47 (m, 2H), 4.87-4.85 (m, 1H), 4.32 (d, *J* = 15, 4H), 4.28 (t, *J* = 6.6, 2H), 4.07-4.01 (m, 3H), 3.86-3.74 (m, 4H), 3.52 (d, *J* = 13, 2H), 3.31-3.24 (m, 2H), 3.17 (dt, *J* = 12, 3.6, 2H), 3.07 (d, *J* = 11, 5H), 3.01-2.92 (m, 4H), 2.44-2.35 (m, 2H).




Example 153; 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-sulfonamide.

[0313] The compound was purified using preparatory HPLC (Method F; HCl salt). MS (ESI): mass calcd. for $C_{37}H_{42}Cl_2N_6O_3S$, 720.24; m/z found, 721.3 $[M+H]^+$. ^1H NMR (DMSO): 7.90 (d, *J* = 1.7, 1H), 7.71-7.62 (m, 7H), 7.60 (dd, *J* = 8.4, 1.7, 1H), 7.51 (d, *J* = 8.3, 2H), 4.49 (s, 2H), 4.22-4.13 (m, 6H), 3.93 (d, *J* = 11, 2H), 3.88-3.84 (m, 3H), 3.58 (t, *J* = 5.3, 2H), 3.41 (d, *J* = 12, 2H), 3.19-3.11 (m, 2H), 3.11-2.99 (m, 2H), 2.90-2.86 (m, 2H), 2.80-2.73 (m, 6H), 2.34-2.27 (m, 2H).




Example 154; 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanamine.

[0314] The compound was purified using preparatory HPLC (Method E). Collected fractions were concentrated and the residue was treated with HCl (1.25 N in MeOH; 3 mL) in CH_2Cl_2 (3 mL). After 18 h, the mixture was concentrated to give the compound as the HCl salt. MS (ESI): mass calcd. for $C_{37}H_{40}Cl_2N_6O_2$, 670.26; m/z found, 671.3 $[M+H]^+$. ^1H NMR: 7.99-7.89 (m, 1H), 7.72-7.64 (m, 3H), 7.63-7.59 (m, 3H), 7.57-7.52 (m, 2H), 7.51-7.48 (m, 2H), 4.86 (s, 2H), 4.70 (d, J = 18, 1H), 4.36-4.25 (m, 6H), 4.17 (s, 1.3H), 4.11 (s, 0.7H), 4.04 (d, J = 13, 3H), 3.89-3.75 (m, 4H), 3.54 (d, J = 12, 2H), 3.31-3.24 (m, 3H), 3.18 (t, J = 11, 2H), 3.05 (s, 1.3H), 2.92 (s, 0.7H), 2.41 (d, J = 1.0, 2H).



Example 155; 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.


[0315] The compound was purified using preparatory HPLC (Method F; HCl salt). MS (ESI): mass calcd. for $C_{37}H_{40}Cl_2N_6O_2$, 670.26; m/z found, 671.3 $[M+H]^+$. ^1H NMR: 7.84 (d, J = 2.1, 1H), 7.61-7.54 (m, 3H), 7.53-7.48 (m, 3H), 7.47-7.45 (m, 2H), 7.40-7.36 (m, 2H), 4.94 (s, 1H), 4.54 (s, 2H), 4.24-4.18 (m, 6H), 3.93 (dd, J = 13, 3.2, 2H), 3.75-3.67 (m, 4H), 3.42 (d, J = 13, 2H), 3.20-3.16 (m, 2H), 3.07 (dt, J = 12, 3.6, 2H), 2.77 (t, J = 5.6, 2H), 2.66 (s, 3H), 2.35-2.25 (m, 2H).



Example 156; 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.


[0316] This compound was prepared according to the methods described in Example 150, following sequentially Steps A, B, C, E, F, and then D with the appropriate substituent changes. The compound was purified using preparatory HPLC (Method B; TFA salt). MS (ESI): mass calcd. for $C_{41}H_{42}Cl_2N_8O$, 732.29; m/z found, 733.3 $[M+H]^+$. ^1H NMR: 8.17 (t, J = 7.7, 1H), 8.08 (d, J = 5.8, 1H), 7.96-7.93 (m, 1H), 7.69 (d, J = 7.9, 3H), 7.64-7.57 (m, 3H), 7.57-7.53 (m, 2H), 7.53-7.45 (m, 3H), 7.17 (t, J = 6.5, 1H), 4.73 (s, 2H), 4.53-4.36 (m, 2H), 4.31 (d, J = 12.2, 6H), 4.01-3.55 (m, 8H), 3.43-3.34 (m, 3H), 2.98-2.91 (m, 2H), 2.52-2.43 (m, 2H), 1.43-1.25 (m, 2H).

[0317] The compounds in Examples 157-165 were prepared using methods analogous to those described for Example 156.



Example 157; 2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S,5S)-3,5-dimethylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide.

[0318] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{39}H_{42}Cl_2N_6O_3$, 712.27; m/z found, 714.2 $[M+H]^+$. ^1H NMR: 7.93-7.83 (m, 1H), 7.71-7.67 (m, 3H), 7.60 (t, J = 9.3, 3H), 7.55-7.49 (m, 4H), 4.93-4.90 (m, 1H), 4.84-4.81 (m, 1H), 4.31 (d, J = 13.2, 4H), 4.28-4.24 (m, 3H), 4.06-3.93 (m, 3H), 3.89 (q, J = 13.0, 2H), 3.77-3.69 (m, 1H), 3.69-3.60 (m, 1H), 3.62-3.42 (m, 2H), 3.38-3.35 (m, 2H), 3.22-3.08 (m, 1H), 3.09-2.87 (m, 2H), 2.50-2.36 (m, 1H), 2.31-2.19 (m, 1H), 1.42 (d, J = 6.5, 3H), 1.30 (d, J = 6.1, 3H).



Example 158; 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide.

[0319] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{38}H_{40}Cl_2N_6O_3$, 698.25; m/z found, 699.2 $[M+H]^+$. ^1H NMR: 7.90-7.89 (m, 0.7H), 7.84-7.82 (m, 0.3H), 7.70-7.66 (m, 3H), 7.61-7.55 (m, 3H), 7.53-7.45 (m, 4H), 4.81 (s, 1H), 4.31 (s, 2H), 4.28 (s, 2H), 4.27-4.22 (m, 2H), 4.05 (d, *J* = 13, 1H), 4.02-3.94 (m, 3H), 3.87-3.68 (m, 2H), 3.58-3.39 (m, 4H), 3.35-3.32 (m, 1H), 3.26-3.13 (m, 3H), 3.02-2.85 (m, 2H), 2.47-2.35 (m, 1H), 2.33-2.20 (m, 1H), 1.45-1.22 (m, 4H).

Alternative Synthesis of 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide.

[0320] A. 4-(3-Chloro-propyl)-(3S)-methyl-morpholine. A solution of (3S)-methyl-morpholine (1 g, 9.9 mmol, 1.0 equiv) and 1-bromo-3-chloro-propane (3.1 g, 19.8 mmol, 2.0 equiv) in THF (5 mL) was treated with NaH (60%, 2 equiv) in two portions. The resulting slurry was heated at 65 ºC for 18 h. Slowly, the reaction was quenched with ice water (20 mL). During the addition, excess bubbling occurred. The resulting mixture was stirred for 16 h and then was extracted with EtOAc (3 x 15 mL). The combined organic layers were extracted with 1 N HCl (40 mL). The aqueous layer was cooled in an ice bath and basified slowly to pH ~9-10 with NaOH pellets. The aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic layers were dried and concentrated to give the title compound as a clear oil (1.3 g, 74%).

[0321] B. 3-(4-Chloro-3-iodo-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. A suspension of 3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (260 g, 0.57 mol, 1.0 equiv) in CH_2Cl_2 (750


mL) was treated with TFA (250 mL) over 20 min. The resulting solution was stirred at rt for 16 h. The mixture was diluted with water (2 L) and then basified with satd. aq. NaOH to a pH > 12. The mixture was stirred for 3 h. The white precipitate was collected by filtration, washed with water and dried in a vacuum oven to provide the title compound (205 g, 0.57 mol, 100%), which was used in the next reaction without further purification.

[0322] C. 2-[3-(4-Chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide. A suspension of CDI (110.5 g, 0.68 mol, 1.2 equiv) in DMF (1.5 L) was treated with oxalamic acid (60.7 g, 0.68 mol, 1.2 equiv). After 3 h at rt, 3-(4-chloro-3-iodo-phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (205 g, 0.57 mol, 1.0 equiv) was added as solid over 10 min. After 20 min, water (2.5 L) was added slowly over 2 h and the mixture was stirred at rt for 16 h. The resulting white precipitate was collected by filtration, washed with water and dried in a vacuum oven to provide the title compound (243 g, 0.56 mol, 100%), which was used in the next reaction without further purification.

[0323] D. 2-{3-(4-Chloro-3-iodo-phenyl)-1-[3-((3S)-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide. A solution of 2-[3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide (190 g, 0.44 mol, 1.0 equiv) in DMF (1.8 L) was treated with Cs_2CO_3 (180 g, 0.55 mol, 1.25 equiv) followed by 4-(3-chloro-propyl)-(3S)-methyl-morpholine (86 g, 0.48 mol, 1.1 equiv). The reaction mixture was stirred via mechanical stirrer at 50 °C under N_2 for 12 h and then cooled to rt. Water (3.5 L) was added slowly over 30 min. The mixture was stirred at rt for 16 h and the resulting white solid was collected by filtration, washed with water and dried in a vacuum oven. The crude compound was triturated from hot EtOH (~1.5 L) to provide the title compound (176 g, 0.31 mol, 70%).


[0324] E. 2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide. To a 5 L flask equipped with a mechanical stirrer and an internal thermocouple, was added 2-{3-(4-chloro-3-iodo-phenyl)-1-[3-((3S)-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide (120 g, 0.21 mol, 1.0 equiv), (4-chloro-benzyl)-(4-ethynyl-benzyl)-amine (56.3 g, 0.22 mol, 1.0 equiv), DMF (1.5 L) and Et_3N (120 mL, 0.84 mol, 4.0 equiv) sequentially. A stream of N_2 was bubbled into the solution for 15 min. A mixture of $Pd(PPh_3)_2Cl_2$ (0.37 g, 0.5 mmol, 0.0025 equiv) and CuI (0.2 g, 1.0 mmol, 0.005 equiv) was added under N_2. The

solution was degassed with N_2 for another 10 min. The reaction solution was stirred at 50 °C for 16 h. The reaction solution was cooled to rt and water (2 L) was added with stirring. The liquid layer was decanted away from an oily precipitate, which was then partitioned between EtOAc (2 L) and 2:1 water/satd. aq. $NaHCO_3$ (1.5 L). The organic layer was dried and concentrated to provide the crude material as a foamy yellow solid (145 g, ~85% purity by HPLC). The crude material was purified (SiO_2; 2 N NH_3 in $MeOH/CH_2Cl_2$) to provide the title compound (87 g, 59%, >98% purity).



Example 159; 2-{3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide.


[0325] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{39}H_{40}Cl_2N_6O_3$, 710.25; m/z found, 711.2 $[M+H]^+$. ^1H NMR: 7.80-7.69 (m, 1H), 7.59-7.54 (m, 1H), 7.54-7.38 (m, 6H), 7.35 (s, 1H), 7.25 (d, J = 7.9, 1H), 4.70 (s, 2H), 4.43 (s, 2H), 4.36 (d, J = 7.3, 2H), 4.20-4.09 (m, 2H), 4.01-3.77 (m, 4H), 3.72 (s, 1H), 3.64 (t, J = 12.0, 2H), 3.40 (d, J = 12.8, 3H), 3.18-3.12 (m, 5H), 3.11-2.96 (m, 3H), 2.87 (s, 1H), 2.83-2.78 (m, 1H), 2.34-2.14 (m, 2H).



Example 160; 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.


[0326] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6OS$, 672.22; m/z found, 673.3 $[M+H]^+$. ^1H NMR: 7.92-7.90 (m, 1H), 7.70-7.65 (m, 3H), 7.60-7.55 (m, 3H), 7.53-7.47 (m, 4H), 4.93-

4.90 (m, 1H), 4.66 (s, 2H), 4.29 (d, J = 16.2, 4H), 4.24 (t, J = 6.4, 2H), 3.85-3.74 (m, 4H), 3.35-3.33 (m, 1H), 3.28-3.17 (m, 5H), 3.06 (t, J = 13.3, 2H), 2.87-2.81 (m, 4H), 2.38-2.31 (m, 2H).




Example 161; 3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0327] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{35}H_{37}ClN_6O_2S$, 640.24; m/z found, 641.2 $[M+H]^+$. ^1H NMR: 8.89 (s, 1H), 8.81 (d, J = 5.4, 1H), 8.67 (d, J = 7.9, 1H), 8.11 (dd, J = 7.8, 6.0, 1H), 7.91 (s, 1H), 7.65 (d, J = 8.3, 1H), 7.62-7.56 (m, 3H), 7.51-7.47 (m, 2H), 4.85 (s, 2H), 4.77 (s, 2H), 4.67 (s, 2H), 4.27-4.23 (m, 2H), 3.87-3.74 (m, 4H), 3.28-3.17 (m, 5H), 3.14-3.03 (m, 2H), 2.89-2.79 (m, 4H), 2.36 (d, J = 1.2, 2H), 1.29-1.28 (m, 1H).




Example 162; 3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0328] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{35}H_{36}ClN_7O_2S$, 653.23; m/z found, 654.2 $[M+H]^+$. ^1H NMR: 8.92 (s, 1H), 8.80 (d, J = 5.2, 1H), 8.68 (d, J = 8.0, 1H), 8.11 (dd, J = 7.9, 5.8, 1H), 7.99-7.90 (m, 3H), 7.73-7.65 (m, 3H), 7.59 (d, J = 8.3, 1H), 4.83-4.74 (m, 3H), 4.70 (s, 2H), 4.30-4.20 (m, 2H), 3.82 (d, J = 10.3, 3H), 3.35 (s, 4H), 3.28-3.17 (m, 4H), 3.17-3.06 (m, 2H), 2.95-2.73 (m, 3H), 2.43-2.30 (m, 2H).




Example 163; 3-{4-Chloro-3-[(4-{[(piperidin-4-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0329] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{35}H_{43}ClN_6O_2S$, 646.29; m/z found, 647.3 $[M+H]^+$. ^1H NMR: 7.91 (s, 1H), 7.65 (dd, J = 8.4, 2.1, 1H), 7.57 (dd, J = 9.6, 8.4, 3H), 7.40 (d, J = 8.1, 2H), 4.93 (s, 1H), 4.66 (s, 2H), 4.56 (s, 2H), 4.24 (t, J = 6.5, 2H), 3.85-3.75 (m, 4H), 3.47-3.36 (m, 5H), 3.28-3.17 (m, 5H), 3.14-3.03 (m, 2H), 3.00 (t, J = 11.8, 2H), 2.88-2.79 (m, 4H), 2.42-2.28 (m, 2H), 2.03-1.96 (m, 3H), 1.57-1.48 (m, 2H).




Example 164; 3-(4-Chloro-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0330] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{33}H_{37}ClN_6O_2S$, 616.24; m/z found, 617.2 $[M+H]^+$. ^1H NMR (DMSO): 7.93 (d, J = 1.6, 1H), 7.70 (dd, J = 8.5, 1.7, 1H), 7.67 (d, J = 8.5, 3H), 7.60 (d, J = 8.1, 2H), 4.57 (s, 2H), 4.14 (t, J = 6.8, 2H), 3.71 (d, J = 8.4, 2H), 3.64 (t, J = 5.4, 2H), 3.48 (t, J = 6.7, 2H), 3.44-3.31 (m, 4H), 3.20-3.09 (m, 6H), 2.81 (d, J = 13.1, 2H), 2.73 (t, J = 4.5, 2H), 2.31-2.18 (m, 2H), 1.88 (td, J = 13.0, 6.4, 2H), 1.85-1.79 (m, 2H).




Example 165; 3-{4-Chloro-3-[(4-{[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0331] The compound was purified using preparatory HPLC (Method B; HCl salt). MS (ESI): mass calcd. for $C_{38}H_{46}ClN_7O_2S$, 699.31; m/z found, 700.3 $[M+H]^+$. ^1H NMR: 7.95 (d, J = 2.0, 1H), 7.72 (d, J = 8.2, 2H), 7.69 (dd, J = 8.4, 2.1, 1H), 7.65 (d, J = 8.2, 2H), 7.60 (d, J = 8.4, 1H), 4.69 (s, 2H), 4.39 (s, 2H), 4.26 (t, J = 6.5, 2H), 4.21-4.08 (m, 1H), 3.86-3.80 (m, 4H), 3.60 (d, J = 12.6, 2H), 3.46 (t, J = 7.0, 2H), 3.30-3.05 (m, 9H), 2.91-2.80 (m, 4H), 2.39 (dd, J = 15.2, 6.9, 4H), 2.21-2.10 (m, 2H), 2.10-2.01 (m, 2H), 2.00-1.92 (m, 2H), 1.30 (s, 1H).



Example 166; 1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine.

[0332] The title compound was prepared according to the methods describe for Example 150, but the reaction described in Step G proceeded for 1 h. The compound was purified using preparatory HPLC (Method B; TFA salt). MS (ESI): mass calcd. for $C_{35}H_{37}Cl_2N_5O$, 613.24; m/z found, 614.2 $[M+H]^+$. ^1H NMR: 7.88 (s, 1H), 7.66 (d, J = 8.1, 2H), 7.60-7.58 (m, 2H), 7.56 (d, J = 8.2, 2H), 7.52-7.47 (m, 4H), 4.94-4.91 (m, 2H), 4.48 (s, 2H), 4.33-4.23 (m, 6H), 4.12-3.91 (m, 2H), 3.87-3.67 (m, 2H), 3.61 (t, J = 6.1, 2H), 3.57-3.42 (m, 2H), 3.34 (s, 1H), 3.25 (dd, J = 9.4, 6.7, 2H), 3.16 (t, J = 6.0, 3H), 2.41-2.34 (m, 2H).




Example 167; 3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0333] A. 3-(4-Chloro-3-iodo-phenyl)-1-(3-piperidin-1-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide. This compound was prepared according to the methods described in Example 150, following sequentially Steps A, B, C, E, and then F, with the appropriate substituent changes. MS (ESI): mass calcd. for $C_{21}H_{27}ClIN_5O$, 527.09; m/z found, 528.1 $[M+H]^+$.

[0334] B. 3-(4-Chloro-3-trimethylsilanylethynyl-phenyl)-1-(3-piperidin-1-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide. This compound was prepared according to the methods described for Intermediate 1, Step E. MS (ESI): mass calcd. for $C_{26}H_{36}ClN_5OSi$, 497.24; m/z found, 498.2 $[M+H]^+$.


[0335] C. 3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide. This compound was prepared according to the methods described for Intermediate 1, Step E, substituting (2-chloro-5-iodo-benzyl)-ethyl-amine for (trimethylsilyl)acetylene, DMF instead of THF, DBU instead of TEA, and adding 2.8 eq. H_2O. The compound was purified using preparatory HPLC (Method C; HCl salt). MS (ESI): mass calcd. for $C_{32}H_{38}Cl_2N_6O$, 592.25; m/z found, 593.1 $[M+H]^+$. ^1H NMR: 8.02-7.78 (m, 2H), 7.70-7.55 (m, 4H), 4.76-4.67 (m, 2H), 4.46-4.37 (m, 2H), 4.30-4.22 (m, 2H), 3.94-3.79 (m, 2H), 3.54 (d, J = 9.2, 2H), 3.29-3.13 (m, 4H), 3.03-2.85 (m, 4H), 2.45-2.30 (m, 2H), 1.92 (d, J = 12.6, 2H), 1.80 (d, J = 11.5, 4H), 1.59-1.46 (m, 1H), 1.43-1.38 (m, 4H), 1.31-1.26 (m, 1H).

[0336] The compounds in Examples 168-169 were prepared using methods analogous to those described in Example 167, with the appropriate substituent changes.




Example 168; 5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(2-morpholin-4-ylethyl)benzamide.

[0337] The compound was purified using preparatory HPLC (Method B; TFA salt). MS (ESI): mass calcd. for $C_{37}H_{43}Cl_2N_7O_5$, 735.27; m/z found, 736.3 $[M+H]^+$. ^1H NMR: 7.88-7.79 (m, 1H), 7.74 (d, J = 1.9, 1H), 7.66 (dd, J = 8.4, 2.1, 1H), 7.62 (dd, J = 8.3, 2.0, 1H), 7.58-7.52 (m, 2H), 4.83-4.76 (m, 1H), 4.25-4.19 (m, 2H), 4.17-4.00 (m, 3H), 3.99-3.91 (m, 4H), 3.87-3.70 (m, 5H), 3.69-3.59 (m, 2H), 3.59-3.49 (m, 3H), 3.49-3.42 (m, 3H), 3.28-3.12 (m, 5H), 2.96-2.92 (m, 1.3H), 2,89-2.85 (m, 0.7H), 2.47-2.32 (m, 1H), 2.32-2.18 (m, 1H), 1.39 (s, 1H), 1.27 (d, J = 5.6, 2H).



Example 169; 4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(2-morpholin-4-ylethyl)benzamide.


[0338] The compound was purified using preparatory HPLC (Method D; formic acid salt). MS (ESI): mass calcd. for $C_{37}H_{44}ClN_7O_5$, 701.31; m/z found, 702.2 $[M+H]^+$. ^1H NMR: 7.92-7.80 (m, 3H), 7.66 (d, J = 8.4, 2H), 7.63 (dd, J = 8.4, 2.1, 1H), 7.56-7.54 (m, 1H), 4.88-4.85 (m, 2H), 4.79 (s, 2H), 4.14 (t, J = 5.9, 2H), 3.95 (td, J = 19.4, 5.8, 2H), 3.85-3.79 (m, 1H), 3.73 (dd, J = 11.8, 2.7, 1H), 3.69-3.64 (m, 1H), 3.51 (t, J = 6.6, 2H), 3.36-3.32 (m, 2H), 3.08-3.04 (m, 2H), 3.02-2.97 (m, 2H), 2.97-2.86 (m, 2H), 2.72 (s, 4H), 2.62-2.49 (m, 2H), 2.23-2.13 (m, 1H), 2.12-2.05 (m, 1H), 2.03-1.97 (m, 2H), 1.04 (d, J = 6.4, 3H).



Example 170; 3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0339] A. (4-{5-[5-Carbamoyl-1-(3-hydroxy-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chloro-phenylethynyl}-benzyl)-(4-chloro-benzyl)-carbamic acid tert-butyl ester. This compound was prepared according to the methods described in Example 150, following sequentially Steps A, E, F, D, B, and then C, with the appropriate substituent changes. MS (ESI): mass calcd. for $C_{37}H_{39}Cl_2N_5O_4$, 687.24; m/z found, 688.2 $[M+H]^+$.


[0340] B. 3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide. A solution of the carbamate above in 2.5:1 CH_2Cl_2:TFA (7 mL) was stirred at rt for 2 h. The reaction was quenched with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (2x). The combined organic layers were dried and concentrated, and the residue was purified using preparatory HPLC (Method E; HCl salt). MS (ESI): mass calcd. for $C_{38}H_{40}Cl_2N_6O_2$, 682.26; m/z found, 683.2 $[M+H]^+$. ^1H NMR: 7.91 (d, J = 1.7, 1H), 7.71-7.62 (m, 3H), 7.60-7.55 (m, 3H), 7.56-7.45 (m, 4H), 4.67 (s, 2H), 4.29 (d, J = 10.3, 4H), 4.26-4.21 (m, 2H), 4.00-3.88 (m, 1H), 3.86-3.77 (m, 4H), 3.72-3.65 (m, 1H), 3.59 (d, J = 11.6, 1H), 3.53 (dd, J = 9.6, 5.3, 1H), 3.34 (s, 3H), 3.25-3.15 (m, 2H), 3.14-3.05 (m, 1H), 2.86 (t, J = 5.6, 2H), 2.77 (dd, J = 10.6, 8.8, 1H), 2.40-2.23 (m, 2H).



Example 171; 3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0341] A. 3-[4-Chloro-3-(3-formyl-phenylethynyl)-phenyl]-1-(3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide. This compound was prepared according to the methods described in Example 150, following sequentially Steps A, B, C, E, and F, and then Example 167, Step C, with the appropriate substituent changes. MS (ESI): mass calcd. for $C_{29}H_{30}ClN_5O_2S$, 547.18; m/z found, 548.2 $[M+H]^+$.


[0342] B. 3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide. A solution of the aldehyde above (0.194 mmol), 4-chlorobenzylamine (0.388 mmol), and AcOH (16 μL) in CH_2Cl_2 (2 mL) was stirred for 30 min, and then treated with $NaBH(OAc)_3$ (0.388 mmol). After 23 h, the mixture was diluted with satd. aq. $NaHCO_3$ and extracted CH_2Cl_2 (3x). The combined organic layers were dried and concentrated. The residue was purified using preparatory HPLC (Method F; HCl salt). MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6OS$, 672.22; m/z found, 673.3 $[M+H]^+$. ^1H NMR: 7.84 (s, 1H), 7.70 (s, 1H), 7.58 (d, J = 7.8, 2H), 7.53-7.35 (m, 7H), 4.60 (s, 2H), 4.21 (d, J = 13.9, 4H), 4.16 (t, J = 6.0, 2H), 3.77-3.68 (m, 4H), 3.21-3.07 (m, 5H), 3.03 (t, J = 13.1, 2H), 2.79 (s, 2H), 2.74 (d, J = 13.8, 2H), 2.32-2.25 (m, 2H).



Example 172; 2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethanol.

[0343] The title compound was prepared using methods analogous to those described for Example 150, following sequentially Steps A, D, B, C, E, F, and then G. MS (ESI): mass calcd. for $C_{43}H_{44}Cl_2N_6O_2$, 746.29; m/z found, 748.2 $[M+H]^+$. ^1H NMR:

7.65-7.51 (m, 4H), 7.41-7.39 (m, 1H), 7.25 (dd, J = 8.6, 7.4, 1H), 6.92 (d, J = 7.9, 1H), 4.34-4.11 (m, 4H), 3.56-2.92 (m, 24H).




Example 173; 3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0344] A. 3-[4-Chloro-3-(4-formyl-phenylethynyl)-phenyl]-1-(3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide. The title compound was prepared using methods analogous to those described for Example 151. MS (ESI): mass calcd. for $C_{29}H_{30}ClN_5O_2S$, 548.10; m/z found 549.3 $[M+H]^+$.


[0345] B. 3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide. The title compound was prepared using methods analogous to those described for Example 171, Step B. The compound was purified by Preparative HPLC Method B. MS (ESI): mass calcd. for $C_{37}H_{41}ClN_6OS$, 652.29; m/z found, 653.3 $[M+H]^+$. ^1H NMR: 7.91 (d, J = 2.1, 1H), 7.70-7.65 (m, 3H), 7.59 (dd, J = 11.1, 8.4, 3H), 7.41 (d, J = 8.1, 2H), 7.30 (d, J = 7.9, 2H), 4.66 (s, 2H), 4.30-4.21 (m, 6H), 3.87-3.75 (m, 4H), 3.30-3.08 (m, 6H), 2.92-2.78 (m, 4H), 2.40-2.34 (m, 4H).

[0346] The compounds in Examples 174-176 were prepared using methods analogous to those described for Example 173.




Example 174; 3-{4-Chloro-3-[(4-{[({4-[(1-methylethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0347] MS (ESI): mass calcd. for $C_{39}H_{45}ClN_6O_2S$, 696.34; m/z found, 697.3 $[M+H]^+$. ^1H NMR: 7.92 (d, J = 2.1, 1H), 7.71-7.67 (m, 3H), 7.62-7.54 (m, 3H), 7.47-7.35 (m, 2H), 7.01-6.98 (m, 2H), 4.72-4.62 (m, 3H), 4.29-4.19 (m, 5H), 3.87-3.70 (m, 3H), 3.30-3.15 (m, 4H), 3.14-2.75 (m, 6H), 2.38-2.32 (m, 2H), 1.33 (d, J = 6.0, 6H).




Example 175; 3-[4-Chloro-3-({4-[({[4-(dimethylamino)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0348] MS (ESI): mass calcd. for $C_{38}H_{44}ClN_7OS$, 681.33; m/z found, 682.3 $[M+H]^+$. ^1H NMR: 7.92 (d, J = 2.1, 1H), 7.71-7.65 (m, 3H), 7.61-7.53 (m, 3H), 7.41-7.37 (m, 1H), 6.98 (d, J = 8.8, 2H), 4.66 (s, 2H), 4.30-4.18 (m, 6H), 3.89-3.77 (m, 4H), 3.30-3.19 (m, 4H), 3.08-3.03 (m, 7H), 2.91-2.78 (m, 4H), 2.38-2.32 (m, 2H), 2.05 (s, 2H).



Example 176; 3-{4-Chloro-3-[(4-{[({4-[(difluoromethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0349] MS (ESI): mass calcd. for $C_{37}H_{39}ClF_2N_6O_2S$, 704.27; m/z found, 705.2 $[M+H]^+$. ^1H NMR: 7.93 (d, J = 2.1, 1H), 7.71-7.67 (m, 3H), 7.62-7.54 (m, 5H), 7.26 (d, J = 8.6, 2H), 4.66 (s, 2H), 4.31 (d, J = 11.1, 4H), 4.24 (t, J = 6.5, 2H), 3.79 (t, J = 5.7, 3H), 3.29-2.76 (m, 10H), 2.39-2.31 (m, 2H).




Example 177; 1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine.

[0350] A. (4-Chlorobenzyl)-(4-ethynylbenzyl)-amine. Acetic acid (0.95g, 15.7 mmol) was added at once to a solution of 4-chlorobenzylamine (2.2 g, 15.4 mmol) and 4-ethynylbenzaldehyde (1.0 g, 7.7 mmol) in CH_2Cl_2 (40 mL). The resulting slurry was stirred for 30 min and sodium triacetoxyborohydride (2.5 g, 11.6 mmol) was added portionwise. After 3 days, the reaction mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (x3). The combined organic extracts were dried (Na_2SO_4) and concentrated to give a yellow oil. Purification by silica gel chromatography (0 to 30% EtOAc/hexanes) afforded the title compound as a colorless oil (1.7 g, 85%). HPLC: R_t = 4.70. MS (ESI): mass calcd. for $C_{16}H_{14}ClN$, 256.7; m/z found, 256.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.46 (d, J = 8.2, 2H), 7.31-7.27 (m, 4H), 3.78 (s, 2H), 3.75 (s, 2H), 3.06 (s, 1H), 1.58 (br s, 1H).


[0351] B. 1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine. The title compound was prepared using methods analogous to those described for intermediate 1, substituting 2-(4 piperidinyl)pyridine for morpholine in Step D, and (4-chlorobenzyl)-(4-ethynylbenzyl)-amine for TMSA in Step E. HPLC: R_t = 4.39. HPLC: R_t = 4.39. MS (ESI): mass calcd. for $C_{42}H_{44}Cl_2N_6O_2S$, 766.3; m/z found, 767.4 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.55-8.52 (m, 1H), 7.82 (d, J = 2.0, 1H), 7.62 (dt, J = 7.7, 1.8, 1H), 7.56 (d, J = 8.1, 2H), 7.49 (dd, J = 8.4, 2.1, 1H), 7.45 (d, J = 8.4, 1H), 7.38 (d, J = 8.1, 2H), 7.30-7.27 (m, 4H), 7.17 (d, J = 7.9, 1H), 7.12 (ddd, J = 7.5, 4.9, 1.0, 1H), 4.54 (s, 2H), 4.12 (t, J = 6.7, 2H), 3.81 (s, 2H), 3.76 (s, 2H), 3.66 (t, J = 5.7, 2H), 3.00-2.91 (m, 5H), 2.89 (s, 3H), 2.74-2.65 (m, 1H), 2.33 (d, J = 6.7, 2H), 2.14-2.02 (m, 4H), 1.98-1.91 (m, 2H), 1.87-1.75 (m, 2H).

[0352] The compounds in Examples 178-183 were prepared using methods analogous to those described for Example 177, substituting the appropriate amine for 2-(4-piperidinyl)pyridine in Step B.




Example 178; 1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine.

[0353] HPLC: R_t = 4.77. MS (ESI): mass calcd. for $C_{43}H_{45}Cl_2N_5O_2S$, 765.3; m/z found, 766.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.81 (d, J = 2.0, 1H), 7.58-7.54 (m, 2H), 7.50 (dd, J = 8.4, 2.1, 1H), 7.45 (d, J = 8.4, 1H), 7.35-7.30 (m, 4H), 7.29 (d, J = 2.7, 4H), 7.24-7.19 (m, 3H), 4.54 (s, 2H), 4.12 (t, J = 6.8, 2H), 3.81 (s, 2H), 3.77 (s, 2H), 3.66 (t, J = 5.7, 2H), 3.00-2.90 (m, 4H), 2.89 (s, 3H), 2.54-2.45 (m, 1H), 2.35 (t, J = 6.9, 2H), 2.15-2.08 (m, 2H), 2.07-2.00 (m, 2H), 1.88-1.82 (m, 2H), 1.79-1.68 (m, 3H).




Example 179; 1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine.

[0354] HPLC: R_t = 4.35. MS (ESI): mass calcd. for $C_{41}H_{43}Cl_2N_7O_2S$, 767.3; m/z found, 768.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.20-8.17 (m, 1H), 7.81 (d, J = 1.9, 1H), 7.59-7.55 (m, 2H), 7.57-7.44 (m, 3H), 7.36-7.33 (m, 2H), 7.30-7.28 (m, 4H), 6.66-6.61 (m, 2H), 4.54 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.81 (s, 2H), 3.77 (s, 2H), 3.65 (t, J = 5.8, 2H), 3.55-3.51 (m, 4H), 2.93-2.91 (m, 2H), 2.90 (s, 3H), 2.54-2.51 (m, 4H), 2.37 (t, J = 6.7, 2H), 2.16-2.09 (m, 2H), 1.64 (bs, 1H).




Example 180; 1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine.

[0355] HPLC: R_t = 4.76. MS (ESI): mass calcd. for $C_{42}H_{44}Cl_2N_6O_2S$, 766.3; m/z found, 767.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.81 (d, *J* = 1.9, 1H), 7.58-7.55 (m, 2H), 7.49 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.36-7.32 (m, 2H), 7.30-7.25 (m, 6H), 6.94-6.90 (m, 2H), 6.88-6.83 (m, 1H), 4.53 (s, 2H), 4.12 (t, *J* = 6.8, 2H), 3.80 (s, 2H), 3.76 (s, 2H), 3.64 (t, *J* = 5.8, 2H), 3.20-3.17 (m, 4H), 2.92-2.89 (m, 2H), 2.89 (s, 3H), 2.58-2.55 (m, 4H), 2.37 (t, *J* = 6.8, 2H), 2.15-2.08 (m, 2H), 1.87-1.83 (m, 1H).




Example 181; 1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine.

[0356] HPLC: R_t = 4.60. MS (ESI): mass calcd. for $C_{37}H_{41}Cl_2N_5O_2S$, 689.2; m/z found, 690.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, *J* = 1.9, 1H), 7.58-7.55 (m, 2H), 7.49 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.35-7.32 (m, 2H), 7.30-7.28 (m, 4H), 4.53 (s, 2H), 4.08 (t, *J* = 6.8, 2H), 3.81 (2, 2H), 3.77 (s, 2H), 3.65 (t, *J* = 5.8, 2H), 2.93-2.90 (m, 2H), 2.89 (s, 3H), 2.36-2.30 (bm, 4H), 2.25 (t, *J* = 6.8, 2H), 2.10-2.02 (m, 2H), 1.83 (bs, 1H), 1.59-1.53 (m, 4H), 1.47-1.40 (m, 2H).




Example 182; 1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine.

[0357] HPLC: R_t = 4.53. MS (ESI): mass calcd. for $C_{37}H_{41}Cl_2N_5O_3S$, 705.2; m/z found, 706.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80-7.79 (m, 1H), 7.56 (d, *J* = 7.9, 2H), 7.48 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.34 (d, *J* = 8.0, 2H), 7.31-7.27 (m, 4H), 4.53 (s, 2H), 4.12-4.01 (m, 2H), 3.81 (s, 2H), 3.81-3.79 (m, 1H), 3.79 (s, 2H), 3.68-3.61 (m, 4H), 3.24 (dd, *J* = 11.0, 8.8, 1H), 2.95-2.85 (m, 2H), 2.90 (s, 3H), 2.80-2.70 (m, 2H), 2.44-2.36 (m, 1H), 2.30-2.20 (m, 2H), 2.12-1.98 (m, 2H), 1.77 (bs, 1H), 0.91 (d, *J* = 6.3, 3H).




Example 183; 1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine.

[0358] HPLC: R_t = 4.57. MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_2S$, 707.2; m/z found, 708.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, *J* = 1.8, 1H), 7.56 (d, *J* = 8.1, 2H), 7.48 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.3, 1H), 7.34 (d, *J* = 8.1, 2H), 7.30-7.28 (m, 6H), 4.53 (s, 2H), 4.07 (t, *J* = 6.8, 2H), 3.81 (s, 2H), 3.79 (s, 2H), 3.64 (t, *J* = 5.8, 2H), 3.28 (s, 3H), 2.89-2.85 (m, 2H), 2.68-2.63 (m, 8H), 2.34 (t, *J* = 6.8, 2H), 2.09-2.01 (m, 2H).



Example 184; 3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde.


[0359] A solution of DMF (15 mL) and distilled water (1.6 mL) was degassed with nitrogen for 1 h and transferred via syringe to a degassed flask containing 3-(4-chloro-3-iodophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (2.3 g, 4.0 mmol), $Pd(PPh_3)_2Cl_2$ (281 mg, 0.4 mmol), and CuI (76 mg, 0.4 mmol). The mixture was treated with 3-trimethylsilanylethynyl-benzaldehyde (1.2 g, 6.0 mmol) and DBU (1.8 g, 12 mmol), and the resulting mixture was stirred at rt under N_2 for 18 h. The mixture was concentrated under high vacuum, and the crude residue was diluted with satd. aq. NaCl and extracted with CH_2Cl_2. The combined organic layers were dried and concentrated to give a brown oil. Purification by silica gel chromatography (0 to 3% MeOH/CH_2Cl_2) afforded the title compound as a beige foam (1.7 g, 76%). HPLC: R_t = 4.86. MS (ESI): mass calcd. for $C_{29}H_{31}ClN_4O_4S$, 566.2; m/z found, 567.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 10.00 (s, 1H), 8.10-8.09 (m, 1H), 7.90-7.87 (m, 1H), 7.86-7.84 (m, 1H), 7.82 (d, J = 1.9, 1H), 7.57 (t, J = 7.7, 1H), 7.52 (d, J = 2.1, 1H), 7.48 (d, J = 8.4, 1H), 4.55 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.70 (t, J = 4.6, 4H), 3.67 (t, J = 5.8, 2H), 2.93 (s, 3H), 2.93-2.89 (m, 2H), 2.44-2.40 (m, 4H), 2.34 (t, J = 6.8, 2H), 2.12-2.06 (m, 2H).



Example 185; 1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine.

[0360] To a solution of 3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde (77 mg, 0.14 mmol) in CH_2Cl_2 (1.4 mL) were added 1-tetrahydro-2H-pyran-4-


ylmethanamine (31 mg, 0.27 mmol) and AcOH (4 μL). The resulting slurry was stirred at rt for 30 min, then was treated with $Na(OAc)_3BH$ (57 mg, 0.27 mmol) and stirred for an additional 16 h. The mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (3x). The combined organic layers were dried and concentrated to afford a yellow oil. Purification of the residue (SiO_2; 0-3% 2 M NH_3 in $MeOH/CH_2Cl_2$) afforded the title compound as a white powder (72 mg, 79%). HPLC: R_t = 4.24. MS (ESI): mass calcd. for $C_{35}H_{44}ClN_5O_4S$, 665.3; m/z found, 666.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, *J* = 1.8, 1H), 7.68 (s, 1H), 7.51-7.47 (m, 2H), 7.46 (d, *J* = 8.4, 1H), 7.33 (d, *J* = 4.9, 1H), 4.54 (s, 2H), 4.10 (t, *J* = 6.8, 2H), 4.02-3.95 (m, 3H), 3.70 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 3.43-3.35 (m, 3H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.43-2.38 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.11-2.04 (m, 2H), 1.77-1.61 (m, 4H), 1.37-1.25 (m, 4H).



Example 186; 1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine.


[0361] The title compound was prepared from 1-[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine using a method analogous to described for Example 2. HPLC: R_t = 4.24. MS (ESI): mass calcd. for $C_{35}H_{48}ClN_5O_4S$, 669.3; m/z found, 670.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.51 (d, *J* = 2.1, 1H), 7.40 (d, *J* = 8.3, 1H), 7.32 (dd, *J* = 8.3, 2.1, 1H), 7.27 (t, *J* = 7.5, 1H), 7.21-7.14 (m, 3H), 4.47 (s, 2H), 4.10 (t, *J* = 6.8, 2H), 3.97 (dd, *J* = 10.8, 3.5, 2H), 3.77 (s, 2H), 3.70 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 3.39 (dt, *J* = 11.8, 1.8, 2H), 3.08-3.03 (m, 2H), 2.97-2.92 (m, 2H), 2.89 (s, 3H), 2.91-2.88 (m, 2H), 2.53 (d, *J* = 6.5, 2H), 2.43-2.39 (m, 4H), 2.33 (t, *J* = 6.8, 2H), 2.11-2.04 (m, 2H), 1.76-1.63 (m, 4H), 1.36-1.25 (m, 2H).

[0362] The compounds in Examples 187-188 were prepared using methods analogous to those described for Example 185.




Example 187; 1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine.

[0363] HPLC: R_t = 4.27. MS (ESI): mass calcd. for $C_{35}H_{39}ClN_6O_3S$, 658.3; m/z found, 659.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.57 (d, J = 4.4, 1H), 7.79 (d, J = 1.9, 1H), 7.65 (dt, J = 7.7, 1.8, 1H), 7.61 (s, 1H), 7.56-7.44 (m, 3H), 7.40-7.36 (m, 1H), 7.34 (t, J = 7.4, 2H), 7.19-7.15 (m, 1H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.94 (s, 2H), 3.87 (s, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.42-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.05 (m, 3H).




Example 188; Methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate.

[0364] HPLC: R_t = 4.42. MS (ESI): mass calcd. for $C_{32}H_{38}ClN_5O_5S$, 639.2; m/z found, 640.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.8, 1H), 7.58 (s, 1H), 7.52-7.47 (m, 2H), 7.45 (d, J = 8.3, 1H), 7.35-7.33 (m, 2H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.83 (s, 2H), 3.74 (s, 3H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 3.44 (s, 2H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.43-2.38 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.96 (bs, 1H).



Example 189; N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycine.

[0365] To a solution of methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate (46 mg, 0.07 mmol) in THF (0.3 mL) was added 1 N NaOH (0.3 mL). After 2 h at rt, the mixture was neutralized with 1 N HCl and extracted with 20% IPA/$CHCl_3$ (3x). The combined organic extracts were dried and concentrated to give the title compound as a beige solid (36 mg, 82%). HPLC: R_t = 4.17. MS (ESI): mass calcd. for $C_{31}H_{36}ClN_5O_5S$, 625.2; m/z found, 626.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.74 (d, J = 1.6, 1H), 7.64 (bs, 1H), 7.57 (m, 1H), 7.50 (dd, J = 8.4, 1.9, 1H), 7.46 (d, J = 8.4, 2H), 7.42-7.38 (bm, 1H), 4.51 (s, 2H), 4.09 (t, J = 6.8, 4H), 3.73-3.68 (m, 6H), 3.64 (t, J = 5.7, 2H), 3.43-3.39 (m, 2H), 2.92 (s, 3H), 2.91-2.87 (m, 2H), 2.45-2.41 (bm, 4H), 2.34 (t, J = 7.0, 2H), 2.10-2.03 (m, 2H).



Example 190; 2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate.

[0366] A. 7-Hydroxy-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester. To a cooled (0 °C) slurry of 7-hydroxy-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (770 mg, 3.6 mmol) in MeOH (13 mL) was added oxalyl choride (1.8 mL, 18 mmol) dropwise. The resulting mixture was heated at 65 °C for 5 h. After cooling to rt, the reaction was slowly quenched with satd. aq. $NaHCO_3$, and the solvent was removed in vacuo. The crude residue was dissolved in 20% IPA/$CHCl_3$ and washed with satd. aq $NaHCO_3$. The organic layer was dried and


concentrated to give the title compound as a white solid (523 mg, 63%). ^{1}H NMR: 6.92 (d, J = 8.3, 1H), 6.59 (dd, J = 8.3, 2.5, 1H), 6.47 (d, J = 2.4, 1H), 5.48 (s, 1H), 3.97 (d, J = 15.9, 1H), 3.91 (d, J = 15.9, 1H), 3.75 (s, 3H), 3.67 (dd, J = 10.3, 4.7, 1H), 2.97 (dd, J = 15.9, 4.7, 1H), 2.82 (dd, J = 15.9, 10.3, 1H).

[0367] B. 7-Hydroxy-(3S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester. To a solution of the above amine (100 mg, 0.48 mmol) in 2:1 THF:water (2.4 mL) was added di-tert-butyldicarbonate (105 mg, 0.48 mmol) dropwise. After stirring for 18 h, the reaction mixture was diluted with 0.5 N HCl and extracted with EtOAc (3x). The combined organic extracts were dried and concentrated to afford the title compound as a colorless oil (124 mg, 84%). ^{1}H NMR ($CDCl_3$): 7.21 (bs, 1H), 6.98 (d, J = 8.0, 1H), 6.68 (dt, J = 8.1, 2.3, 1H), 6.62-6.60 (m, 1H), 5.11-5.09 (m, 0.4H, minor rotamer), 4.74 (t, J = 5.5, 0.6H, major rotamer), 4.68-4.59 (m, 1H), 4.50-4.40 (m, 1H), 3.66 (s, 1.8H, major rotamer), 3.59 (s, 1.2H, minor rotamer), 3.18-3.02 (m, 2H), 1.52 (s, 3.6H, minor rotamer), 1.46 (s, 5.4H, major rotamer).

[0368] C. 7-Trifluoromethanesulfonyloxy-(3S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester. To an ice-cooled solution of the above phenol (157 mg, 0.51 mmol) in CH_2Cl_2 (2.6 mL) was added pyridine (161 mg, 2.04 mmol) and trifluoromethanesulfonic anhydride (288 mg, 1.02 mmol). The mixture was warmed to rt and stirred at rt for 4 h. The reaction mixture was diluted with 0.5 N HCl and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated to give the title compound as an orange oil (220 mg, 98%). ^{1}H NMR ($CDCl_3$): 7.23 (d, J = 8.4, 1H), 7.11 (d, J = 8.5, 1H), 7.06 (d, J = 9.8, 1H), 5.20 (dd, J = 6.2, 2.5, 0.4H, minor rotamer), 4.84 (t, J = 5.2, 0.6H, major rotamer), 4.58-4.44 (m, 1H), 3.65 (s, 1.2H, minor rotamer), 3.64 (s, 1.8H, major rotamer), 3.30 (dd, J = 16.2, 2.2, 0.6H, major rotamer), 3.20-3.16 (m, 1H), 3.16-3.12 (m, 0.4H, minor rotamer), 1.53 (s, 5.4H, major rotamer), 1.47 (s, 3.6H, minor rotamer).


[0369] D. 2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate. The title compound was prepared using methods analogous to those described in Example 1, Step B, substituting DMF for THF and 7-trifluoromethanesulfonyloxy-(3S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester for 5-iodoindole. HPLC: R_t = 5.38. MS (ESI): mass calcd. for $C_{38}H_{46}ClN_5O_7S$, 751.3; m/z found, 752.1 $[M+H]^+$. ^{1}H NMR ($CDCl_3$): 7.78-7.76 (m, 1H), 7.51-7.47 (m, 1H), 7.44 (d, J = 8.4, 1H), 7.39 (d, J = 8.7, 2H), 7.16 (d, J = 7.7, 1H), 5.17 (dd, J = 6.0, 2.8, 0.6H, major rotamer),

4.82 (t, J = 5.2, 0.4H, minor rotamer), 4.74 (d, J = 16.9, 1H), 4.56-4.47 (m, 1H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.69 (t, J = 4.6, 4H), 3.67-3.63 (m, 2H), 3.65 (s, 1.2H, minor rotamer), 3.63 (s, 1.8H, major rotamer), 3.28 (dd, J = 16.1, 2.6, 0.6H, major rotamer), 3.21-3.14 (m, 0.4H, minor rotamer), 3.19-3.17 (m, 1H), 2.90 (s, 3H), 2.90-2.86 (m, 2H), 2.42-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.03 (m, 2H), 1.54 (s, 5H, major rotamer), 1.50 (s, 4H, minor rotamer).



Example 191; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

[0370] To a solution of 2-(1,1-dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate (379 mg, 0.50 mmol) in THF (2 mL) was added 1 N NaOH (2 mL). The reaction mixture was stirred at rt for 4 h and then neutralized with 1 N HCl. Following extraction with CH_2Cl_2 (2x) and 20% IPA/$CHCl_3$, the combined organic extracts were dried and concentrated to afford the title compound as a white solid (356 mg, 96%). HPLC: R_t = 5.14. MS (ESI): mass calcd. for $C_{37}H_{44}ClN_5O_7S$, 737.3; m/z found, 738.1 $[M+H]^+$.




Example 192; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide.

[0371] To a solution of (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-


dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (68 mg, 0.09 mmol), HOBt (14 mg, 0.10 mmol), and EDC (19 mg, 0.10 mmol) in CH_2Cl_2 (1.0 mL) was added methylamine (2.0 M in THF; 70 μL, 0.14 mmol) and iPr_2NEt (24 mg, 0.18 mmol). The reaction mixture was stirred at rt for 16 h, diluted with satd. aq. $NaHCO_3$, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated to give a brown oil. Purification (SiO_2: 0 to 3% 2 M NH_3 in MeOH/CH_2Cl_2) afforded a white foam, which was dissolved in 2:1 CH_2Cl_2:TFA (1.0 mL) and stirred at rt for 1 h. The mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated to give the title compound as a white solid (34 mg, 56%). HPLC: R_t = 4.12. MS (ESI): mass calcd. for $C_{33}H_{39}ClN_6O_4S$, 650.2; m/z found, 651.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.9, 1H), 7.49 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.40 (dd, *J* = 7.8, 1.4, 1H), 7.30 (s, 1H), 7.23-7.20 (m, 1H), 7.17 (d, *J* = 7.9, 1H), 4.53 (s, 2H), 4.10 (t, *J* = 6.8, 2H), 4.00 (s, 2H), 3.79 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 3.55 (dd, *J* = 10.5, 5.1, 1H), 3.27 (dd, *J* = 16.9, 5.1, 1H), 2.91 (s, 3H), 2.91-2.88 (m, 3H), 2.86 (d, *J* = 5.0, 3H), 2.85-2.80 (m, 1H), 2.43-2.39 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.11-2.05 (m, 2H), 1.80 (bs, 1H).

[0372] The compounds in Examples 193-194 were prepared using methods analogous to those described for Examples 190-192, substituting the appropriate amine for methylamine.




Example 193; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N,N-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide.

[0373] HPLC: R_t = 4.17. MS (ESI): mass calcd. for $C_{34}H_{41}ClN_6O_4S$, 664.3; m/z found, 665.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.9, 1H), 7.49 (dd, *J* = 8.4, 2.0, 1H), 7.45 (d, *J* = 8.4, 1H), 7.37 (dd, *J* = 7.9, 1.4, 1H), 7.30 (s, 1H), 7.10 (d, *J* = 7.9, 1H), 4.54 (s, 2H), 4.13-4.08 (m, 4H), 3.94 (dd, *J* = 10.8, 3.8, 1H), 3.70 (t, *J* = 4.6, 4H), 3.65 (t, *J* = 5.8, 2H), 3.14 (s, 3H), 3.02 (s, 3H), 2.99-2.94 (m, 1H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.85-2.79 (m, 1H), 2.43-2.39 (m, 4H), 2.32 (t, *J* = 6.8, 2H), 2.11-2.04 (m, 2H), 1.94 (bs, 1H).




Example 194; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline.

[0374] HPLC: R_t = 4.10. MS (ESI): mass calcd. for $C_{36}H_{43}ClN_6O_5S$, 706.3; m/z found, 707.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.38 (dd, J = 7.9, 1.4, 1H), 7.29 (s, 1H), 7.11 (d, J = 7.9, 1H), 4.53 (s, 2H), 4.12-4.08 (m, 4H), 3.89 (dd, J = 10.9, 4.2, 1H), 3.76-3.72 (m, 4H), 3.71-3.68 (m, 7H), 3.65 (t, J = 5.8, 2H), 3.56-3.52 (m, 1H), 3.07-2.99 (m, 1H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.79 (dd, J = 16.9, 3.6, 1H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.90 (bs, 1H).




Example 195; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide.

[0375] The title compound was prepared using methods analogous to those described for Examples 190-192, substituting ammonium chloride for methylamine, DMF for THF, and N-methylmorpholine for iPr_2NEt in Example 192. HPLC: R_t = 4.09. MS (ESI): mass calcd. for $C_{32}H_{37}ClN_6O_4S$, 636.2; m/z found, 637.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.40 (dd, J = 7.8, 1.4, 1H), 7.30 (s, 1H), 7.16 (d, J = 7.9, 1H), 7.07 (bs, 1H), 5.73 (bs, 1H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 4.03 (s, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 3.59 (dd, J = 10.4, 5.1, 1H), 3.23 (dd, J = 16.8, 5.1, 1H), 2.92-2.87 (m, 3H), 2.91 (s, 3H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.88 (bs, 1H).



Example 196; (3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline.


[0376] The title compound was prepared using methods analogous to those described for Examples 190-192, substituting 7-hydroxy-(3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid for 7-hydroxy-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in Example 190, Step A, and pyrrolidine for methylamine in Example 192. HPLC: R_t = 4.24. MS (ESI): mass calcd. for $C_{36}H_{43}ClN_6O_4S$, 690.3; m/z found, 691.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.8, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.3, 1H), 7.37 (dd, J = 7.9, 1.4, 1H), 7.29 (s, 1H), 7.10 (d, J = 7.9, 1H), 4.54 (s, 2H), 4.13-4.08 (m, 4H), 3.77 (dd, J = 11.0, 4.1, 1H), 3.72-3.68 (m, 5H), 3.65 (t, J = 5.7, 2H), 3.58-3.44 (m, 3H), 3.00 (dd, J = 16.6, 11.1, 1H), 2.91 (s, 3H), 2.91-2.87 (m, 2H), 2.83 (dd, J = 16.8, 3.1, 1H), 2.43-2.39 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.05 (m, 2H), 2.02-1.87 (m, 6H).



Example 197; (3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide.


[0377] The title compound was prepared using methods analogous to those described for Example 195, substituting 7-hydroxy-(3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid for 7-hydroxy-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in Example 190, Step A. HPLC: R_t = 4.10. MS (ESI): mass calcd. for $C_{32}H_{37}ClN_6O_4S$, 636.2; m/z found, 637.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.49 (dd, J =

8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.40 (dd, J = 7.8, 1.3, 1H), 7.30 (s, 1H), 7.16 (d, J= 7.9, 1H), 7.06 (bs, 1H), 5.72 (bs, 1H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 4.03 (s, 2H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 3.59 (dd, J = 10.4, 5.2, 1H), 3.23 (dd, J = 16.9, 5.1, 1H), 2.93-2.85 (m, 3H), 2.90 (s, 3H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H).




Example 198; Methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate.

[0378] To an ice-cooled solution of 2-(1,1-dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate (160 mg, 0.21 mmol) in CH_2Cl_2 was added TFA (0.8 mL). After 3 h, the mixture was diluted with satd. aq $NaHCO_3$ and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated to afford the title compound as a white foam (133 mg, 96%). HPLC: R_t = 4.22. MS (ESI): mass calcd. for $C_{33}H_{38}ClN_5O_5S$, 651.1; m/z found, 652.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.9, 1H), 7.48 (dd, J = 8.4, 2.0, 1H), 7.44 (d, J = 8.4, 1H), 7.37 (dd, J = 7.8, 1.5, 1H), 7.29 (s, 1H), 7.12 (d, J = 7.9, 1H), 4.52 (s, 2H), 4.13-4.07 (m, 4H), 3.78 (s, 3H), 3.78-3.74 (m, 1H), 3.69 (t, J = 4.6, 4H), 3.64 (t, J = 5.7, 2H), 3.11 (dd, J = 16.6, 4.6, 1H), 3.02-2.94 (m, 1H), 2.90 (s, 3H), 2.90-2.86 (m, 2H), 2.43-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.13 (bs,1H), 2.10-2.13 (m, 2H).




Example 199; (3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.

[0379] The title compound was prepared from (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid using methods analogous to those described for Example 189. HPLC: R_t = 4.10. MS (ESI): mass calcd. for $C_{32}H_{36}ClN_5O_5S$, 637.2; m/z found, 638.1 $[M+H]^+$. ^1H NMR: 7.86 (d, J = 1.9, 1H), 7.60 (dd, J = 8.5, 2.0, 1H), 7.56 (d, J = 8.4, 1H), 7.55-7.49 (m, 3H), 7.37 (d, J = 7.9, 1H), 4.55-4.47 (m, 1H), 4.51 (s, 2H), 4.45-4.40 (m, 1H), 4.23 (t, J = 6.5, 2H), 4.06-4.00 (m, 2H), 3.76-3.68 (m, 2H), 3.65 (t, J = 5.8, 2H), 3.56-3.47 (m, 3H), 3.33-3.29 (m, 3H), 3.28-3.22 (m, 2H), 3.17-3.09 (m, 2H), 2.98 (s, 3H), 2.92 (t, J = 5.6, 2H), 2.38-2.30 (m, 2H).




Example 200; Methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate.

[0380] The title compound was prepared from 2-(1,1-dimethylethyl) 3-methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate using methods analogous to those described for Example 198. HPLC: R_t = 4.23. MS (ESI): mass calcd. for $C_{33}H_{38}ClN_5O_5S$, 651.2; m/z found, 652.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.9, 1H), 7.48 (dd, J = 8.4, 2.0, 1H), 7.44 (d, J = 8.4, 1H), 7.37 (dd, J = 7.9, 1.4, 1H), 7.29 (s, 1H), 7.12 (d, J = 7.9, 1H), 4.52 (s, 2H), 4.14-4.08 (m, 4H), 3.79 (s, 3H), 3.78-3.74 (m, 1H), 3.69 (t, J = 4.6, 4H), 3.64 (t, J = 5.8, 2H), 3.11 (dd, J = 16.6, 4.5, 1H), 2.98 (dd, J = 16.6, 9.9, 1H), 2.90 (s, 3H), 2.90-2.87 (m, 2H), 2.42-2.38 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.20 (bs, 1H), 2.10-2.03 (m, 2H).



Example 201; [(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol.


[0381] To a cooled (-78 °C) solution of methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (67 mg, 0.10 mmol) in THF was added DIBAL-H (1.5 M in toluene; 0.35 mL, 0.53 mmol). The reaction mixture was stirred at –78 °C for 1 h and at 0 °C for 30 min. After cooling to –78 °C, the reaction was quenched with MeOH (1 mL), diluted with 1 N NaOH, and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated to give a brown oil. Purification (SiO_2: 0 to 5% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the title compound as a yellow oil (19 mg, 30%). HPLC: R_t = 4.13. MS (ESI): mass calcd. for $C_{32}H_{38}ClN_5O_4S$, 623.2; m/z found, 624.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.9, 1H), 7.48 (dd, J = 8.4, 2.0, 1H), 7.44 (d, J = 8.4, 1H), 7.39-7.35 (m, 1H), 7.29 (s, 1H), 7.09 (d, J = 7.9, 1H), 4.53 (s, 2H), 4.10 (t, J = 6.8, 2H), 4.07 (s, 2H), 3.82 (dd, J = 10.8, 3.4, 1H), 3.70 (t, J = 4.6, 4H), 3.65 (t, J = 5.8, 2H), 3.55 (dd, J = 10.6, 8.1, 1H), 3.15-3.08 (m, 1H), 2.91 (s, 3H), 2.91-2.87 (m, 2H), 2.75 (dd, J = 16.7, 4.0, 1H), 2.61 (dd, J = 16.7, 10.8, 1H), 2.43-2.38 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.21 (bs, 2H), 2.11-2.04 (m, 2H).



Example 202; (3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.


[0382] The title compound was prepared from (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-

3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid using methods analogous to those described for Example 199. HPLC: R_t = 4.16. MS (ESI): mass calcd. for $C_{32}H_{36}ClN_5O_5S$, 637.2; m/z found, 638.2 $[M+H]^+$. ^1H NMR: 7.85 (d, 1.8, 1H), 7.59 (dd, *J* = 8.4, 2.0, 1H), 7.55 (d, *J* = 8.4, 1H), 7.53-7.49 (m, 3H), 7.36 (d, *J* = 8.0, 1H), 4.55-4.47 (m, 1H), 4.50 (s, 2H), 4.46-4.40 (m, 1H), 4.22 (t, *J* = 6.5, 2H), 4.05-3.98 (m, 2H), 3.77-3.69 (m, 2H), 3.64 (t, *J* = 5.7, 2H), 3.55-3.47 (m, 3H), 3.33-3.29 (m, 3H), 3.28-3.22 (m, 2H), 3.17-3.09 (m, 2H), 2.98 (s, 3H), 2.91 (t, *J* = 5.6, 2H), 2.37-2.30 (m, 2H).




Example 203; 2-(1,1-Dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate.

[0383] The title compound was prepared from 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid using methods analogous to those described for Example 190. HPLC: R_t = 5.47. MS (ESI): mass calcd. for $C_{32}H_{38}ClN_5O_4S$, 751.3; m/z found, 752.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, *J* = 1.9, 1H), 7.50 (dd, *J* = 8.4, 2.1, 1H), 7.45 (d, *J* = 8.4, 1H), 7.40 (s, 1H), 7.39-7.36 (m, 1H), 7.17 (d, *J* = 7.9, 0.55H, major rotamer), 7.12 (d, *J* = 7.9, 0.45H, minor rotamer), 5.19 (dd, *J* = 6.1, 2.7, 0.55H, major rotamer), 4.84 (t, *J* = 5.2, 0.45H, minor rotamer), 4.74 (dd, *J* = 17.0, 7.5, 1H), 4.59-4.49 (m, 1H), 4.54 (s, 2H), 4.10 (t, *J* = 6.8, 2H), 3.70 (t, *J* = 4.6, 4H), 3.68-3.64 (m, 2H), 3.65 (s, 1.65H, major rotamer), 3.64 (s, 1.35H, minor rotamer), 3.29 (dd, *J* = 16.0, 2.5, 0.55H, major rotamer), 3.18 (d, *J* = 5.3, 1H), 3.15 (d, *J* = 6.3, 0.45H, minor rotamer), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.43-2.39 (m, 4H), 2.33 (t, *J* = 6.8, 2H), 2.11-2.04 (m, 2H), 1.54 (s, 5H, major rotamer), 1.47 (s, 4H, minor rotamer).



Example 204; 6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline.


[0384] The title compound was prepared from 2-(1,1-dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate using methods analogous to those described for Examples 191-192. HPLC: R_t = 5.47. MS (ESI): mass calcd. for $C_{37}H_{45}ClN_6O_4S$, 704.3; m/z found, 705.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.50 (dd, J = 8.4, 2.1, 1H), 7.45 (d, J = 8.3, 1H), 7.37 (d, J = 7.9, 1H), 7.35 (s, 1H), 7.05 (d, J = 7.9, 1H), 4.54 (s, 2H), 4.15-4.12 (m, 2H), 4.10 (t, J = 6.9, 2H), 3.95 (dd, J = 10.9, 4.2, 1H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 3.64-3.60 (m, 2H), 3.52-3.48 (m, 2H), 2.97-2.92 (m, 1H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.80 (dd, J = 16.5, 3.7, 1H), 2.43-2.39 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.83 (bs, 1H), 1.71-1.57 (m, 6H).



Example 205; Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate.


[0385] The title compound was prepared from 2-(1,1-dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate using methods analogous to those described for Example 198. HPLC: R_t = 4.17. MS (ESI): mass calcd. for $C_{33}H_{38}ClN_5O_5S$, 651.2; m/z found, 652.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.8, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.39-

7.36 (m, 2H), 7.04 (d, J = 8.0, 1H), 4.53 (s, 2H), 4.16-4.08 (m, 4H), 3.79 (s, 3H), 3.78-3.74 (m, 2H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 3.11 (dd, J = 16.4, 4.5, 1H), 2.98 (dd, J = 16.3, 9.9, 1H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.43-2.38 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H).




Example 206; [6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol.

[0386] The title compound was prepared from methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate using methods analogous to those described for Example 201. HPLC: R_t = 4.10. MS (ESI): mass calcd. for $C_{32}H_{38}ClN_5O_4S$, 623.2; m/z found, 624.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.8, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.37 (d, J = 8.1, 1H), 7.37 (s, 1H), 7.05 (d, J = 7.8, 1H), 5.80 (s, 2H), 4.13-4.07 (m, 4H), 3.82 (dd, J = 10.7, 3.5, 1H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 3.57-3.52 (m, 1H), 3.27-3.21 (m, 1H), 3.15-3.08 (m, 1H), 2.91 (s, 3H), 2.91-2.87 (m, 2H), 2.75 (dd, J = 16.2, 3.8, 1H), 2.57 (dd, J = 16.0, 10.9, 1H), 2.44-2.38 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.68-1.60 (bm, 1H).



Example 207; 2-(1,1-Dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate.


[0387] The title compound was prepared from 6-hydroxy-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid using methods analogous to those described for Example 190. HPLC: R_t = 5.73. MS (ESI): mass calcd. for $C_{38}H_{46}ClN_5O_7S$, 751.3; m/z found, 752.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 2.0, 1H), 7.50 (dd, J = 8.4, 2.0, 1H), 7.50-7.44 (m, 2H), 7.45 (d, J = 8.4, 1H), 7.41 (s, 1H), 5.62 (s, 0.4H, minor rotamer), 5.46 (s, 0.6H, major rotamer), 4.54 (s, 2H), 4.13-4.08 (m, 2H), 3.81-3.75 (m, 2H), 3.73 (s, 3H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 2.98-2.93 (m, 2H), 2.91 (s, 3H), 2.91-2.87 (m, 2H), 2.43-2.39 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 2H), 1.51 (s, 3.6H, minor rotamer), 1.49 (5.4H, major rotamer).



Example 208; Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate.


[0388] The title compound was prepared from 2-(1,1-dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate using methods analogous to those described for Example 198. HPLC: R_t = 4.23. MS (ESI): mass calcd. for $C_{33}H_{38}ClN_5O_5S$, 651.2; m/z found, 652.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.49 (dd, J = 8.4, 2.0, 1H), 7.45 (d, J = 8.4, 1H), 7.40 (dd, J = 7.9, 1.6, 1H), 7.38-7.35 (m, 2H), 4.76 (s, 1H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.78 (s, 3H), 3.70 (t, J = 4.6, 4H), 3.66 (t, J = 5.8, 2H), 3.32-3.25 (m, 1H), 3.09 (dt, J = 12.6, 5.4, 1H), 2.91 (s, 3H), 2.91-2.88 (m, 2H), 2.87-2.75 (m, 2H), 2.43-2.39 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.11-2.04 (m, 1H).

[0389] The compounds in Examples 209-219 were prepared using methods analogous to those described for Example 177, substituting the appropriate amines for 4-chlorobenzylamine in Step A and 2-(4-piperidinyl)pyridine in Step B.




Example 209; (2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol.

[0390] MS (ESI): mass calcd. for $C_{37}H_{42}ClN_5O_4S$, 687.3; m/z found, 688.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.6, 1H), 7.55 (d, J = 8.2, 2H), 7.51-7.43 (m, 2H), 7.41-7.36 (m, 2H), 7.35-7.28 (m, 5H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.84-3.73 (m, 3H), 3.72-3.68 (m, 4H), 3.68-3.56 (m, 4H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.46-2.37 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.13-2.03 (m, 2H).




Example 210; N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine.

[0391] MS (ESI): mass calcd. for $C_{37}H_{42}ClN_5O_3S$, 671.3; m/z found, 672.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.7, 1H), 7.54 (d, J = 8.2, 2H), 7.50-7.44 (m, 2H), 7.36 (d, J = 4.4, 4H), 7.31-7.25 (m, 3H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.80 (q, J = 6.6, 1H), 3.73-3.68 (m, 4H), 3.68-3.59 (m, 4H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.45-2.37 (m, 4H), 2.33 (t, J = 6.8, 2H), 2.12-2.04 (m, 2H), 1.38 (d, J = 6.6, 3H).




Example 211; Methyl (2R)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate.

[0392] MS (ESI): mass calcd. for $C_{38}H_{42}ClN_5O_5S$, 715.3; m/z found, 716.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.8, 1H), 7.55 (d, J = 8.2, 2H), 7.50-7.44 (m, 2H), 7.40-7.35 (m, 4H), 7.35-7.31 (m, 3H), 4.54 (s, 2H), 4.38 (s, 1H), 4.11 (t, J = 6.8, 2H), 3.75 (s, 2H), 3.74-3.68 (m, 7H), 3.66 (t, J = 5.8, 2H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.48-2.39 (m, 4H), 2.34 (t, J = 6.6, 2H), 2.14-2.03 (m, 2H).



Example 212; 1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3,4-dichlorophenyl)methyl]methanamine.


[0393] MS (ESI): mass calcd. for $C_{37}H_{40}ClF_3N_6O_2S$, 724.3; m/z found, 725.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 1.8, 1H), 7.57 (d, J = 8.2, 2H), 7.51-7.44 (m, 3H), 7.40 (d, J = 8.2, 1H), 7.35 (d, J = 8.2, 2H), 7.19 (dd, J = 8.2, 1.9, 1H), 4.54 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.83-3.76 (m, 4H), 3.73-3.69 (m, 4H), 3.66 (t, J = 5.7, 2H), 2.91 (s, 3H), 2.90-2.87 (m, 2H), 2.49-2.38 (m, 4H), 2.34 (t, J = 6.8, 2H), 2.13-2.04 (m, 2H).



Example 213; (1S,2R)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-1-ol.


[0394] MS (ESI): mass calcd. for $C_{43}H_{46}ClN_7O_3S$, 775.3; m/z found, 776.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.20-8.18 (m, 1H), 7.81 (d, J = 1.9, 1H), 7.63-7.61 (m, 1H), 7.60-7.59 (m, 1H), 7.53-7.45 (m, 3H), 7.42 (d, J = 8.2, 2H), 7.26-7.21 (m, 4H), 6.68-6.60 (m, 2H), 4.55 (s, 2H), 4.44-4.39 (m, 1H), 4.18-4.10 (m, 3H), 4.04 (d, J = 2.4, 2H), 3.66

(t, J = 5.8, 2H), 3.58-3.49 (m, 4H), 3.11-2.94 (m, 2H), 2.94-2.91 (m, 2H), 2.90 (s, 3H), 2.59-2.49 (m, 4H), 2.44-2.32 (m, 2H), 2.20-2.09 (m, 2H).




Example 214; (1R,2S)-1-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-2-ol.

[0395] MS (ESI): mass calcd. for $C_{44}H_{47}ClN_6O_3S$, 774.3; m/z found, 775.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.81 (d, J = 1.9, 1H), 7.60 (d, J = 8.2, 2H), 7.53-7.44 (m, 2H), 7.42 (d, J = 8.2, 2H), 7.30-7.21 (m, 6H), 6.96-6.90 (m, 2H), 6.86 (t, J = 7.3, 1H), 4.54 (s, 2H), 4.44-4.39 (m, 1H), 4.16-4.10 (m, 3H), 4.04 (d, J = 2.5, 2H), 3.65 (t, J = 5.8, 2H), 3.22-3.16 (m, 4H), 3.10-2.94 (m, 2H), 2.93-2.90 (m, 2H), 2.90 (s, 3H), 2.63-2.54 (m, 4H), 2.38 (t, J = 6.8, 2H), 2.20-2.07 (m, 2H).




Example 215; (1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine.

[0396] MS (ESI): mass calcd. for $C_{44}H_{48}ClN_7O_2S$, 773.3; m/z found, 774.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.19 (dd, J = 4.9, 1.3, 1H), 7.81 (d, J = 1.9, 1H), 7.57 (d, J = 8.2, 2H), 7.52-7.44 (m, 3H), 7.42 (d, J = 8.2, 2H), 7.38-7.35 (m, 1H), 7.18-7.12 (m, 2H), 7.11-7.06 (m, 1H), 6.68-6.59 (m, 2H), 4.55 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.99-3.86 (m, 2H), 3.81 (t, J = 4.9, 1H), 3.66 (t, J = 5.7, 2H), 3.56-3.50 (m, 4H), 2.94-2.91 (m, 2H), 2.90 (s, 3H), 2.88-2.69 (m, 2H), 2.55-2.50 (m, 4H), 2.37 (t, J = 6.7, 2H), 2.17-2.07 (m, 2H), 2.06-1.97 (m, 1H), 1.94-1.88 (m, 2H), 1.80-1.70 (m, 1H).




Example 216; (1S)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine.

[0397] MS (ESI): mass calcd. for $C_{44}H_{48}ClN_7O_2S$, 773.3; m/z found, 774.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.19 (dd, J = 4.9, 1.2, 1H), 7.81 (d, J = 1.8, 1H), 7.57 (d, J = 8.2, 2H), 7.52-7.44 (m, 3H), 7.42 (d, J = 8.3, 2H), 7.39-7.34 (m, 1H), 7.18-7.13 (m, 2H), 7.11-7.07 (m, 1H), 6.68-6.59 (m, 2H), 4.55 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.99-3.86 (m, 2H), 3.81 (t, J = 4.9, 1H), 3.66 (t, J = 5.8, 2H), 3.56-3.50 (m, 4H), 2.94-2.91 (m, 2H), 2.90 (s, 3H), 2.89-2.68 (m, 2H), 2.55-2.51 (m, 4H), 2.37 (t, J = 6.8, 2H), 2.17-2.08 (m, 2H), 2.06-1.96 (m, 1H), 1.94-1.87 (m, 2H), 1.80-1.71 (m, 1H).




Example 217; (1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine.

[0398] MS (ESI): mass calcd. for $C_{45}H_{49}ClN_6O_2S$, 772.3; m/z found, 773.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.81 (d, J = 1.9, 1H), 7.57 (d, J = 8.2, 2H), 7.52-7.44 (m, 2H), 7.42 (d, J = 8.2, 2H), 7.39-7.34 (m, 1H), 7.29-7.23 (m, 2H), 7.19-7.12 (m, 2H), 7.11-7.07 (m, 1H), 6.93 (d, J = 7.9, 2H), 6.86 (t, J = 7.3, 1H), 4.54 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.99-3.86 (m, 2H), 3.81 (t, J = 4.9, 1H), 3.66 (t, J = 5.7, 2H), 3.23-3.14 (m, 4H), 2.94-2.90 (m, 2H), 2.90 (s, 3H), 2.87-2.69 (m, 2H), 2.60-2.56 (m, 4H), 2.38 (t, J = 6.8, 2H), 2.17-2.07 (m, 2H), 2.07-1.95 (m, 1H), 1.95-1.87 (m, 2H), 1.80-1.69 (m, 1H).




Example 218; (2S)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2-phenylethanol.

[0399] MS (ESI): mass calcd. for $C_{42}H_{46}ClN_7O_3S$, 763.3; m/z found, 764.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.21-8.16 (m, 1H), 7.81 (d, J = 1.8, 1H), 7.55 (d, J = 8.2, 2H), 7.52-7.44 (m, 3H), 7.41-7.36 (m, 2H), 7.35-7.28 (m, 5H), 6.68-6.60 (m, 2H), 4.54 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.86-3.69 (m, 3H), 3.68-3.56 (m, 4H), 3.55-3.51 (m, 4H), 2.94-2.91 (m, 2H), 2.90 (s, 3H), 2.56-2.51 (m, 4H), 2.38 (t, J = 6.8, 2H), 2.17-2.08 (m, 2H).




Example 219; N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine.

[0400] MS (ESI): mass calcd. for $C_{42}H_{46}ClN_7O_2S$, 747.3; m/z found, 748.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.20-8.17 (m, 1H), 7.81 (d, J = 1.8, 1H), 7.55 (d, J = 8.2, 2H), 7.51-7.44 (m, 3H), 7.36 (d, J = 4.4, 4H), 7.29 (d, J = 8.2, 2H), 7.28-7.24 (m, 1H), 6.68-6.59 (m, 2H), 4.54 (s, 2H), 4.13 (t, J = 6.8, 2H), 3.81 (q, J = 6.6, 1H), 3.69-3.62 (m, 4H), 3.56-3.50 (m, 4H), 2.94-2.90 (m, 2H), 2.90 (s, 3H), 2.55-2.50 (m, 4H), 2.37 (t, J = 6.8, 2H), 2.17-2.07 (m, 2H), 1.38 (d, J = 6.6, 3H).



Example 220; Methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate.


[0401] The title compound was prepared using methods analogous to those described for Example 285. MS (ESI): mass calcd. for $C_{33}H_{38}Cl_2N_6O_4$, 652.2; m/z found, 653.2 $[M+H]^+$. ^1H NMR ($CDCl_3$; mixture of rotamers): 7.78 (d, J = 2.1, 1H), 7.65 (d, J = 1.9, 1H), 7.56 (d, J = 2.1, 0.4H), 7.54 (d, J = 2.2, 0.6H), 7.46 (s, 0.6H), 7.45-7.43 (m, 0.8H), 7.42 (d, J = 2.0, 0.6H), 7.37 (s, 0.6H), 7.35 (s, 0.4H), 4.69 (s, 2H), 4.59 (s, 2H), 4.16-3.99 (m, 2H), 3.92 (s, 2H), 3.84-3.75 (m, 3H), 3.74 (s, 3H), 3.69-3.59 (m, 2H), 3.48 (s, 2H), 3.24 (dd, J = 11.1, 8.8, 1H), 2.88-2.69 (m, 4H), 2.47-2.35 (m, 1H), 2.30-2.20 (m, 2H), 2.13-1.96 (m, 3H), 0.91 (d, J = 6.3, 3H).



Example 221; N-{[5-({5-[5-(Aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycine.


[0402] A solution of methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate (387 mg, 0.592 mmol) and LiOH (71 mg, 2.96 mmol) in 3:1:1 THF:MeOH:H_2O (3.2 mL) was stirred at rt for 18 h. The mixture was diluted with 1 M HCl and washed with CH_2Cl_2. The aqueous layer was concentrated and purified by reverse-phase HPLC (0-100% MeCN/5mM NH_4OH in H_2O) to afford the desired product as a yellow solid (226 mg, 60%). MS (ESI): mass calcd. for $C_{32}H_{36}Cl_2N_6O_4$, 638.2; m/z found, 639.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (s, 1H), 7.73-7.70 (m, 1H), 7.64-7.59 (m, 1H), 7.51-7.38 (m, 3H), 4.59 (s, 2H), 4.26 (s, 2H), 4.12-3.97 (m, 2H), 3.85-3.59 (m, 5H), 3.51 (s, 2H), 3.37 (td, J = 3.3, 1.6, 1H), 3.30-3.22 (m, 1H), 2.84-2.70 (m, 4H), 2.51-2.40 (m, 1H), 2.36-2.25 (m, 2H), 2.15-1.92 (m, 2H), 0.94 (d, J = 6.3, 3H).

[0403] The compounds in Examples 222-224 were prepared using methods analogous to those described for Example 285.




Example 222; 3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0404] MS (ESI): mass calcd. for $C_{33}H_{40}Cl_2N_6O_3$, 638.3; m/z found, 639.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 2.1, 1H), 7.59-7.54 (m, 2H), 7.47-7.41 (m, 2H), 7.36 (d, J = 8.2, 1H), 4.78 (s, 2H), 4.60 (s, 2H), 4.15-3.98 (m, 2H), 3.90 (s, 2H), 3.85-3.81 (m, 2H), 3.81-3.71 (m, 3H), 3.69-3.58 (m, 2H), 3.24 (dd, J = 11.1, 8.8, 1H), 2.92-2.88 (m, 2H), 2.86-2.69 (m, 5H), 2.47-2.34 (m, 1H), 2.30-2.19 (m, 2H), 2.12-1.96 (m, 2H), 1.80-1.72 (m, 2H), 0.90 (t, J = 7.5, 3H).




Example 223; 3-{4-Chloro-3-[(4-chloro-3-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0405] MS (ESI): mass calcd. for $C_{35}H_{42}Cl_2N_6O_3$, 664.3; m/z found, 665.2 $[M+H]^+$. ^1H NMR ($CDCl_3$; mixture of rotamers): 7.78 (d, J = 2.1, 1H), 7.66 (d, J = 1.8, 1H), 7.56 (d, J = 2.2, 0.4H), 7.54 (d, J = 2.2, 0.6H), 7.47 (s, 0.6H), 7.45 (s, 0.4H), 7.42 (d, J = 2.0, 0.4H), 7.40 (d, J = 2.0, 0.6H), 7.36 (s, 0.6H), 7.34 (s, 0.4H), 4.67 (d, J = 9.8, 3H), 4.17-4.01 (m, 3H), 3.95-3.91 (m, 2H), 3.90-3.82 (m, 1H), 3.81-3.72 (m, 3H), 3.69-3.58 (m, 2H), 3.28-3.19 (m, 1H), 2.85-2.65 (m, 6H), 2.44-2.33 (m, 1H), 2.31-2.20 (m, 2H), 2.12-1.95 (m, 3H), 1.93-1.85 (m, 2H), 1.64-1.53 (m, 1H), 0.91 (d, J = 6.3, 3H).




Example 224; 3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0406] MS (ESI): mass calcd. for $C_{37}H_{40}Cl_2N_6O_2$, 670.3; m/z found, 671.2 $[M+H]^+$. ^1H NMR ($CDCl_3$; mixture of rotamers): 7.79 (d, $J = 2.1$, 1H), 7.66 (d, $J = 1.9$, 1H), 7.55 (d, $J = 2.2$, 0.4H), 7.53 (d, $J = 2.1$, 0.6H), 7.47 (s, 0.6H), 7.45 (s, 0.4H), 7.43 (d, $J = 2.0$, 0.4H), 7.41 (d, $J = 2.0$, 0.6H), 7.40-7.32 (m, 5H), 7.30-7.24 (m, 1H), 4.65-4.59 (m, 3H), 4.15-3.99 (m, 2H), 3.92 (s, 2H), 3.84 (s, 2H), 3.82-3.71 (m, 3H), 3.69-3.58 (m, 2H), 3.24 (dd, $J = 11.1$, 8.8, 1H), 2.89-2.67 (m, 4H), 2.48-2.34 (m, 1H), 2.31-2.19 (m, 2H), 2.12-1.96 (m, 2H), 0.91 (d, $J = 6.3$, 3H).




Example 225; 7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline.

[0407] The title compound was prepared using methods analogous to those described for Example 135. MS (ESI): mass calcd. for $C_{37}H_{41}ClN_6O_2S$, 668.3; m/z found, 669.3 $[M+H]^+$. ^1H NMR: 7.81-7.79 (m, 1H), 7.52-7.50 (m, 2H), 7.40-7.37 (m, 1H), 7.30 (s, 1H), 7.25 (dd, $J = 8.7$, 7.4, 2H), 7.15 (d, $J = 7.9$, 1H), 6.95 (d, $J = 7.9$, 2H), 6.86 (t, $J = 7.3$, 1H), 4.53 (s, 2H), 4.16 (t, $J = 6.7$, 2H), 4.04 (s, 2H), 3.67 (t, $J = 5.8$, 2H), 3.21-3.15 (m, 6H), 2.96 (s, 3H), 2.95-2.89 (m, 4H), 2.65-2.61 (m, 4H), 2.43 (t, $J = 7.2$, 2H), 2.16-2.11 (m, 2H).



Example 226; 7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline.

[0408] Formaldehyde (37% in H_2O; 0.06 mL) and sodium triacetoxyborohydride (16 mg, 0.075 mmol) were added to a solution of 7-[(2-chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline (25 mg, 0.037 mmol) in dichloroethane (0.1 mL) and the resulting mixture was stirred at rt for 18 h. Additional formaldehyde (37% in H_2O, 0.06 mL) and sodium triacetoxyborohydride (16 mg, 0.075 mmol) were added and the mixture was stirred an additional 4 h. The mixture was diluted with 1 M NaOH and extracted with 20% isopropanol in $CHCl_3$. The organic layer was washed with H_2O, dried, and concentrated. Purification by preparative thin layer chromatography (SiO_2; 3% 2 M NH_3 in MeOH/CH_2Cl_2) afforded the desired product as a white solid (10 mg, 40%). MS (ESI): mass calcd. for $C_{38}H_{43}ClN_6O_2S$, 682.3; m/z found, 683.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (s, 1H), 7.51-7.48 (m, 2H), 7.42-7.38 (m, 1H), 7.33-7.24 (m, 3H), 7.16 (d, J = 7.9, 1H), 6.95 (d, J = 8.2, 2H), 6.89 (t, J = 7.3, 1H), 4.54 (s, 2H), 4.14 (t, J = 6.8, 2H), 3.74-3.70 (m, 2H), 3.67 (t, J = 5.7, 2H), 3.26-3.18 (m, 4H), 3.01 (t, J = 5.9, 2H), 2.97-2.91 (m, 5H), 2.85 (t, J = 5.9, 2H), 2.68-2.62 (m, 4H), 2.55-2.52 (m, 3H), 2.45 (t, J = 5.9, 2H), 2.21-2.08 (m, 2H).




Example 227; N-[1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydroisoquinolin-7-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]acetamide.

[0409] The title compound was prepared using methods analogous to those described for Example 135. MS (ESI): mass calcd. for $C_{34}H_{41}ClN_6O_3S$, 648.3; m/z


found, 649.3 $[M+H]^+$. ^1H NMR: 7.83 (s, 1H), 7.55 (s, 2H), 7.37-7.33 (m, 1H), 7.29 (s, 1H), 7.16 (d, $J = 8.0$, 1H), 4.51 (s, 2H), 4.14 (t, $J = 6.5$, 2H), 4.00 (s, 2H), 3.65 (t, $J = 5.8$, 2H), 3.62-3.56 (m, 1H), 3.13 (t, $J = 6.0$, 2H), 2.97 (s, 3H), 2.96-2.92 (m, 2H), 2.91-2.83 (m, 4H), 2.36 (t, $J = 7.2$, 2H), 2.13-1.99 (m, 4H), 1.90 (s, 3H), 1.86-1.78 (m, 2H), 1.53-1.40 (m, 2H).

[0410] The compounds in Examples 227-228 were prepared using methods analogous to those described for Example 2.



Example 228; 7-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)-1,2,3,4-tetrahydroisoquinoline.


[0411] MS (ESI): mass calcd. for $C_{32}H_{42}ClN_5O_2S$, 595.3; m/z found, 596.2 $[M+H]^+$. ^1H NMR: 7.44-7.39 (m, 3H), 7.07-7.04 (m, 2H), 6.92 (s, 1H), 4.40 (s, 2H), 4.12 (m, 2H), 4.05 (s, 2H), 3.64 (t, $J = 5.8$, 2H), 3.21 (t, $J = 6.1$, 2H), 3.10-3.02 (m, 2H), 2.97-2.84 (m, 9H), 2.55-2.42 (m, 4H), 2.41-2.36 (m, 2H), 2.12-2.01 (m, 2H), 1.66-1.56 (m, 4H), 1.53-1.42 (m, 2H).



Example 229; 7-[2-(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline.


[0412] MS (ESI): mass calcd. for $C_{34}H_{45}ClN_6O_2S$, 636.3; m/z found, 637.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.58-7.49 (m, 1H), 7.42-7.37 (m, 1H), 7.34-7.29 (m, 1H), 7.09-7.00 (m, 2H), 6.97-6.86 (m, 1H), 4.48 (s, 2H), 4.09 (t, $J = 6.8$, 2H), 4.00 (s, 2H), 3.66 (t, $J = 5.8$, 2H), 3.13 (t, $J = 5.9$, 2H), 3.06-3.00 (m, 2H), 2.93-2.84 (m, 8H), 2.77 (t, $J = 5.7$, 2H), 2.70-2.55 (m, 4H), 2.47-2.35 (m, 3H), 2.30 (t, $J = 6.8$, 3H), 2.12-1.99 (m, 2H), 0.53-0.35 (m, 4H).

[0413] The compounds in Examples 230-237 were prepared according to the methods described for Example 249.




Example 230; 1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate.

[0414] MS (ESI): mass calcd. for $C_{39}H_{49}Cl_2N_5O_5S$, 769.3; m/z found, 770.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.75 (d, J = 1.8, 1H), 7.52–7.42 (m, 4H), 7.36 (d, J = 7.4, 2H), 4.54 (dd, J = 14.5, 6.4, 2H), 4.20-3.95 (m, 5H), 3.70-3.57 (m, 2H), 3.10-3.00 (m, 2H), 2.95-2.85 (m, 2H), 2.85 (s, 3H), 2.70-2.35 (m, 4H), 2.30 (t, J = 10.8, 2H), 2.03 (t, J = 11.5, 2H), 1.70-1.60 (m, 4H), 1.42 (s, 9H), 1.40-1.10 (m, 4H).




Example 231; 1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate.

[0415] MS (ESI): mass calcd. for $C_{37}H_{54}ClN_5O_5S$, 715.3; m/z found, 716.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.60 (d, J = 1.7, 1H), 7.35-7.30 (m, 2H), 4.48 (q, J = 14.4, 2H), 4.10-3.85 (m, 5H), 3.65-3.52 (m, 2H), 3.00-2.82 (m, 4H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.35-2.30 (m, 2H), 2.30 (d, J = 6.5, 2H), 2.22-2.18 (m, 2H), 1.95-1.85 (m, 2H), 1.65-1.55 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 5H), 1.00 (d, J = 6.7, 6H).




Example 232; 1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate.

[0416] MS (ESI): mass calcd. for $C_{40}H_{52}ClN_5O_5S$, 749.3; m/z found, 750.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.62 (s, 1H), 7.40-7.30 (m, 4H), 7.28 (t, J = 7.5, 2H), 7.21-7.17 (m, 1H), 4.48 (q, J = 14.4, 2H), 4.10-3.88 (m, 5H), 3.85 (s, 2H), 3.65-3.52 (m, 2H), 3.00-2.92 (m, 2H), 2.85-2.80 (m, 2H), 2.80 (s, 3H), 2.57-2.50 (m, 2H), 2.43-2.33 (m, 2H), 2.23-2.18 (m, 2H), 1.95-1.90 (m, 2H), 1.65-1.55 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 4H).




Example 233; 1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate.

[0417] MS (ESI): mass calcd. for $C_{39}H_{56}ClN_5O_5S$, 741.4; m/z found, 742.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.58 (s, 1H), 7.32 (s, 2H), 4.45 (q, J = 14.4, 2H), 4.15-3.88 (m, 5H), 3.62-3.52 (m, 2H), 3.07 (q, J = 7.3, 1H), 3.00-2.82 (m, 4H), 2.80 (s, 3H), 2.60-2.38 (m, 4H), 2.25 (t, J = 11.4, 1H), 1.94 (t, J = 11.4, 1H), 1.85-1.80 (m, 2H), 1.75-1.67 (m, 2H), 1.65-1.40 (m, 7H), 1.38 (s, 9H), 1.40-1.10 (m, 9H).




Example 234; 1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate.

[0418] MS (ESI): mass calcd. for $C_{38}H_{49}ClN_6O_5S$, 736.3; m/z found, 737.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.57 (d, J = 4.2, 1H), 7.80 (d, J = 2.1, 1H), 7.65 (dt, J = 7.7, 1.8, 1H), 7.55 (dd, J = 7.8, 1.0, 1H), 7.47 (dd, J = 8.4, 2.1, 1H), 7.40 (d, J = 8.4, 1H), 7.20 (m, 1H), 4.47 (q, J = 14.4, 2H), 4.10-3.85 (m, 5H), 3.65-3.50 (m, 2H), 3.00-2.75 (m, 4H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.35-2.25 (m, 2H), 2.17 (t, J = 11.5, 2H), 1.90-1.80 (m, 2H), 1.70-1.60 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 4H).




Example 235; 1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate.

[0419] MS (ESI): mass calcd. for $C_{38}H_{49}ClN_6O_5S$, 736.3; m/z found, 737.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.75 (s, 1H), 8.50 (d, J = 4.3, 1H), 7.80 (d, J = 8.7, 1H), 7.74 (s, 1H), 7.45-7.35 (m, 2H), 7.25-7.22 (m, 1H), 4.48 (q, J = 14.4, 2H), 4.10-3.90 (m, 5H), 3.65-3.52 (m, 2H), 3.00-2.93 (m, 2H), 2.87-2.82 (m, 2H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.43-2.33 (m, 2H), 2.22-2.18 (m, 2H), 1.97-1.90 (m, 2H), 1.65-1.55 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 4H).



Example 236; 1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate.


[0420] MS (ESI): mass calcd. for $C_{38}H_{57}ClN_6O_5S$, 744.4; m/z found, 745.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.62 (d, J = 1.9, 1H), 7.40-7.30 (m, 2H), 4.48 (q, J = 14.4, 2H), 4.10-3.88 (m, 5H), 3.65 (s, 2H), 3.65-3.52 (m, 2H), 3.00-2.80 (m, 4H), 2.80 (s, 3H), 2.62 (q, J = 7.2, 4H), 2.57-2.50 (m, 2H), 2.35-2.25 (m, 2H), 2.20-2.10 (m, 2H), 1.90-1.80 (m, 2H), 1.65-1.55 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 4H), 1.13 (t, J = 7.2, 6H).



Example 237; 1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate.

[0421] MS (ESI): mass calcd. for $C_{39}H_{48}Cl_2N_6O_4$, 734.3; m/z found, 735.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 2.0, 1H), 7.55–7.40 (m, 4H), 7.36 (d, J = 8.6, 2H), 5.05 (br s, 2H), 4.54 (q, J = 14.5, 2H), 4.20-3.95 (m, 5H), 3.80-3.60 (m, 2H), 2.95-2.65 (m, 6H), 2.37 (d, J = 6.6, 2H), 2.22-2.15 (m, 2H), 1.95-1.85 (m, 2H), 1.70-1.60 (m, 4H), 1.42 (s, 9H), 1.40-1.10 (m, 4H).


[0422] The compounds in Examples 238-239 were prepared according to the methods described for Example 132.



Example 238; 1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.


[0423] MS (ESI): mass calcd. for $C_{34}H_{40}Cl_2N_6O_2$, 634.3; m/z found, 635.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.72 (d, J = 2.0, 1H), 7.45–7.35 (m, 4H), 7.24 (d, J = 8.6, 2H), 4.80 (br s, 2H), 4.52 (br s, 2H), 4.10-3.85 (m, 5H), 3.75-3.55 (m, 2H), 3.15 (d, J =

12, 2H), 2.90-2.50 (m, 6H), 2.28 (d, J = 6.6, 2H), 2.10 (t, J = 11.2, 1H), 1.82 (t, J = 11.2, 1H), 1.70-1.50 (m, 4H), 1.40-1.10 (m, 4H).




Example 239; (2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol.

[0424] MS (ESI): mass calcd. for $C_{32}H_{46}ClN_5O_3S$, 615.3; m/z found, 616.2 $[M+H]^+$. ^1H NMR: 7.62 (s, 1H), 7.40 (s, 2H), 4.40-4.35 (m, 2H), 4.12-3.05 (m, 2H), 3.65-3.50 (m, 4H), 3.35-3.30 (m, 2H), 3.17-3.08(m, 2H), 3.00-2.80 (m, 4H), 2.85 (s, 3H), 2.30 (d, J = 6.5, 2H), 2.18-1.80 (m, 4H), 1.95-1.85 (m, 2H), 1.65-1.55 (m, 4H), 1.40-1.30 (m, 4H), 1.00 (d, J = 6.7, 6H).



Example 240; (2S)-1-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol.


[0425] The title compound was prepared by methods analogous to those described for Example 74, using formaldehyde (37 wt% in H_2O; 3 equiv.) in dichloroethane. MS (ESI): mass calcd. for $C_{35}H_{43}Cl_2N_5O_3S$, 683.3; m/z found, 684.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.72 (d, J = 1.8, 1H), 7.47–7.38 (m, 4H), 7.28 (d, J = 8.7, 2H), 4.50 (dd, J = 14.5, 6.4, 2H), 4.10-3.85 (m, 5H), 3.70-3.52 (m, 2H), 3.05-2.80 (m, 4H), 2.80 (s, 3H), 2.30-2.10 (m, 4H), 2.25 (s, 3H), 1.95-1.80 (m, 4H), 1.65-1.55 (m, 4H), 1.40-0.90 (m, 4H).



Example 241; (2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol.


[0426] The title compound was prepared using methods analogous to those described for Example 66. MS (ESI): mass calcd. for $C_{36}H_{43}Cl_2N_5O_4S$, 711.2; m/z found, 712.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.70 (s, 1H), 7.47-7.40 (m, 4H), 7.30-7.25 (m, 2H), 4.52-4.42 (m, *2*H), 4.35-4.25 (m, 1H), 4.15-4.10 (m, 1H), 4.05-3.95 (m, 1H), 3.80-3.70 (m, 1H), 3.65-3.55 (m, 2H), 3.30-3.10 (m, 2H), 2.95-2.85(m, 3H), 2.80 (s, 3H), 2.70-2.60 (m, 2H), 2.40 (t, J = 7.6, 2H), 2.30-1.70 (m, 4H), 2.00 (s, 3H), 1.75-1.40 (m, 4H), 1.30-1.00 (m, 4H).

[0427] The compounds in Examples 242-248 were prepared using methods analogous to those described for Example 2, using the appropriate alkynes as starting materials.




Example 242; 1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate.

[0428] MS (ESI): mass calcd. for $C_{39}H_{52}Cl_2N_6O_4$, 738.3; m/z found, 739.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.35-7.10 (m, 5H), 7.07 (d, J = 7.4, 2H), 4.55 (br s, 2H), 4.40 (br s, 2H), 4.10-3.85 (m, 5H), 3.65-3.50 (m, 2H), 3.05-2.75 (m, 8H), 2.60-2.50 (m, 2H), 2.35-2.30 (d, J = 6.5, 2H), 2.15 (t, J = 10.3, 1H), 1.90 (t, J = 10.5, 1H), 1.65-1.52 (m, 4H), 1.38 (s, 9H), 1.40-1.10 (m, 6H).




Example 243; 2-[3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide.

[0429] MS (ESI): mass calcd. for $C_{38}H_{44}Cl_2N_6O_3$, 702.3; m/z found, 703.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.50-7.15 (m, 11H), 5.65 (br s, 2H), 4.52 (br s, 2H), 4.10-4.00 (m, 2H), 3.70-3.55 (m, 9H), 3.23 (dd, J = 11.1, 8.8, 1H), 3.10-3.00 (m, 2H), 2.95-2.90 (m, 2H), 2.80-2.70 (m, 4H), 2.43-2.35 (m, 1H), 2.30-2.20 (m, 2H), 2.10-1.95 (m, 2H), 0.90 (d, J = 6.3, 3H).




Example 244; 3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0430] MS (ESI): mass calcd. for $C_{37}H_{44}Cl_2N_6O_2$, 674.3; m/z found, 675.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.45-7.15 (m, 11H), 4.65 (br s, 2H), 4.52 (br s, 2H), 4.10-4.00 (m, 2H), 3.70-3.55 (m, 9H), 3.23 (dd, J = 11.1, 8.8, 1H), 3.10-3.00 (m, 2H), 2.95-2.90 (m, 2H), 2.80-2.70 (m, 4H), 2.43-2.35 (m, 1H), 2.30-2.20 (m, 2H), 2.10-1.95 (m, 2H), 0.90 (d, J = 6.3, 3H).




Example 245; 1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate.

[0431] MS (ESI): mass calcd. for $C_{39}H_{53}Cl_2N_5O_5S$, 773.3; m/z found, 774.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.32-7.12 (m, 5H), 7.07 (d, J = 7.4, 2H), 4.54 (q, J = 14.5, 2H), 4.10-3.85 (m, 5H), 3.65-3.50 (m, 2H), 3.05-2.75 (m, 10H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.32-2.20 (m, 2H), 2.15 (t, J = 11.4, 1H), 1.85 (t, J = 11.4, 1 H), 1.65-1.52 (m, 4H), 1.48 (s, 9H), 1.40-1.10 (m, 4H).



Example 246; (2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol.


[0432] MS (ESI): mass calcd. for $C_{34}H_{45}Cl_2N_5O_3S$, 673.3; m/z found, 674.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.35-7.12 (m, 5H), 7.07 (d, J = 7.4, 2H), 4.38 (q, J = 14.5, 2H), 4.10-3.85 (m, 5H), 3.65-3.50 (m, 2H), 3.05-2.75 (m, 10H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.32-2.20 (m, 2H), 2.12 (t, J = 11.4, 1H), 1.85 (t, J = 11.4, 1 H), 1.65-1.52 (m, 4H), 1.40-1.10 (m, 4H).



Example 247; (2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol.


[0433] MS (ESI): mass calcd. for $C_{36}H_{47}Cl_2N_5O_4S$, 715.3; m/z found, 716.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.32-7.15 (m, 5H), 7.05 (d, J = 7.4, 2H), 4.60-4.50 (br s, 1H), 4.38 (q, J = 14.5, 2H), 4.15-3.90 (m, 5H), 3.80-3.70 (m, 2H), 3.60-3.50 (m, 2H), 3.20-

3.05 (m, 2H), 3.05-2.75 (m, 6H), 2.80 (s, 3H), 2.60-2.50 (m, 2H), 2.32-2.20 (m, 4H), 2.00 (s, 3H), 1.70-1.60 (m, 4H), 1.40-1.10 (m, 4H).



Example 248; (2S)-1-[3-{4-Chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol.

[0434] MS (ESI): mass calcd. for $C_{35}H_{47}Cl_2N_5O_3S$, 687.3; m/z found, 688.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.82-7.18 (m, 5H), 7.07 (d, J = 7.4, 2H), 4.38 (q, J = 14.5, 2H), 4.15-4.00 (m, 2H), 3.92-3.85 (m, 1H), 3.65-3.50 (m, 2H), 3.05-2.75 (m, 9H), 2.80 (s, 3H), 2.32-2.10 (m, 3H), 2.25 (s, 3H), 2.00-1.80 (m, 4H), 1.68-1.58 (m, 4H), 1.40-0.90 (m, 6H).



Example 249; (S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide.

[0435] A. (R)-3-(4-Chloro-3-iodo-phenyl)-1-oxiranylmethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. (S)-(+)-Glycidylnosylate (17.5 g, 67.5 mmol) was added to a stirring mixture of 3-(4-chloro-3-iodo-phenyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (15.1g, 33.0 mmol) and Cs_2CO_3 (21.8 g, 67.0 mmol) in DMF (200 mL) at rt. After 21 h, the mixture was filtered and concentrated to give a crude oil. The oil was diluted with CH_2Cl_2 (150 mL) and washed with satd. aq. Na_2CO_3 (2 x 75 mL). The organic layer was dried and concentrated to give a gold oil. The oil was purified on SiO_2 (CH_2Cl_2 to 5% acetone/CH_2Cl_2) to provide the desired product (11.9 g, 70%) as a white solid. TLC: R_f

= 0.36 [5% acetone/CH_2Cl_2]. MS (ESI): mass calcd. for $C_{20}H_{23}ClIN_3O_3$, 515.1; m/z found, 516.0 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.07 (s, 1H), 7.55 (d, J = 8.4, 1H), 7.47 (br s, 1H), 4.45 (s, 2H), 4.33 (dd, J = 14.8, 3.2, 1H), 4.03 (dd, J = 15.2, 6.0, 1H), 3.62-3.48 (m, 2H), 3.23 (br s, 1H), 2.74-2.68 (m, 1H), 2.65 (br s, 2H), 2.49-2.45 (m, 1H), 1.32 (s, 9H).

[0436] B. (S)-3-(4-Chloro-3-iodo-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester. Thiomorpholine (11 mL, 116 mmol) was added to a stirring mixture of (R)-3-(4-chloro-3-iodo-phenyl)-1-oxiranylmethyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (11.8 g, 22.9 mmol) in EtOH (120 mL). After 20 h, the mixture was concentrated to give a golden oil. The oil was purified on SiO_2 (CH_2Cl_2 to 20% acetone/CH_2Cl_2) to give the desired product (13.7 g, 97%) as a white solid. TLC: R_f = 0.46 [15% acetone/CH_2Cl_2]. MS (ESI): mass calcd. for $C_{24}H_{32}ClIN_4O_3S$, 618.1; m/z found, 619.1 $[M+H]^+$. ^1H NMR (d_6-DMSO): 7.97 (s, 1H), 7.46 (d, J = 8.0, 1H), 7.38 (br s, 1H), 4.72 (d, J = 4.8, 1H), 4.36 (s, 2H), 3.98-3.92 (m, 1H), 3.89-3.71 (m, 2H), 3.45 (br s, 2H), 2.58 (d, J = 4.4, 2H), 2.51 (d, J = 4.8, 4H), 2.42-2.35 (m, 4H), 2.18 (t, J = 6.0, 2H), 1.24 (s, 9H).

[0437] C. 1-[3-(4-Chloro-3-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol. Trifluoroacetic acid (30 mL) was added to a stirring solution of (S)-3-(4-chloro-3-iodo-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester (13.6 g, 22.0 mmol) in CH_2Cl_2 (30 mL). After 2 h, the mixture was concentrated to give a golden liquid. The liquid was set stirring in CH_2Cl_2 (200 mL) and satd. aq. K_2CO_3 (200 mL) was added slowly over 15 min. The organic layer was separated, dried, and concentrated to give the desired product (9.3 g, 82%) as a white solid. MS (ESI): mass calcd. for $C_{19}H_{24}ClIN_4OS$, 518.0; m/z found, 519.0 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.34 (s, 1H), 7.79 (d, J = 8.4, 1H), 7.74 (dd, J = 8.4, 2.0, 1H), 5.06 (d, J = 4.8, 1H), 4.28 (dd, J = 13.6, 3.6, 1H), 4.27-4.23 (m, 1H), 4.22-4.07 (m, 1H), 4.05 (s, 2H), 3.12 (br s, 2H), 2.95-2.73 (m, 11H), 2.54 (t, J = 6.0, 2H).

[0438] D. (S)-2-[3-(4-Chloro-3-iodo-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide. Oxamic acid (1.76 g, 19.8 mmol) was added to a stirring mixture of 1,1'-carbonyldiimidazole (CDI) (3.19 g, 19.7 mmol) in DMF (50 mL). After 75 min, a solution of 1-[3-(4-chloro-3-iodo-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol (5.3 g, 10.2 mmol) in DMF (50 mL) was added and the mixture was stirred at rt. After


15 min, the mixture was concentrated to give a cloudy yellow liquid. The liquid was diluted with EtOAc (200 mL) and washed twice with H_2O (200 mL). The organic layer was dried and concentrated to give the desired product (6.0 g, 100%) as a white solid. MS (ESI): mass calcd. for $C_{21}H_{25}ClIN_5O_3S$, 589.0; m/z found, 590.0 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.30-8.25 (m, 2H), 8.21-7.90 (m, 2H), 7.88-7.50 (m, 1H), 5.06-4.75 (m, 3H), 4.28-4.00 (m, 2H), 3.97-3.78 (m, 2H), 3.05-2.75 (m, 11H), 2.62-2.42 (m, 2H).

[0439] E. (4-Chloro-benzyl)-(4-ethynyl-benzyl)-amine. 4-Trimethylsilanylethynyl-benzaldehyde (commercially available or available via Sonogashira coupling; 1.0 g, 4.9 mmol, 1.0 equiv) was dissolved in MeOH (20 mL) and 4-chlorobenzylamine (0.74 g, 5.2 mmol, 1.05 equiv) was added. After stirring at rt for 16 h, $NaBH_4$ (0.19 g, 4.9 mmol, 1.0 equiv) was added slowly. 1 N HCl was slowly added to quench the unreacted $NaBH_4$. The mixture was concentrated and the residue was partitioned between CH_2Cl_2 and satd. aq. $NaHCO_3$. The organic layer was dried and concentrated. The crude compound was purified (SiO_2; EtOAc/hexanes) to provide the title compound (1.1 g, 4.3 mmol, 90%). TLC: $R_f = 0.54$ (50% EtOAc/hexanes). Alternatively, the material was converted to the corresponding HCl salt and purified by recrystallization.

[0440] F. (S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide. Triethylamine (1.5 mL, 10.8 mmol) was added to a stirring mixture of (S)-2-[3-(4-chloro-3-iodo-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide (2.1 g, 3.5 mmol) and (4-chloro-benzyl)-(4-ethynyl-benzyl)-amine (1.5 g, 6.0 mmol) in DMF (15 mL). The flask was equipped with a nitrogen inlet, septum, and vacuum line. The mixture was evacuated and flushed with nitrogen three times. To the mixture was added $Pd(PPh_3)_2Cl_2$ (51 mg, 0.073 mmol) and CuI (36 mg, 0.19 mmol) in one portion while keeping the contents under a positive pressure of nitrogen. After 3 h, the mixture was added to H_2O (100 mL) and EtOAc (100 mL). The organic layer was separated, washed once with H_2O (50 mL), dried, and concentrated to give a golden brown oil. The oil was purified on SiO_2 (CH_2Cl_2 to 100% (5% MeOH(2 M NH_3)/CH_2Cl_2)) to give the desired product (1.72 g, 68%) as a light yellow solid. TLC: $R_f = 0.42$ [10% MeOH(2 M NH_3)/CH_2Cl_2]. MS (ESI): mass calcd. for $C_{37}H_{38}Cl_2N_6O_3S$, 716.2; m/z found, 717.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.00-7.88 (m, 2H), 7.82-7.75 (m, 2H), 7.74-7.65 (m, 2H), 7.55 (d, $J = 8.4$, 2H), 7.50 (s, 4H), 5.08-5.00 (m, 1H), 4.89-4.83 (m, 2H), 4.30-4.23


(m, 1H), 4.21-4.07 (m, 2H), 3.95-3.72 (m, 6H), 3.12-2.91 (m, 4H), 2.90-2.80 (m, 4H), 2.79-2.69 (m, 4H), 2.54-2.47 (m, 2H).

[0441] The compounds in Examples 250-275 were prepared using methods analogous to those described for Example 249, with exceptions as noted.




Example 250; (R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide.

[0442] MS (ESI): mass calcd. for $C_{37}H_{38}Cl_2N_6O_3S$, 716.2; m/z found, 717.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.00-7.88 (m, 2H), 7.82-7.75 (m, 2H), 7.74-7.65 (m, 2H), 7.55 (d, $J = 8.4$, 2H), 7.50 (s, 4H), 5.08-5.00 (m, 1H), 4.89-4.83 (m, 2H), 4.30-4.23 (m, 1H), 4.21-4.07 (m, 2H), 3.95-3.72 (m, 6H), 3.12-2.91 (m, 4H), 2.90-2.80 (m, 4H), 2.79-2.69 (m, 4H), 2.54-2.47 (m, 2H).




Example 251; (S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0443] MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6O_2S$, 688.2; m/z found, 689.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.11 (s, 1H), 9.69 (s, 2H), 7.83 (s, 1H), 7.65-7.48 (m, 8H), 7.42 (d, $J = 8.4$, 2H), 4.54-4.44 (m, 6H), 4.18-4.00 (m, 5H), 3.68-3.52 (m, 4H), 3.35-3.25 (m, 1H), 3.24-3.00 (m, 6H), 2.78-2.60 (m, 4H).




Example 252; (R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0444] MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6O_2S$, 688.2; m/z found, 689.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.11 (s, 1H), 9.69 (s, 2H), 7.83 (s, 1H), 7.65-7.48 (m, 8H), 7.42 (d, $J = 8.4$, 2H), 4.54-4.44 (m, 6H), 4.18-4.00 (m, 5H), 3.68-3.52 (m, 4H), 3.35-3.25 (m, 1H), 3.24-3.00 (m, 6H), 2.78-2.60 (m, 4H).




Example 253; (S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide.

[0445] MS (ESI): mass calculated for $C_{37}H_{38}Cl_2N_6O_4$, 700.2; m/z found, 701.2 $[M+H]^+$. ^1H NMR (d_6-DMSO) 8.16 (s, 1H), 7.90-7.75 (m, 2H), 7.73-7.50 (m, 4H), 7.43 (d, $J = 8.4$, 2H), 7.38 (s, 4H), 5.00-4.95 (m, 1H), 4.80-4.70 (m, 2H), 4.25-4.15 (m, 1H), 4.13-3.95 (m, 2H), 3.94-3.65 (m, 6H), 3.59-3.50 (br s, 4H), 2.90-2.80 (m, 3H), 2.48-2.30 (m, 6H).




Example 254; (R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide.

[0446] MS (ESI): mass calcd. for $C_{37}H_{38}Cl_2N_6O_4$, 700.2; m/z found, 701.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.16 (s, 1H), 7.90-7.75 (m, 2H), 7.73-7.50 (m, 4H), 7.43 (d, J = 8.4, 2H), 7.38 (s, 4H), 5.00-4.95 (m, 1H), 4.80-4.70 (m, 2H), 4.25-4.15 (m, 1H), 4.13-3.95 (m, 2H), 3.94-3.65 (m, 6H), 3.59-3.50 (br s, 4H), 2.90-2.80 (m, 3H), 2.48-2.30 (m, 6H).



Example 255; 2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0447] MS (ESI): mass calcd. for $C_{38}H_{40}Cl_2N_6O_4$, 714.3; m/z found, 715.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 12.40 (br s, 1H), 10.91 (br s, 2H), 9.16 (s, 1H), 8.90-8.35 (m, 10H), 8.28 (d, J = 9.8, 2H), 7.38 (s, 4H), 5.05-5.00 (m, 1H), 4.70-4.60 (m, 1H), 4.50-4.35 (m, 6H), 4.32-3.85 (m, 5H), 3.82-3.65 (m, 3H), 3.50-3.15 m, 2H), 3.10-2.90 (m, 2H), 1.06 (d, J = 7.6, 2H).



Example 256; 2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2R)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0448] MS (ESI): mass calcd. for $C_{38}H_{40}Cl_2N_6O_4$, 714.3; m/z found, 715.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 12.40 (br s, 1H), 10.91 (br s, 2H), 9.16 (s, 1H), 8.90-8.35

(m, 10H), 8.28 (d, J = 9.8, 2H), 7.38 (s, 4H), 5.05-5.00 (m, 1H), 4.70-4.60 (m, 1H), 4.50-4.35 (m, 6H), 4.32-3.85 (m, 5H), 3.82-3.65 (m, 3H), 3.50-3.15 m, 2H), 3.10-2.90 (m, 2H), 1.06 (d, J = 7.6, 2H).




Example 257; 3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0449] MS (ESI): mass calcd. for $C_{37}H_{40}Cl_2N_6O_3$, 686.3; m/z found, 687.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 12.30 (br s, 1H), 10.83 (br s, 2H), 8.73 (s, 1H), 8.65-8.38 (m, 10H), 8.27 (d, J = 7.6, 2H), 4.98-4.35 (m, 8H), 4.25-3.95 (m, 4H), 3.92-3.55 (m, 7H), 3.50-3.15 m, 3H), 2.79 (s, 2H), 1.05 (d, J = 7.8, 2H).




Example 258; 3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0450] MS (ESI): mass calcd. for $C_{37}H_{40}Cl_2N_6O_3$, 686.3; m/z found, 687.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 12.30 (br s, 1H), 10.83 (br s, 2H), 8.73 (s, 1H), 8.65-8.38 (m, 10H), 8.27 (d, J = 7.6, 2H), 4.98-4.35 (m, 8H), 4.25-3.95 (m, 4H), 3.92-3.55 (m, 7H), 3.50-3.15 m, 3H), 2.79 (s, 2H), 1.05 (d, J = 7.8, 2H).




Example 259; (S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0451] MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6O_3$, 672.2; m/z found, 673.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.30 (br s, 1H), 9.77 (br s, 2H), 7.92 (s, 1H), 7.80-7.55 (m, 10H), 7.52 (d, $J = 6.6$, 2H), 4.58 (s, 2H), 4.40 (br s, 1H), 4.25-3.90 (m, 9H), 3.89-3.73 (m, 2H), 3.70-3.58 (br s, 2H), 3.56-3.38 (m, 3H), 3.16 (br s, 3H), 2.77 (s, 2H).




Example 260; (R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide.

[0452] MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6O_3$, 672.2; m/z found, 673.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.30 (br s, 1H), 9.77 (br s, 2H), 7.92 (s, 1H), 7.80-7.55 (m, 10H), 7.52 (d, $J = 6.6$, 2H), 4.58 (s, 2H), 4.40 (br s, 1H), 4.25-3.90 (m, 9H), 3.89-3.73 (m, 2H), 3.70-3.58 (br s, 2H), 3.56-3.38 (m, 3H), 3.16 (br s, 3H), 2.77 (s, 2H).




Example 261; (S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol.

[0453] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_3S_2$, 723.2; m/z found, 724.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.23 (br s, 1H), 9.78 (br s, 2H), 7.90 (s, 1H), 7.75-7.58 (m, 8H), 7.51 (d, J = 8.4, 2H), 4.46 (s, 2H), 4.30-4.05 (m, 6H), 3.82-3.68 (m, 2H), 3.55-3.45 (m, 2H), 3.40-3.32 (m, 1H), 3.25-3.00 (m, 10H), 2.93 (br s, 2H), 2.86-2.76 (m, 2H).




Example 262; (R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol.

[0454] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_3S_2$, 723.2; m/z found, 724.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.23 (br s, 1H), 9.78 (br s, 2H), 7.90 (s, 1H), 7.75-7.58 (m, 8H), 7.51 (d, J = 8.4, 2H), 4.46 (s, 2H), 4.30-4.05 (m, 6H), 3.82-3.68 (m, 2H), 3.55-3.45 (m, 2H), 3.40-3.32 (m, 1H), 3.25-3.00 (m, 10H), 2.93 (br s, 2H), 2.86-2.76 (m, 2H).




Example 263; (S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol.

[0455] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_4S$, 707.2; m/z found, 708.1 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.28 (br s, 1H), 9.71 (br s, 2H), 7.91 (s, 1H), 7.74-7.57 (m, 8H), 7.52 (d, J = 6.5, 2H), 4.47 (s, 3H), 4.28-4.06 (m, 6H), 3.98-3.90 (m, 2H), 3.89-3.27 (m, 10H), 3.23-3.05 (m, 4H), 2.94 (br s, 2H).




Example 264; (R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol.

[0456] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_4S$, 707.2; m/z found, 708.1 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.28 (br s, 1H), 9.71 (br s, 2H), 7.91 (s, 1H), 7.74-7.57 (m, 8H), 7.52 (d, $J = 6.5$, 2H), 4.47 (s, 3H), 4.28-4.06 (m, 6H), 3.98-3.90 (m, 2H), 3.89-3.27 (m, 10H), 3.23-3.05 (m, 4H), 2.94 (br s, 2H).




Example 265; (2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol.

[0457] MS (ESI): mass calcd. for $C_{37}H_{41}Cl_2N_5O_4S$, 721.2; m/z found, 722.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 12.28 (br s, 1H), 10.81 (br s, 2H), 8.73 (s, 1H), 8.74-8.57 (m, 8H), 8.52 (d, $J = 9.8$, 2H), 4.76 (s, 3H), 4.48-4.34 (m, 6H), 4.25-4.00 (m, 3H), 3.91-3.67 (m, 5H), 3.50-2.95 (m, 10H), 1.02 (d, $J = 7.2$, 2H).




Example 266; (2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol.

[0458] MS (ESI): mass calcd. for $C_{37}H_{41}Cl_2N_5O_4S$, 721.2; m/z found, 722.3 $[M+H]^+$. ^1H NMR (d_6-DMSO): 9.81 (br s, 1H), 9.69 (br s, 2H), 7.82 (s, 1H), 7.72-7.52 (m, 8H), 7.43 (d, $J = 6.4$, 2H), 4.39 (s, 1H), 4.32 (br s, 2H), 4.20-4.01 (m, 6H), 4.00-3.62 (m, 9H), 3.55-3.25 (m, 5H), 3.18-2.95 (m, 2H), 2.86 (br s, 2H), 1.10 (d, $J = 7.2$, 2H).




Example 267; 2-{3-[4-Chloro-3-(4-chloro-3-{[((2S)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.

[0459] MS (ESI): mass calcd. for $C_{36}H_{42}Cl_2N_6O_4$, 692.3; m/z found, 693.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 11.08 (br s, 1H), 9.18 (br s, 2H), 8.06 (s, 1H), 7.92-7.68 (m, 3H), 7.61-7.45 (m, 4H), 4.65 (s, 2H), 4.32-4.17 (m, 2H), 4.16-3.98 (m, 3H), 3.92-3.53 (m, 7H), 3.20-2.90 (m, 5H), 2.89-2.68 (m, 3H), 2.25-2.00 (br s, 2H), 1.98-1.82 (m, 1H), 1.78-1.68 (m, 2H), 1.58-1.45 (m, 1H), 1.23-1.05 (m, 5H).



Example 268; 2-{3-[4-Chloro-3-(4-chloro-3-{[((2R)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.

[0460] MS (ESI): mass calcd. for $C_{36}H_{42}Cl_2N_6O_4$, 692.3; m/z found, 693.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 11.08 (br s, 1H), 9.18 (br s, 2H), 8.06 (s, 1H), 7.92-7.68 (m, 3H), 7.61-7.45 (m, 4H), 4.65 (s, 2H), 4.32-4.17 (m, 2H), 4.16-3.98 (m, 3H), 3.92-3.53 (m, 7H), 3.20-2.90 (m, 5H), 2.89-2.68 (m, 3H), 2.25-2.00 (br s, 2H), 1.98-1.82 (m, 1H), 1.78-1.68 (m, 2H), 1.58-1.45 (m, 1H), 1.23-1.05 (m, 5H).



Example 269; (S)-2-{3-[4-Chloro-3-(4-chloro-3-cyclopentylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0461] A. 2-Chloro-5-iodo-benzoyl chloride. A stirring solution of 2-chloro-5-iodo-benzoic acid (12.4 g, 43.9 mmol) in $SOCl_2$ (40 mL, 550 mmol) was heated to reflux under a N_2 atmosphere. After 20 h, the mixture was concentrated to give the product (13.2 g, 100%) as a yellow solid. ^1H NMR (d_6-DMSO): 7.88 (s, 1H), 7.65 (dd, J = 8.4, 2.0, 1H), 7.14 (d, J = 8.4, 1H).

[0462] B. 2-Chloro-N-cyclopentyl-5-iodo-benzamide. 2-Chloro-5-iodo-benzoyl chloride (4.1 g, 13.6 mmol) was added to a stirring solution of cyclopentylamine (4.0 mL, 40.5 mmol) in THF (50 mL) at rt. After 1 h, the mixture was concentrated, and the residue was diluted with CH_2Cl_2 (100 mL) and washed with 0.5 M HCl. The organic layer was dried and concentrated to give the desired product (4.5 g, 94%) as a white solid. MS (ESI): mass calcd. for $C_{12}H_{13}ClINO$, 349.0; m/z found, 350.0 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.22 (d, J = 7.2, 1H), 7.52 (d, J = 8.4, 1H), 7.4 (s, 1H), 7.04 (d, J = 8.4, 1H), 3.98-3.80 (m, 1H), 1.69-1.55 (m, 2H), 1.48-1.38 (m, 2H), 1.37-1.18 (m, 4H).

[0463] C. (2-Chloro-5-iodo-benzyl)-cyclopentyl-amine. Borane dimethyl sulfide (3.5 mL, 76.0 mmol) was added via syringe over 5 min to a stirring solution of 2-chloro-N-cyclopentyl-5-iodo-benzamide (4.3 g, 12.3 mmol) in THF (75 mL). Once addition was complete the mixture was heated to 70 °C. After 3 h, the mixture was cooled to rt and MeOH (10 mL) was added slowly over 10 min. Once addition of MeOH was complete, 1 M NaOH (10 mL) was added and the mixture was heated to 70 °C. After 2 h, the mixture was cooled to rt and concentrated to give a golden oil. The oil was diluted with CH_2Cl_2 (100 mL) and washed with H_2O (75 mL). The organic layer was dried and concentrated to give a clear golden oil. The oil was purified on SiO_2 (CH_2Cl_2 to 5% acetone/CH_2Cl_2) to provide a colorless oil. The oil was diluted with 1:1 CH_2Cl_2/Et_2O (25 mL) and treated with 1 M HCl/Et_2O. The mixture was concentrated to give the desired product (3.3 g, 72%) as a white solid. MS (ESI): mass calcd. for $C_{12}H_{15}ClIN$, 335.0; m/z found, 336.0 $[M+H]^+$. ^1H NMR (d_6-DMSO): 9.39 (s, 2H), 8.18 (d, J = 2.1, 1H), 7.80 (dd,


J = 8.4, 2.2, 1H), 7.36 (s, J = 8.4, 1H), 4.20 (t, J = 6.2, 2H), 3.62-3.46 (m, 2H), 2.10-1.96 (m, 2H), 1.80-1.68 (m, 3H), 1.62-1.46 (m, 2H).

[0464] D. The title compound was prepared using methods analogous to those described for Example 249. MS (ESI): mass calcd. for $C_{36}H_{42}Cl_2N_6O_3$, 676.3; m/z found, 677.3 $[M+H]^+$. ^1H NMR (d_6-DMSO): 11.15 (br s, 1H), 9.24 (br s, 2H), 8.17 (s, 1H), 8.05-7.80 (m, 3H), 7.77-7.50 (m, 4H), 4.75 (s, 2H), 4.32-4.17 (m, 2H), 4.00-3.68 (m, 6H), 3.67-3.53 (m, 2H), 3.52-3.32 (m, 2H), 3.31-3.05 (m, 2H), 2.98-2.75 (br s, 2H), 2.35-2.15 (m, 2H), 2.12-1.98 (m, 2H), 1.85-1.48 (m, 6H), 1.24 (dd, J = 12.4, 6.4, 5H).



Example 270; (S)-2-{3-[4-Chloro-3-(4-chloro-3-propylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0465] MS (ESI): mass calcd. for $C_{34}H_{40}Cl_2N_6O_3$, 650.3; m/z found, 651.3 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.95 (br s, 1H), 9.05 (br s, 2H), 8.07 (s, 1H), 7.92 (s, 1H), 7.85-7.68 (m, 2H), 7.72-7.45 (m, 4H), 4.65 (s, 2H), 4.35-3.98 (m, 4H), 3.95-3.58 (m, 3H), 3.55-3.20 (m, 4H), 3.18-2.68 (m, 7H), 2.25-2.09 (br s, 2H), 1.70-1.50 (m, 2H), 1.19 (dd, J = 20.8, 6.4, 4H), 0.86 (t, J = 7.6, 3H).



Example 271; (S)-2-{3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0466] MS (ESI): mass calcd. for $C_{34}H_{40}Cl_2N_6O_4$, 666.3; m/z found, 667.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 11.08 (br s, 1H), 9.08 (br s, 2H), 8.08 (s, 1H), 7.94 (s,

1H), 7.87-7.68 (m, 2H), 7.67-7.43 (m, 4H), 4.78-4.58 (m, 3H), 4.25 (s, 2H), 4.09 (s, 3H), 3.95-3.58 (m, 7H), 3.44 (t, J = 5.6, 3H), 3.02 (s, 4H), 2.77 (br s, 2H), 2.30-2.05 (br s, 2H), 1.90-1.69 (m, 2H), 1.12 (br s, 3H).




Example 272; (S)-2-{3-[3-(3-{[Bis-(2-hydroxy-ethyl)-amino]-methyl}-4-chloro-phenylethynyl)-4-chloro-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.

[0467] MS (ESI): mass calcd. for $C_{35}H_{42}Cl_2N_6O_5$, 696.3; m/z found, 697.4 $[M+H]^+$. ^1H NMR (d_6-DMSO): 11.08 (br s, 1H), 9.57 (br s, 1H), 8.25-8.05 (m, 2H), 7.94-7.80 (m, 2H), 7.79-7.50 (m, 4H), 5.39 (br s, 2H), 4.73 (s, 2H), 4.65 (s, 2H), 4.25-4.05 (s, 2H), 4.00-3.62 (m, 10H), 3.56-3.46 (m, 2H), 3.22 (s, 3H), 3.07 (br s, 3H), 2.95-2.75 (m, 2H), 2.22 (br s, 2H), 1.24 (d, J = 6.8, 4H).



Example 273; (S)-5-(5-{5-Aminooxalyl-1-[3-(3-methyl-morpholin-4-yl)-propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-2-chloro-N-(3-methylamino-propyl)-benzamide.


[0468] MS (ESI): mass calcd. for $C_{35}H_{41}Cl_2N_7O_4$, 693.3; m/z found, 694.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.71 (br s, 1H), 8.51 (t, J = 5.6, 1H), 8.38 (br s, 2H), 7.94 (br s, 1H), 7.69 (s, 1H), 7.65-7.55 (m, 2H), 7.54-7.32 (m, 4H), 4.58-4.40 (m, 2H), 4.05-3.88 (m, 2H), 3.78-3.05 (s, 11H), 3.02-2.55 (m, 6H), 2.33 (t, J = 5.2, 2H), 2.12-1.92 (m, 2H), 1.70-1.50 (m, 2H), 1.04 (d, J = 6.8, 4H).



Example 274; (S)-2-{3-{4-Chloro-3-[4-chloro-3-(3-hydroxy-propoxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.


[0469] A. 3-(2-Chloro-5-iodo-benzyloxy)-propan-1-ol. 1,3-Propanediol (700 µL, 9.7 mmol) was added to a stirring mixture of NaH (60% in oil; 0.45 g, 11.3 mmol) and 2-bromomethyl-1-chloro-4-iodo-benzene (2.6 g, 7.7 mmol) in THF (20 mL). The mixture was heated at reflux under a N_2 atmosphere for 20 h. The mixture was cooled to rt, diluted with satd. aq. NH_4Cl and extracted with CH_2Cl_2 (2 x 25 mL). The organic layers were combined, dried, and concentrated to give a golden oil. The oil was purified on SiO_2 (CH_2Cl_2 to 10% acetone/CH_2Cl_2) to give the desired product (1.5 g, 60%) as a clear light golden oil. TLC: R_f = 0.17 [CH_2Cl_2]. MS (ESI): mass calcd. $C_{10}H_{12}ClIO_2$, 326.0; m/z found, 349.0 $[M+Na]^+$. ^1H NMR (d_6-DMSO): 7.80 (d, J = 2.2, 1H), 7.66 (dd, J = 8.4, 2.2, 1H), 7.25 (d, J = 8.3, 1H), 4.48 (s, 2H), 4.46 (t, J = 5.2, 1H), 3.57 (t, J = 6.4, 2H), 3.49 (q, J = 6.3, 2H), 1.72 (p, J = 6.4, 2H).

[0470] B. The title compound was prepared using methods analogous to those described for Example 249. MS (ESI): mass calcd. for $C_{34}H_{39}Cl_2N_5O_5$, 667.2; m/z found, 668.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 8.09 (s, 1H), 7.88-7.68 (m, 2H), 7.65-7.54 (m, 3H), 7.52-7.42 (m, 2H), 4.67 (s, 2H), 4.49 (s, 2H), 4.38 (t, J = 5.2, 2H), 3.99 (t, J = 6.8, 2H), 3.78-3.68 (m, 2H), 3.67-3.32 (m, 7H), 3.08-2.98 (m, 1H), 2.90-2.70 (m, 2H), 2.68-2.55 (m, 2H), 2.32-2.14 (m, 2H), 1.98-1.75 (m, 2H), 1.67 (p, J = 6.4, 2H), 0.77 (d, J = 6.0, 3H).



Example 275; (S)-2-{3-{4-Chloro-3-[4-chloro-3-(pyrrolidin-3-yloxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide.

[0471] MS (ESI): mass calcd. for $C_{35}H_{40}Cl_2N_6O_4$, 678.3; m/z found, 679.2 $[M+H]^+$. ^1H NMR (d_6-DMSO): 10.92 (br s, 1H), 8.91 (br s, 2H), 7.93 (s, 1H), 7.75-7.55 (m, 3H), 7.54-7.44 (m, 2H), 7.40-7.32 (m, 2H), 4.52 (s, 2H), 4.39 (s, 2H), 4.17 (s, 1H), 4.02-3.85 (m, 2H), 3.80-38 (m, 4H), 3.36-2.95 (m, 9H), 2.94-2.75 (m, 2H), 2.70-2.50 (m, 2H), 2.10-1.92 (m, 3H), 1.90-1.66 (m, 1H), 1.00 (d, J = 8.2, 3H).




Example 276; 7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline.

[0472] A. 7-Bromo-2-cyclopropyl-1,2,3,4-tetrahydro-isoquinoline. A sample of 7-bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.31 g, 5.27 mmol) was partitioned between 1.0 N NaOH (10 mL) and EtOAc (30 mL). The organic layer was concentrated. A solution of the resulting free amine in MeOH (7 mL), THF (7 mL) and acetic acid (1.5 mL) was treated with (1-ethoxy-cyclopropoxy)-trimethyl-silane (1.84 g, 10.5 mmol) followed by sodium cyanoborohydride (1.09 g. 17.4 mmol). The mixture was heated at 60 ºC for 24 h. The mixture was partitioned between EtOAc and satd. aq. $NaHCO_3$. The aqueous layer was extracted with CH_2Cl_2. The combined organic layers were dried and concentrated. Purification of the residue (SiO_2; hexanes to 30% EtOAc/hexanes) afforded the desired product (1.17 g, 88%). ^1H NMR ($CDCl_3$): 7.22 (dd, J = 8.2, 2.0, 1H), 7.18-7.15 (m, 1H), 6.94 (d, J = 8.2, 1H), 3.74 (s, 2H), 2.90 (t, J = 5.9, 2H), 2.80 (t, J = 5.9, 2H), 1.82-1.74 (m, 4H).


[0473] B. The title compound was prepared according to the methods described for Example 134, substituting 7-bromo-2-cyclopropyl-1,2,3,4-tetrahydro-isoquinoline for 7-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester in Step B. MS (ESI): mass calcd. for $C_{37}H_{45}ClN_6O_2S$, 672.3; m/z found, 673.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.70 (d, J = 1.8, 1H), 7.42-7.36 (m, 2H), 7.29-7.26 (m, 1H), 7.22 (s, 1H), 7.02 (d, J = 7.9, 1H), 4.47 (s, 2H), 4.03 (t, J = 6.7, 2H), 3.73 (s, 2H), 3.59 (t, J = 5.7,

2H), 2.90-2.80 (m, 9H), 2.70-2.26 (m, 10H), 2.11-1.99 (m, 2H), 1.78-1.71 (m, 1H), 1.62-1.55 (m, 1H), 0.50-0.44 (m, 4H), 0.41-0.32 (m, 4H).




Example 277; 7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline.

[0474] The title compound was prepared using methods analogous to those described for Example 276. MS (ESI): mass calcd. for $C_{35}H_{42}ClN_5O_3S$, 647.3; m/z found, 648.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.9, 1H), 7.50-7.43 (m, 2H), 7.36-7.33 (m, 1H), 7.30-7.29 (m, 1H), 7.09 (d, J = 7.9, 1H), 4.54 (s, 2H), 4.15-4.00 (m, 2H), 3.83-3.76 (m, 3H), 3.71-3.59 (m, 4H), 3.28-3.21 (m, 1H), 2.98-2.70 (m, 12H), 2.47-2.36 (m, 1H), 2.32-2.19 (m, 2H), 2.16-1.98 (m, 1H), 1.85-1.78 (m, 1H), 0.92 (d, J = 6.30, 3H), 0.57-0.51 (m, 4H).




Example 278; 7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline.

[0475] The title compound was prepared using methods analogous to those described for Example 134. MS (ESI): mass calcd. for $C_{32}H_{38}ClN_5O_3S$, 607.2; m/z found, 608.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 2.0, 1H), 7.53-7.43 (m, 2H), 7.39-7.35 (m, 1H), 7.32-7.27 (m, 1H), 7.10 (d, J = 7.9, 1H), 4.54 (s, 2H), 4.14-4.00 (m, 3H), 3.82-3.75 (m, 1H), 3.70-3.59 (m, 4H), 3.32-3.14 (m, 3H), 2.97-2.70 (m, 10H), 2.46-2.35 (m, 1H), 2.32-2.18 (m, 2H), 2.16-1.97 (m, 2H), 1.77-1.68 (m, 1H), 0.92 (d, J = 6.3, 3H).



Example 279; 7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(1-methylethyl)-1,2,3,4-tetrahydroisoquinoline.


[0476] To a solution of 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline (0.05 g, 0.082 mmol) in CH_2Cl_2 (0.41 mL) was added acetone (7 mg, 0.121 mmol) followed by sodium triacetoxyborohydride (0.043 g, 0.206 mmol). After 18 h, the mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2. The combined organic layers were dried and concentrated. Purification of the residue (SiO_2; CH_2Cl_2 to 3% MeOH/CH_2Cl_2) afforded the desired product (0.04 g, 75%). MS (ESI): mass calcd. for $C_{35}H_{44}ClN_5O_3S$, 649.3; m/z found, 650.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.9, 1H), 7.54-7.41 (m, 2H), 7.36-7.33 (m, 1H), 7.31-7.29 (m, 1H), 7.10 (d, J = 7.9, 1H), 4.54 (s, 2H), 4.15-4.00 (m, 2H), 3.84-3.57 (m, 7H), 3.24 (dd, J = 11.1, 8.7, 1H), 2.99-2.69 (m, 12H), 2.46-2.35 (m, 1H), 2.31-2.20 (m, 2H), 2.14-1.98 (m, 2H), 1.16 (d, J = 6.5, 6H), 0.92 (d, J = 6.3, 3H).



Example 280; 7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline.

[0477] The title compound was prepared using methods analogous to those described for Example 276. MS (ESI): mass calcd. for $C_{40}H_{45}ClN_6O_2S$, 708.3; m/z found, 709.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.9, 1H), 7.53-7.43 (m, 2H), 7.37-7.33 (m, 1H), 7.31-7.23 (m, 3H), 7.09 (d, J = 7.9, 1H), 6.95-6.91 (m, 2H), 6.89-6.84 (m, 1H), 4.54 (s, 2H), 4.12 (t, J = 6.8, 2H), 3.80 (s, 2H), 3.65 (t, J = 5.8, 2H), 3.22-3.17 (m,


4H), 2.97-2.87 (m, 9H), 2.60-2.56 (m, 4H), 2.38 (t, J = 6.8, 2H), 2.17-2.08 (m, 2H), 1.86-1.77 (m, 1H), 0.58-0.50 (m, 4H).



Example 281; 7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline.


[0478] The title compound was prepared using methods analogous to those described for Example 279. MS (ESI): mass calcd. for $C_{33}H_{40}ClN_5O_3S$, 621.3; m/z found, 622.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.51-7.42 (m, 2H), 7.38-7.35 (m, 1H), 7.28 (s, 1H), 7.11 (d, J = 1.9, 1H), 4.54 (s, 2H), 4.14-4.00 (m, 2H), 3.82-3.76 (m, 1H), 3.72-3.58 (m, 6H), 3.24 (dd, J = 11.2, 8.7, 1H), 2.98-2.69 (m, 11H), 2.48 (s, 3H), 2.45-2.36 (m, 1H), 2.31-2.19 (m, 2H), 2.15-1.97 (m, 2H), 0.92 (d, J = 6.3, 3H).

[0479] The compounds in Examples 282-284 were prepared using methods analogous to those described for Example 276.




Example 282; 3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0480] MS (ESI): mass calcd. for $C_{35}H_{41}ClN_6O_2$, 612.3; m/z found, 613.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 2.1, 1H), 7.52 (dd, J = 8.4, 2.1, 1H), 7.45 (d, J = 8.4, 1H), 7.36-7.32 (m, 1H), 7.29-7.28 (m, 1H), 7.09 (d, J = 8.4, 1H), 4.61-4.54 (m, 4H), 4.14-4.00 (m, 2H), 3.85-3.74 (m, 5H), 3.68-3.59 (m, 2H), 3.24 (dd, J = 11.1, 8.8, 1H), 2.97-2.87 (m, 4H), 2.86-2.70 (m, 4H), 2.45-2.36 (m, 1H), 2.31-2.20 (m, 2H), 2.14-1.97 (m, 2H), 1.84-1.78 (m, 1H), 0.92 (d, J = 6.3, 3H), 0.57-0.52 (m, 4H).




Example 283; 2-(3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide.

[0481] MS (ESI): mass calcd. for $C_{36}H_{41}ClN_6O_3$, 640.3; m/z found, 641.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.87-7.79 (m, 1H), 7.55-7.40 (m, 2H), 7.36-7.32 (m, 1H), 7.30-7.28 (m, 1H), 7.09 (d, J = 7.9, 1H), 5.67-5.59 (m, 1H), 5.24-5.19 (m, 1H), 4.85-4.77 (m, 1H), 4.33-4.20 (m, 2H), 4.14-3.99 (m, 2H), 3.82-3.75 (m, 3H), 3.70-3.57 (m, 2H), 3.28-3.20 (m, 1H), 3.00-2.69 (m, 9H), 2.46-2.35 (m, 1H), 2.31-2.19 (m, 2H), 2.13-1.98 (m, 2H), 1.84-1.78 (m, 1H), 0.95-0.87 (m, 3H), 0.59-0.49 (m, 4H).



Example 284; 6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline.

[0482] MS (ESI): mass calcd. for $C_{34}H_{40}ClN_5O_3S$, 633.3; m/z found, 634.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.77 (d, J = 1.8, 1H), 7.50-7.43 (m, 2H), 7.37-7.32 (m, 2H), 7.04 (d, J = 8.4, 1H), 4.54 (s, 2H), 4.10 (t, J = 6.8, 2H), 3.81 (s, 2H), 3.72-3.63 (m, 6H), 2.97-2.86 (m, 9H), 2.45-2.37 (m, 4H), 2.33 (t, J = 6.9, 2H), 2.13-2.02 (m, 2H), 1.84-1.77 (m, 1H), 0.57-0.50 (m, 4H).



Example 285; 2-(3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide.


[0483] A. 2-Chloro-5-iodo-benzaldehyde. To a 0° C solution of 2-chloro-5-iodo-benzonitrile (10.6 g, 40.4 mmol) in toluene (100 mL) was added DiBAL-H (1.5 M in toluene; 40.4 mL, 60.6 mmol). The mixture was stirred at 0 °C for 15 min and then warmed to rt for 3 h. The mixture was poured over 1.0 M H_2SO_4 (10 mL), MeOH (100 mL), and ice. The mixture was stirred vigorously and then was extracted with EtOAc (200 mL). The organic layer was dried and concentrated to give the title compound (2.98 g, 31%). ^{1}H NMR ($CDCl_3$): 10.37 (s, 1H), 8.22 (d, J = 2.2, 1H), 7.83 (dd, J = 8.4, 2.2, 1H), 7.21 (d, J = 8.4, 1H).

[0484] B. Benzyl-(2-chloro-5-iodo-benzyl)-amine. To a slurry of 2-chloro-5-iodo-benzaldehyde (5.1 g, 21.5 mmol) and benzylamine (4.6 g, 43.1 mmol) in dichlorothethane (100 mL) was added sodium triacetoxyborohydride (13.7 g, 64.5 mmol). The reaction mixture was stirred for 18 h, then was diluted with satd. aq. $NaHCO_3$, and extracted with CH_2Cl_2 (2x). The combined organic extracts were washed with water (3x), dried, and concentrated. Purification by silica gel chromatography (hexanes to 20% EtOAc/hexanes) afforded the desired product (5.48 g, 80%).

[0485] C. To a solution of 2-[3-(4-chloro-3-iodo-phenyl)-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide (prepared as described for Example 158, Step D; 103 mg, 0.180 mmol), $PdCl_2(PPh)_3$ (13 mg, 0.018 mmol), trimethylsilylacetylene (21 mg, 0.216 mmol), and CuI (3 mg, 0.018 mmol) in degassed DMF (1 mL) was added Et_3N (75 µL, 0.54 mmol). The reaction mixture was stirred under N_2 for 18 h. The mixture was then treated with benzyl-(2-chloro-5-iodo-benzyl)-amine (97 mg, 0.270 mmol), DBU (81 µL, 0.54 mmol), and degassed water (25 µL), and the reaction was stirred for an additional 24 h. The mixture was diluted with satd. aq. $NaHCO_3$ and extracted with CH_2Cl_2 (3x). The combined organic extracts were dried and concentrated. Purification by preparative thin layer chromatography (SiO_2; 7% MeOH/NH_3/CH_2Cl_2) afforded the desired product (68 mg, 54%). MS (ESI): mass


calcd. for $C_{38}H_{40}Cl_2N_6O_3$, 698.3; m/z found, 699.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.88-7.76 (m, 1H), 7.73-7.64 (m, 1H), 7.59-7.51 (m, 1H), 7.51-7.21 (m, 7H), 7.17-6.99 (m, 1H), 5.78-5.62 (m, 1H), 5.31-5.14 (m, 1H), 4.88-4.75 (m, 1H), 4.32-4.19 (m, 2H), 4.16-3.59 (m, 9H), 3.35-3.22 (m, 1H), 3.06-2.68 (m, 4H), 2.54-1.96 (m, 5H), 0.94 (d, J = 5.8, 3H).

[0486] The compounds in Examples 286-287 were prepared using methods analogous to those described for Example 285.



Example 286; 1-[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine.


[0487] MS (ESI): mass calcd. for $C_{37}H_{41}Cl_2N_5O_3S$, 705.2; m/z found, 706.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.9, 1H), 7.67 (d, J = 1.9, 1H), 7.53-7.41 (m, 3H), 7.40-7.32 (m, 5H), 7.30-7.24 (m, 1H), 4.61-4.46 (m, 2H), 4.17-3.99 (m, 2H), 3.92 (s, 2H), 3.85 (s, 2H), 3.83-3.76 (m, 1H), 3.73-3.59 (m, 4H), 3.25 (dd, J = 11.1, 8.8, 1H), 2.98-2.83 (m, 5H), 2.83-2.69 (m, 2H), 2.48-2.36 (m, 1H), 2.33-2.20 (m, 2H), 2.17-1.96 (m, 2H), 0.92 (d, J = 6.3, 3H).



Example 287; 1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine.

[0488] MS (ESI): mass calcd. for $C_{36}H_{39}Cl_2N_5O_3S$, 691.2; m/z found, 692.1 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 1.9, 1H), 7.67 (d, J = 1.9, 1H), 7.53-7.41 (m, 3H), 7.41-7.31 (m, 5H), 7.29-7.24 (m, 1H), 4.54 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.92 (s, 2H), 3.85 (s, 2H), 3.74-3.63 (m, 6H), 2.93-2.87 (m, 5H), 2.47-2.37 (m, 4H), 2.33 (t, J = 6.8,


2H), 2.13-2.03 (m, 2H).



Example 288; 1-[2-Chloro-5-(2-{2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine.


[0489] The title compound was prepared using methods analogous to those described for Example 2. MS (ESI): mass calcd. for $C_{36}H_{43}Cl_2N_5O_3S$, 695.3; m/z found, 696.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.45 (d, J = 2.0, 1H), 7.41-7.37 (m, 1H), 7.36-7.30 (m, 5H), 7.30-7.23 (m, 3H), 7.08 (dd, J = 8.1, 2.2, 1H), 4.44 (s, 2H), 4.09 (t, J = 6.8, 2H), 3.87 (s, 2H), 3.78 (s, 2H), 3.74-3.60 (m, 6H), 3.09-3.01 (m, 2H), 2.95-2.84 (m, 7H), 2.44-2.37 (m, 4H), 2.32 (t, J = 6.8, 2H), 2.11-2.02 (m, 2H).

[0490] The compounds in Examples 289-295 were prepared using methods analogous to those described for Example 285.




Example 289; 2-(3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide.

[0491] MS (ESI): mass calcd. for $C_{37}H_{39}Cl_2N_7O_3$, 699.3; m/z found, 700.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.59-8.55 (m, 1H), 7.86-7.81 (m, 1H), 7.73-7.62 (m, 2H), 7.59-7.52 (m, 1H), 7.51-7.32 (m, 5H), 7.20-7.14 (m, 1H), 7.10-6.99 (m, 1H), 5.87-5.56 (m, 1H), 5.31-5.19 (m, 1H), 4.85-4.80 (m, 1H), 4.35-4.18 (m, 2H), 4.16-3.87 (m, 6H), 3.84-3.74 (m, 1H), 3.72-3.56 (m, 2H), 3.26 (t, J = 9.9, 1H), 3.03-2.69 (m, 4H), 2.48-1.99 (m, 5H), 0.92 (d, J = 6.2, 3H).




Example 290; 1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine.

[0492] MS (ESI): mass calcd. for $C_{36}H_{39}ClFN_5O_3S$, 675.2; m/z found, 676.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.78 (d, J = 1.9, 1H), 7.64 (dd, J = 7.1, 2.1, 1H), 7.53-7.44 (m, 3H), 7.40-7.31 (m, 4H), 7.29-7.25 (m, 1H), 7.05 (dd, J = 9.7, 8.5, 1H), 4.54 (s, 2H), 4.11 (t, J = 6.8, 2H), 3.88 (s, 2H), 3.84 (s, 2H), 3.73-3.64 (m, 6H), 2.93-2.87 (m, 5H), 2.46-2.39 (m, 4H), 2.34 (t, J = 6.8, 2H), 2.14-2.04 (m, 2H).




Example 291; 3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0493] MS (ESI): mass calcd. for $C_{36}H_{38}Cl_2N_6OS$, 672.2; m/z found, 673.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.80 (d, J = 9.9, 1H), 7.66 (d, J = 9.9, 1H), 7.56-7.51 (m, 1H), 7.48-7.31 (m, 7H), 7.30-7.25 (m, 1H), 4.68-4.51 (m, 4H), 4.07 (t, J = 6.8, 2H), 3.92 (s, 2H), 3.85 (s, 2H), 3.77 (t, J = 5.7, 2H), 2.79 (t, J = 5.6, 2H), 2.71-2.62 (m, 8H), 2.35 (t, J = 5.6, 2H), 2.10-2.01 (m, 2H).




Example 292; 3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide.

[0494] MS (ESI): mass calcd. for $C_{35}H_{37}Cl_2N_7OS$, 673.2; m/z found, 674.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 8.63-8.51 (m, 1H), 7.78 (d, J = 2.1, 1H), 7.71-7.63 (m, 2H), 7.57-7.52 (m, 1H), 7.49-7.31 (m, 4H), 7.21-7.15 (m, 1H), 4.66-4.52 (m, 4H), 4.08 (t, J = 6.8, 2H), 3.98 (s, 2H), 3.97 (s, 2H), 3.78 (t, J = 5.7, 2H), 2.79 (t, J = 5.3, 2H), 2.71-2.62 (m, 8H), 2.36 (t, J = 6.8, 2H), 2.10-2.00 (m, 2H).



Example 293; 2-({[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol.


[0495] MS (ESI): mass calcd. for $C_{32}H_{39}Cl_2N_5O_4S$, 659.2; m/z found, 660.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.79 (d, J = 2.0, 1H), 7.62 (d, J = 1.9, 1H), 7.54-7.42 (m, 3H), 7.37 (d, J = 8.2, 1H), 4.55 (s, 2H), 4.16-4.00 (m, 2H), 3.93 (s, 2H), 3.82-3.76 (m, 1H), 3.73-3.58 (m, 6H), 3.25 (dd, J = 11.2, 8.7, 1H), 2.96-2.70 (m, 9H), 2.47-2.37 (m, 1H), 2.33-2.19 (m, 2H), 2.15-1.98 (m, 2H), 0.92 (d, J = 6.3, 3H).



Example 294; Methyl N-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)methyl]glycinate.

[0496] MS (ESI): mass calcd. for $C_{34}H_{38}Cl_2N_6O_5$, 680.2; m/z found, 681.3 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.87-7.80 (m, 1H), 7.67-7.63 (m, 1H), 7.56 (dd, J = 8.4, 2.2, 1H), 7.51-7.40 (m, 2H), 7.39-7.33 (m, 1H), 7.11-7.00 (m, 1H), 5.83-5.58 (m, 1H), 5.31-

5.17 (m, 1H), 4.89-4.78 (m, 1H), 4.35-4.21 (m, 2H), 4.15-3.95 (m, 3H), 3.93 (s, 2H), 3.82-3.75 (m, 2H), 3.74 (s, 2H), 3.69-3.56 (m, 2H), 3.48 (s, 2H), 3.28-3.19 (m, 1H), 3.04-2.67 (m, 4H), 2.47-2.33 (m, 1H), 2.31-2.18 (m, 2H), 2.14-1.97 (m, 2H), 0.93-0.89 (m, 3H).



Example 295; 2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxyethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide.

[0497] MS (ESI): mass calcd. for $C_{33}H_{38}Cl_2N_6O_4$, 652.2; m/z found, 653.2 $[M+H]^+$. ^1H NMR ($CDCl_3$): 7.83-7.74 (m, 1H), 7.69-7.64 (m, 1H), 7.61-7.39 (m, 4H), 5.17-5.10 (m, 1H), 4.81 (s, 1H), 4.20-3.92 (m, 6H), 3.87-3.59 (m, 5H), 3.41-3.35 (m, 2H), 3.30-3.24 (m, 1H), 3.01-2.72 (m, 6H), 2.52-2.40 (m, 1H), 2.38-2.24 (m, 2H), 2.15-1.96 (m, 2H), 0.96-0.93 (m, 3H).

[0498] The compounds in Table 1 (Examples 296-621) were prepared using methods analogous to those described in the preceding examples.

Table 1.

EX#	Chemical Name	MS Found
296	3-(2-{3-[5-(Methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenol	525.60
297	3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	495.30
298	8-{3-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-2,8-diazaspiro[4.5]decan-1-one	656.40
299	4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}but-3-yn-1-ol	507.40
300	4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}butan-1-ol	511.50

301	5-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}pentan-1-ol	525.50
302	3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-ol	497.50
303	3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}prop-2-yn-1-amine	492.40
304	3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-amine	496.50
305	N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}prop-2-yn-1-yl)benzenesulfonamide	682.40
306	N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}propyl)benzenesulfonamide	686.50
307	1-[1-(3-{3-[3-(3-Aminoprop-1-yn-1-yl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one	573.40
308	1-[1-(3-{3-[3-(3-Aminopropyl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one	577.30
309	Methyl 2-{[(3-{2-chloro-5-[5-(methylsulfonyl)-1-{3-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propyl)amino]sulfonyl}benzoate	775.30
310	1-[1-(3-{3-[4-Chloro-3-(3-hydroxyprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one	574.30
311	1-[1-(3-{3-[4-Chloro-3-(4-hydroxybutyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one	592.40
312	1-(1-{3-[3-{4-Chloro-3-[4-(dimethylamino)butyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one	619.40
313	1-[1-(3-{3-[4-Chloro-3-(3-hydroxypropyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one	578.30

314	1-(1-{3-[3-{4-Chloro-3-[3-(dimethylamino)propyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one	605.40
315	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methylmethanamine	582.30
316	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine	672.40
317	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-N-ethylethanamine	624.40
318	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine	624.40
319	1-[4-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	696.30
320	3-(3-{[4-(1H-Benzimidazol-2-yl)phenyl]ethynyl}-4-chlorophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	655.30
321	4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(phenylmethyl)aniline	644.40
322	{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]amino}acetonitrile	593.30
323	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopropanamine	608.30
324	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclobutanamine	622.40
325	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopentanamine	636.40

326	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclohexanamine	650.40
327	4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-phenylethyl)aniline	658.30
328	1-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one	773.30
329	1,1-Dimethylethyl (1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)carbamate	805.30
330	1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-ol	706.30
331	1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-amine	705.30
332	1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-ylpropan-2-ol	708.30
333	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-pyrrolidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	676.20
334	Ethyl 1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylate	762.30
335	1-{4-[(2-Chloro-5-{1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	748.30

336	1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylic acid	734.30
337	(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanol	720.30
338	1'-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4'-bipiperidin-2-one	787.30
339	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methyloxy)phenyl]methyl}methanamine	688.30
340	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2,2,2-trifluoroethanamine	650.20
341	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(cyclopropylmethyl)methanamine	622.30
342	(2S)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol	688.30
343	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-morpholin-4-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	775.30
344	1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	704.30
345	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	758.30
346	N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide	747.30

347	Methyl N-{[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate	640.30
348	1-(1-{3-[3-{4-Chloro-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one	731.30
349	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}prop-2-en-1-amine	608.30
350	1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxamide	733.30
351	Methyl (2S)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate	716.30
352	1-(1-{3-[3-(4-Chloro-3-{[4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one	769.40
353	1-{4-[(5-{1-[3-(4-Acetylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	733.40
354	1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	705.30
355	1-{4-[(2-Chloro-5-{1-[3-(4,4-dimethylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	718.30
356	N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)-2-hydroxyacetamide	763.30
357	1-{4-[(2-Chloro-5-{1-[3-(4,4-difluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	726.30

358	1-{4-[(2-Chloro-5-{1-[3-(4-fluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	708.10
359	N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanesulfonamide	783.30
360	7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline	594.20
361	1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-piperidin-1-ylpropan-2-ol	706.30
362	N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidin-4-yl)acetamide	763.30
363	1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidine-4-carboxamide	749.30
364	3-(4-Chloro-3-{[2-(trifluoroacetyl)-2,3-dihydro-1H-isoindol-5-yl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	676.20
365	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline	594.20
366	8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline	594.20
367	1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazine-1-carboxylate	791.30

368	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperazin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	691.30
369	N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide	669.30
370	1,1-Dimethylethyl 7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate	694.30
371	1,1-Dimethylethyl 7-({2-chloro-5-[1-(2-hydroxy-3-piperidin-1-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate	708.30
372	1-[4-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	746.30
373	1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]-2-hydroxypropyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate	751.30
374	1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate	735.40
375	7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-3-benzazepine	608.30
376	1,1-Dimethylethyl {[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate	668.30
377	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine	568.20
378	7-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline	648.30
379	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine	658.20

380	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(phenylcarbonyl)piperazin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	795.30
381	7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline	
382	(3S)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol	692.30
383	(3R)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol	692.30
384	1,1-Dimethylethyl {[2-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate	668.30
385	1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine	568.20
386	1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine	658.30
387	1-[4-({2-Chloro-5-[1-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	720.30
388	1-{4-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	731.30
389	(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-2-yl)methanol	722.30
390	1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4-diazepane-1-carboxylate	805.40

391	1-{4-[(2-Chloro-5-{1-[3-(1,4-diazepan-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	705.20
392	1,1-Dimethylethyl 5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,3-dihydro-2H-isoindole-2-carboxylate	680.10
393	3-[4-Chloro-3-(2,3-dihydro-1H-isoindol-5-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	580.10
394	3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine	595.10
395	1-{4-[2-(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	771.10
396	7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline	634.50
397	4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-2-one	705.10
398	1-{4-[(2-Chloro-5-{1-[3-(1,1-dioxidothiomorpholin-4-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	740.00
399	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1,4-oxazepan-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	706.10
400	1-(4-{[5-(5-Acetyl-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}phenyl)-N-[(4-chlorophenyl)methyl]methanamine	670.20
401	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	671.20

402	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol	686.20
403	3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine	585.10
404	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine	659.10
405	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine	659.10
406	4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-3-methylpiperazin-2-one	719.10
407	2-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol	783.10
408	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine	659.10
409	3-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol	783.10
410	4-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol	783.10
411	3-[3-(1H-Benzimidazol-5-ylethynyl)-4-chlorophenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	579.00
412	1-[4-({5-[5-Acetyl-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	672.22

413	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol	690.20
414	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	703.20
415	7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline	633.20
416	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	768.10
417	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-3-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	768.10
418	Methyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylate	750.10
419	(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-3-yl)methanol	722.10
420	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	704.10
421	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine	664.00
422	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine	664.10

423	N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-(2-thienyl)ethanamine	678.10
424	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine	678.10
425	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine	648.10
426	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl}methanamine	730.10
427	1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-(phenylmethyl)methanamine	659.10
428	1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-[(4-chlorophenyl)methyl]methanamine	693.00
429	2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide	760.30
430	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	732.30
431	1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine	692.10
432	1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine	662.10
433	1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine	678.10

434	1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine	678.10
435	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	697.24
436	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-[(4-chlorophenyl)methyl]methanamine	710.00
437	4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylic acid	736.00
438	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	692.10
439	1-[3-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	706.10
440	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	704.10
441	3-[4-Chloro-3-(1H-imidazol-4-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	529.00
442	2-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline	684.20
443	3-(4-Chloro-3-{[4-(1,3-dihydro-2H-isoindol-2-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	670.10
444	(1R)-N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydronaphthalen-1-amine	698.20

445	(1S,2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2,3-dihydro-1H-inden-1-ol	700.20
446	1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	767.10
447	1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	768.10
448	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol	670.10
449	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	683.26
450	1-(3-{5-[Amino(oxo)acetyl]-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidine-4-carboxamide	727.30
451	2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide	743.30
452	2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	753.30
453	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-pyrrolidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	641.20
454	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(1-oxidopyridin-2-yl)piperazin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	749.28
455	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	723.25

456	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(1,3-thiazol-2-ylmethyl)methanamine	665.10
457	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]methanamine	662.20
458	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	655.26
459	1-{3-[4-(Acetylamino)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	712.29
460	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclobutylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	710.31
461	1-{3-[4-(Aminocarbonyl)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	700.30
462	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	713.27
463	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	696.29
464	(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid	738.10
465	3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	683.20
466	(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	691.20

467	1,1-Dimethylethyl 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate	708.20
468	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(2-oxa-6-azaspiro[3.3]hept-6-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	704.10
469	2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol	612.20
470	N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,3-dihydro-1H-inden-1-amine	760.20
471	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol	745.30
472	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol	642.30
473	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol	637.20
474	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol	650.20
475	(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol	637.20
476	3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	661.28
477	3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	663.20
478	N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine	747.20

479	1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	639.20
480	N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,2,2-trifluoroethanamine	725.20
481	7-{[2-Chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline	570.30
482	3-[4-Chloro-3-(1H-pyrrolo[2,3-b]pyridin-6-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	579.10
483	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	707.20
484	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	691.20
485	(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-[(4-methylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline	720.20
486	(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	705.20
487	3-(4-Chloro-3-{[4-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	673.30
488	3-(4-Chloro-3-{[4-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	673.30
489	8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-2-benzazepine	608.20

490	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine	781.20
491	1,1-Dimethylethyl (1S,4S)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate	803.20
492	1,1-Dimethylethyl (1R,4R)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate	803.20
493	1-[4-({2-Chloro-5-[1-{3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	703.20
494	1-[4-({2-Chloro-5-[1-{3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	703.20
495	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine	706.20
496	2-[3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	691.30
497	1-[4-({2-Chloro-5-[5-(morpholin-4-ylcarbonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	729.30
498	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	687.30
499	N-{2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl}acetamide	713.27

500	1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine	720.20
501	7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline	690.20
502	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine	782.20
503	1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine	722.10
504	N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine	672.20
505	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(cyclopropylmethyl)-1,2,3,4-tetrahydroisoquinoline	648.20
506	2-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol	612.20
507	N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine	672.20
508	3-(4-Chloro-3-{[4-({[(3-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	653.30
509	3-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)propan-1-ol	626.20
510	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydrofuran-2-ylmethyl)methanamine	652.20

511	N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}aniline	644.20
512	6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline	648.20
513	3-(4-Chloro-3-{[3-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	673.22
514	3-(4-Chloro-3-{[3-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	673.22
515	3-(4-Chloro-3-{[3-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	657.30
516	3-(4-Chloro-3-{[3-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	657.25
517	3-(4-Chloro-3-{[3-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	657.25
518	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline	608.20
519	6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline	622.20
520	N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine	624.20

521	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine	659.20
522	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine	659.20
523	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinoline	650.20
524	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methylsulfonyl)phenyl]methyl}methanamine	736.20
525	1,1-Dimethylethyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate	708.20
526	Ethyl [6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetate	680.20
527	6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-prop-2-en-1-yl-1,2,3,4-tetrahydroisoquinoline	634.20
528	1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine	672.20
529	(2R)-1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-[(3S)-3-methylmorpholin-4-yl]propan-2-ol	722.10
530	1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine	676.30
531	N-{[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]methyl}-2-methylpropan-1-amine	628.20

532	3-(4-Chloro-3-{[4-({[(2-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	653.30
533	3-[4-Chloro-3-({4-[({[2-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	669.30
534	3-[4-Chloro-3-({4-[({[3-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	669.30
535	1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine	662.20
536	1-[4-({2-Chloro-5-[1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	706.20
537	1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1-oxidothiomorpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine	724.10
538	3-[4-Chloro-3-({4-[({[4-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	669.30
539	1-[5-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine	690.20
540	1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(methyloxy)phenyl]-N-(phenylmethyl)methanamine	688.20
541	(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline	707.20

542	3-(4-Chloro-3-{[4-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	657.20
543	3-(4-Chloro-3-{[4-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	357.20
544	3-(4-Chloro-3-{[4-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	657.20
545	1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine	692.20
546	1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine	726.10
547	3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}carbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	687.20
548	3-{4-Chloro-3-[(4-{[(morpholin-2-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	649.20
549	3-(4-Chloro-3-{[4-({4-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]piperidin-1-yl}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	716.31
550	3-[4-Chloro-3-({4-[({[4-(methylsulfanyl)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	685.20
551	3-(3-{[4-({[(4-Aminophenyl)methyl]amino}methyl)phenyl]ethynyl}-4-chlorophenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	655.20

552	3-{4-Chloro-3-[(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	633.23
553	N-[(2-Chloro-5-{[2-chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}phenyl)methyl]glycine	595.90
554	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(3-hydroxypropyl)benzamide	684.20
555	3-[4-Chloro-3-({4-chloro-3-[(3-hydroxypropyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	656.20
556	5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide	707.30
557	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide	710.20
558	3-{4-Chloro-3-[(4-chloro-3-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	682.20
559	tert-Butyl 3-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorobenzyl)oxy]pyrrolidine-1-carboxylate	779.30
560	5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(3-hydroxypropyl)benzamide	683.20
561	2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	681.20
562	2-[3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	683.23
563	2-[3-(4-Chloro-3-{[4-chloro-3-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	731.20

564	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(1R)-2-hydroxy-1-phenylethyl]benzamide	745.21
565	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[3-(methylamino)propyl]benzamide	696.22
566	2-(3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	637.20
567	2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	679.20
568	2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	694.21
569	2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	708.22
570	3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	651.20
571	3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	666.21
572	3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	680.23
573	2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	677.23
574	2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	692.24
575	2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	706.20

576	tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)methylcarbamate	794.30
577	tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)carbamate	780.20
578	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide	708.22
579	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(piperidin-3-ylmethyl)benzamide	724.20
580	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(morpholin-2-ylmethyl)benzamide	724.22
581	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide	739.20
582	3-{4-Chloro-3-[(4-chloro-3-{[(3R)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	680.23
583	3-[4-Chloro-3-({4-chloro-3-[(piperidin-3-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	694.30
584	3-[4-Chloro-3-({4-chloro-3-[(morpholin-2-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	696.22
585	3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	710.24
586	5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide	706.26
587	5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(piperidin-3-ylmethyl)benzamide	722.30

588	2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	679.25
589	2-(3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	649.20
590	3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	692.20
591	5-[(5-{5-[Amino(oxo)acetyl]-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide	720.20
592	2-{3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide	621.24
593	2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide	727.20
594	N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]ethanamine	628.10
595	2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide	661.20
596	3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	605.25
597	N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopentanamine	668.20
598	5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(azetidin-3-ylmethyl)-2-chlorobenzamide	694.10
599	3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	651.24

600	2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide	633.24
601	2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	663.20
602	3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	635.20
603	N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopropanamine	640.10
604	3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine	670.10
605	3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	623.10
606	3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	653.10
607	3-[4-Chloro-3-({4-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	676.20
608	4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide	693.20
609	3-{4-Chloro-3-[(4-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	646.20
610	4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide	672.20
611	4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide	663.20

612	3-{4-Chloro-3-[(4-{[3-(methylamino)propyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	634.27
613	4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[3-(methylamino)propyl]benzamide	660.20
614	4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[3-(methylamino)propyl]benzamide	651.20
615	3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide	611.20
616	2-(3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	637.20
617	1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N,N-dimethylmethanamine	628.20
618	2-[3-(4-Chloro-3-{[4-(hydroxymethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide	576.20
619	2-(3-{4-Chloro-3-[(4-chloro-3-{[(1-methylethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	651.20
620	2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	699.20
621	2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-[3-(3-methylmorpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide	700.20

Biological Testing:

[0499] Recombinant human cathepsin S (CatS) was expressed in the baculovirus system and purified in one step with a thiopropyl-sepharose column. 10-L yielded ~700 mg of CatS and N-terminal sequencing confirmed identity. The assay is

run in 150 mM sodium acetate pH 5.0 containing 1.5 mM DTT and 150 mM NaCl. The substrate for the assay is: Z-Valine-Valine-Arginine-AMC (catalog # I-1540, Bachem). The K_m for the substrate is around 5 μM but the presence of substrate inhibition makes kinetic analysis difficult. With 10 μM substrate the assay rate is linear over the range of 1-8 ng CatS in 100 μL reaction. Using 2 ng/well of CatS, the production of product is linear and yields ~7-fold signal after 20 min with only 20% loss of substrate. Measurements are taken every min for 20 min. The rate is calculated from the slope of the increase in fluorescence and the percent inhibition is calculated from this.

[0500] Results for the compounds tested in this assay are presented in Tables 2, 3, and 4 as an average of results obtained. Compounds were tested in free base, hydrochloride salt, trifluoroacetic acid salt, citric acid salt, or formic acid salt forms.

Table 2.

EX.	CatS IC_{50} (μM)		EX.	CatS IC_{50} (μM)		EX.	CatS IC_{50} (μM)
1	0.19		**51**	8.25		**101**	2.06
2	0.35		**52**	13.5		**102**	0.84
3	0.27		**53**	15.5		**103**	0.31
4	0.75		**54**	7.05		**104**	0.93
5	0.29		**55**	1.07		**105**	1.43
6	0.95		**56**	0.91		**106**	4.42
7	0.25		**57**	0.23		**107**	0.50
8	0.19		**58**	0.53		**108**	0.66
9	0.16		**59**	0.66		**109**	2.27
10	0.42		**60**	0.88		**110**	3.03
11	2.60		**61**	0.20		**111**	2.04
12	0.79		**62**	1.23		**112**	4.92
13	0.32		**63**	1.40		**113**	3.58
14	20.0		**64**	5.40		**114**	1.52
15	0.15		**65**	1.07		**115**	1.69
16	1.15		**66**	0.25		**116**	0.04
17	1.90		**67**	3.05		**117**	0.04
18	0.18		**68**	2.85		**118**	0.13
19	0.42		**69**	0.53		**119**	0.06
20	0.54		**70**	0.27		**120**	0.03
21	1.32		**71**	0.17		**121**	0.15

22	1.85		**72**	0.49		**122**	0.26
23	1.44		**73**	0.35		**123**	0.01
24	0.56		**74**	0.43		**124**	0.15
25	0.70		**75**	0.35		**125**	0.08
26	0.72		**76**	0.24		**126**	0.01
27	1.01		**77**	0.64		**127**	0.02
28	0.20		**78**	1.40		**128**	0.11
29	0.28		**79**	1.50		**129**	0.12
30	0.43		**80**	9.93		**130**	0.08
31	0.44		**81**	5.47		**131**	0.16
32	0.49		**82**	6.10		**132**	0.39
33	0.75		**83**	7.10		**133**	0.29
34	0.87		**84**	8.10		**134**	0.18
35	1.05		**85**	8.93		**135**	0.06
36	1.45		**86**	13.0		**136**	0.05
37	0.12		**87**	11.4		**137**	0.14
38	0.33		**88**	0.52		**138**	0.35
39	0.61		**89**	0.29		**139**	0.23
40	0.41		**90**	0.42		**140**	0.25
41	3.95		**91**	0.94		**141**	0.31
42	9.75		**92**	1.04		**142**	0.28
43	5.45		**93**	1.05		**143**	0.22
44	7.85		**94**	1.10		**144**	0.06
45	0.92		**95**	1.15		**145**	0.09
46	7.95		**96**	1.20		**146**	0.06
47	10.6		**97**	1.31		**147**	0.41
48	6.75		**98**	1.41		**148**	0.08
49	19.5		**99**	2.45		**149**	0.11
50	6.80		**100**	2.50			

Table 3.

EX.	**CatS IC_{50} (μM)**		**EX.**	**CatS IC_{50} (μM)**		**EX.**	**CatS IC_{50} (μM)**
150	0.08		**199**	0.06		**248**	0.02
151	0.09		**200**	0.09		**249**	0.05

152	0.11		**201**	0.19		**250**	0.08
153	0.18		**202**	0.39		**251**	0.04
154	0.26		**203**	0.57		**252**	0.11
155	0.79		**204**	0.12		**253**	0.06
156	0.05		**205**	0.27		**254**	0.24
157	0.04		**206**	0.21		**255**	0.07
158	0.05		**207**	2.86		**256**	0.05
159	0.06		**208**	3.13		**257**	0.07
160	0.06		**209**	0.10		**258**	0.08
161	0.07		**210**	0.19		**259**	0.08
162	0.09		**211**	0.11		**260**	0.13
163	0.13		**212**	0.08		**261**	0.13
164	0.73		**213**	0.02		**262**	0.12
165	0.83		**214**	0.04		**263**	0.13
166	2.52		**215**	0.03		**264**	0.37
167	0.03		**216**	0.07		**265**	0.14
168	0.03		**217**	0.02		**266**	0.35
169	0.05		**218**	0.03		**267**	0.01
170	0.05		**219**	0.04		**268**	0.02
171	0.20		**220**	0.03		**269**	0.01
172	0.03		**221**	0.02		**270**	0.02
173	0.12		**222**	0.02		**271**	0.02
174	0.27		**223**	0.02		**272**	0.03
175	0.19		**224**	0.02		**273**	0.04
176	0.23		**225**	0.01		**274**	0.04
177	0.01		**226**	0.03		**275**	0.05
178	0.01		**227**	0.04		**276**	0.18
179	0.02		**228**	0.09		**277**	0.20
180	0.02		**229**	0.09		**278**	0.11
181	0.06		**230**	0.01		**279**	0.11
182	0.08		**231**	2.69		**280**	0.04
183	0.08		**232**	1.53		**281**	0.12
184	0.32		**233**	7.92		**282**	0.15
185	0.52		**234**	0.28		**283**	0.10
186	0.69		**235**	0.33		**284**	0.20

187	0.15		**236**	7.13		**285**	0.02
188	0.55		**237**	0.01		**286**	0.03
189	0.14		**238**	0.003		**287**	0.05
190	1.11		**239**	0.61		**288**	0.12
191	0.63		**240**	0.01		**289**	0.01
192	0.08		**241**	0.03		**290**	0.21
193	0.05		**242**	0.03		**291**	0.03
194	0.02		**243**	0.04		**292**	0.02
195	0.13		**244**	0.06		**293**	0.05
196	0.65		**245**	0.03		**294**	0.02
197	0.20		**246**	0.01		**295**	0.03
198	0.07		**247**	0.07			

Table 4.

EX.	**CatS IC_{50} (μM)**		**EX.**	**CatS IC_{50} (μM)**		**EX.**	**CatS IC_{50} (μM)**
296	15.50		**405**	0.29		**513**	0.23
297	1.60		**406**	0.46		**514**	0.14
298	0.05		**407**	0.02		**515**	0.25
299	4.80		**408**	0.28		**516**	0.19
300	9.20		**409**	0.02		**517**	0.19
301	7.05		**410**	0.04		**518**	0.39
302	11.50		**411**	0.13		**519**	0.40
303	>20		**412**	0.16		**520**	0.44
304	17.00		**413**	0.10		**521**	0.37
305	3.95		**414**	0.03		**522**	0.33
306	3.22		**415**	0.09		**523**	0.53
307	4.65		**416**	0.07		**524**	0.53
308	5.65		**417**	0.02		**525**	0.35
309	0.32		**418**	1.03		**526**	0.37
310	2.12		**419**	0.18		**527**	0.30
311	1.35		**420**	0.10		**528**	0.58
312	5.62		**421**	0.19		**529**	0.12
313	1.96		**422**	0.17		**530**	1.33
314	3.66		**423**	0.27		**531**	0.64

315	1.36		**424**	0.20		**532**	0.09
316	0.58		**425**	0.07		**533**	0.10
317	2.71		**426**	0.39		**534**	0.09
318	1.15		**427**	1.99		**535**	0.64
319	0.13		**428**	3.75		**536**	0.20
320	0.09		**429**	0.02		**537**	0.28
321	4.65		**430**	0.04		**538**	0.11
322	0.73		**431**	0.17		**539**	0.21
323	0.75		**432**	0.23		**540**	0.14
324	1.34		**433**	0.24		**541**	0.96
325	1.45		**434**	0.20		**542**	0.18
326	1.37		**435**	0.08		**543**	0.13
327	0.76		**436**	0.28		**544**	0.13
328	0.02		**437**	0.57		**545**	0.27
329	0.03		**438**	0.72		**546**	0.30
330	0.09		**439**	0.32		**547**	0.12
331	0.17		**440**	0.39		**548**	0.12
332	0.19		**441**	3.06		**549**	1.01
333	0.18		**442**	0.30		**550**	0.10
334	0.03		**443**	0.69		**551**	0.10
335	0.06		**444**	0.21		**552**	0.50
336	0.15		**445**	0.20		**553**	0.45
337	0.07		**446**	0.07		**554**	0.02
338	0.02		**447**	0.07		**555**	0.02
339	0.23		**448**	0.01		**556**	0.03
340	0.39		**449**	0.10		**557**	0.03
341	0.83		**450**	0.07		**558**	0.03
342	0.31		**451**	0.10		**559**	0.10
343	0.04		**452**	0.10		**560**	0.02
344	0.06		**453**	0.14		**561**	0.03
345	0.11		**454**	0.04		**562**	0.03
346	0.02		**455**	0.04		**563**	0.03
347	0.61		**456**	0.12		**564**	0.03
348	0.10		**457**	0.09		**565**	0.02
349	0.55		**458**	0.06		**566**	0.02


350	0.04		**459**	0.02		**567**	0.16
351	0.12		**460**	0.17		**568**	0.14
352	0.02		**461**	0.03		**569**	0.15
353	0.15		**462**	0.05		**570**	0.26
354	0.36		**463**	0.11		**571**	0.13
355	0.11		**464**	0.63		**572**	0.17
356	0.02		**465**	0.15		**573**	0.19
357	0.21		**466**	0.05		**574**	0.14
358	0.10		**467**	0.26		**575**	0.17
359	0.08		**468**	0.19		**576**	0.05
360	0.17		**469**	0.53		**577**	0.02
361	0.17		**470**	0.05		**578**	0.02
362	0.05		**471**	7.42		**579**	0.02
363	0.09		**472**	4.51		**580**	0.03
364	0.17		**473**	0.12		**581**	0.03
365	0.28		**474**	0.43		**582**	0.04
366	0.68		**475**	0.18		**583**	0.03
367	0.09		**476**	0.12		**584**	0.04
368	0.33		**477**	0.10		**585**	0.04
369	0.41		**478**	0.04		**586**	0.02
370	0.72		**479**	0.02		**587**	0.02
371	0.38		**480**	0.10		**588**	0.04
372	0.06		**481**	3.52		**589**	0.03
373	0.17		**482**	0.18		**590**	0.07
374	0.16		**483**	0.14		**591**	0.03
375	0.41		**484**	0.18		**592**	0.02
376	1.01		**485**	0.05		**593**	0.06
377	0.47		**486**	0.03		**594**	0.03
378	0.08		**487**	0.06		**595**	0.01
379	0.29		**488**	0.14		**596**	0.03
380	0.06		**489**	0.48		**597**	0.04
381	0.10		**490**	0.07		**598**	0.03
382	0.11		**491**	0.12		**599**	0.03
383	0.12		**492**	0.22		**600**	0.03
384	2.79		**493**	0.30		**601**	0.03

385	2.72		**494**	0.31		**602**	0.04
386	0.77		**495**	0.77		**603**	0.05
387	0.13		**496**	0.07		**604**	0.08
388	0.06		**497**	1.63		**605**	0.04
389	0.23		**498**	4.56		**606**	0.04
390	0.15		**499**	0.16		**607**	0.05
391	0.26		**500**	0.58		**608**	0.07
392	0.18		**501**	0.75		**609**	0.07
393	0.22		**502**	0.11		**610**	0.03
394	3.81		**503**	0.66		**611**	0.10
395	0.02		**504**	0.28		**612**	0.08
396	0.23		**505**	0.63		**613**	0.04
397	0.51		**506**	0.52		**614**	0.06
398	0.38		**507**	0.57		**615**	0.03
399	0.11		**508**	0.11		**616**	0.012
400	0.19		**509**	0.50		**617**	0.04
401	0.11		**510**	0.45		**618**	0.02
402	0.15		**511**	1.61		**619**	0.02
403	8.52		**512**	0.22		**620**	0.15
404	0.37					**621**	0.13

[0501] While the invention has been illustrated by reference to examples, it is understood that the invention is intended not to be limited to the foregoing detailed description.

What is claimed is:

1. A compound of Formula (I):



(I)

wherein:

R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated monocyclic heterocycloalkyl group, each group optionally containing one additional heteroatom ring member that is O, S, or NR^a, and each group unsubstituted or substituted with one, two, or three R^b substituents;

where R^a is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -CO(phenyl), or -CO_2C_{1-4}alkyl, or a monocyclic cycloalkyl ring, phenyl ring, or monocyclic heteroaryl ring, each ring unsubstituted or substituted with OH, C_{1-4}alkyl, CF_3, halo, -OC_{1-4}alkyl, cyano, or -COC_{1-4}alkyl; and

each R^b substituent is independently:

i) OH, C_{1-4}alkyl, -C_{1-4}alkyl-OH, CF_3, -NR^cR^d, halo, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, -CO_2H, or -$CONR^eR^f$;

ii) a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

iii) a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

iv) a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

v) two R^b substituents on the same carbon taken together with the carbon to which they are attached form a saturated monocyclic heterocycloalkyl group, unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

vi) two R^b substituents form a methylene or ethylene bridge; or

vii) two R^b substituents on adjacent carbons taken together with the carbons to which they are attached form a saturated monocyclic cycloalkyl group or saturated monocyclic heterocycloalkyl group, each group unsubstituted or

substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

where R^c is H or C_{1-4}alkyl;

R^d is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COC_{1-4}alkyl-OH, -CO_2C_{1-4}alkyl,–$CONR^xR^y$, or –SO_2C_{1-4}alkyl;

where R^x and R^y are each independently H or C_{1-4}alkyl; and

R^e and R^f are each independently H or C_{1-4}alkyl;

R^3 is H, OH, C_{1-4}alkyl, or -OC_{1-4}alkyl;

R^4 is H; C_{1-4}alkyl; -COC_{1-4}alkyl unsubstituted or substituted with OH, F, -$OCOC_{1-4}$alkyl, or -NR^tR^u; -$COCF_3$; -CO-(monocyclic heteroaryl); -CO-(C-linked monocyclic heterocycloalkyl); -CO-(phenyl); -SO_2C_{1-4}alkyl; -SO_2CF_3; -$SO_2NR^tR^u$; -$CONR^tR^u$; -$COCO_2C_{1-4}$alkyl; or –$COCONR^tR^u$;

where R^t and R^u are each independently H, C_{1-4}alkyl, or –COC_{1-4}alkyl; or R^t and R^u taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring;

R^5 is halo or CF_3;

each R^6 is independently H or F;

D is –C≡C–R^7, –CH=CH–R^8, –$(CH_2)_{2-3}$–R^8, or –$(CH_2)_{3-5}$–R^9;

where R^7 is:

I) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -NR^gR^h, phenyl, or phenoxy, each phenyl or phenoxy being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^g and R^h are each independently H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, or -SO_2-phenyl; or R^g and R^h taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl group; or

II) a monocyclic cycloalkyl group, phenyl group, or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^8 is a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^9 is OH or -NR^nR^o;

where R^n is H or C_{1-4}alkyl; and


R^o is H, C_{1-4}alkyl, monocyclic cycloalkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, -SO_2-phenyl, -SO_2-benzyl, or -$SO_2NR^pR^q$, each phenyl or benzyl group being unsubstituted or substituted with one or two R^k substituents;

where R^p and R^q are each independently H or C_{1-4}alkyl;

or R^n and R^o taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl ring unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where each R^k substituent in D is independently:

a) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -OC_{1-4}alkyl-OH, halo, -CO_2C_{1-4}alkyl, CO_2H, CN, -NR^rR^s, -$N(R^r)CO$-phenyl, -$N(R^r)SO_2C_{1-4}$alkyl, -$N(R^r)SO_2$-phenyl, -SO_2C_{1-4}alkyl, phenyl, or phenoxy;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, -CH_2OH, or -CO_2C_{1-4}alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or –CH_2-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, -OC_{1-4}alkyl, -OCF_3, -$OCHF_2$, -$NR^{dd}R^{ee}$, -CO_2C_{1-4}alkyl, -SC_{1-4}alkyl, and -SO_2C_{1-4}alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl;

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-OH, -C_{1-4}alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, -$CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH; or

d) OH; -OC_{1-4}alkyl; halo; CF_3; -CHO; -CO_2C_{1-4}alkyl; CO_2H; CN; -NO_2; -$CONR^rR^s$, -NR^rR^s; -$N(R^r)$-phenyl; -$N(R^r)$-benzyl; -$N(R^r)$-phenethyl; -$N(R^r)COC_{1-4}$alkyl; -$N(R^r)CO$-phenyl; -$N(R^r)SO_2C_{1-4}$alkyl; -$N(R^r)SO_2$-phenyl; -SO_2C_{1-4}alkyl; phenoxy;

or a heteroaryl group; where each phenyl, benzyl, phenethyl, phenoxy, or heteroaryl group is unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and

R^s is H, C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-CN, -C_{2-4}alkyl-OH, -C_{2-4}alkyl-$NR^{bb}R^{cc}$, -C_{1-4}alkylCO_2C_{1-4}alkyl, -C_{1-4}alkylCO_2H, C_{3-4}alkenyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

where R^{bb} is H or C_{1-4}alkyl; and


R^{cc} is H, C_{1-4}alkyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

or a pharmaceutically acceptable salt, prodrug, or metabolite thereof.

2. A compound as defined in claim 1, wherein –NR^1R^2 is a structure of Formula (II):



(II)

wherein:

W is NR^a, O, S, or $C(R^{b1})(R^{b2})$;

where R^a is H or C_{1-4}alkyl;

R^{b1} is H, OH, or C_{1-4}alkyl; and

R^{b2} is H; C_{1-4}alkyl; a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, NR^cR^d, or halo; or a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, NR^cR^d, or halo;


one of R^{b3} and R^{b4} is H and the other is H or C_{1-4}alkyl;

p is 0, 1, or 2; and

q is 0, 1, 2, or 3;

with the proviso that when W is NR^a, O, or S, then p and q are each greater than or equal to 1.

3. A compound as defined in claim 1, wherein $-NR^1R^2$ is a structure of Formula (III):



(III)

wherein W is O or S; and R^{b5} and R^{b6} are each independently H or C_{1-4}alkyl.

4. A compound as defined in claim 1, wherein R^1 and R^2 taken together with the nitrogen to which they are attached form azetidine, pyrrolidine, piperidine, piperazine substituted with R^a, morpholine, or thiomorpholine, each unsubstituted or substituted with one, two, or three R^b substituents.

5. A compound as defined in claim 1, wherein R^1 and R^2 taken together with the nitrogen to which they are attached form piperidine, piperazine substituted with R^a, or morpholine, each unsubstituted or substituted with one, two, or three R^b substituents.

6. A compound as defined in claim 1, wherein R^1 and R^2 taken together with the nitrogen to which they are attached form 1,1-dioxo-1λ^6-thiomorpholine, thiomorpholine 1-oxide, piperazinone substituted with R^a, [1,4]oxazepane, each unsubstituted or substituted with one, two, or three R^b substituents; or 2,5-diaza-bicyclo[2.2.1]heptane substituted with R^a, 2-oxa-5-aza-bicyclo[2.2.1]heptane, 2-oxa-6-aza-spiro[3.3]heptane, or hexahydro-furo[3,4-c]pyrrole, each of the latter four groups unsubstituted or substituted with one R^b substituent.

7. A compound as defined in claim 1, wherein R^a is H, methyl, isopropyl, acetyl, or tert-butoxycarbonyl.

8. A compound as defined in claim 1, wherein R^a is phenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, benzoyl, pyridyl, 1-hydroxy-pyridyl, or cyclobutyl.

9. A compound as defined in claim 1, wherein each R^b substituent is independently OH, methyl, CF_3, methoxycarbonyl, dimethylamino, acetamido, tert-butoxycarbamoyl, fluoro, or methoxy.

10. A compound as defined in claim 1, wherein each R^b substituent is independently carbamoyl, amino, ethoxycarbonyl, carboxy, hydroxymethyl, 2-hydroxyacetylamino, methanesulfonylamino, or tert-butyl; or two R^b substituents on the same carbon taken together with the carbon to which they are attached form a dioxolane ring.

11. A compound as defined in claim 1, wherein each R^b substituent is independently pyrrolidinyl, 2-oxo-pyrrolidinyl, or piperidinyl, each optionally substituted.

12. A compound as defined in claim 1, wherein each R^b substituent is independently 2-oxo-piperidinyl, morpholinyl, 1-tert-butoxycarbonyl-piperidin-4-yl, 1-methyl-piperidin-4-yl, or 1-acetyl-piperidin-4-yl.

13. A compound as defined in claim 1, wherein each R^b substituent is independently pyrrolidin-1-yl, 2-oxo-pyrrolidin-1-yl, or 5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-onyl, or two R^b substituents on the same carbon taken together with the carbon to which they are attached form 2-oxo-pyrrolidin-3-yl.

14. A compound as defined in claim 1, wherein each R^b substituent is independently phenyl or pyridyl, each optionally substituted.

15. A compound as defined in claim 1, wherein R^3 is H or OH.

16. A compound as defined in claim 1, wherein R^4 is $-SO_2CH_3$, $-CONH_2$, or $-COCONH_2$.

17. A compound as defined in claim 1, wherein R^4 is dimethylaminooxalyl, acetyl, dimethylsulfamoyl, methylcarbamoyl, dimethylcarbamoyl, 2-aminoacetyl, 2-acetoxyacetyl, 2-acetylamino-acetyl, tetrahydrofuran-2-carbonyl, or morpholine-4-carbonyl.

18. A compound as defined in claim 1, wherein R^4 is $-SO_2CH_3$.

19. A compound as defined in claim 1, wherein R^5 is chloro or CF_3.

20. A compound as defined in claim 1, wherein R^5 is chloro.

21. A compound as defined in claim 1, wherein each R^6 is H.

22. A compound as defined in claim 1, wherein D is $-C\equiv C-R^7$, and R^7 is benzyl, phenethyl, phenpropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, butyl, phenoxymethyl, 2-methylpropyl, diethylaminomethyl, (1,1-dioxo-1λ^6-thiomorpholin-4-yl)-methyl, benzamidomethyl, or (benzenesulfonamido)methyl.

23. A compound as defined in claim 1, wherein R^7 is cyclopentyl, cyclohexyl, phenyl, thiophenyl, or pyridyl, each unsubstituted or substituted with one or two R^k substituents.

24. A compound as defined in claim 1, wherein R^7 is phenyl, unsubstituted or substituted with two R^k substituents.

25. A compound as defined in claim 1, wherein each R^k substituent in D is independently a methyl group or ethyl group unsubstituted or substituted with OH, methoxy, fluoro, $-CO_2CH_3$, CO_2H, CN, amino, tert-butoxycarbamoyl, methylsulfonamido, acetamido, pyrrolidinyl, or piperidinyl.

26. A compound as defined in claim 1, wherein each R^k substituent in D is a methyl group substituted with NR^rR^s.


27. A compound as defined in claim 1, wherein each R^k substituent in D is methylaminomethyl, dimethylaminomethyl, diethylaminomethyl, isobutylaminomethyl, tert-butoxycarbonylamino-methyl, (2-hydroxyethyl)aminomethyl, (3-hydroxypropyl)aminomethyl, (methoxycarbonylmethyl-amino)-methyl, (carboxymethyl-amino)-methyl, (2,2,2-trifluoroethyl-amino)-methyl, allylamino-methyl, (2-hydroxy-2-methyl-propylamino)-methyl, ethylaminomethyl, propylaminomethyl, [bis-(2-hydroxy-ethyl)-amino]-methyl, 3-hydroxy-propoxymethyl, phenylsulfonylamino-methyl, or benzoylamino-methyl.

28. A compound as defined in claim 1, wherein each R^k substituent in D is 3,4-dihydro-1H-isoquinolin-2-ylmethyl, 1,3-dihydro-isoindol-2-ylmethyl, 4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-ylmethyl, or 4-(4-hydroxy-2-oxo-pyrrolidin-1-yl)-piperidin-1-ylmethyl, morpholin-4-ylmethyl.

29. A compound as defined in claim 1, wherein each R^k substituent in D is independently OH, methoxy, chloro, bromo, fluoro, CF_3, CO_2H, CN, amino, dimethylamino, acetylamino, methylsulfonamido, or methylsulfonyl.

30. A compound as defined in claim 1, wherein each R^k substituent in D is phenoxy, 4-iodo-phenoxy, benzylamino, cyanomethyl-amino, benzimidazol-2-yl, phenethyl-amino, 3-(tert-butoxycarbonyl-methyl-amino)-propylcarbamoyl, 3-methylamino-propylcarbamoyl, pyrrolidine-1-carbonyl, 3-hydroxy-pyrrolidine-1-carbonyl, piperazine-1-carbonyl, [1,4]diazepane-1-carbonyl, 3-hydroxy-propylcarbamoyl, or 2-morpholin-4-yl-ethylcarbamoyl.

31. A compound as defined in claim 1, wherein R^k is a substituent of formula



.

32. A compound as defined in claim 31, wherein R^k is phenethylamino-methyl, cyclopropylamino-methyl, cyclobutylamino-methyl, cyclopentylamino-methyl, cyclohexylamino-methyl, cyclopropylmethylamino-methyl, benzylamino-methyl, (4-chloro-benzylamino)-methyl, (4-methanesulfonyl-benzylamino)-methyl, (2-chloro-benzylamino)-methyl, (3-chloro-benzylamino)-methyl, (2-fluoro-benzylamino)-methyl, (3-fluoro-benzylamino)-methyl, (4-fluoro-benzylamino)-methyl, (3,4-dichloro-benzylamino)-methyl, (2-methoxy-benzylamino)-methyl, (3-methoxy-benzylamino)-methyl, (4-methoxy-benzylamino)-methyl, (2-methyl-benzylamino)-methyl, (3-methyl-benzylamino)-methyl, (4-methyl-benzylamino)-methyl, (4-dimethylamino-benzylamino)-methyl, (4-isopropoxy-benzylamino)-methyl, (4-difluoromethoxy-benzylamino)-methyl, (4-amino-benzylamino)-methyl, (benzyl)-methyl-amino)-methyl, [(4-chloro-benzyl)-methyl-amino]-methyl, (1-phenyl-ethylamino)-methyl, phenylaminomethyl, [(pyridin-2-ylmethyl)-amino]-methyl, [(pyridin-3-ylmethyl)-amino]-methyl, [(pyridin-4-ylmethyl)-amino]-methyl, (2-hydroxy-1-phenyl-ethylamino)-methyl, [(methoxycarbonyl-phenyl-methyl)-amino]-methyl, [(thiophen-2-ylmethyl)-amino]-methyl, [(thiophen-3-ylmethyl)-amino]-methyl, (2-thiophen-2-yl-ethylamino)-methyl, [(3-methyl-thiophen-2-ylmethyl)-amino]-methyl, [(furan-2-ylmethyl)-amino]-methyl, [(2-trifluoromethyl-furan-3-ylmethyl)-amino]-methyl, (1,2,3,4-tetrahydro-naphthalen-1-ylamino)-methyl, indan-1-ylaminomethyl, (2-hydroxy-indan-1-ylamino)-methyl, [(thiazol-2-ylmethyl)-amino]-methyl, [(1-methyl-1H-imidazol-2-

ylmethyl)-amino]-methyl, [(tetrahydro-furan-2-ylmethyl)-amino]-methyl, or [(tetrahydro-pyran-4-ylmethyl)-amino]-methyl.

33. A compound as defined in claim 31, wherein R^k is (pyridin-2-ylmethyl)-carbamoyl, (pyridin-3-ylmethyl)-carbamoyl, (pyridin-4-ylmethyl)-carbamoyl, benzyl-carbamoyl, (4-chlorobenzyl)-carbamoyl, (pyrrolidin-2-ylmethyl)-carbamoyl, (pyrrolidin-3-ylmethyl)-carbamoyl, 2-hydroxy-1-phenyl-ethylcarbamoyl, (morpholin-2-ylmethyl)-carbamoyl, (piperidin-3-ylmethyl)-carbamoyl, or (azetidin-3-ylmethyl)-carbamoyl.

34. A compound as defined in claim 31, wherein R^k is pyridin-2-ylmethoxymethyl, pyridin-3-ylmethoxymethyl, pyridin-4-ylmethoxymethyl, piperidin-4-ylmethoxymethyl, morpholin-2-ylmethoxymethyl, pyrrolidin-3-yloxymethyl, or 1-tert-butoxycarbonyl-pyrrolidin-3-yloxymethyl.

35. A compound as defined in claim 1, wherein two adjacent R^k substituents taken together with the ring to which they are attached form a bicyclic fused ring system selected from the group consisting of indole, tetrahydroisoquinoline, 3,4-dihydro-2H-isoquinolin-1-one, 2,3,4,5-tetrahydro-1H-benzo[d]azepine, 2,3,4,5-tetrahydro-1H-benzo[c]azepine, 2,3-dihydro-1H-isoindole, benzimidazole, imidazole, 1H-pyrrolo[2,3-b]pyridine, and 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, each fused ring system optionally substituted.

36. A compound as defined in claim 35, wherein the fused ring system is substituted with methyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, hydroxymethyl, ethoxycarbonylmethyl, allyl, acetyl, $-COCF_3$, tert-butoxycarbonyl, methoxycarbonyl, carboxy, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, pyrrolidine-1-carbonyl, piperidine-1-carbonyl, 4-methyl-piperazine-1-carbonyl, or morpholine-4-carbonyl.

37. A compound as defined in claim 1, wherein R^r is H or methyl.

38. A compound as defined in claim 1, wherein R^s is H, methyl, acetyl, or tert-butoxycarbonyl.

39. A compound as defined in claim 1, wherein R^r and R^s taken together with the nitrogen to which they are attached form azetidinyl, pyrrolidinyl, or piperidinyl, each unsubstituted or substituted with methyl, OH, methoxy, fluoro, or CF_3.

40. A compound as defined in claim 1, wherein R^7 is 1H-indol-5-yl, 4-cyanomethyl-phenyl, 3-cyanomethyl-phenyl, 4-hydroxymethyl-phenyl, 3-hydroxymethyl-phenyl, 4-hydroxy-phenyl, 4-(3-carboxy-propyl)-phenyl, 4-(2-carboxy-ethyl)-phenyl, 4-(methoxycarbonyl)methyl-phenyl, 3-(methoxycarbonyl)methyl-phenyl, thiophen-2-yl, 3,4-dichloro-phenyl, 4-(4-iodo-phenoxy)-phenyl, 4-carboxymethyl-phenyl, 3-carboxymethyl-phenyl, 4-phenoxy-phenyl, 4-bromo-phenyl, 4-carboxy-phenyl, pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, thiophen-3-yl, 2-methoxy-phenyl, 3-chlorophenyl, 2-chlorophenyl, 3-hydroxyphenyl, 4-chlorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-fluorophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2-trifluoromethylphenyl, 2-methylphenyl, 3-trifluoromethylphenyl, 4-amino-phenyl, phenyl, 4-(tert-butoxcarbamoyl)methyl-phenyl, benzyl, phenethyl, phenpropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, butyl, cyclohexyl, (diethylamino)methyl, (1,1-dioxo-1λ^6-thiomorpholin-4-yl)methyl, 2-methylpropyl, phenoxymethyl, (benzamido)methyl, (benzenesulfonamido)methyl, 4-acetamido-phenyl, 4-aminomethyl-phenyl, 4-(methanesulfonamido)methyl-phenyl, 4-(benzenesulfonamido)methyl-phenyl, 4-(acetamido)methyl-phenyl, 4-(benzamido)methyl-phenyl, 4-(benzylamino)methyl-phenyl, 4-(4-methyl-benzylamino)methyl-phenyl, 4-(4-chloro-benzylamino)methyl-phenyl, 4-[benzyl(methyl)amino]methyl-phenyl, 4-pyrrolidin-1-ylmethyl-phenyl, 4-piperidin-1-ylmethyl-phenyl, or 1,2,3,4-tetrahydro-isoquinolin-1-yl.

41. A compound as defined in claim 1, wherein D is $-CH=CH-R^8$ or $-(CH_2)_{2-3}-R^8$, and R^8 is phenyl, unsubstituted or substituted with one or two R^k substituents.

42. A compound as defined in claim 1, wherein R^8 is 1H-indol-5-yl, phenyl, 4-phenoxyphenyl, 3-hydroxyphenyl, 4-chlorophenyl, 4-methoxyphenyl, 2,4-difluorophenyl, 2-methylphenyl, or 4-hydroxymethyl-phenyl.

43. A compound as defined in claim 1, wherein D is $-(CH_2)_{3-5}-R^9$, and R^9 is OH.

44. A compound as defined in claim 1, wherein R^9 is NR^nR^o.


45. A compound as defined in claim 1, wherein R^9 is dimethylamino, cyclopentylamino, acetamido, or methanesulfonamido.

46. A compound as defined in claim 1, wherein R^9 is benzamido, benzene-sulfonamido, or benzylsulfonamido, each unsubstituted or substituted with one or two R^k substituents.

47. A compound as defined in claim 1, wherein R^9 is pyrrolidine, piperidine, morpholine, piperazine, or azepine, each unsubstituted or substituted with methyl, OH, fluoro, or CF_3.

48. A compound as defined in claim 1, wherein R^9 is OH, benzamido, methanesulfonamido, benzene-sulfonamido, benzylsulfonamido, 3,4-dichlorobenzene-sulfonamido, 4-chlorobenzene-sulfonamido, 4-methylbenzenesulfonamido, 4-methoxybenzene-sulfonamido, N,N-dimethyl-sulfamoylurea, acetamido, 2-carboxybenzenesulfonamido, 2-nitrobenzene-sulfonamido, 3-chlorobenzene-sulfonamido, 3-methoxybenzene-sulfonamido, 2-methylbenzene-sulfonamido, 2-chlorobenzenesulfonamido, 3-nitrobenzenesulfonamido, 3-methylbenzenesulfonamido, 3-cyanobenzenesulfonamido, 3-methanesulfonyl-benzenesulfonamido, 2-methanesulfonyl-benzenesulfonamido, pyrrolidin-1-yl, piperidin-1-yl, 3-methyl-pipieridin-1-yl, 4,4-difluoro-piperidin-1-yl, morpholin-4-yl, 4-methyl-piperazin-1-yl, azepan-1-yl, or cyclopentylamino.

49. A compound as defined in claim 1, wherein compounds of Formula (I) are selected from compounds of the following Formula (IV):



(IV)

wherein:

W is O or S;

R^{b5} and R^{b6} are each independently H or C_{1-4}alkyl;

R^3 is H or OH;

R^4 is $-SO_2CH_3$, $-CONH_2$, or $-COCONH_2$;

R^5 is chloro; and

each R^k substituent is independently:

a) a methyl group or ethyl group, each group unsubstituted or substituted with OH, $-OC_{1-4}$alkyl, halo, $-CO_2C_{1-4}$alkyl, CO_2H, CN, $-NR^rR^s$, $-N(R^r)CO$-phenyl, $-N(R^r)SO_2C_{1-4}$alkyl, $-N(R^r)SO_2$-phenyl, or $-SO_2C_{1-4}$alkyl;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and


R^s is H, C_{1-4}alkyl, C_{1-4}alkyl-CF_3, C_{1-4}alkyl-CN, C_{2-4}alkyl-OH, C_{2-4}alkyl-$NR^{bb}R^{cc}$, $-C_{1-4}$alkylCO_2C_{1-4}alkyl, $-C_{1-4}$alkylCO_2H, C_{3-4}alkenyl, $-COC_{1-4}$alkyl, or $-CO_2C_{1-4}$alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, $-COC_{1-4}$alkyl, or $-CO_2C_{1-4}$alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, $-OC_{1-4}$alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, $-CH_2OH$, or $-CO_2C_{1-4}$alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or $-CH_2$-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, $-OC_{1-4}$alkyl, $-OCF_3$, $-OCHF_2$, $NR^{dd}R^{ee}$, $-CO_2C_{1-4}$alkyl, $-SC_{1-4}$alkyl, and $-SO_2C_{1-4}$alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl; or

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, $-C_{1-4}$alkyl-CF_3, $-C_{1-4}$alkyl-OH, $-C_{1-4}$alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, $-OC_{1-4}$alkyl, $-COC_{1-4}$alkyl, $-COCF_3$, $-CO_2C_{1-4}$alkyl, $-CO_2H$, $CONR^{ff}R^{gg}$, or $-SO_2C_{1-4}$alkyl; or a with cycloalkyl group, $-CH_2$-(cycloalkyl) group, or

benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH;

and pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

50. A compound selected from the group consisting of:

3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-{4-Chloro-3-[2-(1H-indol-5-yl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;

4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;

4-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-butyric acid;

3-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-propionic acid;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;

3-(4-Chloro-3-thiophen-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-[4-Chloro-3-(3,4-dichloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-{4-Chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
3-[4-Chloro-3-(4-phenoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[3-(4-Bromo-phenylethynyl)-4-chloro-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzoic acid;
3-(4-Chloro-3-pyridin-4-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-thiophen-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-p-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-fluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2,4-difluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-[4-Chloro-3-(2-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-o-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine;
3-(4-Chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester;
3-[4-Chloro-3-(3-phenyl-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-phenyl-but-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(5-phenyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-yn-1-ol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-but-3-yn-1-ol;
5-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-pent-4-yn-1-ol;
3-(4-Chloro-3-hex-1-ynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-cyclohexylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-diethyl-amine;
3-{4-Chloro-3-[3-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenoxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzenesulfonamide;
3-{4-Chloro-3-[2-(4-phenoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenol;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(4-methoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-o-tolyl-ethyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
[4-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenyl]-methanol;
3-(4-Chloro-3-phenethyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenyl-propyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetamide;
3-(4-Chloro-3-*Z*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-*E*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methanesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzenesulfonamide;

N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-acetamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzamide;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-(4-methyl-benzyl)-amine;
(4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methyl-amine;
3-[4-Chloro-3-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-piperidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-C-phenyl-methanesulfonamide;
3,4-Dichloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
4-Chloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methyl-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methoxy-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-N,N-dimethyl-sulfamoylurea;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-acetamide;
2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-nitro-benzenesulfonamide;
3-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;

N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-4-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methoxy-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methyl-benzenesulfonamide;
2-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-nitro-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-cyano-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methanesulfonyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methanesulfonyl-benzenesulfonamide;
1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-piperidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(3-methyl-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(4,4-difluoro-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-morpholin-4-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[3-(3-Azepan-1-yl-propyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-cyclopentylamino-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-piperidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(3-methyl-piperidin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-morpholin-4-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[3-(4-Azepan-1-yl-butyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-cyclopentylamino-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
8-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
3-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
1-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;

2-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-cyclopentanone;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
3-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-pyrrolidin-1-yl-propan-2-ol;
[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
4-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperazin-1-yl-propan-2-ol;
1-(4-Amino-piperidin-1-yl)-3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propan-2-ol;
1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyridin-2-yl-methanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-furan-2-yl-methanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2,2-trifluoro-ethanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-fluoro-ethanone;

[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(tetrahydro-furan-2-yl)-methanone;
Acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-hydroxy-ethanone;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
1-{1-[3-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
8-[3-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-2,8-diaza-spiro[4.5]decan-1-one; and
1-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
and pharmaceutically acceptable salts thereof.

51. A compound selected from the group consisting of:
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N,N-dimethyl-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-sulfonamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S,5S)-3,5-dimethylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-{3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(piperidin-4-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethanol;

3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(1-methylethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(dimethylamino)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(difluoromethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
Methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;

N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycine;
2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N,N-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
Methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
Methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
2-(1,1-Dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
2-(1,1-Dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate;
(2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
Methyl (2R)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3,4-dichlorophenyl)methyl]methanamine;
(1S,2R)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-1-ol;
(1R,2S)-1-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-2-ol;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(2S)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2-phenylethanol;

N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
Methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate;
N-{[5-({5-[5-(Aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycine;
3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[(4-chloro-3-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-[1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydroisoquinolin-7-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]acetamide;
7-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;

(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

2-[3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

(2S)-1-[3-{4-Chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;

(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2R)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;

(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;

(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2S)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2R)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-cyclopentylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-propylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[3-(3-{[Bis-(2-hydroxy-ethyl)-amino]-methyl}-4-chloro-phenylethynyl)-4-chloro-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-5-(5-{5-Aminooxalyl-1-[3-(3-methyl-morpholin-4-yl)-propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-2-chloro-N-(3-methylamino-propyl)-benzamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(3-hydroxy-propoxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(pyrrolidin-3-yloxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(1-methylethyl)-1,2,3,4-tetrahydroisoquinoline;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-(2-{2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-({[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
Methyl N-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)methyl]glycinate; and
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxyethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

and pharmaceutically acceptable salts thereof.

52. A compound selected from the group consisting of:

3-(2-{3-[5-(Methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenol;

3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

8-{3-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-2,8-diazaspiro[4.5]decan-1-one;

4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}but-3-yn-1-ol;

3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}prop-2-yn-1-amine;

N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}prop-2-yn-1-yl)benzenesulfonamide;

N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}propyl)benzenesulfonamide;

1-[1-(3-{3-[3-(3-Aminoprop-1-yn-1-yl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

Methyl 2-{[(3-{2-chloro-5-[5-(methylsulfonyl)-1-{3-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propyl)amino]sulfonyl}benzoate;

1-[1-(3-{3-[4-Chloro-3-(3-hydroxyprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-hydroxybutyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-(1-{3-[3-{4-Chloro-3-[4-(dimethylamino)butyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(3-hydroxypropyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-(1-{3-[3-{4-Chloro-3-[3-(dimethylamino)propyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methylmethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-N-ethylethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[4-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(3-{[4-(1H-Benzimidazol-2-yl)phenyl]ethynyl}-4-chlorophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(phenylmethyl)aniline;
{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]amino}acetonitrile;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopropanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclobutanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopentanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclohexanamine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-phenylethyl)aniline;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1,1-Dimethylethyl (1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)carbamate;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-ol;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-amine;
1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-ylpropan-2-ol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-pyrrolidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
Ethyl 1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylate;

1-{4-[(2-Chloro-5-{1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylic acid;
(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanol;
1'-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4'-bipiperidin-2-one;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methyloxy)phenyl]methyl}methanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2,2,2-trifluoroethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(cyclopropylmethyl)methanamine;
(2S)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-morpholin-4-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;
Methyl N-{[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;
1-(1-{3-[3-{4-Chloro-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}prop-2-en-1-amine;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxamide;

Methyl (2S)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;

1-(1-{3-[3-(4-Chloro-3-{[4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-{4-[(5-{1-[3-(4-Acetylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4,4-dimethylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)-2-hydroxyacetamide;

1-{4-[(2-Chloro-5-{1-[3-(4,4-difluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-fluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanesulfonamide;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-piperidin-1-ylpropan-2-ol;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidin-4-yl)acetamide;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidine-4-carboxamide;

3-(4-Chloro-3-{[2-(trifluoroacetyl)-2,3-dihydro-1H-isoindol-5-yl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazine-1-carboxylate;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperazin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;
1,1-Dimethylethyl 7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1,1-Dimethylethyl 7-({2-chloro-5-[1-(2-hydroxy-3-piperidin-1-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1-[4-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]-2-hydroxypropyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1,1-Dimethylethyl {[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
7-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(phenylcarbonyl)piperazin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
(3R)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
1,1-Dimethylethyl {[2-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-2-yl)methanol;
1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4-diazepane-1-carboxylate;
1-{4-[(2-Chloro-5-{1-[3-(1,4-diazepan-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1,1-Dimethylethyl 5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,3-dihydro-2H-isoindole-2-carboxylate;
3-[4-Chloro-3-(2,3-dihydro-1H-isoindol-5-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine;
1-{4-[2-(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-2-one;
1-{4-[(2-Chloro-5-{1-[3-(1,1-dioxidothiomorpholin-4-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1,4-oxazepan-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-(4-{[5-(5-Acetyl-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}phenyl)-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-3-methylpiperazin-2-one;
2-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
3-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
4-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
3-[3-(1H-Benzimidazol-5-ylethynyl)-4-chlorophenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
1-[4-({5-[5-Acetyl-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-3-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
Methyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylate;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-3-yl)methanol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-(2-thienyl)ethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl}methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-(phenylmethyl)methanamine;

1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-[(4-chlorophenyl)methyl]methanamine;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-[(4-chlorophenyl)methyl]methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylic acid;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-(1H-imidazol-4-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

2-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-(1,3-dihydro-2H-isoindol-2-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(1R)-N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S,2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2,3-dihydro-1H-inden-1-ol;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-(3-{5-[Amino(oxo)acetyl]-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidine-4-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-pyrrolidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(1-oxidopyridin-2-yl)piperazin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(1,3-thiazol-2-ylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Acetylamino)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclobutylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Aminocarbonyl)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(2-oxa-6-azaspiro[3.3]hept-6-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,3-dihydro-1H-inden-1-amine;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,2,2-trifluoroethanamine;
7-{[2-Chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-[4-Chloro-3-(1H-pyrrolo[2,3-b]pyridin-6-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-[(4-methylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;

3-(4-Chloro-3-{[4-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-2-benzazepine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
1,1-Dimethylethyl (1S,4S)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1,1-Dimethylethyl (1R,4R)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1-[4-({2-Chloro-5-[1-{3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
2-[3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(morpholin-4-ylcarbonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-{2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl}acetamide;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(cyclopropylmethyl)-1,2,3,4-tetrahydroisoquinoline;
2-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
3-(4-Chloro-3-{[4-({[(3-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)propan-1-ol;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydrofuran-2-ylmethyl)methanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}aniline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[3-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methylsulfonyl)phenyl]methyl}methanamine;
1,1-Dimethylethyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate;
Ethyl [6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-prop-2-en-1-yl-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
(2R)-1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-[(3S)-3-methylmorpholin-4-yl]propan-2-ol;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
N-{[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]methyl}-2-methylpropan-1-amine;
3-(4-Chloro-3-{[4-({[(2-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[2-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[3-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1-oxidothiomorpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-[({[4-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[5-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(methyloxy)phenyl]-N-(phenylmethyl)methanamine;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}carbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(morpholin-2-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({4-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]piperidin-1-yl}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(methylsulfanyl)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(3-{[4-({[(4-Aminophenyl)methyl]amino}methyl)phenyl]ethynyl}-4-chlorophenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[(2-Chloro-5-{[2-chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}phenyl)methyl]glycine;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(3-hydroxypropyl)benzamide;
3-[4-Chloro-3-({4-chloro-3-[(3-hydroxypropyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
tert-Butyl 3-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorobenzyl)oxy]pyrrolidine-1-carboxylate;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(3-hydroxypropyl)benzamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(1R)-2-hydroxy-1-phenylethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[3-(methylamino)propyl]benzamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)methylcarbamate;
tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)carbamate;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(piperidin-3-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(morpholin-2-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(3R)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-chloro-3-[(piperidin-3-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(morpholin-2-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(piperidin-3-ylmethyl)benzamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
2-{3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]ethanamine;
2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopentanamine;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(azetidin-3-ylmethyl)-2-chlorobenzamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopropanamine;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-{[3-(methylamino)propyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[3-(methylamino)propyl]benzamide; and
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[3-(methylamino)propyl]benzamide;
3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N,N-dimethylmethanamine;


2-[3-(4-Chloro-3-{[4-(hydroxymethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(1-methylethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-[3-(3-methylmorpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

53. A compound selected from the group consisting of:
4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}butan-1-ol;
5-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}pentan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-amine;
1-[1-(3-{3-[3-(3-Aminopropyl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynylamine; and
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propylamine;
and pharmaceutically acceptable salts thereof.

54. A compound as defined in claim 1, wherein said compound is a compound of Formula (I) or a pharmaceutically acceptable salt of a compound of Formula (I).

55. A pharmaceutical composition for treating a disease, disorder, or medical condition mediated by cathepsin S activity, comprising:

(a) an effective amount of at least one chemical entity selected from compounds of Formula (I):



(I)

wherein:

R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated monocyclic heterocycloalkyl group, each group optionally containing one additional heteroatom ring member that is O, S, or NR^a, and each group unsubstituted or substituted with one, two, or three R^b substituents;

where R^a is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -CO(phenyl), or -CO_2C_{1-4}alkyl, or a monocyclic cycloalkyl ring, phenyl ring, or monocyclic heteroaryl ring, each ring unsubstituted or substituted with OH, C_{1-4}alkyl, CF_3, halo, -OC_{1-4}alkyl, cyano, or -COC_{1-4}alkyl; and

each R^b substituent is independently:

i) OH, C_{1-4}alkyl, -C_{1-4}alkyl-OH, CF_3, -NR^cR^d, halo, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, -CO_2H, or -$CONR^eR^f$;

ii) a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

iii) a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

iv) a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

v) two R^b substituents on the same carbon taken together with the carbon to which they are attached form a saturated monocyclic heterocycloalkyl group, unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

vi) two R^b substituents form a methylene or ethylene bridge; or

vii) two R^b substituents on adjacent carbons taken together with the carbons to which they are attached form a saturated monocyclic cycloalkyl group or saturated monocyclic heterocycloalkyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

where R^c is H or C_{1-4}alkyl;

R^d is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COC_{1-4}alkyl-OH, -CO_2C_{1-4}alkyl,–$CONR^xR^y$, or –SO_2C_{1-4}alkyl;

where R^x and R^y are each independently H or C_{1-4}alkyl; and

R^e and R^f are each independently H or C_{1-4}alkyl;

R^3 is H, OH, C_{1-4}alkyl, or -OC_{1-4}alkyl;

R^4 is H; C_{1-4}alkyl; -COC_{1-4}alkyl unsubstituted or substituted with OH, F, -$OCOC_{1-4}$alkyl, or -NR^tR^u; -$COCF_3$; -CO-(monocyclic heteroaryl); -CO-(C-linked monocyclic heterocycloalkyl); -CO-(phenyl); -SO_2C_{1-4}alkyl; -SO_2CF_3; -$SO_2NR^tR^u$; -$CONR^tR^u$; -$COCO_2C_{1-4}$alkyl; or –$COCONR^tR^u$;

where R^t and R^u are each independently H, C_{1-4}alkyl, or –COC_{1-4}alkyl; or R^t and R^u taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring;

R^5 is halo or CF_3;

each R^6 is independently H or F;

D is –C≡C–R^7, –CH=CH–R^8, –$(CH_2)_{2-3}$–R^8, or –$(CH_2)_{3-5}$–R^9;

where R^7 is:

I) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -NR^gR^h, phenyl, or phenoxy, each phenyl or phenoxy being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^g and R^h are each independently H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, or -SO_2-phenyl; or R^g and R^h taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl group; or

II) a monocyclic cycloalkyl group, phenyl group, or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^8 is a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^9 is OH or -NR^nR^o;

where R^n is H or C_{1-4}alkyl; and


R^o is H, C_{1-4}alkyl, monocyclic cycloalkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, -SO_2-phenyl, -SO_2-benzyl, or -$SO_2NR^pR^q$, each phenyl or benzyl group being unsubstituted or substituted with one or two R^k substituents;

where R^p and R^q are each independently H or C_{1-4}alkyl;

or R^n and R^o taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl ring unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where each R^k substituent in D is independently:

a) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -OC_{1-4}alkyl-OH, halo, -CO_2C_{1-4}alkyl, CO_2H, CN, -NR^rR^s, -$N(R^r)CO$-phenyl, -$N(R^r)SO_2C_{1-4}$alkyl, -$N(R^r)SO_2$-phenyl, -SO_2C_{1-4}alkyl, phenyl, or phenoxy;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, -CH_2OH, or -CO_2C_{1-4}alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or –CH_2-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, -OC_{1-4}alkyl, -OCF_3, -$OCHF_2$, -$NR^{dd}R^{ee}$, -CO_2C_{1-4}alkyl, -SC_{1-4}alkyl, and -SO_2C_{1-4}alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl;

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-OH, -C_{1-4}alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, -$CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH; or

d) OH; -OC_{1-4}alkyl; halo; CF_3; -CHO; -CO_2C_{1-4}alkyl; CO_2H; CN; -NO_2; -$CONR^rR^s$, -NR^rR^s; -$N(R^r)$-phenyl; -$N(R^r)$-benzyl; -$N(R^r)$-phenethyl; -$N(R^r)COC_{1-4}$alkyl; -$N(R^r)CO$-phenyl; -$N(R^r)SO_2C_{1-4}$alkyl; -$N(R^r)SO_2$-phenyl; -SO_2C_{1-4}alkyl; phenoxy; or a heteroaryl group; where each phenyl, benzyl, phenethyl, phenoxy, or

heteroaryl group is unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and

R^s is H, C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-CN, -C_{2-4}alkyl-OH, -C_{2-4}alkyl-$NR^{bb}R^{cc}$, -C_{1-4}alkylCO_2C_{1-4}alkyl, -C_{1-4}alkylCO_2H, C_{3-4}alkenyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

and pharmaceutically acceptable salts, prodrugs, and metabolites thereof; and

(b) a pharmaceutically acceptable excipient.

56. A pharmaceutical composition according to claim 55, wherein said chemical entity is selected from the group consisting of:

3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-{4-Chloro-3-[2-(1H-indol-5-yl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;

4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;

4-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-butyric acid;

3-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-propionic acid;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
3-(4-Chloro-3-thiophen-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3,4-dichloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
3-[4-Chloro-3-(4-phenoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[3-(4-Bromo-phenylethynyl)-4-chloro-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzoic acid;
3-(4-Chloro-3-pyridin-4-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-thiophen-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;

3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-p-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-fluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2,4-difluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-o-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine;
3-(4-Chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester;
3-[4-Chloro-3-(3-phenyl-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-phenyl-but-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(5-phenyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-yn-1-ol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-but-3-yn-1-ol;
5-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-pent-4-yn-1-ol;

3-(4-Chloro-3-hex-1-ynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-cyclohexylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-diethyl-amine;
3-{4-Chloro-3-[3-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenoxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzenesulfonamide;
3-{4-Chloro-3-[2-(4-phenoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenol;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(4-methoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-o-tolyl-ethyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
[4-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenyl]-methanol;
3-(4-Chloro-3-phenethyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenyl-propyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;

N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetamide;
3-(4-Chloro-3-*Z*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-*E*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methanesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-acetamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzamide;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-(4-methyl-benzyl)-amine;
(4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methyl-amine;
3-[4-Chloro-3-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-piperidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-C-phenyl-methanesulfonamide;
3,4-Dichloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
4-Chloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methyl-benzenesulfonamide;

N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methoxy-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-N,N-dimethyl-sulfamoylurea;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-acetamide;
2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-nitro-benzenesulfonamide;
3-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-4-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methoxy-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methyl-benzenesulfonamide;
2-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-nitro-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-cyano-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methanesulfonyl-benzenesulfonamide;

N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methanesulfonyl-benzenesulfonamide;

1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(3-piperidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[3-(3-methyl-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[3-(4,4-difluoro-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(3-morpholin-4-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;

1-[1-(3-{3-[3-(3-Azepan-1-yl-propyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(3-cyclopentylamino-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-piperidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[4-(3-methyl-piperidin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;

1-{1-[3-(3-{4-Chloro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-morpholin-4-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[3-(4-Azepan-1-yl-butyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-cyclopentylamino-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;

8-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
3-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
1-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
2-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-cyclopentanone;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
3-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-pyrrolidin-1-yl-propan-2-ol;
[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
4-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperazin-1-yl-propan-2-ol;
1-(4-Amino-piperidin-1-yl)-3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propan-2-ol;
1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;

1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyridin-2-yl-methanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-furan-2-yl-methanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2,2-trifluoro-ethanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-fluoro-ethanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(tetrahydro-furan-2-yl)-methanone;
Acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-hydroxy-ethanone;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
1-{1-[3-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
8-[3-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-2,8-diaza-spiro[4.5]decan-1-one; and
1-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
and pharmaceutically acceptable salts thereof.

57. A pharmaceutical composition according to claim 55, wherein said chemical entity is selected from the group consisting of:
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N,N-dimethyl-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-sulfonamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S,5S)-3,5-dimethylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-{3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(piperidin-4-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethanol;
3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(1-methylethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(dimethylamino)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(difluoromethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
Methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycine;
2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N,N-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
Methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;

(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
Methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
2-(1,1-Dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
2-(1,1-Dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate;
(2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
Methyl (2R)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3,4-dichlorophenyl)methyl]methanamine;
(1S,2R)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-1-ol;
(1R,2S)-1-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-2-ol;

(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(2S)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2-phenylethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
Methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate;
N-{[5-({5-[5-(Aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycine;
3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[(4-chloro-3-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-[1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydroisoquinolin-7-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]acetamide;
7-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;

(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

2-[3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-[3-{4-Chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2R)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;
(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;
(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;
2-{3-[4-Chloro-3-(4-chloro-3-{[((2S)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
2-{3-[4-Chloro-3-(4-chloro-3-{[((2R)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-2-{3-[4-Chloro-3-(4-chloro-3-cyclopentylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-2-{3-[4-Chloro-3-(4-chloro-3-propylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-2-{3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-2-{3-[3-(3-{[Bis-(2-hydroxy-ethyl)-amino]-methyl}-4-chloro-phenylethynyl)-4-chloro-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-5-(5-{5-Aminooxalyl-1-[3-(3-methyl-morpholin-4-yl)-propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-2-chloro-N-(3-methylamino-propyl)-benzamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(3-hydroxy-propoxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
(S)-2-{3-{4-Chloro-3-[4-chloro-3-(pyrrolidin-3-yloxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(1-methylethyl)-1,2,3,4-tetrahydroisoquinoline;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-(2-{2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;

3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-({[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
Methyl N-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)methyl]glycinate; and
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxyethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

58. A pharmaceutical composition according to claim 55, wherein said chemical entity is selected from the group consisting of:
3-(2-{3-[5-(Methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenol;
3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
8-{3-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-2,8-diazaspiro[4.5]decan-1-one;
4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}but-3-yn-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}prop-2-yn-1-amine;
N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}prop-2-yn-1-yl)benzenesulfonamide;
N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}propyl)benzenesulfonamide;
1-[1-(3-{3-[3-(3-Aminoprop-1-yn-1-yl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
Methyl 2-{[(3-{2-chloro-5-[5-(methylsulfonyl)-1-{3-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propyl)amino]sulfonyl}benzoate;
1-[1-(3-{3-[4-Chloro-3-(3-hydroxyprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-hydroxybutyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
1-(1-{3-[3-{4-Chloro-3-[4-(dimethylamino)butyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-hydroxypropyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
1-(1-{3-[3-{4-Chloro-3-[3-(dimethylamino)propyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methylmethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-N-ethylethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[4-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(3-{[4-(1H-Benzimidazol-2-yl)phenyl]ethynyl}-4-chlorophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(phenylmethyl)aniline;
{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]amino}acetonitrile;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopropanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclobutanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopentanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclohexanamine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-phenylethyl)aniline;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1,1-Dimethylethyl (1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)carbamate;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-ol;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-amine;

1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-ylpropan-2-ol;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-pyrrolidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

Ethyl 1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylate;

1-{4-[(2-Chloro-5-{1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylic acid;

(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanol;

1'-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4'-bipiperidin-2-one;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methyloxy)phenyl]methyl}methanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2,2,2-trifluoroethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(cyclopropylmethyl)methanamine;

(2S)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-morpholin-4-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;
Methyl N-{[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;
1-(1-{3-[3-{4-Chloro-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}prop-2-en-1-amine;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxamide;
Methyl (2S)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-{4-[(5-{1-[3-(4-Acetylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4,4-dimethylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)-2-hydroxyacetamide;
1-{4-[(2-Chloro-5-{1-[3-(4,4-difluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-fluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanesulfonamide;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-piperidin-1-ylpropan-2-ol;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidin-4-yl)acetamide;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidine-4-carboxamide;

3-(4-Chloro-3-{[2-(trifluoroacetyl)-2,3-dihydro-1H-isoindol-5-yl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazine-1-carboxylate;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperazin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;

1,1-Dimethylethyl 7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1,1-Dimethylethyl 7-({2-chloro-5-[1-(2-hydroxy-3-piperidin-1-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1-[4-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]-2-hydroxypropyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1,1-Dimethylethyl {[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
7-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(phenylcarbonyl)piperazin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
(3R)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
1,1-Dimethylethyl {[2-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-2-yl)methanol;

1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4-diazepane-1-carboxylate;

1-{4-[(2-Chloro-5-{1-[3-(1,4-diazepan-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1,1-Dimethylethyl 5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,3-dihydro-2H-isoindole-2-carboxylate;

3-[4-Chloro-3-(2,3-dihydro-1H-isoindol-5-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine;

1-{4-[2-(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-2-one;

1-{4-[(2-Chloro-5-{1-[3-(1,1-dioxidothiomorpholin-4-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1,4-oxazepan-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-(4-{[5-(5-Acetyl-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}phenyl)-N-[(4-chlorophenyl)methyl]methanamine;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;

3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;

4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-3-methylpiperazin-2-one;
2-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
3-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
4-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
3-[3-(1H-Benzimidazol-5-ylethynyl)-4-chlorophenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
1-[4-({5-[5-Acetyl-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-3-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
Methyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylate;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-3-yl)methanol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-(2-thienyl)ethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl}methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-(phenylmethyl)methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-[(4-chlorophenyl)methyl]methanamine;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-[(4-chlorophenyl)methyl]methanamine;

4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylic acid;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-(1H-imidazol-4-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
2-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-(1,3-dihydro-2H-isoindol-2-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(1R)-N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S,2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2,3-dihydro-1H-inden-1-ol;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-(3-{5-[Amino(oxo)acetyl]-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidine-4-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-pyrrolidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(1-oxidopyridin-2-yl)piperazin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(1,3-thiazol-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Acetylamino)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclobutylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Aminocarbonyl)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(2-oxa-6-azaspiro[3.3]hept-6-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;

N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,3-dihydro-1H-inden-1-amine;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;

1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,2,2-trifluoroethanamine;

7-{[2-Chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

3-[4-Chloro-3-(1H-pyrrolo[2,3-b]pyridin-6-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-[(4-methylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-2-benzazepine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
1,1-Dimethylethyl (1S,4S)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1,1-Dimethylethyl (1R,4R)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1-[4-({2-Chloro-5-[1-{3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

2-[3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

1-[4-({2-Chloro-5-[5-(morpholin-4-ylcarbonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-{2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl}acetamide;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(cyclopropylmethyl)-1,2,3,4-tetrahydroisoquinoline;

2-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;

N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;

3-(4-Chloro-3-{[4-({[(3-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)propan-1-ol;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydrofuran-2-ylmethyl)methanamine;

N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}aniline;

6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[3-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methylsulfonyl)phenyl]methyl}methanamine;
1,1-Dimethylethyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate;
Ethyl [6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-prop-2-en-1-yl-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;

(2R)-1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-[(3S)-3-methylmorpholin-4-yl]propan-2-ol;

1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;

N-{[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]methyl}-2-methylpropan-1-amine;

3-(4-Chloro-3-{[4-({[(2-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-[({[2-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-[({[3-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;

1-[4-({2-Chloro-5-[1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1-oxidothiomorpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

3-[4-Chloro-3-({4-[({[4-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-[5-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;

1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(methyloxy)phenyl]-N-(phenylmethyl)methanamine;

(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;

3-(4-Chloro-3-{[4-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}carbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(morpholin-2-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({4-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]piperidin-1-yl}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(methylsulfanyl)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(3-{[4-({[(4-Aminophenyl)methyl]amino}methyl)phenyl]ethynyl}-4-chlorophenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[(2-Chloro-5-{[2-chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}phenyl)methyl]glycine;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(3-hydroxypropyl)benzamide;
3-[4-Chloro-3-({4-chloro-3-[(3-hydroxypropyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
tert-Butyl 3-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorobenzyl)oxy]pyrrolidine-1-carboxylate;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(3-hydroxypropyl)benzamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

2-[3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(1R)-2-hydroxy-1-phenylethyl]benzamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[3-(methylamino)propyl]benzamide;

2-(3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)methylcarbamate;

tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)carbamate;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(piperidin-3-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(morpholin-2-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(3R)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(piperidin-3-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(morpholin-2-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(piperidin-3-ylmethyl)benzamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
2-{3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]ethanamine;
2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopentanamine;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(azetidin-3-ylmethyl)-2-chlorobenzamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopropanamine;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;

3-{4-Chloro-3-[(4-{[3-(methylamino)propyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[3-(methylamino)propyl]benzamide; and
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[3-(methylamino)propyl]benzamide;
3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N,N-dimethylmethanamine;
2-[3-(4-Chloro-3-{[4-(hydroxymethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(1-methylethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-[3-(3-methylmorpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

59. A pharmaceutical composition according to claim 55, wherein said chemical entity is selected from the group consisting of:
4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}butan-1-ol;
5-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}pentan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-amine;


1-[1-(3-{3-[3-(3-Aminopropyl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynylamine; and

3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propylamine;

and pharmaceutically acceptable salts thereof.

60. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by cathepsin S activity, comprising administering to a subject in need of such treatment an effective amount of at least one chemical entity selected from compounds of Formula (I):



(I)

wherein:

R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated monocyclic heterocycloalkyl group, each group optionally containing one additional heteroatom ring member that is O, S, or NR^a, and each group unsubstituted or substituted with one, two, or three R^b substituents;

where R^a is H, C_{1-4}alkyl, $-COC_{1-4}$alkyl, -CO(phenyl), or $-CO_2C_{1-4}$alkyl, or a monocyclic cycloalkyl ring, phenyl ring, or monocyclic heteroaryl ring, each ring unsubstituted or substituted with OH, C_{1-4}alkyl, CF_3, halo, $-OC_{1-4}$alkyl, cyano, or $-COC_{1-4}$alkyl; and

each R^b substituent is independently:

i) OH, C_{1-4}alkyl, $-C_{1-4}$alkyl-OH, CF_3, $-NR^cR^d$, halo, $-OC_{1-4}$alkyl, $-COC_{1-4}$alkyl, $-CO_2C_{1-4}$alkyl, $-CO_2H$, or $-CONR^eR^f$;

ii) a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, $-COC_{1-4}$alkyl, $-CO_2C_{1-4}$alkyl, OH, $-OC_{1-4}$alkyl, $-NR^cR^d$, or halo;

iii) a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, $-OC_{1-4}$alkyl, $-NR^cR^d$, or halo; or

iv) a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

v) two R^b substituents on the same carbon taken together with the carbon to which they are attached form a saturated monocyclic heterocycloalkyl group, unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

vi) two R^b substituents form a methylene or ethylene bridge; or

vii) two R^b substituents on adjacent carbons taken together with the carbons to which they are attached form a saturated monocyclic cycloalkyl group or saturated monocyclic heterocycloalkyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

where R^c is H or C_{1-4}alkyl;

R^d is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COC_{1-4}alkyl-OH, -CO_2C_{1-4}alkyl,–$CONR^xR^y$, or –SO_2C_{1-4}alkyl;

where R^x and R^y are each independently H or C_{1-4}alkyl; and

R^e and R^f are each independently H or C_{1-4}alkyl;

R^3 is H, OH, C_{1-4}alkyl, or -OC_{1-4}alkyl;

R^4 is H; C_{1-4}alkyl; -COC_{1-4}alkyl unsubstituted or substituted with OH, F, -$OCOC_{1-4}$alkyl, or -NR^tR^u; -$COCF_3$; -CO-(monocyclic heteroaryl); -CO-(C-linked monocyclic heterocycloalkyl); -CO-(phenyl); -SO_2C_{1-4}alkyl; -SO_2CF_3; -$SO_2NR^tR^u$; -$CONR^tR^u$; -$COCO_2C_{1-4}$alkyl; or –$COCONR^tR^u$;

where R^t and R^u are each independently H, C_{1-4}alkyl, or –COC_{1-4}alkyl; or R^t and R^u taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring;

R^5 is halo or CF_3;

each R^6 is independently H or F;

D is –C≡C–R^7, –CH=CH–R^8, –$(CH_2)_{2-3}$–R^8, or –$(CH_2)_{3-5}$–R^9;

where R^7 is:

I) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -NR^gR^h, phenyl, or phenoxy, each phenyl or phenoxy being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^g and R^h are each independently H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, or -SO_2-phenyl; or R^g and R^h taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl group; or

II) a monocyclic cycloalkyl group, phenyl group, or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^8 is a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^9 is OH or $-NR^nR^o$;

where R^n is H or C_{1-4}alkyl; and


R^o is H, C_{1-4}alkyl, monocyclic cycloalkyl, $-COC_{1-4}$alkyl, -COphenyl, $-CO_2C_{1-4}$alkyl, $-SO_2C_{1-4}$alkyl, $-SO_2$-phenyl, $-SO_2$-benzyl, or $-SO_2NR^pR^q$, each phenyl or benzyl group being unsubstituted or substituted with one or two R^k substituents;

where R^p and R^q are each independently H or C_{1-4}alkyl;

or R^n and R^o taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl ring unsubstituted or substituted with C_{1-4}alkyl, OH, $-OC_{1-4}$alkyl, halo, or CF_3;

where each R^k substituent in D is independently:

a) a C_{1-4}alkyl group unsubstituted or substituted with OH, $-OC_{1-4}$alkyl, $-OC_{1-4}$alkyl-OH, halo, $-CO_2C_{1-4}$alkyl, CO_2H, CN, $-NR^rR^s$, $-N(R^r)CO$-phenyl, $-N(R^r)SO_2C_{1-4}$alkyl, $-N(R^r)SO_2$-phenyl, $-SO_2C_{1-4}$alkyl, phenyl, or phenoxy;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, $-CH_2OH$, or $-CO_2C_{1-4}$alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or $-CH_2$-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, $-OC_{1-4}$alkyl, $-OCF_3$, $-OCHF_2$, $-NR^{dd}R^{ee}$, $-CO_2C_{1-4}$alkyl, $-SC_{1-4}$alkyl, and $-SO_2C_{1-4}$alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl;

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, $-C_{1-4}$alkyl-CF_3, $-C_{1-4}$alkyl-OH, $-C_{1-4}$alkyl-CO_2C_{1-}

$_4$alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, -$CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH; or

d) OH; -OC_{1-4}alkyl; halo; CF_3; -CHO; -CO_2C_{1-4}alkyl; CO_2H; CN; -NO_2; -$CONR^rR^s$, -NR^rR^s; -$N(R^r)$-phenyl; -$N(R^r)$-benzyl; -$N(R^r)$-phenethyl; -$N(R^r)COC_{1-4}$alkyl; -$N(R^r)$CO-phenyl; -$N(R^r)SO_2C_{1-4}$alkyl; -$N(R^r)SO_2$-phenyl; -SO_2C_{1-4}alkyl; phenoxy; or a heteroaryl group; where each phenyl, benzyl, phenethyl, phenoxy, or heteroaryl group is unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and

R^s is H, C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-CN, -C_{2-4}alkyl-OH, -C_{2-4}alkyl-$NR^{bb}R^{cc}$, -C_{1-4}alkylCO_2C_{1-4}alkyl, -C_{1-4}alkylCO_2H, C_{3-4}alkenyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH;

and pharmaceutically acceptable salts, prodrugs, and metabolites thereof.

61. A method according to claim 60, wherein said chemical entity is selected from the group consisting of:

3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-{4-Chloro-3-[2-(1H-indol-5-yl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;

(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;
4-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-butyric acid;
3-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-propionic acid;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
3-(4-Chloro-3-thiophen-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3,4-dichloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
3-[4-Chloro-3-(4-phenoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[3-(4-Bromo-phenylethynyl)-4-chloro-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzoic acid;
3-(4-Chloro-3-pyridin-4-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-(4-Chloro-3-thiophen-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-p-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-fluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2,4-difluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-o-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine;
3-(4-Chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester;
3-[4-Chloro-3-(3-phenyl-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-[4-Chloro-3-(4-phenyl-but-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(5-phenyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-yn-1-ol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-but-3-yn-1-ol;
5-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-pent-4-yn-1-ol;
3-(4-Chloro-3-hex-1-ynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-cyclohexylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-diethyl-amine;
3-{4-Chloro-3-[3-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenoxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzenesulfonamide;
3-{4-Chloro-3-[2-(4-phenoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenol;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(4-methoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-o-tolyl-ethyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

[4-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenyl]-methanol;
3-(4-Chloro-3-phenethyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenyl-propyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetamide;
3-(4-Chloro-3-*Z*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-*E*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methanesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-acetamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzamide;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-(4-methyl-benzyl)-amine;
(4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methyl-amine;
3-[4-Chloro-3-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-piperidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-C-phenyl-methanesulfonamide;
3,4-Dichloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
4-Chloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methyl-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methoxy-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-N,N-dimethyl-sulfamoylurea;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-acetamide;
2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-nitro-benzenesulfonamide;
3-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-4-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methoxy-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methyl-benzenesulfonamide;
2-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-nitro-benzenesulfonamide;

N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-cyano-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methanesulfonyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methanesulfonyl-benzenesulfonamide;
1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-piperidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(3-methyl-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(4,4-difluoro-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-morpholin-4-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[3-(3-Azepan-1-yl-propyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-cyclopentylamino-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-piperidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(3-methyl-piperidin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-morpholin-4-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[3-(4-Azepan-1-yl-butyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-cyclopentylamino-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
8-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
3-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
1-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
2-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-cyclopentanone;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
3-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-pyrrolidin-1-yl-propan-2-ol;
[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;

4-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperazin-1-yl-propan-2-ol;
1-(4-Amino-piperidin-1-yl)-3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propan-2-ol;
1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyridin-2-yl-methanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-furan-2-yl-methanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2,2-trifluoro-ethanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-fluoro-ethanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(tetrahydro-furan-2-yl)-methanone;
Acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-hydroxy-ethanone;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
1-{1-[3-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
8-[3-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-2,8-diaza-spiro[4.5]decan-1-one; and
1-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;

and pharmaceutically acceptable salts thereof.

62. A method according to claim 60, wherein said chemical entity is selected from the group consisting of:

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N,N-dimethyl-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-sulfonamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanamine;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S,5S)-3,5-dimethylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-{3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-{4-Chloro-3-[(4-{[(piperidin-4-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethanol;
3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(1-methylethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(dimethylamino)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(difluoromethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
Methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycine;
2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N,N-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;

(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
Methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
Methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
2-(1,1-Dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
2-(1,1-Dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate;
(2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
Methyl (2R)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3,4-dichlorophenyl)methyl]methanamine;
(1S,2R)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-1-ol;
(1R,2S)-1-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-2-ol;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(2S)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2-phenylethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
Methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate;
N-{[5-({5-[5-(Aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycine;
3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[(4-chloro-3-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-[1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydroisoquinolin-7-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]acetamide;
7-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)-1,2,3,4-tetrahydroisoquinoline;
7-[2-(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;

(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
2-[3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-[3-{4-Chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2R)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;

(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;

(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;

(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;

(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;

(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2S)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2R)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-cyclopentylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-propylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[3-(3-{[Bis-(2-hydroxy-ethyl)-amino]-methyl}-4-chloro-phenylethynyl)-4-chloro-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-5-(5-{5-Aminooxalyl-1-[3-(3-methyl-morpholin-4-yl)-propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-2-chloro-N-(3-methylamino-propyl)-benzamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(3-hydroxy-propoxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(pyrrolidin-3-yloxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(1-methylethyl)-1,2,3,4-tetrahydroisoquinoline;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;

3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-(3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

2-(3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

1-[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;

1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-(2-{2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-({[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
Methyl N-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)methyl]glycinate; and
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxyethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

63. A method according to claim 60, wherein said chemical entity is selected from the group consisting of:
3-(2-{3-[5-(Methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenol;
3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
8-{3-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-2,8-diazaspiro[4.5]decan-1-one;
4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}but-3-yn-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}prop-2-yn-1-amine;
N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}prop-2-yn-1-yl)benzenesulfonamide;

N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}propyl)benzenesulfonamide;
1-[1-(3-{3-[3-(3-Aminoprop-1-yn-1-yl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
Methyl 2-{[(3-{2-chloro-5-[5-(methylsulfonyl)-1-{3-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propyl)amino]sulfonyl}benzoate;
1-[1-(3-{3-[4-Chloro-3-(3-hydroxyprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-hydroxybutyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
1-(1-{3-[3-{4-Chloro-3-[4-(dimethylamino)butyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-hydroxypropyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
1-(1-{3-[3-{4-Chloro-3-[3-(dimethylamino)propyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methylmethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-N-ethylethanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[4-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(3-{[4-(1H-Benzimidazol-2-yl)phenyl]ethynyl}-4-chlorophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(phenylmethyl)aniline;
{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]amino}acetonitrile;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopropanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclobutanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopentanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclohexanamine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-phenylethyl)aniline;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1,1-Dimethylethyl (1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)carbamate;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-ol;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-amine;
1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-ylpropan-2-ol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-pyrrolidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
Ethyl 1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylate;
1-{4-[(2-Chloro-5-{1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylic acid;
(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanol;
1'-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4'-bipiperidin-2-one;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methyloxy)phenyl]methyl}methanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2,2,2-trifluoroethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(cyclopropylmethyl)methanamine;
(2S)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-morpholin-4-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;
Methyl N-{[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;
1-(1-{3-[3-{4-Chloro-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}prop-2-en-1-amine;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxamide;
Methyl (2S)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1-{4-[(5-{1-[3-(4-Acetylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4,4-dimethylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)-2-hydroxyacetamide;

1-{4-[(2-Chloro-5-{1-[3-(4,4-difluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-fluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanesulfonamide;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-piperidin-1-ylpropan-2-ol;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidin-4-yl)acetamide;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidine-4-carboxamide;

3-(4-Chloro-3-{[2-(trifluoroacetyl)-2,3-dihydro-1H-isoindol-5-yl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazine-1-carboxylate;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperazin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;

1,1-Dimethylethyl 7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1,1-Dimethylethyl 7-({2-chloro-5-[1-(2-hydroxy-3-piperidin-1-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1-[4-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]-2-hydroxypropyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
1,1-Dimethylethyl {[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
7-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(phenylcarbonyl)piperazin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
(3R)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
1,1-Dimethylethyl {[2-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;

1-[4-({2-Chloro-5-[1-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-2-yl)methanol;
1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4-diazepane-1-carboxylate;
1-{4-[(2-Chloro-5-{1-[3-(1,4-diazepan-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1,1-Dimethylethyl 5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,3-dihydro-2H-isoindole-2-carboxylate;
3-[4-Chloro-3-(2,3-dihydro-1H-isoindol-5-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine;
1-{4-[2-(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-2-one;
1-{4-[(2-Chloro-5-{1-[3-(1,1-dioxidothiomorpholin-4-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1,4-oxazepan-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-(4-{[5-(5-Acetyl-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}phenyl)-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-3-methylpiperazin-2-one;
2-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
3-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
4-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
3-[3-(1H-Benzimidazol-5-ylethynyl)-4-chlorophenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
1-[4-({5-[5-Acetyl-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-3-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
Methyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylate;

(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-3-yl)methanol;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-(2-thienyl)ethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl}methanamine;

1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-(phenylmethyl)methanamine;

1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-[(4-chlorophenyl)methyl]methanamine;

2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-[(4-chlorophenyl)methyl]methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylic acid;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-(1H-imidazol-4-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
2-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-(1,3-dihydro-2H-isoindol-2-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(1R)-N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S,2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2,3-dihydro-1H-inden-1-ol;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;

2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-(3-{5-[Amino(oxo)acetyl]-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidine-4-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-pyrrolidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(1-oxidopyridin-2-yl)piperazin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(1,3-thiazol-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Acetylamino)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclobutylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Aminocarbonyl)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(2-oxa-6-azaspiro[3.3]hept-6-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,3-dihydro-1H-inden-1-amine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;

1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,2,2-trifluoroethanamine;
7-{[2-Chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-[4-Chloro-3-(1H-pyrrolo[2,3-b]pyridin-6-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-[(4-methylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-2-benzazepine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
1,1-Dimethylethyl (1S,4S)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1,1-Dimethylethyl (1R,4R)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;
1-[4-({2-Chloro-5-[1-{3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[1-{3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
2-[3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(morpholin-4-ylcarbonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-{2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl}acetamide;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(cyclopropylmethyl)-1,2,3,4-tetrahydroisoquinoline;
2-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
3-(4-Chloro-3-{[4-({[(3-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)propan-1-ol;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydrofuran-2-ylmethyl)methanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}aniline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[3-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methylsulfonyl)phenyl]methyl}methanamine;
1,1-Dimethylethyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate;
Ethyl [6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetate;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-prop-2-en-1-yl-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
(2R)-1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-[(3S)-3-methylmorpholin-4-yl]propan-2-ol;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
N-{[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]methyl}-2-methylpropan-1-amine;
3-(4-Chloro-3-{[4-({[(2-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[2-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[3-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1-oxidothiomorpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-[({[4-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[5-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(methyloxy)phenyl]-N-(phenylmethyl)methanamine;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}carbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(morpholin-2-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({4-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]piperidin-1-yl}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(methylsulfanyl)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(3-{[4-({[(4-Aminophenyl)methyl]amino}methyl)phenyl]ethynyl}-4-chlorophenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[(2-Chloro-5-{[2-chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}phenyl)methyl]glycine;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(3-hydroxypropyl)benzamide;
3-[4-Chloro-3-({4-chloro-3-[(3-hydroxypropyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
tert-Butyl 3-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorobenzyl)oxy]pyrrolidine-1-carboxylate;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(3-hydroxypropyl)benzamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(1R)-2-hydroxy-1-phenylethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[3-(methylamino)propyl]benzamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)methylcarbamate;

tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)carbamate;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(piperidin-3-ylmethyl)benzamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(morpholin-2-ylmethyl)benzamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;

3-{4-Chloro-3-[(4-chloro-3-{[(3R)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-chloro-3-[(piperidin-3-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-chloro-3-[(morpholin-2-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(piperidin-3-ylmethyl)benzamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-(3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
2-{3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]ethanamine;
2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopentanamine;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(azetidin-3-ylmethyl)-2-chlorobenzamide;
3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopropanamine;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;

3-{4-Chloro-3-[(4-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-{[3-(methylamino)propyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[3-(methylamino)propyl]benzamide; and
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[3-(methylamino)propyl]benzamide;
3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N,N-dimethylmethanamine;
2-[3-(4-Chloro-3-{[4-(hydroxymethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(1-methylethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-[3-(3-methylmorpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

64. A method according to claim 60, wherein said chemical entity is selected from the group consisting of:
4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}butan-1-ol;


5-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}pentan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-ol;
3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propan-1-amine;
1-[1-(3-{3-[3-(3-Aminopropyl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynylamine; and
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propylamine;
and pharmaceutically acceptable salts thereof.

65. A method according to claim 60, wherein the disease, disorder, or medical condition is an autoimmune disease, an allergic condition, inflammation, a bowel disorder, tissue transplant rejection, pain, or cancer.

66. A method according to claim 60, wherein the disease, disorder, or medical condition is selected from the group consisting of: lupus, asthma, allergic reaction, atopic allergy, hay fever, atopic dermatitis, food allergy, rhinitis, skin immune system disorders, psoriasis, uveitis, inflammation, upper airway inflammation, Sjögren's syndrome, arthritis, rheumatoid arthritis, osteoarthritis, type I diabetes, atherosclerosis, multiple sclerosis, coeliac disease, inflammatory bowel disease, chronic obstructive pulmonary disorder, tissue transplant rejection, pain, chronic pain, and cancer.

67. A method according to claim 60, wherein the disease, disorder, or medical condition is selected from the group consisting of: psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

68. A method for modulating cathepsin S activity, comprising exposing cathepsin S to an effective amount of at least one chemical entity selected from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I), and pharmaceutically active metabolites of compounds of Formula (I):



(I)

wherein:

R^1 and R^2 taken together with the nitrogen to which they are attached form a saturated monocyclic heterocycloalkyl group, each group optionally containing one additional heteroatom ring member that is O, S, or NR^a, and each group unsubstituted or substituted with one, two, or three R^b substituents;

where R^a is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -CO(phenyl), or -CO_2C_{1-4}alkyl, or a monocyclic cycloalkyl ring, phenyl ring, or monocyclic heteroaryl ring, each ring unsubstituted or substituted with OH, C_{1-4}alkyl, CF_3, halo, -OC_{1-4}alkyl, cyano, or -COC_{1-4}alkyl; and

each R^b substituent is independently:

i) OH, C_{1-4}alkyl, -C_{1-4}alkyl-OH, CF_3, -NR^cR^d, halo, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, -CO_2H, or -$CONR^eR^f$;

ii) a monocyclic heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, -COC_{1-4}alkyl, -CO_2C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

iii) a monocyclic heterocycloalkyl group fused with a phenyl or pyridyl group, the resulting fused bicyclic group being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

iv) a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo; or

v) two R^b substituents on the same carbon taken together with the carbon to which they are attached form a saturated monocyclic heterocycloalkyl group, unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

vi) two R^b substituents form a methylene or ethylene bridge; or

vii) two R^b substituents on adjacent carbons taken together with the carbons to which they are attached form a saturated monocyclic cycloalkyl group or saturated monocyclic heterocycloalkyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, -NR^cR^d, or halo;

where R^c is H or C_{1-4}alkyl;

R^d is H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COC_{1-4}alkyl-OH, -CO_2C_{1-4}alkyl,–$CONR^xR^y$, or –SO_2C_{1-4}alkyl;

where R^x and R^y are each independently H or C_{1-4}alkyl; and

R^e and R^f are each independently H or C_{1-4}alkyl;

R^3 is H, OH, C_{1-4}alkyl, or -OC_{1-4}alkyl;

R^4 is H; C_{1-4}alkyl; -COC_{1-4}alkyl unsubstituted or substituted with OH, F, -$OCOC_{1-4}$alkyl, or -NR^tR^u; -$COCF_3$; -CO-(monocyclic heteroaryl); -CO-(C-linked monocyclic heterocycloalkyl); -CO-(phenyl); -SO_2C_{1-4}alkyl; -SO_2CF_3; -$SO_2NR^tR^u$; -$CONR^tR^u$; -$COCO_2C_{1-4}$alkyl; or –$COCONR^tR^u$;

where R^t and R^u are each independently H, C_{1-4}alkyl, or –COC_{1-4}alkyl; or R^t and R^u taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring;

R^5 is halo or CF_3;

each R^6 is independently H or F;

D is –C≡C–R^7, –CH=CH–R^8, –$(CH_2)_{2-3}$–R^8, or –$(CH_2)_{3-5}$–R^9;

where R^7 is:

I) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -NR^gR^h, phenyl, or phenoxy, each phenyl or phenoxy being unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^g and R^h are each independently H, C_{1-4}alkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, or -SO_2-phenyl; or R^g and R^h taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl group; or

II) a monocyclic cycloalkyl group, phenyl group, or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^8 is a phenyl group or monocyclic heteroaryl group, each group unsubstituted or substituted with one or two R^k substituents;

where R^9 is OH or -NR^nR^o;

where R^n is H or C_{1-4}alkyl; and


R^o is H, C_{1-4}alkyl, monocyclic cycloalkyl, -COC_{1-4}alkyl, -COphenyl, -CO_2C_{1-4}alkyl, -SO_2C_{1-4}alkyl, -SO_2-phenyl, -SO_2-benzyl, or -$SO_2NR^pR^q$, each phenyl or benzyl group being unsubstituted or substituted with one or two R^k substituents;

where R^p and R^q are each independently H or C_{1-4}alkyl;

or R^n and R^o taken together with the nitrogen to which they are attached form a monocyclic saturated heterocycloalkyl ring unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where each R^k substituent in D is independently:

a) a C_{1-4}alkyl group unsubstituted or substituted with OH, -OC_{1-4}alkyl, -OC_{1-4}alkyl-OH, halo, -CO_2C_{1-4}alkyl, CO_2H, CN, -NR^rR^s, -N(R^r)CO-phenyl, -N(R^r)SO_2C_{1-4}alkyl, -N(R^r)SO_2-phenyl, -SO_2C_{1-4}alkyl, phenyl, or phenoxy;

b) a substituent of formula  ;

where each R^v is independently H or C_{1-4}alkyl, or both R^v substituents together form a carbonyl;

R^w is H, C_{1-4}alkyl, -CH_2OH, or -CO_2C_{1-4}alkyl;

A is O or NR^{aa};

where R^{aa} is H or C_{1-4}alkyl; and

Z is a phenyl group, benzyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or –CH_2-(heteroaryl) group, each group unsubstituted or substituted with one or two substituents independently selected from the group consisting of C_{1-4}alkyl, CF_3, halo, OH, -OC_{1-4}alkyl, -OCF_3, -$OCHF_2$, -$NR^{dd}R^{ee}$, -CO_2C_{1-4}alkyl, -SC_{1-4}alkyl, and -SO_2C_{1-4}alkyl;

where R^{dd} and R^{ee} are each independently H or C_{1-4}alkyl;

c) two adjacent R^k substituents taken together with the carbons to which they are attached form a fused phenyl ring, monocyclic heteroaryl ring, monocyclic heterocycloalkyl ring, or monocyclic cycloalkyl ring, each fused ring unsubstituted or substituted with: C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-OH, -C_{1-4}alkyl-CO_2C_{1-4}alkyl, CF_3, C_{2-4}alkenyl, halo, OH, -OC_{1-4}alkyl, -COC_{1-4}alkyl, -$COCF_3$, -CO_2C_{1-4}alkyl, -CO_2H, -$CONR^{ff}R^{gg}$, or -SO_2C_{1-4}alkyl; or with a cycloalkyl group, -CH_2-(cycloalkyl) group, or benzyl group, each group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^{ff} and R^{gg} are each independently H or C_{1-4}alkyl, or R^{ff} and R^{gg} taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C_{1-4}alkyl or OH; or

d) OH; -OC_{1-4}alkyl; halo; CF_3; -CHO; -CO_2C_{1-4}alkyl; CO_2H; CN; -NO_2; -$CONR^rR^s$, -NR^rR^s; -N(R^r)-phenyl; -N(R^r)-benzyl; -N(R^r)-phenethyl; -N(R^r)COC_{1-4}alkyl; -N(R^r)CO-phenyl; -N(R^r)SO_2C_{1-4}alkyl; -N(R^r)SO_2-phenyl; -SO_2C_{1-4}alkyl; phenoxy; or a heteroaryl group; where each phenyl, benzyl, phenethyl, phenoxy, or

heteroaryl group is unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, or CF_3;

where R^r is H, C_{1-4}alkyl, C_{2-4}alkyl-OH; and

R^s is H, C_{1-4}alkyl, -C_{1-4}alkyl-CF_3, -C_{1-4}alkyl-CN, -C_{2-4}alkyl-OH, -C_{2-4}alkyl-$NR^{bb}R^{cc}$, -C_{1-4}alkylCO_2C_{1-4}alkyl, -C_{1-4}alkylCO_2H, C_{3-4}alkenyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

where R^{bb} is H or C_{1-4}alkyl; and

R^{cc} is H, C_{1-4}alkyl, -COC_{1-4}alkyl, or –CO_2C_{1-4}alkyl;

or R^{bb} and R^{cc} taken together with the nitrogen to which they are attached from a monocyclic heterocycloalkyl ring;

or R^r and R^s taken together with the nitrogen to which they are attached form a heterocycloalkyl group unsubstituted or substituted with C_{1-4}alkyl, OH, -OC_{1-4}alkyl, halo, CF_3, or a monocyclic heterocycloalkyl ring unsubstituted or substituted with OH.

69. A method according to claim 68, wherein the cathepsin S is in a subject with a disease, disorder, or medical condition mediated by cathepsin S activity.

70. A method according to claim 69, wherein the disease, disorder, or medical condition is an autoimmune disease, an allergic condition, inflammation, a bowel disorder, tissue transplant rejection, pain, or cancer.

71. A method according to claim 69, wherein the disease, disorder, or medical condition is selected from the group consisting of: lupus, asthma, allergic reaction, atopic allergy, hay fever, atopic dermatitis, food allergy, rhinitis, skin immune system disorders, psoriasis, uveitis, inflammation, upper airway inflammation, Sjögren's syndrome, arthritis, rheumatoid arthritis, osteoarthritis, type I diabetes, atherosclerosis, multiple sclerosis, coeliac disease, inflammatory bowel disease, chronic obstructive pulmonary disorder, tissue transplant rejection, pain, chronic pain, and cancer.

72. A method as in claim 69, wherein the disease, disorder, or medical condition is psoriasis, pain, multiple sclerosis, atherosclerosis, or rheumatoid arthritis.

73. A method according to claim 68, wherein said chemical entity is selected from the group consisting of:

3-[4-Chloro-3-(1H-indol-5-ylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(1H-indol-5-yl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetonitrile;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-methanol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;
4-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-butyric acid;
3-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-propionic acid;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid methyl ester;
3-(4-Chloro-3-thiophen-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3,4-dichloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[4-(4-iodo-phenoxy)-phenylethynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetic acid;
3-[4-Chloro-3-(4-phenoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[3-(4-Bromo-phenylethynyl)-4-chloro-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzoic acid;

3-(4-Chloro-3-pyridin-4-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-pyridin-2-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-thiophen-3-ylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenol;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-p-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-fluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methoxy-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2,4-difluoro-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-o-tolylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-trifluoromethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzaldehyde;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenylamine;

3-(4-Chloro-3-phenylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-carbamic acid tert-butyl ester;
3-[4-Chloro-3-(3-phenyl-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-phenyl-but-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(5-phenyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-yn-1-ol;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-but-3-yn-1-ol;
5-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-pent-4-yn-1-ol;
3-(4-Chloro-3-hex-1-ynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-cyclohexylethynyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-diethyl-amine;
3-{4-Chloro-3-[3-(1,1-dioxo-1λ^6-thiomorpholin-4-yl)-prop-1-ynyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-methyl-pent-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenoxy-prop-1-ynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-prop-2-ynyl)-benzenesulfonamide;
3-{4-Chloro-3-[2-(4-phenoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenol;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

3-{4-Chloro-3-[2-(4-methoxy-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-{4-Chloro-3-[2-(2,4-difluoro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(2-o-tolyl-ethyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
[4-(2-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-ethyl)-phenyl]-methanol;
3-(4-Chloro-3-phenethyl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(3-phenyl-propyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-phenyl)-acetamide;
3-(4-Chloro-3-*Z*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-(4-Chloro-3-*E*-styryl-phenyl)-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzylamine;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methanesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzenesulfonamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-acetamide;
N-(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-benzamide;
Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;
(4-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-(4-methyl-benzyl)-amine;
(4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine;

Benzyl-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-methyl-amine;
3-[4-Chloro-3-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-(4-piperidin-1-ylmethyl-phenylethynyl)-phenyl]-5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-methanesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-C-phenyl-methanesulfonamide;
3,4-Dichloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
4-Chloro-N-(3-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methyl-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-4-methoxy-benzenesulfonamide;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-N,N-dimethyl-sulfamoylurea;
N-(3-{2-Chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenyl}-propyl)-acetamide;
2-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propylsulfamoyl}-benzoic acid;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-nitro-benzenesulfonamide;
3-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-4-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methoxy-benzenesulfonamide;

N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methyl-benzenesulfonamide;
2-Chloro-N-{3-[2-chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-nitro-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-cyano-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-3-methanesulfonyl-benzenesulfonamide;
N-{3-[2-Chloro-5-(5-methanesulfonyl-1-{3-[4-(2-oxo-pyrrolidin-1-yl)-piperidin-1-yl]-propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-phenyl]-propyl}-2-methanesulfonyl-benzenesulfonamide;
1-[1-(3-{3-[4-Chloro-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-piperidin-1-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(3-methyl-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(4,4-difluoro-piperidin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-morpholin-4-yl-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[3-(4-methyl-piperazin-1-yl)-propyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[3-(3-Azepan-1-yl-propyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(3-cyclopentylamino-propyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-pyrrolidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-piperidin-1-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(3-methyl-piperidin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-{1-[3-(3-{4-Chloro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-morpholin-4-yl-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[3-(4-Azepan-1-yl-butyl)-4-chloro-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[4-Chloro-3-(4-cyclopentylamino-butyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-pyrrolidin-2-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
8-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-2,8-diaza-spiro[4.5]decan-1-one;
1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
3-[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;
[1-(3-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
1-{3-[3-(4-Chloro-phenylethynyl)-4-trifluoromethyl-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
2-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-cyclopentanone;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-morpholin-4-yl-propan-2-ol;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
3-[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-5-dimethylamino-1-methyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one;

1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid methyl ester;
1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidine-4-carboxylic acid amide;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-pyrrolidin-1-yl-propan-2-ol;
[1-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperidin-4-yl]-carbamic acid tert-butyl ester;
4-(3-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxy-propyl)-piperazine-1-carboxylic acid tert-butyl ester;
1-{3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperazin-1-yl-propan-2-ol;
1-(4-Amino-piperidin-1-yl)-3-{3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propan-2-ol;
1-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-3-piperidin-1-yl-propan-2-ol;
1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydro-isoquinolin-7-ylethynyl)-phenyl]-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl}-propyl)-piperidine-4-carboxylic acid amide;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-oxo-acetic acid methyl ester;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-pyridin-2-yl-methanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-furan-2-yl-methanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2,2,2-trifluoro-ethanone;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-fluoro-ethanone;
[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-(tetrahydro-furan-2-yl)-methanone;
Acetic acid 2-[3-[4-chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-ethyl ester;
1-[3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-hydroxy-ethanone;
3-[4-Chloro-3-(4-chloro-phenylethynyl)-phenyl]-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-1-(3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

1-{1-[3-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-piperidin-4-yl}-pyrrolidin-2-one;
1-(3-{3-[2-(4-Chloro-phenyl)-ethyl]-4-trifluoromethyl-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
8-[3-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-2-hydroxy-propyl]-2,8-diaza-spiro[4.5]decan-1-one; and
1-(3-{4-Chloro-3-[2-(4-chloro-phenyl)-ethyl]-phenyl}-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl)-3-morpholin-4-yl-propan-2-ol;
and pharmaceutically acceptable salts thereof.

74. A method according to claim 68, wherein said chemical entity is selected from the group consisting of:
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N,N-dimethyl-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-sulfonamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S,5S)-3,5-dimethylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-{3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(pyridin-3-ylmethyl)amino]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(piperidin-4-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3aR,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethanol;
3-(4-Chloro-3-{[4-({[(4-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(1-methylethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(dimethylamino)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[({4-[(difluoromethyl)oxy]phenyl}methyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzaldehyde;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;

1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)methanamine;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;

Methyl N-{[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;

N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycine;

2-(1,1-Dimethylethyl) 3-methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;

(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;

(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N,N-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
Methyl (3S)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
Methyl (3R)-7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
2-(1,1-Dimethylethyl) 3-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2,3(1H)-dicarboxylate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate;
[6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;

2-(1,1-Dimethylethyl) 1-methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-1,2(1H)-dicarboxylate;
Methyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate;
(2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
Methyl (2R)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3,4-dichlorophenyl)methyl]methanamine;
(1S,2R)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-1-ol;
(1R,2S)-1-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2,3-dihydro-1H-inden-2-ol;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(1R)-N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1,2,3,4-tetrahydronaphthalen-1-amine;
(2S)-2-[({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)amino]-2-phenylethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
Methyl N-{[5-({5-[5-(aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycinate;
N-{[5-({5-[5-(Aminocarbonyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-2-chlorophenyl]methyl}glycine;

3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

3-{4-Chloro-3-[(4-chloro-3-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydroisoquinoline;

N-[1-(3-{3-[4-Chloro-3-(1,2,3,4-tetrahydroisoquinolin-7-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]acetamide;

7-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)-1,2,3,4-tetrahydroisoquinoline;

7-[2-(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-[(2S)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}-2-hydroxypropyl]-4,4'-bipiperidine-1-carboxylate;

1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(4-methylpent-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;
(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
1,1-Dimethylethyl 1'-{(2S)-3-[5-(aminocarbonyl)-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
2-[3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1,1-Dimethylethyl 1'-{(2S)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-4,4'-bipiperidine-1-carboxylate;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(1'-Acetyl-4,4'-bipiperidin-1-yl)-3-[3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-[3-{4-Chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-(1'-methyl-4,4'-bipiperidin-1-yl)propan-2-ol;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;

(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-thiomorpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(R)-2-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-acetamide;
(2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
2-{3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2R)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[(2S)-2-hydroxy-3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(R)-3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-(2-hydroxy-3-morpholin-4-yl-propyl)-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid amide;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-thiomorpholin-4-yl-propan-2-ol;
(S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;
(R)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-yl-propan-2-ol;
(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;
(2S)-1-[3-(4-Chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-5-methanesulfonyl-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-3-((3S)-3-methyl-morpholin-4-yl)-propan-2-ol;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2S)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

2-{3-[4-Chloro-3-(4-chloro-3-{[((2R)-tetrahydro-furan-2-ylmethyl)-amino]-methyl}-phenylethynyl)-phenyl]-1-[3-((3S)-3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-cyclopentylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[4-Chloro-3-(4-chloro-3-propylaminomethyl-phenylethynyl)-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-(4-Chloro-3-{4-chloro-3-[(3-hydroxy-propylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-[3-(3-{[Bis-(2-hydroxy-ethyl)-amino]-methyl}-4-chloro-phenylethynyl)-4-chloro-phenyl]-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-5-(5-{5-Aminooxalyl-1-[3-(3-methyl-morpholin-4-yl)-propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chloro-phenylethynyl)-2-chloro-N-(3-methylamino-propyl)-benzamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(3-hydroxy-propoxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

(S)-2-{3-{4-Chloro-3-[4-chloro-3-(pyrrolidin-3-yloxymethyl)-phenylethynyl]-phenyl}-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide;

7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(1-methylethyl)-1,2,3,4-tetrahydroisoquinoline;

7-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;

3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-(3-{4-Chloro-3-[(2-cyclopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-5-(2-{2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
3-{4-Chloro-3-[(4-chloro-3-{[(phenylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-chloro-3-{[(pyridin-2-ylmethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-({[2-Chloro-5-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
Methyl N-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)methyl]glycinate; and
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxyethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
and pharmaceutically acceptable salts thereof.

75. A method according to claim 68, wherein said chemical entity is selected from the group consisting of:

3-(2-{3-[5-(Methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenol;

3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

8-{3-[3-{4-Chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}-2,8-diazaspiro[4.5]decan-1-one;

4-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}but-3-yn-1-ol;

3-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}prop-2-yn-1-amine;

N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}prop-2-yn-1-yl)benzenesulfonamide;

N-(3-{5-[1-(2-Hydroxy-3-morpholin-4-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-(trifluoromethyl)phenyl}propyl)benzenesulfonamide;

1-[1-(3-{3-[3-(3-Aminoprop-1-yn-1-yl)-4-chlorophenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

Methyl 2-{[(3-{2-chloro-5-[5-(methylsulfonyl)-1-{3-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}propyl)amino]sulfonyl}benzoate;

1-[1-(3-{3-[4-Chloro-3-(3-hydroxyprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(4-hydroxybutyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-(1-{3-[3-{4-Chloro-3-[4-(dimethylamino)butyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-[1-(3-{3-[4-Chloro-3-(3-hydroxypropyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidin-4-yl]pyrrolidin-2-one;

1-(1-{3-[3-{4-Chloro-3-[3-(dimethylamino)propyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methylmethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-N-ethylethanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;

1-[4-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

3-(3-{[4-(1H-Benzimidazol-2-yl)phenyl]ethynyl}-4-chlorophenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(phenylmethyl)aniline;
{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]amino}acetonitrile;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopropanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclobutanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclopentanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}cyclohexanamine;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-phenylethyl)aniline;
1-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;
1,1-Dimethylethyl (1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)carbamate;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-ol;
1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-amine;
1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-morpholin-4-ylpropan-2-ol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-pyrrolidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
Ethyl 1-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylate;
1-{4-[(2-Chloro-5-{1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxylic acid;

(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanol;

1'-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4'-bipiperidin-2-one;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methyloxy)phenyl]methyl}methanamine;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2,2,2-trifluoroethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(cyclopropylmethyl)methanamine;

(2S)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2-phenylethanol;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-morpholin-4-ylpiperidin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;

Methyl N-{[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}glycinate;

1-(1-{3-[3-{4-Chloro-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}prop-2-en-1-amine;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidine-4-carboxamide;

Methyl (2S)-({[4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)(phenyl)ethanoate;

1-(1-{3-[3-(4-Chloro-3-{[4-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)pyrrolidin-2-one;

1-{4-[(5-{1-[3-(4-Acetylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-methylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4,4-dimethylpiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)-2-hydroxyacetamide;

1-{4-[(2-Chloro-5-{1-[3-(4,4-difluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

1-{4-[(2-Chloro-5-{1-[3-(4-fluoropiperidin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)methanesulfonamide;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-piperidin-1-ylpropan-2-ol;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidin-4-yl)acetamide;

1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-2-hydroxypropyl}piperidine-4-carboxamide;

3-(4-Chloro-3-{[2-(trifluoroacetyl)-2,3-dihydro-1H-isoindol-5-yl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazine-1-carboxylate;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperazin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

N-(1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperidin-4-yl)acetamide;

1,1-Dimethylethyl 7-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1,1-Dimethylethyl 7-({2-chloro-5-[1-(2-hydroxy-3-piperidin-1-ylpropyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1-[4-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]-2-hydroxypropyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

1,1-Dimethylethyl 7-({5-[1-{3-[4-(aminocarbonyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;

1,1-Dimethylethyl {[3-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;

7-({2-Chloro-5-[1-{3-[4-(1,1-dimethylethyl)piperidin-1-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[4-(phenylcarbonyl)piperazin-1-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,2,3,4-tetrahydroisoquinoline;

(3S)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
(3R)-1-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}pyrrolidin-3-ol;
1,1-Dimethylethyl {[2-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}carbamate;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methanamine;
1-[2-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-2-yl)methanol;
1,1-Dimethylethyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-1,4-diazepane-1-carboxylate;
1-{4-[(2-Chloro-5-{1-[3-(1,4-diazepan-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1,1-Dimethylethyl 5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1,3-dihydro-2H-isoindole-2-carboxylate;
3-[4-Chloro-3-(2,3-dihydro-1H-isoindol-5-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro-1,6-naphthyridine;
1-{4-[2-(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-2-one;

1-{4-[(2-Chloro-5-{1-[3-(1,1-dioxidothiomorpholin-4-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1,4-oxazepan-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-(4-{[5-(5-Acetyl-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}phenyl)-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-3-methylpiperazin-2-one;
2-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine;
3-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
4-(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}piperazin-1-yl)phenol;
3-[3-(1H-Benzimidazol-5-ylethynyl)-4-chlorophenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
1-[4-({5-[5-Acetyl-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-chlorophenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethanol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

7-[(2-Chloro-5-{1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]-1,2,3,4-tetrahydroisoquinoline;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-4-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-3-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
Methyl 4-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylate;
(4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholin-3-yl)methanol;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-(2-thienyl)ethanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[5-methyl-2-(trifluoromethyl)furan-3-yl]methyl}methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-(phenylmethyl)methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)pyridin-3-yl]-N-[(4-chlorophenyl)methyl]methanamine;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(3-methyl-2-thienyl)methyl]methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(furan-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(2-thienylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(3-thienylmethyl)methanamine;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-[(4-chlorophenyl)methyl]methanamine;
4-{3-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}morpholine-3-carboxylic acid;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-{3-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-[4-Chloro-3-(1H-imidazol-4-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
2-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-(1,3-dihydro-2H-isoindol-2-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;

(1R)-N-{[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1,2,3,4-tetrahydronaphthalen-1-amine;
(1S,2R)-2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)-2,3-dihydro-1H-inden-1-ol;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
1-{3-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[(4-chlorophenyl)ethynyl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
1-(3-{5-[Amino(oxo)acetyl]-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propyl)piperidine-4-carboxamide;
2-{3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-pyrrolidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(1-oxidopyridin-2-yl)piperazin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-{3-[4-(trifluoromethyl)piperidin-1-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(1,3-thiazol-2-ylmethyl)methanamine;
1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(1-methyl-1H-imidazol-5-yl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

1-{3-[4-(Acetylamino)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclobutylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-{3-[4-(Aminocarbonyl)piperidin-1-yl]propyl}-3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-[3-(4-cyclopropylpiperazin-1-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-{[(1,1-dimethylethyl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;
3-[4-Chloro-3-({2-[(4-chlorophenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-7-yl}ethynyl)phenyl]-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
1,1-Dimethylethyl 7-({2-chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(2-oxa-6-azaspiro[3.3]hept-6-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;
2-({[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,3-dihydro-1H-inden-1-amine;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-[3-{4-chloro-3-[3-(diethylamino)prop-1-yn-1-yl]phenyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(cyclohexylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-2-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;

(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(3-phenylprop-1-yn-1-yl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
(2S)-1-(4,4'-Bipiperidin-1-yl)-3-{3-[4-chloro-3-(pyridin-3-ylethynyl)phenyl]-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl}propan-2-ol;
3-(4-Chloro-3-{2-[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-1-phenylethanamine;
1-[(2S)-3-(4,4'-Bipiperidin-1-yl)-2-hydroxypropyl]-3-{4-chloro-3-[2-(4-chlorophenyl)ethyl]phenyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-({4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}methyl)-2,2,2-trifluoroethanamine;
7-{[2-Chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-[4-Chloro-3-(1H-pyrrolo[2,3-b]pyridin-6-ylethynyl)phenyl]-5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(pyrrolidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-[(4-methylpiperazin-1-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline;
(3S)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
8-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2,3,4,5-tetrahydro-1H-2-benzazepine;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-phenylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

1,1-Dimethylethyl (1S,4S)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;

1,1-Dimethylethyl (1R,4R)-5-{3-[3-(4-chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]propyl}-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate;

1-[4-({2-Chloro-5-[1-{3-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[1-{3-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

2-[3-{4-Chloro-3-[(4-{[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylamino]methyl}phenyl)ethynyl]phenyl}-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

1-[4-({2-Chloro-5-[5-(morpholin-4-ylcarbonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;

3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N,N-dimethyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-{2-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoethyl}acetamide;

1-[4-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

7-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydroisoquinoline;

1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;

1-[4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]-N-methylmethanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-phenylethanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(cyclopropylmethyl)-1,2,3,4-tetrahydroisoquinoline;
2-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)ethanol;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-1-phenylethanamine;
3-(4-Chloro-3-{[4-({[(3-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-({[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}amino)propan-1-ol;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(tetrahydrofuran-2-ylmethyl)methanamine;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}aniline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-cyclopropyl-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[3-({[(2-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[3-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
6-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline;
N-{[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]methyl}-2-methylpropan-1-amine;

1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-3-ylmethyl)methanamine;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(pyridin-4-ylmethyl)methanamine;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(2-methylpropyl)-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-{[4-(methylsulfonyl)phenyl]methyl}methanamine;
1,1-Dimethylethyl 6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate;
Ethyl [6-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3,4-dihydroisoquinolin-2(1H)-yl]acetate;
6-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-prop-2-en-1-yl-1,2,3,4-tetrahydroisoquinoline;
1-[3-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
(2R)-1-[3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl]-3-[(3S)-3-methylmorpholin-4-yl]propan-2-ol;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-methyl-N-(phenylmethyl)methanamine;
N-{[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]methyl}-2-methylpropan-1-amine;
3-(4-Chloro-3-{[4-({[(2-methylphenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[2-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[3-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[3-(2-{2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethyl)phenyl]-N-(phenylmethyl)methanamine;
1-[4-({2-Chloro-5-[1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
1-{4-[(2-Chloro-5-{5-(methylsulfonyl)-1-[3-(1-oxidothiomorpholin-4-yl)propyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}phenyl)ethynyl]phenyl}-N-[(4-chlorophenyl)methyl]methanamine;

3-[4-Chloro-3-({4-[({[4-(methyloxy)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[5-({2-Chloro-5-[1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-5-(methylsulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-fluorophenyl]-N-(phenylmethyl)methanamine;
1-[5-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-2-(methyloxy)phenyl]-N-(phenylmethyl)methanamine;
(3R)-7-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-3-(morpholin-4-ylcarbonyl)-1,2,3,4-tetrahydroisoquinoline;
3-(4-Chloro-3-{[4-({[(2-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(3-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({[(4-fluorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-(phenylmethyl)methanamine;
1-[2-Chloro-4-({2-chloro-5-[5-(methylsulfonyl)-1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine;
3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}carbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(morpholin-2-ylmethyl)oxy]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-({4-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]piperidin-1-yl}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[({[4-(methylsulfanyl)phenyl]methyl}amino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(3-{[4-({[(4-Aminophenyl)methyl]amino}methyl)phenyl]ethynyl}-4-chlorophenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-{4-Chloro-3-[(4-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
N-[(2-Chloro-5-{[2-chloro-5-(1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]ethynyl}phenyl)methyl]glycine;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(3-hydroxypropyl)benzamide;

3-[4-Chloro-3-({4-chloro-3-[(3-hydroxypropyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
tert-Butyl 3-[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorobenzyl)oxy]pyrrolidine-1-carboxylate;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(3-hydroxypropyl)benzamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-{4-Chloro-3-[(4-chloro-3-{[(2-hydroxy-2-methylpropyl)amino]methyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(1R)-2-hydroxy-1-phenylethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[3-(methylamino)propyl]benzamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(pyrrolidin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(piperazin-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-[3-(4-Chloro-3-{[4-chloro-3-(1,4-diazepan-1-ylcarbonyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)methylcarbamate;
tert-Butyl (3-{[(5-{[5-(5-[amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chlorophenyl)carbonyl]amino}propyl)carbamate;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(piperidin-3-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(morpholin-2-ylmethyl)benzamide;
5-[(5-{5-[Amino(oxo)acetyl]-1-(3-thiomorpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-chloro-3-{[(3R)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(piperidin-3-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(morpholin-2-ylmethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-[(3R)-pyrrolidin-3-ylmethyl]benzamide;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-2-chloro-N-(piperidin-3-ylmethyl)benzamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

2-(3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;

3-[4-Chloro-3-({4-chloro-3-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

5-[(5-{5-[Amino(oxo)acetyl]-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-chlorophenyl)ethynyl]-2-chloro-N-(2-morpholin-4-ylethyl)benzamide;

2-{3-[4-Chloro-3-({4-chloro-3-[(ethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;

N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]ethanamine;

2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopentanamine;

5-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-(azetidin-3-ylmethyl)-2-chlorobenzamide;

3-[4-Chloro-3-({4-chloro-3-[(cyclopentylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

2-{3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoacetamide;

2-[3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;

3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-piperidin-1-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;

N-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)benzyl]cyclopropanamine;

3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
3-[4-Chloro-3-({4-chloro-3-[(cyclopropylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-(4-Chloro-3-{[4-chloro-3-(morpholin-4-ylmethyl)phenyl]ethynyl}phenyl)-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
3-[4-Chloro-3-({4-[(2-morpholin-4-ylethyl)carbamoyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-(2-morpholin-4-ylethyl)benzamide;
3-{4-Chloro-3-[(4-{[(2S)-pyrrolidin-2-ylmethyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[(2S)-pyrrolidin-2-ylmethyl]benzamide;
3-{4-Chloro-3-[(4-{[3-(methylamino)propyl]carbamoyl}phenyl)ethynyl]phenyl}-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
4-{[5-(5-[Amino(oxo)acetyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-chlorophenyl]ethynyl}-N-[3-(methylamino)propyl]benzamide; and
4-({2-Chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)-N-[3-(methylamino)propyl]benzamide;
3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-(3-thiomorpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide;
2-(3-[4-Chloro-3-({4-chloro-3-[(dimethylamino)methyl]phenyl}ethynyl)phenyl]-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
1-[2-Chloro-5-({2-chloro-5-[5-(methylsulfonyl)-1-(3-piperidin-1-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N,N-dimethylmethanamine;
2-[3-(4-Chloro-3-{[4-(hydroxymethyl)phenyl]ethynyl}phenyl)-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-chloro-3-{[(1-methylethyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3S)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;
2-(3-{4-Chloro-3-[(4-{[(4-chlorobenzyl)amino]methyl}phenyl)ethynyl]phenyl}-1-{3-[(3R)-3-methylmorpholin-4-yl]propyl}-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl)-2-oxoacetamide;